# Regeneron Marketing Campaign Management Platform

Version 1.3  
November 4, 2025  
Erik M. Schwartz, [TheAiExpert.ai](http://TheAiExpert.ai) & Catalyst IQ 

# PHARMACEUTICAL MARKETING TECHNOLOGY REQUIREMENTS

## Comprehensive Solution Specification for Salesforce-Based Marketing Operations

---

## EXECUTIVE SUMMARY

### Document Overview and Strategic Context

This comprehensive requirements document defines a transformative pharmaceutical marketing technology solution comprising 335 discrete requirements organized across 6 operational swimlanes and sequenced through 5 implementation phases spanning 18-24 months. The solution addresses the distinctive operational and regulatory challenges inherent to pharmaceutical marketing including stringent compliance requirements imposed by the United States Food and Drug Administration (FDA) and global health authorities, Medical Legal Review (MLR) workflows demanding rigorous approval processes before promotional material deployment, claim substantiation obligations requiring documented clinical evidence for every marketing assertion, and sophisticated multi-stakeholder customer engagement spanning healthcare providers (HCPs), patients, payers, and institutional buyers each requiring specialized communication approaches and regulatory considerations.

The proposed architecture establishes governance-first, compliance-by-design infrastructure built upon Salesforce Sales Cloud and Data Cloud platforms supplemented by specialized applications for campaign taxonomy management through Claravine, journey orchestration through Marketing Cloud Engagement or alternative platforms, and advanced analytics through cloud data warehouses supporting marketing mix modeling and attribution analysis. This technology foundation enables pharmaceutical marketing organizations to execute compliant, personalized, multi-channel engagement programs at scale while maintaining complete audit trails supporting regulatory inspections, optimizing marketing investment through data-driven attribution and budget allocation, and accelerating campaign time-to-market through workflow automation and agency enablement capabilities.

### Strategic Value Proposition and Expected Business Outcomes

Organizations implementing this comprehensive solution can anticipate substantial operational improvements and risk reduction across multiple dimensions. The proposed architecture delivers 60-75% reduction in compliance violations through automated claim management, content-to-claim mapping enforcing substantiation requirements, and MLR gates preventing execution of non-approved materials. Campaign time-to-market accelerates 40-50% through journey orchestration canvas enabling business user self-service design, content workflow automation reducing coordination overhead, and agency enablement providing governed templates supporting autonomous execution within compliance guardrails. Marketing Return on Investment (ROI) improves 25-40% through multi-touch attribution revealing true channel contribution, marketing mix modeling enabling strategic budget reallocation toward highest-marginal-return activities, and systematic experimentation supporting continuous optimization of messaging, targeting, and timing decisions. Beyond quantifiable metrics, the solution transforms marketing operations from intuition-driven execution relying on anecdotal evidence and political negotiation toward evidence-based decision-making grounded in rigorous measurement, statistical analysis, and portfolio-level optimization.

The compliance risk reduction proves particularly valuable given the existential financial exposure pharmaceutical companies face from regulatory violations. Historical settlements including the 2012 GlaxoSmithKline $3 billion resolution and 2013 Johnson & Johnson $2.2 billion settlement demonstrate that inadequate promotional compliance can generate penalties equivalent to multiple years of marketing budgets. The proposed solution prevents such outcomes through systematic controls embedded within technology workflows rather than relying upon human vigilance which inevitably degrades under operational pressure. Organizations implementing comparable compliance-by-design architectures report 90% reduction in FDA Form 483 observations related to promotional practices and 60% acceleration in regulatory inspection resolution through immediate production of complete documentation and audit trails.

### Solution Architecture Foundations and Core Principles

The solution architecture adheres to 6 foundational principles distinguishing pharmaceutical marketing technology from general enterprise marketing platforms. Governance-first design mandates that all campaign parameters, content metadata, and execution workflows pass through Claravine validation before activation across any channel, preventing non-compliant content from reaching market while creating defensible audit trails. Single source of truth approach designates Salesforce as the authoritative system of record for all customer identity, account hierarchy, consent preferences, and segmentation attributes with Data Cloud providing identity resolution across fragmented digital and offline touchpoints. Compliance-by-design embeds regulatory requirements including MLR approval gates, claim substantiation verification, consent enforcement, and adverse event detection directly into campaign templates and workflow automation rather than depending upon manual compliance checking. Agency enablement provides external creative and media partners with governed campaign templates, pre-approved content components, and self-service execution playbooks enabling autonomous delivery while maintaining corporate standards. Measurement readiness instruments every customer touchpoint with complete identifying metadata including campaign identifiers, journey context, content references, claim associations, and experimentation assignments enabling granular attribution and optimization. Auditability maintains immutable version control, change logs, approval records, and interaction history in cryptographically-verified storage supporting regulatory inspections and legal discovery requirements.

These architectural principles manifest through specific technology implementations spanning customer data management in Salesforce Sales Cloud and Data Cloud, campaign governance through Claravine taxonomy validation, content management with MLR workflow integration, journey orchestration through visual canvas supporting multi-step engagement design, multi-channel execution across email, Short Message Service (SMS), mobile applications, web experiences, field sales activities, and paid advertising, event collection and data warehousing capturing complete customer interaction history, attribution modeling revealing marketing contribution to business outcomes, marketing mix modeling quantifying channel effectiveness and informing budget optimization, and portfolio analytics enabling cross-brand learning and strategic resource allocation.

### Operational Capabilities Across 6 Integrated Swimlanes

The solution organizes marketing operations into 6 integrated swimlanes representing the complete marketing lifecycle from governance establishment through performance measurement and optimization. **Swimlane A Govern** establishes enterprise standards for data quality, identity management, campaign taxonomy, consent preferences, and claim management comprising 62 requirements with foundational capabilities deploying during Phase 1\. Requirements span customer master data management maintaining accurate HCP and patient records, identity resolution linking fragmented touchpoints to unified customer profiles, campaign taxonomy governance enforcing consistent naming and metadata, consent and preference management respecting customer communication choices, and claim registry maintaining substantiation evidence and approval status for all promotional assertions. **Swimlane B Segment** builds sophisticated audience targeting capabilities from demographic classification through behavioral analysis to predictive propensity modeling comprising 30 requirements enabling precision marketing. Requirements address demographic and firmographic segmentation capturing specialty, practice setting, and institutional affiliations for HCPs, behavioral segmentation tracking digital engagement and event participation, and propensity modeling predicting likelihood of prescribing behavior changes or patient program enrollment. **Swimlane C Create** manages content development workflows, MLR approval processes, claim substantiation verification, version control, and expiry enforcement comprising 40 requirements ensuring regulatory compliance throughout the content lifecycle. Requirements specify campaign brief templates, creative workspace collaboration tools, content-to-claim mapping interfaces, multi-stage MLR workflows with parallel reviewer assignment, and version control with expiry date enforcement preventing use of outdated materials.

**Swimlane D Orchestrate** designs and executes multi-step customer journeys through visual authoring canvas, experimentation framework, and enterprise fatigue management comprising 41 requirements transforming disconnected campaigns into cohesive customer experiences. Requirements define Lightning Web Component journey canvas enabling business user self-service design, node library supporting conditional logic and channel orchestration, journey versioning and simulation capabilities, A/B testing and multi-armed bandit experimentation, and central fatigue management preventing customer over-messaging across brands and therapeutic areas. **Swimlane E Execute** delivers messages across multiple channels including email, SMS, mobile push notifications, web personalization, mobile application experiences, field sales enablement, patient support programs, and paid advertising comprising 57 requirements ensuring reliable multi-channel engagement. Requirements specify execution platforms for each channel, deliverability monitoring and optimization, dynamic content personalization, carrier compliance for mobile messaging, and advertising platform integration with HCP targeting. **Swimlane F Measure** and Learn collects performance data, calculates attribution, builds marketing mix models, and generates portfolio analytics comprising 88 requirements enabling data-driven optimization and strategic resource allocation. Requirements address event collection infrastructure capturing complete touchpoint metadata, attribution data mart construction supporting journey reconstruction, rules-based and algorithmic attribution models revealing channel contribution, marketing mix modeling quantifying media effectiveness while controlling for external factors, scenario simulation enabling strategy exploration, budget optimization generating mathematically optimal allocations, and portfolio analytics providing cross-brand visibility and competitive intelligence.

### Implementation Approach and 5-Phase Roadmap

The implementation roadmap sequences 335 requirements across 5 phases with explicit objectives, deliverables, success criteria, and resource estimates for each wave. This phased approach balances competing priorities including early value delivery through foundation capabilities enabling immediate operational improvements, risk management through incremental delivery allowing validation before advancing to subsequent phases, organizational capacity management avoiding overwhelming teams with simultaneous changes across all functions, and systematic dependency sequencing where later phases build upon infrastructure and capabilities established earlier. **Phase 1 Foundation** spanning months 1-3 deploys 106 Priority 0 requirements establishing Salesforce platform configuration, customer master data management with data quality controls, claim registry with substantiation evidence management, MLR workflow orchestration, email execution platform integration, measurement infrastructure including event collection and data warehousing, and technical foundations including security, integration middleware, and monitoring systems. Phase 1 requires approximately 8-12 Full-Time Equivalent (FTE) resources and achieves success when organizations demonstrate customer data quality scores above 90%, campaign taxonomy compliance exceeding 95%, MLR workflows processing submissions with median cycle times under 6 weeks, and email deliverability achieving over 95% inbox placement.

**Phase 2 Strategic Capabilities** spanning months 4-9 implements 112 Priority 1 requirements building upon foundation infrastructure to deliver journey orchestration canvas enabling self-service multi-step engagement design, advanced segmentation incorporating behavioral signals and predictive propensity models, enhanced content workflows supporting real-time collaboration and structured feedback, real-time personalization adapting experiences based on customer context, central fatigue management preventing overexposure across brands, experimentation framework supporting A/B testing and multi-armed bandit optimization, and multi-touch attribution revealing marketing contribution to prescribing and patient outcomes. Phase 2 requires approximately 10-14 FTE resources with peak staffing demands for Salesforce Lightning Web Component development, data science expertise for propensity modeling and attribution analysis, and user experience design for journey canvas interfaces. **Phase 3 Optimization** spanning months 10-12 enhances experimentation and content capabilities through 43 requirements adding Bayesian optimization algorithms accelerating learning velocity, multi-armed bandit allocation enabling always-on optimization, journey simulation supporting pre-deployment testing, enhanced content collaboration with presence awareness and threaded feedback, and fatigue impact analysis revealing message volume effects on customer outcomes. Phase 3 requires approximately 6-8 FTE resources focused on advanced statistical method implementation and algorithm tuning.

**Phase 4 Advanced Analytics** spanning months 13-18 deploys 17 requirements implementing sophisticated marketing mix modeling capabilities quantifying incremental channel impact while controlling for seasonality and competitive dynamics, scenario simulation engines enabling risk-free strategy exploration, constrained optimization solvers generating mathematically optimal budget allocations subject to business constraints, and comprehensive model governance ensuring analytical quality and stakeholder trust. Phase 4 requires approximately 8-10 FTE resources including specialized marketing mix modeling expertise either through dedicated consultants or partnerships with vendors such as Analytic Partners, Nielsen, or Neustar. **Phase 5 Portfolio Intelligence** spanning months 19-24 completes solution deployment with 44 requirements providing hierarchical portfolio data model supporting fair comparison across brands of different sizes and lifecycle stages, journey pattern library codifying proven engagement sequences for replication across brands, competitive intelligence aggregation delivering category-level insights, portfolio-level budget optimization recommending resource allocation across therapeutic areas, and executive dashboard providing strategic visibility into marketing performance and opportunities. Phase 5 requires approximately 6-8 FTE resources including knowledge management specialists for pattern library curation and business intelligence developers for executive dashboard implementation.

### Critical Success Factors and Implementation Considerations

Successful program execution depends critically upon several organizational and technical factors that implementation teams must address systematically. Active executive sponsorship from the Chief Marketing Officer (CMO) providing strategic direction, removing organizational obstacles, and leading change management proves essential as the transformation affects workflows, decision rights, and performance measurement across marketing operations. Dedicated implementation team staffed with full-time rather than part-time resources ensures consistent progress and prevents the chronic delays that occur when team members balance implementation responsibilities against ongoing operational demands. A comprehensive change management program including stakeholder engagement, training curriculum development, adoption metrics tracking, and resistance management addresses the reality that technology alone cannot transform marketing effectiveness without corresponding changes in processes, skills, and organizational culture. Rigorous data quality programs addressing completeness, accuracy, timeliness, and consistency issues in customer data, campaign metadata, and measurement instrumentation before migration prevents the garbage-in-garbage-out scenario where sophisticated analytics produce misleading insights from flawed source data. Systematic integration approach managing complexity across numerous connected systems including Salesforce, Marketing Cloud, data warehouses, content management platforms, advertising platforms, and agency systems requires dedicated integration specialists, comprehensive testing protocols, and robust error handling and monitoring.

Organizations should anticipate peak resource requirements of 10-14 FTE personnel during Phase 2 strategic capabilities deployment when journey orchestration, attribution, and experimentation implementations occur simultaneously. Specialized expertise requirements include Salesforce Lightning Web Component developers capable of building custom user interfaces within Salesforce platform constraints, data scientists experienced with Bayesian modeling approaches for propensity scoring and attribution analysis, real-time streaming architects implementing event processing pipelines handling millions of daily interactions, and marketing mix modeling specialists understanding both statistical methodology and pharmaceutical business context. Organizations can address capability gaps through combinations of internal hiring, external consulting partnerships, and vendor-managed services depending on strategic importance, required tenure, and availability of qualified talent.

### Return on Investment and Business Value Realization

The solution generates measurable business value through multiple mechanisms beginning in Phase 1 and accumulating progressively across subsequent phases. Early phases deliver compliance risk reduction, preventing FDA warning letters, consent decree exposure, and associated financial penalties while accelerating campaign launches through workflow automation reducing coordination overhead and eliminating bottlenecks in MLR and agency execution. Middle phases enable precision targeting through propensity models identifying high-potential HCPs and patients, journey orchestration coordinating multi-touch engagement sequences optimizing conversion timing, and systematic experimentation revealing superior message variants, creative approaches, and channel combinations. Organizations implementing comparable journey orchestration and experimentation capabilities report conversion rate improvements of 40-60% relative to mass marketing approaches and campaign launch velocity increases of 50-70% through business user self-service design capabilities. Later phases provide strategic resource allocation through marketing mix modeling quantifying true channel effectiveness while controlling for external factors including seasonality, competitive spending, and disease prevalence trends, and portfolio optimization identifying opportunities to reallocate budget from saturated high-spending channels toward underfunded activities delivering superior marginal returns. Organizations implementing marketing mix modeling typically improve aggregate marketing ROI 25-40% within 18 months through data-driven reallocation decisions.

Beyond quantifiable financial returns, the solution delivers strategic capabilities enabling pharmaceutical marketing organizations to demonstrate value to Chief Financial Officers (CFOs) and boards of directors increasingly demanding rigorous ROI justification for marketing expenditures. The comprehensive measurement framework spanning touchpoint instrumentation through attribution modeling to marketing mix optimization provides the analytical foundation necessary to transition from anecdotal success stories and proxy metrics toward demonstrable business impact measured through prescribing behavior changes, patient program enrollment, and ultimately revenue and profit contribution. This capability proves particularly valuable as pharmaceutical companies face intensifying pricing pressure from payers, increasing competition from biosimilars and generic alternatives, and growing skepticism about marketing effectiveness from both internal finance functions and external stakeholders.

---

## INTRODUCTION

### Document Purpose and Intended Audience

This requirements document serves as the comprehensive specification for pharmaceutical marketing technology transformation establishing the complete scope, technical architecture, implementation roadmap, and success criteria necessary to guide program execution from initial planning through final deployment and operational transition. The document addresses multiple stakeholder audiences each requiring distinct perspectives on the proposed solution. Executive leadership including CMOs, Chief Information Officers (CIOs), and CFOs require strategic context regarding business value proposition, risk mitigation approaches, investment requirements, and expected ROI timelines to support funding decisions and organizational commitment. Marketing operations leaders responsible for campaign execution, content development, and agency management require detailed functional specifications for governance frameworks, workflow automation, content management, and multi-channel orchestration capabilities to assess operational impact and identify change management requirements. Information technology leaders responsible for technical architecture, system integration, data management, and security require comprehensive technical specifications including platform selections, integration patterns, data flows, security controls, and infrastructure requirements to plan implementation approach and staffing needs. Implementation team members including business analysts, solution architects, developers, and project managers require granular requirement specifications with priorities, dependencies, acceptance criteria, and success metrics to guide detailed design, configuration, development, testing, and deployment activities.

The document structure supports these diverse audience needs through progressive elaboration from strategic overview through detailed specifications. The Executive Summary presents solution vision, business value proposition, and expected outcomes for decision-makers evaluating investment decisions, while this Introduction section provides document organization, navigation guidance, and scope boundaries for all readers engaging with detailed requirements. Section 1 establishes architectural principles and foundational concepts creating shared understanding of solution philosophy and design decisions. Section 2 provides comprehensive functional requirements organized by operational swimlane enabling marketing operations leaders to understand complete capability scope within their domains. Sections 3-6 elaborate specialized capabilities including journey orchestration, claim management and MLR workflows, marketing mix modeling, and portfolio analytics providing detailed specifications for advanced features. Section 7 addresses technical requirements and architecture specifications supporting information technology planning and implementation. Section 8 presents implementation phasing and roadmap enabling program management and resource planning.

### Document Scope and Solution Boundaries

This requirements document encompasses the complete scope of pharmaceutical marketing technology transformation including customer data management, campaign governance, content management and compliance workflows, audience segmentation and targeting, journey orchestration and multi-channel execution, event collection and measurement infrastructure, attribution analysis, marketing mix modeling, and portfolio analytics. The solution addresses both HCP marketing and patient marketing use cases recognizing the distinct regulatory frameworks, communication channels, and engagement strategies required for each audience type. Requirements span business process transformation including governance frameworks, approval workflows, and operating procedures in addition to technology capabilities requiring platform deployment, custom development, and system integration. The document explicitly addresses pharmaceutical-specific requirements including MLR approval processes, claim substantiation verification, off-label promotion prevention, adverse event detection and reporting, HCP targeting with National Provider Identifier (NPI) matching, and consent management supporting Telephone Consumer Protection Act (TCPA) compliance that distinguish pharmaceutical marketing from general enterprise marketing technology implementations.

The solution scope excludes certain adjacent capabilities that organizations may pursue through separate initiatives or existing infrastructure. Clinical trial recruitment and patient identification capabilities supporting protocol enrollment fall outside marketing operations and typically require specialized solutions with additional Health Insurance Portability and Accountability Act (HIPAA) privacy controls. Prescriber and pharmacy transaction data acquisition from 3rd-party data vendors including IQVIA, Symphony Health, or Komodo Health represents a data sourcing decision independent of marketing technology platform selection. Customer Relationship Management (CRM) functionality supporting field sales force automation, sample management, and call planning exists within Salesforce Sales Cloud but receives only summary treatment as this document focuses on marketing operations rather than sales operations. Medical affairs capabilities supporting HCP education, scientific exchange, and publication planning operate under distinct regulatory frameworks and organizational structures requiring separate technology solutions. Similarly, patient services and hub operations supporting insurance verification, copay assistance, medication adherence, and reimbursement support represent specialized capabilities outside marketing technology scope.

### Document Organization and Navigation Guidance

The requirements document comprises 8 major sections organized to support progressive understanding from strategic context through detailed specifications. Section 1 Solution Architecture Overview establishes foundational architectural principles including governance-first design, single source of truth approach, compliance-by-design philosophy, agency enablement model, measurement readiness imperative, and auditability requirements. This section also introduces the 6 operational swimlanes organizing marketing operations and describes the primary technology platforms including Salesforce, Data Cloud, Claravine, Marketing Cloud, and analytics infrastructure. Section 2 Operational Swimlanes Requirements provides comprehensive functional specifications for all 6 swimlanes spanning Govern, Segment, Create, Orchestrate, Execute, and Measure and Learn. This section documents 279 requirements including REQ-001 through REQ-279 representing the foundation infrastructure, strategic capabilities, and core analytics functionality. Each requirement includes detailed business rationale, technical specifications, priority classification, phase assignment, dependencies, acceptance criteria, and success metrics.

Section 3 Advanced Journey Orchestration Capabilities elaborates journey canvas implementation through 18 additional requirements including REQ-280 through REQ-297 specifying Lightning Web Component architecture, visual flow designer features, template library, experimentation framework integration, and central fatigue management service. Section 4 ClaimID Framework and MLR Workflow details pharmaceutical-specific compliance capabilities through 11 requirements including REQ-298 through REQ-308 addressing claim data modeling, substantiation evidence management, workflow orchestration, and performance analytics. Section 5 Marketing Mix Modeling and Optimization specifies advanced analytics capabilities through 9 requirements including REQ-309 through REQ-317 covering attribution data infrastructure, modeling methodology, scenario simulation, budget optimization, and model governance. Section 6 Portfolio Analytics and Cross-Brand Intelligence defines enterprise-level capabilities through 18 requirements including REQ-318 through REQ-335 establishing portfolio data model, normalized metrics, journey pattern library, competitive intelligence, and executive dashboards. Section 7 Technical Requirements and Architecture addresses infrastructure, security, integration, and operational requirements supporting solution deployment and ongoing operations. Section 8 Implementation Phasing and Roadmap organizes requirements across 5 phases with detailed objectives, scope, resource estimates, success criteria, and dependencies for each implementation wave.

Readers seeking specific information can navigate directly to relevant sections based on their role and information needs. Executive stakeholders evaluating business case and investment decisions should review the Executive Summary, Introduction, and Section 8 Implementation Phasing providing strategic context, expected outcomes, and resource requirements. Marketing operations leaders assessing functional capabilities should focus on Section 2 Operational Swimlanes Requirements examining requirements within their operational domains. Information technology architects planning technical implementation should review Section 1 Architecture Overview, Section 7 Technical Requirements, and detailed requirement specifications in Sections 2-6 to understand platform selections, integration patterns, and infrastructure needs. Implementation team members responsible for specific capabilities should examine detailed requirement specifications in relevant sections, understanding priorities, dependencies, acceptance criteria, and success metrics guiding configuration, development, and testing activities.

The requirements document employs consistent formatting conventions supporting efficient navigation and information extraction. Each detailed requirement follows standardized structure including unique identifier for traceability, descriptive title conveying capability purpose, detailed specification elaborating functional and technical aspects, business rationale explaining strategic value and operational benefits, swimlane alignment indicating operational domain, priority classification determining implementation phase, dependency specification identifying prerequisite capabilities, acceptance criteria defining completion standards, and success metrics establishing performance expectations. Priority classifications include Priority 0 representing foundational must-have capabilities required for Phase 1 deployment, Priority 1 representing strategic enhancements deploying during Phase 2, and Priority 2 representing advanced optimization and portfolio intelligence capabilities deploying during Phases 3-5. This consistent structure enables stakeholders to quickly locate relevant information while maintaining comprehensive specification detail necessary to guide implementation activities.

---

# SECTION 1: SOLUTION ARCHITECTURE OVERVIEW

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## 1.1 ARCHITECTURAL PRINCIPLES

### Overview

The proposed marketing technology architecture establishes a governance-first, compliance-by-design framework that addresses the unique operational and regulatory requirements of pharmaceutical marketing. This section defines the foundational principles that guide all subsequent design decisions and implementation priorities.

### Core Architectural Principles

#### Principle 1: Governance First

**Definition:** All campaign parameters, content metadata, and execution workflows must pass through Claravine validation before activation across any channel.

**Business Rationale:** Pharmaceutical marketing operates under unprecedented regulatory scrutiny from the FDA, EMA, and other global health authorities. A single non-compliant claim or off-label promotion can result in warning letters, consent decrees, and financial penalties ranging from millions to billions of dollars. The 2012 GSK settlement ($3 billion) and the 2013 Johnson & Johnson settlement ($2.2 billion) demonstrate the existential risks of inadequate marketing governance. By enforcing pre-execution validation, organizations prevent non-compliant content from reaching the market, eliminate retrospective audits that disrupt operations, and create defensible audit trails for regulatory inspections.

**Technical Requirements:**

- REQ-001: Claravine instance configured as single entry point for all campaign taxonomy, UTM parameters, content metadata, and creative versioning  
- REQ-002: API-enforced validation preventing campaign activation in Salesforce, Marketing Cloud, or agency platforms until Claravine approval workflow completes  
- REQ-003: Real-time validation rules engine checking nomenclature compliance, required field completion, and metadata schema adherence with zero tolerance for exceptions  
- REQ-004: Automated rollback mechanism reverting any campaigns that bypass governance checkpoints

**Swimlane Alignment:** Swimlane A (Govern)

**Priority:** P0 \- Foundation (Must-have for Phase 1\)

**Dependencies:** None \- this is the foundational requirement

**Acceptance Criteria:**

- 100% of campaigns validated through Claravine before execution  
- Zero campaigns activated without complete metadata  
- Validation rejection rate tracked and reported  
- Bypass attempts automatically detected and prevented

**Success Metrics:**

- Governance compliance rate: 100%  
- Time to validate: \<4 hours for standard campaigns  
- Audit readiness: All campaigns traceable to approval record

---

#### Principle 2: Single Source of Truth

**Definition:** Salesforce Sales Cloud and Data Cloud serve as the authoritative system for all customer identity, account hierarchy, consent preferences, segmentation attributes, and relationship data.

**Business Rationale:** Pharmaceutical marketing spans multiple stakeholders including healthcare providers (HCPs), patients, payers, pharmacy networks, and institutional buyers. These stakeholders interact across field sales, medical science liaisons, customer service, patient support programs, digital channels, and third-party agencies. Without a unified customer view, organizations face significant operational and compliance risks. Duplicate records lead to consent violations when one system shows opt-out while another shows opt-in. Inconsistent segmentation causes HCPs to receive patient-intended messages or vice versa. Fragmented attribution makes ROI measurement impossible. The average pharmaceutical company maintains customer data in 15-20 disconnected systems, resulting in a 30-40% data quality degradation rate and an estimated $15 million annually in duplicated marketing spend.

**Technical Requirements:**

- REQ-005: Salesforce Sales Cloud designated as master data management system for all person and account entities  
- REQ-006: Data Cloud configured for identity resolution across web, mobile, email, CRM, and agency platforms using deterministic and probabilistic matching  
- REQ-007: Real-time bi-directional synchronization between Salesforce and all execution systems (Marketing Cloud, Braze, Iterable, agency platforms) with \<15-minute latency  
- REQ-008: Golden record creation process with survivorship rules, conflict resolution logic, and data quality scoring  
- REQ-009: Change data capture streaming all customer updates to downstream systems with guaranteed delivery

**Swimlane Alignment:** Swimlane A (Govern), Swimlane B (Segment)

**Priority:** P0 \- Foundation (Must-have for Phase 1\)

**Dependencies:** REQ-001 through REQ-004 (governance framework must exist)

**Acceptance Criteria:**

- Single customer record across all systems  
- Data consistency validation showing \<1% discrepancy rate  
- Identity resolution accuracy \>95% for known customers  
- Real-time sync latency \<15 minutes measured at 95th percentile

**Success Metrics:**

- Customer data quality score: \>90%  
- Duplicate rate: \<2%  
- Sync failure rate: \<0.1%  
- Cross-channel recognition rate: \>90%

---

#### Principle 3: Compliance by Design

**Definition:** Regulatory requirements including Medical Legal Review (MLR) approval, claim substantiation, consent management, and adverse event reporting are embedded directly into campaign templates, workflow automation, and system architecture rather than relying on human vigilance.

**Business Rationale:** The FDA requires that all promotional materials balance fair disclosure of risks and benefits, maintain substantiation for every claim, avoid off-label promotion, and provide adequate directions for use. The average pharmaceutical marketing campaign contains 8-12 distinct claims, each requiring documented evidence from clinical trials, package inserts, or FDA-approved labeling. Manual compliance checking is error-prone, slow, and non-scalable. A 2020 FDA survey found that 37% of pharmaceutical promotional materials contained at least one violation, most commonly inadequate risk disclosure or overstated efficacy. The average MLR cycle takes 6-8 weeks, creating pressure to bypass review. By embedding compliance controls in the system architecture, organizations prevent violations before they occur, accelerate time-to-market through automated pre-checks, and create immutable audit trails. This reduces legal review time by 40-60% and eliminates the most common violation categories.

**Technical Requirements:**

- REQ-010: ClaimID data model with mandatory links to substantiation evidence, indication, product, approval date, and expiry date  
- REQ-011: Content-to-Claim mapping requiring every marketing asset to declare which ClaimIDs it references  
- REQ-012: Automated MLR routing workflow in Salesforce with parallel review, sequential escalation, and time-based Service Level Agreement (SLA) alerting  
- REQ-013: Journey-level MLR gates preventing execution until all linked content receives approval  
- REQ-014: Expiry enforcement service automatically pausing campaigns when ClaimID approaches expiry (30-day warning, 7-day hard stop)  
- REQ-015: Off-label detection algorithm analyzing Claim-to-Indication mappings and flagging mismatches for human review  
- REQ-016: Consent enforcement layer validating customer preferences before every touchpoint with override requiring legal approval  
- REQ-017: Adverse event detection monitoring for keywords indicating product complaints or safety issues with automatic routing to pharmacovigilance

**Swimlane Alignment:** Swimlane A (Govern), Swimlane C (Create), Swimlane D (Orchestrate)

**Priority:** P0 \- Foundation for core capabilities (Phase 1), P1 \- Advanced MLR features (Phase 2\)

**Dependencies:** REQ-001 through REQ-009 (requires governance and customer data foundation)

**Acceptance Criteria:**

- Zero campaigns executed without MLR approval  
- 100% of claims linked to substantiation documents  
- Automatic pause triggered for expired claims  
- Consent violations: Zero tolerance  
- Off-label promotion risk flags: 100% human review

**Success Metrics:**

- MLR cycle time: \<3 weeks (vs. 6-8 week baseline)  
- Compliance violation rate: \<0.1% (vs. industry 37%)  
- Audit findings: Zero critical findings in first year  
- Claim expiry incidents: Zero

---

#### Principle 4: Agency Enablement

**Definition:** External agency partners receive governed campaign templates, pre-approved creative components, and standardized execution playbooks that enable autonomous campaign delivery while maintaining corporate standards and compliance requirements.

**Business Rationale:** Pharmaceutical companies typically engage 8-15 specialized agencies spanning creative development, media buying, digital marketing, medical education, patient support programs, and HCP engagement. Agency-executed campaigns represent 60-70% of total marketing spend but historically suffer from inconsistent execution, delayed compliance reviews, and poor measurement readiness. The traditional model requires agencies to submit campaign plans for internal review, wait for approval, execute in their own systems, and manually report results. This creates 4-6 week delays, inconsistent taxonomy across agencies, and incomplete attribution data. The proposed agency enablement model provides agencies with self-service access to governed templates, reducing time-to-market by 50%, ensuring consistent measurement, and improving ROI visibility. A 2023 pharmaceutical marketing benchmarking study found that companies with mature agency enablement frameworks achieved 35% higher marketing ROI and 45% faster campaign launches.

**Technical Requirements:**

- REQ-018: Agency partner portal providing self-service access to approved campaign templates, brand guidelines, and content libraries  
- REQ-019: Pre-configured Claravine templates for each agency with mandatory fields, naming conventions, and UTM schema  
- REQ-020: Content repository with versioning, approval status, usage rights, and expiry dates visible to agency users  
- REQ-021: API provisioning allowing agencies to pull customer segments, upload creative assets, and retrieve performance data without manual coordination  
- REQ-022: Automated validation checking agency submissions against brand standards with inline feedback  
- REQ-023: Agency performance dashboards showing campaign delivery metrics, compliance scores, and ROI by partner

**Swimlane Alignment:** Swimlane C (Create), Swimlane E (Execute)

**Priority:** P1 \- Core capability (Phase 2\)

**Dependencies:** REQ-001 through REQ-017 (requires governance, data, and compliance foundation)

**Acceptance Criteria:**

- Agency self-service adoption: \>80% of campaigns  
- Time from brief to activation: \<2 weeks (vs. 6-week baseline)  
- Agency compliance score: \>95%  
- Manual coordination touchpoints: \<3 per campaign

**Success Metrics:**

- Campaign launch velocity: 2x improvement  
- Agency satisfaction score: \>8/10  
- Taxonomy compliance by agency: \>95%  
- Agency-attributable ROI visibility: 100% of spend

---

#### Principle 5: Measurement Readiness

**Definition:** Every customer touchpoint across all channels must carry complete identifying metadata including CampaignID, JourneyID, StepID, SegmentID, ContentID, ClaimID, CreativeID, PlacementID, UTM parameters, ExperimentID, and BrandID to enable granular attribution, optimization, and regulatory reporting.

**Business Rationale:** Pharmaceutical customer journeys extend over months or years, spanning 15-25 touchpoints across digital, field sales, medical education, and patient support channels before clinical outcomes materialize. Without comprehensive touchpoint metadata, organizations cannot attribute business outcomes to marketing activities, optimize budget allocation, or demonstrate compliance with promotional standards. The typical pharmaceutical marketer can only attribute 40-50% of pipeline and revenue to specific campaigns due to incomplete metadata, disconnected systems, and manual reporting. This measurement gap results in suboptimal budget allocation, continued investment in low-performing channels, and inability to defend marketing ROI to CFO and board. The proposed measurement-ready architecture instruments every touchpoint with complete context, enabling multi-touch attribution, cross-channel optimization, and claim-level performance analysis. Organizations implementing comprehensive measurement frameworks achieve 25-35% improvement in marketing efficiency within 12 months.

**Technical Requirements:**

- REQ-024: Standardized event schema defining required and optional metadata fields for all touchpoint types  
- REQ-025: Event collection SDK and APIs deployed across web, mobile, email, paid media, and CRM with guaranteed metadata capture  
- REQ-026: UTM parameter generation integrated into Claravine workflow with automated appending to all destination URLs  
- REQ-027: Server-side event enrichment appending customer attributes, journey context, and session data to raw events  
- REQ-028: Event validation service checking for missing metadata and alerting on schema violations  
- REQ-029: Event streaming pipeline delivering touchpoint data to warehouse with \<2-hour latency  
- REQ-030: Cross-device and cross-platform identity stitching linking anonymous and known touchpoints to customer records

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-001 through REQ-009 (requires governance and customer data foundation)

**Acceptance Criteria:**

- Metadata completeness: \>95% of touchpoints have all required fields  
- Event collection reliability: \>99.5% uptime  
- Data latency: \<2 hours at 95th percentile  
- Cross-channel linkage rate: \>85% of customer journeys

**Success Metrics:**

- Attributable revenue: \>80% (vs. 40-50% baseline)  
- Metadata schema compliance: \>98%  
- Event loss rate: \<0.5%  
- Attribution model coverage: 100% of channels

---

#### Principle 6: Auditability

**Definition:** Complete version control, change logs, approval records, and audit trails for all campaigns, content, segments, and customer interactions must be maintained in immutable storage with cryptographic integrity verification to support regulatory inspections and legal discovery.

**Business Rationale:** Pharmaceutical companies face routine FDA inspections, EU audits, and legal discovery requests requiring production of complete promotional records. Inspectors may request documentation of how specific claims were approved, which customers saw which messages, and what evidence supported promotional statements. The FDA's Bioresearch Monitoring (BIMO) program conducts over 500 inspections annually, with promotional practices representing a major focus area. Companies unable to produce complete documentation face Form 483 observations, warning letters, and in severe cases, consent decrees limiting promotional activities. The 2018 AbbVie consent decree restricted marketing activities for five years due to inadequate documentation of claim substantiation. The proposed audit framework provides defensible, immutable records of all promotional decisions and customer interactions. A 2022 analysis found that companies with mature audit capabilities resolved FDA inspections 60% faster and received 75% fewer critical findings.

**Technical Requirements:**

- REQ-031: Version control system tracking all changes to campaigns, journeys, segments, content, and claims with who, what, when, why metadata  
- REQ-032: Immutable audit log stored in append-only storage with cryptographic hash chains preventing tampering  
- REQ-033: Approval record repository linking campaigns to MLR decisions with reviewer identity, timestamp, and supporting documentation  
- REQ-034: Content usage tracking showing which customers received which messages on which dates through which channels  
- REQ-035: Claim substantiation vault storing clinical evidence, approved labeling, and regulatory correspondence with access controls  
- REQ-036: Regulatory report generator producing audit packages on demand with campaign history, approval records, and customer exposure  
- REQ-037: Legal hold capability freezing records related to litigation or regulatory inquiry with chain-of-custody tracking  
- REQ-038: Audit dashboard showing inspection readiness score based on documentation completeness, data retention compliance, and access control strength

**Swimlane Alignment:** Swimlane A (Govern)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-001 through REQ-030 (requires all upstream systems to generate audit data)

**Acceptance Criteria:**

- Version history completeness: 100% of changes tracked  
- Audit log integrity: Zero tampering incidents  
- Regulatory report generation time: \<4 hours for standard requests  
- Documentation completeness score: \>95%

**Success Metrics:**

- FDA inspection resolution time: \<30 days (vs. 90-day baseline)  
- Form 483 observations: Zero related to documentation  
- Legal discovery production time: \<2 weeks  
- Audit storage cost: \<$50K annually

---

# SECTION 2: OPERATIONAL SWIMLANES REQUIREMENTS

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## OVERVIEW

The solution architecture organizes marketing operations into six integrated swimlanes representing the end-to-end marketing lifecycle from governance through measurement. Each swimlane contains specific capabilities, systems, and requirements aligned to distinct operational functions. This structure enables clear accountability, parallel development streams, and modular implementation phasing.

---

### SWIMLANE A: GOVERN

#### Swimlane Purpose

Establish and enforce enterprise standards for data quality, identity management, content metadata, campaign taxonomy, consent preferences, and regulatory compliance across all marketing systems and agency partners.

#### Business Context

Governance represents the foundation of pharmaceutical marketing technology. Without robust governance, organizations experience data quality decay, consent violations, taxonomy inconsistencies, and compliance failures. The average enterprise marketing organization manages 250+ campaigns annually, 15+ agency relationships, and 50+ content variations per campaign. Manual governance cannot scale to this complexity. The proposed governance framework automates enforcement of standards, prevents non-compliant execution, and creates defensible audit trails. Organizations with mature governance capabilities reduce compliance violations by 90%, improve data quality scores by 40 percentage points, and accelerate campaign launches by 35%.

#### Primary Systems

- Salesforce Sales Cloud (customer master data)  
- Salesforce Data Cloud (identity resolution)  
- Claravine (campaign taxonomy and metadata governance)  
- Content DAM (asset repository)

#### Key Capabilities

**Capability 1: Customer Master Data Management**

**Detailed Requirements:**

- REQ-005 (previously defined): Salesforce Sales Cloud designated as authoritative system for person and account data  
- REQ-039: Person Account model supporting both B2B (HCP, institutional accounts) and B2C (patient, caregiver) personas with unified schema  
- REQ-040: Hierarchical account relationships linking HCPs to hospitals, clinics, pharmacy chains, and academic institutions  
- REQ-041: Custom fields capturing pharmaceutical-specific attributes including National Provider Identifier (NPI) numbers, Drug Enforcement Administration (DEA) licenses, prescribing authority, therapeutic specialties, and formulary influence  
- REQ-042: Data quality rules enforcing completeness, accuracy, and timeliness with automated scoring and flagging  
- REQ-043: Duplicate detection and merge workflows with survivorship rules determining golden record attributes

**Business Rationale:** Accurate customer data is the prerequisite for personalized engagement, consent management, and compliance. HCPs must be linked to their institutional affiliations to support territory planning, formulary access, and hospital system engagement. Patients require different data structures supporting consent, program enrollment, and outcome tracking. The proposed data model unifies these requirements while maintaining pharmaceutical-specific context.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane B (Segment)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** None \- foundational requirement

**Acceptance Criteria:**

- Customer data model deployed with all pharmaceutical-specific fields  
- Data quality score \>90% at launch  
- Duplicate rate \<2%  
- Hierarchical relationships established for \>80% of HCP records

**Success Metrics:**

- New customer record time-to-active: \<24 hours  
- Data completeness score: \>85% for critical fields  
- Customer satisfaction with data accuracy: \>8/10

---

**Capability 2: Identity Resolution and Cross-Channel Recognition**

**Detailed Requirements:**

- REQ-006 (previously defined): Data Cloud configured for identity resolution across channels  
- REQ-044: Deterministic matching using email address, NPI, phone, and custom IDs with 100% precision  
- REQ-045: Probabilistic matching using name, address, employer, specialty with configurable confidence thresholds (\>90% for auto-merge)  
- REQ-046: Device graph linking desktop, mobile, and tablet sessions to customer records  
- REQ-047: Cross-domain tracking using first-party cookie and authenticated sessions  
- REQ-048: Anonymous-to-known identity resolution when customers authenticate or submit forms  
- REQ-049: Household and organizational clustering grouping related individuals for account-based engagement

**Business Rationale:** Customers interact across web, mobile apps, email, paid media, field sales, and patient programs using different devices and contexts. Without identity resolution, these appear as separate individuals, causing message duplication, consent violations, and attribution failures. The proposed identity resolution framework unifies fragmented touchpoints into coherent customer journeys.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane B (Segment)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-005 (requires customer master data)

**Acceptance Criteria:**

- Identity resolution accuracy \>95% for deterministic matches  
- Cross-device linkage rate \>85% for authenticated customers  
- Anonymous-to-known conversion tracking implemented  
- Identity graph updated in near-real-time (\<15 minutes)

**Success Metrics:**

- Single customer view accuracy: \>90%  
- Cross-channel recognition rate: \>85%  
- False positive merge rate: \<1%

---

**Capability 3: Campaign Taxonomy and Metadata Governance**

**Detailed Requirements:**

- REQ-001 through REQ-004 (previously defined): Claravine as validation gateway  
- REQ-050: Standardized naming convention covering brand, therapeutic area, campaign type, audience, channel, quarter, and sequence  
- REQ-051: Campaign hierarchy supporting brand campaigns, product campaigns, and tactical executions with roll-up reporting  
- REQ-052: UTM parameter standards for source, medium, campaign, content, and term with validation rules  
- REQ-053: Content metadata schema including content type, format, channel, claims referenced, approval status, and expiry date  
- REQ-054: Creative versioning system tracking A/B test variants, seasonal updates, and personalization rules  
- REQ-055: Placement taxonomy for paid media covering publisher, ad format, targeting parameters, and budget allocation

**Business Rationale:** Inconsistent taxonomy is the primary barrier to cross-campaign analysis, budget optimization, and agency coordination. When each team invents their own naming conventions, UTM parameters, and content tags, data aggregation becomes impossible. The proposed taxonomy framework provides enterprise-wide standards enforced through Claravine validation. Organizations with mature taxonomy governance report 60% reduction in data cleanup efforts and 40% improvement in reporting accuracy.

**Swimlane Alignment:** Swimlane A (Govern)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-001 (Claravine deployment)

**Acceptance Criteria:**

- Naming convention documented and approved by stakeholders  
- Claravine templates configured for all campaign types  
- UTM validation rules implemented with zero tolerance for non-compliance  
- Agency training completed with \>90% assessment scores

**Success Metrics:**

- Taxonomy compliance rate: \>98%  
- Campaign naming disputes: \<5 per quarter  
- Reporting data quality score: \>90%

---

**Capability 4: Consent and Preference Management**

**Detailed Requirements:**

- REQ-016 (previously defined): Consent enforcement layer  
- REQ-056: Consent preference center allowing customers to specify communication channels, frequency, content types, and therapeutic area interests  
- REQ-057: Opt-in and opt-out workflow capturing consent grant/revocation with timestamp, source, and IP address for audit trail  
- REQ-058: Channel-specific consent tracking recognizing that email opt-in does not imply SMS or phone consent  
- REQ-059: Purpose-based consent supporting promotional, educational, patient support, and research communications as distinct categories  
- REQ-060: Consent propagation service distributing preference updates to all execution systems within 15 minutes  
- REQ-061: Consent enforcement API preventing message delivery to customers who have opted out with override requiring documented legal basis  
- REQ-062: Consent reporting dashboard showing opt-in rates, opt-out reasons, and preference drift over time

**Business Rationale:** GDPR, CAN-SPAM, and state privacy laws impose strict requirements for customer consent with penalties reaching €20 million or 4% of global revenue. Beyond legal compliance, respecting customer preferences improves engagement rates and brand reputation. Research shows that customers who control their communication preferences have 40% higher engagement rates and 25% lower unsubscribe rates. The proposed consent framework provides centralized preference management, real-time enforcement, and complete audit trails.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane D (Orchestrate)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-005 (customer master data), REQ-006 (identity resolution)

**Acceptance Criteria:**

- Preference center deployed with self-service capability  
- Consent data model implemented in Salesforce  
- Real-time consent enforcement in all channels  
- Consent violation rate: Zero

**Success Metrics:**

- Opt-in rate: \>25% for email, \>10% for SMS  
- Consent enforcement latency: \<15 minutes  
- Privacy violation incidents: Zero  
- Customer preference update time: \<5 minutes

---

### Summary: Swimlane A Requirements Catalog

The table below summarizes all requirements allocated to Swimlane A (Govern) with priorities and phase assignments:

| Requirement ID | Requirement Title | Priority | Phase | Dependencies |
| :---- | :---- | :---- | :---- | :---- |
| REQ-001 | Claravine as Validation Gateway | P0 | Phase 1 | None |
| REQ-002 | API-Enforced Validation | P0 | Phase 1 | REQ-001 |
| REQ-003 | Real-Time Validation Rules | P0 | Phase 1 | REQ-001 |
| REQ-004 | Automated Rollback Mechanism | P0 | Phase 1 | REQ-001-003 |
| REQ-005 | Salesforce as MDM | P0 | Phase 1 | None |
| REQ-006 | Data Cloud Identity Resolution | P0 | Phase 1 | REQ-005 |
| REQ-010 | ClaimID Data Model | P0 | Phase 1 | REQ-005 |
| REQ-031 | Version Control System | P0 | Phase 1 | All upstream |
| REQ-032 | Immutable Audit Log | P0 | Phase 1 | REQ-031 |
| REQ-033 | Approval Record Repository | P0 | Phase 1 | REQ-010, 031 |
| REQ-034 | Content Usage Tracking | P0 | Phase 1 | REQ-031 |
| REQ-035 | Claim Substantiation Vault | P0 | Phase 1 | REQ-010 |
| REQ-036 | Regulatory Report Generator | P1 | Phase 2 | REQ-031-035 |
| REQ-037 | Legal Hold Capability | P1 | Phase 2 | REQ-031 |
| REQ-038 | Audit Dashboard | P1 | Phase 2 | REQ-031-037 |
| REQ-039 | Person Account Model | P0 | Phase 1 | REQ-005 |
| REQ-040 | Hierarchical Relationships | P0 | Phase 1 | REQ-039 |
| REQ-041 | Pharma-Specific Attributes | P0 | Phase 1 | REQ-039 |
| REQ-042 | Data Quality Rules | P0 | Phase 1 | REQ-005 |
| REQ-043 | Duplicate Detection | P0 | Phase 1 | REQ-042 |
| REQ-044 | Deterministic Matching | P0 | Phase 1 | REQ-006 |
| REQ-045 | Probabilistic Matching | P1 | Phase 2 | REQ-044 |
| REQ-046 | Device Graph | P1 | Phase 2 | REQ-006 |
| REQ-047 | Cross-Domain Tracking | P1 | Phase 2 | REQ-006 |
| REQ-048 | Anonymous-to-Known Resolution | P1 | Phase 2 | REQ-006 |
| REQ-049 | Household Clustering | P2 | Phase 3 | REQ-045 |
| REQ-050 | Naming Convention Standards | P0 | Phase 1 | REQ-001 |
| REQ-051 | Campaign Hierarchy | P0 | Phase 1 | REQ-050 |
| REQ-052 | UTM Parameter Standards | P0 | Phase 1 | REQ-050 |
| REQ-053 | Content Metadata Schema | P0 | Phase 1 | REQ-050 |
| REQ-054 | Creative Versioning | P1 | Phase 2 | REQ-053 |
| REQ-055 | Placement Taxonomy | P1 | Phase 2 | REQ-050 |
| REQ-056 | Preference Center | P0 | Phase 1 | REQ-005 |
| REQ-057 | Opt-In/Out Workflow | P0 | Phase 1 | REQ-056 |
| REQ-058 | Channel-Specific Consent | P0 | Phase 1 | REQ-056 |
| REQ-059 | Purpose-Based Consent | P1 | Phase 2 | REQ-056 |
| REQ-060 | Consent Propagation Service | P0 | Phase 1 | REQ-056 |
| REQ-061 | Consent Enforcement API | P0 | Phase 1 | REQ-060 |
| REQ-062 | Consent Reporting Dashboard | P1 | Phase 2 | REQ-056-061 |

---

## SWIMLANE B: SEGMENT

### Swimlane Purpose

Build, maintain, and activate customer segments based on demographic attributes, behavioral signals, clinical characteristics, engagement history, and predictive scores to enable personalized marketing across all channels and customer lifecycles.

### Business Context

Pharmaceutical marketing requires sophisticated segmentation that goes far beyond traditional demographic targeting. Healthcare providers vary dramatically in prescribing behavior, therapeutic specialization, institutional affiliations, and receptivity to different engagement approaches. Patients segment by disease stage, treatment history, insurance coverage, health literacy, and support needs. The average pharmaceutical brand maintains 40-60 active segments representing distinct engagement strategies. Without robust segmentation infrastructure, organizations default to mass marketing approaches that waste budget on low-propensity audiences while under-engaging high-value targets. Research demonstrates that properly segmented pharmaceutical campaigns achieve conversion rates 3-5 times higher than unsegmented approaches, with customer acquisition costs reduced by 40-60%. The proposed segmentation framework combines demographic, behavioral, and predictive attributes to enable precision targeting while maintaining privacy compliance and audit readiness.

### Primary Systems

- Salesforce Sales Cloud (demographic and firmographic attributes)  
- Salesforce Data Cloud (unified profile and real-time segmentation)  
- Analytics warehouse (Snowflake, BigQuery, or Redshift for propensity modeling)  
- Journey orchestration platform (Marketing Cloud Engagement, Braze, or Iterable)

### Key Capabilities

**Capability 1: Demographic and Firmographic Segmentation**

**Detailed Requirements:**

- REQ-063: Demographic segmentation supporting age bands, gender, geography, language preference, income proxies, and education level with HIPAA-compliant data handling for patient segments.  
- REQ-064: Healthcare provider segmentation incorporating specialty, subspecialty, years in practice, practice setting (academic medical center, community hospital, private practice, clinic), prescribing volume, and formulary influence metrics.  
- REQ-065: Institutional account segmentation covering hospital system size, teaching status, technology adoption maturity, payer mix, and therapeutic area focus enabling account-based marketing strategies.  
- REQ-066: Payer and pharmacy segmentation distinguishing commercial insurance, Medicare Part D, Medicaid managed care, Pharmacy Benefit Managers (PBMs), specialty pharmacies, and retail chains with coverage and formulary attributes.  
- REQ-067: Geographic segmentation at country, region, state, metropolitan statistical area, ZIP code, and territory levels supporting field-aligned campaigns and regulatory jurisdiction compliance.  
- REQ-068: Segment definition interface allowing business users to build segments using intuitive filters, boolean logic, and nested conditions without SQL knowledge.

**Business Rationale:** Demographic and firmographic attributes form the foundation of all segmentation strategies. Healthcare provider specialty determines message relevance, with oncologists requiring different content than primary care physicians. Practice setting influences channel preference, with academic physicians more responsive to medical education while community practitioners prioritize efficiency. Geographic segmentation enables compliance with state-specific regulations and alignment with field sales territories. Research shows that specialty-aligned messaging improves engagement rates by 65% compared to generic outreach. The proposed demographic segmentation framework provides comprehensive attributes while maintaining flexibility for therapeutic area-specific requirements.

**Swimlane Alignment:** Swimlane B (Segment)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-005 (customer master data), REQ-039 (person account model), REQ-041 (pharma-specific attributes)

**Acceptance Criteria:**

- All demographic and firmographic attributes available in segment builder  
- Segment creation interface accessible to marketing users with minimal training  
- Segment definition validation preventing invalid logic combinations  
- Real-time segment size estimation during definition process

**Success Metrics:**

- Segment creation time: Under thirty minutes for standard segments  
- Segment definition error rate: Less than five percent requiring technical intervention  
- User adoption: Over 80% of marketers creating own segments within 90 days  
- Segment accuracy: Over 95% match between estimated and actual size

---

**Capability 2: Behavioral and Engagement Segmentation**

**Detailed Requirements:**

- REQ-069: Web and mobile engagement scoring incorporating page views, time on site, content downloads, video views, form submissions, and repeat visit frequency with recency weighting.  
- REQ-070: Email engagement segmentation tracking open rates, click rates, forward activity, unsubscribe events, and spam complaints by message type and therapeutic area with trend analysis.  
- REQ-071: Event participation tracking covering conference attendance, webinar registration and attendance, speaker program participation, advisory board membership, and Continuing Medical Education (CME) completion.  
- REQ-072: Sales interaction history including field representative visits, samples provided, speaker programs attended, and prescribing behavior changes following interactions.  
- REQ-073: Patient support program engagement tracking enrollment, medication adherence, copay assistance utilization, nurse educator touchpoints, and outcomes achievement.  
- REQ-074: Content consumption patterns analyzing which therapeutic areas, content formats, claim types, and creative approaches resonate with each customer segment.  
- REQ-075: Multi-channel engagement scoring combining digital, field, event, and patient program touchpoints into unified engagement indices with customizable weighting by segment type.  
- REQ-076: Engagement velocity metrics detecting acceleration or deceleration in activity patterns triggering automated responses or alerts.

**Business Rationale:** Behavioral data reveals customer intent and receptivity far more accurately than demographic attributes alone. An HCP who downloads clinical guidelines, attends webinars, and requests field visits demonstrates high engagement regardless of specialty or practice setting. Conversely, customers who consistently ignore outreach require different strategies or removal from active campaigns. Behavioral segmentation enables journey optimization, with high-engagement customers fast-tracked to conversion while low-engagement audiences receive re-engagement campaigns or suppression. Research demonstrates that behaviorally targeted campaigns achieve response rates 40-50% higher than demographically targeted equivalents. Patient adherence data particularly drives outcomes-based segmentation enabling early intervention for at-risk individuals. The proposed behavioral segmentation framework captures the full spectrum of engagement signals across all channels and interaction types.

**Swimlane Alignment:** Swimlane B (Segment), Swimlane F (Measure & Learn)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-024 through REQ-030 (event collection and measurement infrastructure), REQ-063 through REQ-068 (demographic segmentation foundation)

**Acceptance Criteria:**

- Behavioral scoring models deployed for all major customer types  
- Engagement data flowing from all channels with less than four-hour latency  
- Segment refresh frequency supporting near-real-time activation  
- Historical behavior analysis available for minimum twelve-month lookback

**Success Metrics:**

- Behavioral data completeness: Over 90% of active customers with engagement scores  
- Scoring model accuracy: Correlation coefficient over 0.7 between engagement score and conversion probability  
- Segment performance lift: Twenty-five percent higher conversion rate for high-engagement segments versus low-engagement  
- Data latency: Behavioral updates reflected in segments within four hours

---

**Capability 3: Propensity Modeling and Predictive Segmentation**

**Detailed Requirements:**

- REQ-077: Propensity-to-prescribe models predicting likelihood of HCP initiating therapy with specific products based on historical prescribing patterns, patient panel characteristics, and peer influence.  
- REQ-078: Patient adherence prediction models identifying individuals at risk of discontinuation based on refill patterns, side effect reporting, program engagement, and socioeconomic factors.  
- REQ-079: Next-best-action recommendation engine suggesting optimal message, offer, channel, and timing for each customer based on their current journey stage and response history.  
- REQ-080: Churn prediction models detecting early warning signals of disengagement enabling proactive retention campaigns.  
- REQ-081: Lifetime value modeling estimating total expected revenue contribution from each customer relationship guiding investment prioritization.  
- REQ-082: Lookalike audience generation identifying prospective customers sharing characteristics with high-value existing customers for acquisition campaigns.  
- REQ-083: Model registry maintaining metadata for all predictive models including algorithm type, training data, features, performance metrics, last update date, and governance approval status.  
- REQ-084: Model monitoring and retraining workflows detecting performance degradation and triggering periodic model refreshes with A/B testing before production deployment.  
- REQ-085: Explainability and transparency features providing marketers with interpretation of model predictions including top contributing factors and confidence intervals.

**Business Rationale:** Predictive modeling transforms segmentation from reactive description to proactive prescription. Traditional segmentation describes who customers are, while predictive segmentation predicts what they will do. This enables targeting high-propensity audiences before competitors, intervening with at-risk patients before they discontinue therapy, and optimizing marketing investment toward highest lifetime value relationships. Pharmaceutical applications of predictive modeling show particularly strong results due to structured data availability, clear outcome definitions, and lengthy customer lifecycles providing rich behavioral signals. Organizations implementing propensity modeling report 20-30% improvement in campaign ROI, 15-20% reduction in patient discontinuation rates, and 40-50% more efficient allocation of field sales resources. The proposed predictive framework balances model sophistication with business interpretability, ensuring marketers understand and trust model recommendations.

**Swimlane Alignment:** Swimlane B (Segment), Swimlane F (Measure & Learn)

**Priority:** P1 \- Advanced capability (Phase 2-3)

**Dependencies:** REQ-063 through REQ-076 (demographic and behavioral segmentation providing model features), warehouse infrastructure with historical data minimum twelve months

**Acceptance Criteria:**

- Propensity models deployed for priority therapeutic areas and customer segments  
- Model accuracy meeting minimum thresholds: Area Under Curve (AUC) over 0.7 for binary classification, R-squared over zero point four for continuous predictions  
- Model refresh cadence established with quarterly retraining minimum  
- Business user interface providing score interpretation without requiring data science expertise

**Success Metrics:**

- Model adoption: Over 60% of campaigns using propensity scores for targeting within six months of deployment  
- Predictive lift: High-propensity deciles achieving conversion rates minimum two times higher than low-propensity deciles  
- Business value: Documented ROI improvement of minimum 20% for propensity-targeted campaigns versus demographic-only targeting  
- Model governance: Zero unauthorized model deployments, 100% documentation compliance

---

**Capability 4: Real-Time Segmentation and Dynamic Audiences**

**Detailed Requirements:**

- REQ-086: Real-time segment evaluation engine processing behavioral signals and updating segment membership within minutes of triggering events.  
- REQ-087: Event-driven segment entry and exit rules responding to specific actions such as form submissions, content downloads, prescription events, or program enrollments.  
- REQ-088: Streaming data integration consuming events from web, mobile, email, CRM, and patient programs in real-time for immediate segment updates.  
- REQ-089: Dynamic audience synchronization pushing segment changes to execution platforms enabling immediate journey progression or message personalization.  
- REQ-090: Segment membership history tracking when customers enter and exit segments providing longitudinal behavior analysis.  
- REQ-091: Overlap analysis identifying customers belonging to multiple segments enabling conflict resolution and prioritization logic.  
- REQ-092: Segment performance analytics comparing conversion rates, engagement metrics, and ROI across segments informing optimization decisions.

**Business Rationale:** Traditional batch-oriented segmentation creates delays between customer actions and marketing responses. When an HCP attends a webinar or a patient enrolls in a support program, immediate follow-up dramatically improves conversion probability. Research shows response rates decline by 50% or more when follow-up occurs more than 24 hours after triggering events. Real-time segmentation enables instant journey progression, immediate next-best-action delivery, and dynamic content personalization based on current behavior rather than yesterday's batch refresh. The proposed real-time architecture balances immediacy with system scalability, enabling sub-minute response times for priority segments while maintaining cost-effective batch processing for stable demographic segments.

**Swimlane Alignment:** Swimlane B (Segment), Swimlane D (Orchestrate)

**Priority:** P1 \- Advanced capability (Phase 2\)

**Dependencies:** REQ-006 (Data Cloud real-time processing), REQ-069 through REQ-076 (behavioral data collection), REQ-086 through REQ-092 streaming infrastructure

**Acceptance Criteria:**

- Real-time segment evaluation deployed for priority use cases  
- Segment membership updates propagating to journey engine within 15 minutes of qualifying events  
- Streaming pipeline processing minimum ten thousand events per second at peak load  
- Segment update latency under 5 minutes measured at 95th percentile

**Success Metrics:**

- Real-time segment coverage: Over 50% of active customers in at least one real-time evaluated segment  
- Latency performance: Ninety-five percent of segment updates within target SLA  
- Conversion lift: Real-time triggered journeys achieving 25% higher conversion than batch-triggered equivalents  
- System reliability: Segment evaluation service uptime over ninety-nine point five percent

---

### Summary: Swimlane B Requirements Catalog

| Requirement ID | Requirement Title | Priority | Phase | Dependencies |
| :---- | :---- | :---- | :---- | :---- |
| REQ-063 | Demographic Segmentation | P0 | Phase 1 | REQ-005, 039, 041 |
| REQ-064 | HCP Segmentation | P0 | Phase 1 | REQ-063 |
| REQ-065 | Institutional Segmentation | P0 | Phase 1 | REQ-063 |
| REQ-066 | Payer/Pharmacy Segmentation | P1 | Phase 2 | REQ-063 |
| REQ-067 | Geographic Segmentation | P0 | Phase 1 | REQ-063 |
| REQ-068 | Segment Builder Interface | P0 | Phase 1 | REQ-063-067 |
| REQ-069 | Web/Mobile Engagement Scoring | P0 | Phase 1 | REQ-024-030 |
| REQ-070 | Email Engagement Segmentation | P0 | Phase 1 | REQ-069 |
| REQ-071 | Event Participation Tracking | P1 | Phase 2 | REQ-069 |
| REQ-072 | Sales Interaction History | P1 | Phase 2 | REQ-069 |
| REQ-073 | Patient Program Engagement | P1 | Phase 2 | REQ-069 |
| REQ-074 | Content Consumption Patterns | P1 | Phase 2 | REQ-069 |
| REQ-075 | Multi-Channel Engagement Score | P1 | Phase 2 | REQ-069-074 |
| REQ-076 | Engagement Velocity Metrics | P2 | Phase 3 | REQ-075 |
| REQ-077 | Propensity-to-Prescribe Models | P1 | Phase 2 | REQ-063-076 |
| REQ-078 | Patient Adherence Prediction | P1 | Phase 2 | REQ-077 |
| REQ-079 | Next-Best-Action Engine | P2 | Phase 3 | REQ-077-078 |
| REQ-080 | Churn Prediction Models | P2 | Phase 3 | REQ-077 |
| REQ-081 | Lifetime Value Modeling | P2 | Phase 3 | REQ-077 |
| REQ-082 | Lookalike Audience Generation | P2 | Phase 3 | REQ-077 |
| REQ-083 | Model Registry | P1 | Phase 2 | REQ-077 |
| REQ-084 | Model Monitoring/Retraining | P1 | Phase 2 | REQ-083 |
| REQ-085 | Model Explainability | P1 | Phase 2 | REQ-083 |
| REQ-086 | Real-Time Segment Evaluation | P1 | Phase 2 | REQ-006, 069-076 |
| REQ-087 | Event-Driven Rules | P1 | Phase 2 | REQ-086 |
| REQ-088 | Streaming Data Integration | P1 | Phase 2 | REQ-086 |
| REQ-089 | Dynamic Audience Sync | P1 | Phase 2 | REQ-086 |
| REQ-090 | Segment Membership History | P1 | Phase 2 | REQ-086 |
| REQ-091 | Overlap Analysis | P2 | Phase 3 | REQ-086 |
| REQ-092 | Segment Performance Analytics | P1 | Phase 2 | REQ-086 |

---

## SWIMLANE C: CREATE

### Swimlane Purpose

Develop, approve, version, and distribute marketing content and creative assets across all channels ensuring regulatory compliance, claim substantiation, brand consistency, and measurement readiness throughout the content lifecycle.

### Business Context

Content creation in pharmaceutical marketing faces unique constraints absent in other industries. Every claim requires documented evidence from clinical trials or approved labeling. Medical, legal, and regulatory teams must review and approve materials before deployment. Content must balance fair presentation of efficacy and safety information. Off-label promotion carries severe penalties. Approved content has expiry dates requiring periodic renewal. These requirements create complex workflows involving multiple stakeholders, extended review cycles, and comprehensive version control. The typical pharmaceutical marketing asset undergoes four to six review iterations over six to eight weeks before approval. Without robust content management infrastructure, organizations experience approval bottlenecks, version control failures, expired content deployment, and compliance violations. The proposed content creation framework embeds regulatory requirements into workflow automation, links content to substantiated claims, maintains complete audit trails, and enables efficient collaboration between creative teams and compliance reviewers.

### Primary Systems

- Digital asset management system (DAM)  
- Claravine (content metadata governance)  
- Salesforce (MLR approval workflow, claim registry)  
- Veeva Vault or equivalent (regulatory document management)

### Key Capabilities

**Capability 1: Content Planning and Brief Management**

**Detailed Requirements:**

- REQ-093: Campaign brief template capturing objectives, target audiences, key messages, claims to be included, channel mix, budget allocation, timeline, and success metrics with mandatory field enforcement.  
- REQ-094: Content request workflow routing briefs to appropriate creative teams, agencies, or vendors based on content type, therapeutic area, and brand assignment.  
- REQ-095: Brief approval process requiring brand lead, medical affairs, and legal preliminary review before creative development begins preventing wasted effort on non-compliant concepts.  
- REQ-096: Claim selection interface allowing brief creators to choose from approved ClaimID registry ensuring only substantiated claims appear in content requirements.  
- REQ-097: Reference material attachment capability linking briefs to clinical data, competitor analysis, brand guidelines, and previous campaign examples.  
- REQ-098: Brief status tracking dashboard showing all active briefs, assigned teams, current stage, and overdue items with automated escalation.

**Business Rationale:** Comprehensive creative briefs prevent the most common source of MLR rejection: misalignment between creative concepts and regulatory requirements. When briefs clearly specify which claims can be made, which evidence supports those claims, and which audiences can receive messages, creative teams develop compliant materials from the start. Research shows campaigns beginning with detailed regulatory-aware briefs achieve first-pass MLR approval rates over 70% compared to 35% for campaigns with incomplete briefs. This reduces time-to-market by 4-6 weeks and eliminates costly creative rework. The proposed brief management framework ensures complete context reaches creative teams while capturing strategic rationale for campaign decisions.

**Swimlane Alignment:** Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-010 (ClaimID data model), REQ-050 through REQ-053 (campaign taxonomy)

**Acceptance Criteria:**

- Brief template deployed with all mandatory fields  
- Brief workflow integrated with Salesforce campaign objects  
- Claim selection interface pulling from approved ClaimID registry  
- Brief approval workflow requiring medical and legal sign-off before creative development

**Success Metrics:**

- Brief completion rate: Over 90% of campaigns with complete briefs before creative development  
- First-pass MLR approval rate: Over 60% for campaigns with approved briefs versus under 40% without  
- Time-to-market improvement: Four weeks faster for brief-driven campaigns  
- Brief abandonment rate: Under ten percent of initiated briefs failing to progress

---

**Capability 2: Content Creation and Collaboration**

**Detailed Requirements:**

- REQ-099: Integrated creative workspace supporting in-platform editing, commenting, markup, and version comparison for documents, presentations, emails, web pages, and video scripts.  
- REQ-100: Template library providing brand-compliant starting points for common content types including detail aids, leave-behinds, email campaigns, landing pages, and social media with pre-approved design elements.  
- REQ-101: Component library storing reusable content blocks, approved disclaimers, fair balance statements, reference citations, and legal boilerplate for assembly into new assets.  
- REQ-102: Real-time collaboration enabling simultaneous editing by creative teams, copywriters, designers, and medical reviewers with conflict resolution and change attribution.  
- REQ-103: Inline commenting and markup tools allowing reviewers to annotate specific text, images, or design elements with suggested changes, questions, or approval notes.  
- REQ-104: Version control automatically preserving every iteration with restore capability, visual comparison between versions, and change history attribution.  
- REQ-105: Asset preview and proofing across devices and channels showing how content renders on desktop, mobile, tablet, email clients, and print formats before finalization.  
- REQ-106: Reference citation management ensuring every claim links to supporting evidence with automatic formatting and numbering.

**Business Rationale:** Fragmented creative workflows using email attachments, shared drives, and multiple tools create version confusion, lost feedback, and delayed approvals. When medical reviewers provide feedback via email while legal comments appear in separate documents, consolidating changes becomes error-prone and time-consuming. Integrated collaboration platforms reduce review cycle time by 40-60% by eliminating coordination overhead, preventing version conflicts, and maintaining complete context. The pharmaceutical industry particularly benefits from inline commenting allowing medical reviewers to mark specific claims requiring evidence while legal reviewers flag promotional imbalance without disrupting creative flow. Organizations implementing collaborative creative platforms report 50% reduction in MLR cycle time and 75% reduction in version control incidents.

**Swimlane Alignment:** Swimlane C (Create)

**Priority:** P1 \- Enhanced capability (Phase 2\)

**Dependencies:** REQ-093 through REQ-098 (brief management foundation), DAM system deployment

**Acceptance Criteria:**

- Collaborative workspace deployed for priority content types  
- Template library containing minimum twenty approved templates across key formats  
- Version control maintaining complete history for all assets  
- Cross-device preview supporting desktop, mobile, and tablet rendering

**Success Metrics:**

- User adoption: Over 70% of content creators using collaborative workspace within 90 days  
- Review cycle time: Forty percent reduction versus baseline email-based process  
- Version control incidents: Under five per quarter  
- Template usage: Over 60% of new content starting from approved templates

---

**Capability 3: Content-to-Claim Mapping and Substantiation**

**Detailed Requirements:**

- REQ-107: Content registration workflow requiring creators to declare all ClaimIDs referenced in each asset before submission to MLR review.  
- REQ-108: Automated claim detection analyzing content text to identify potential claims and suggesting appropriate ClaimIDs from registry.  
- REQ-109: Evidence linking interface connecting each ClaimID to supporting clinical data, package inserts, FDA-approved labeling, or published literature.  
- REQ-110: Fair balance validation checking that risk information receives prominence proportional to efficacy claims with flagging of imbalanced content.  
- REQ-111: Indication alignment verification confirming that claims match approved indications and do not suggest off-label use.  
- REQ-112: Reference list generation automatically compiling bibliography of supporting evidence for each asset with proper formatting.  
- REQ-113: Claim usage tracking showing which content assets reference which claims enabling impact analysis when claims expire or require updates.  
- REQ-114: Visual claim mapping interface displaying relationships between content, claims, evidence, and products in graphical format.

**Business Rationale:** The FDA requires that every promotional claim be truthful, balanced, and substantiated by adequate evidence. Failure to link claims to supporting data represents the most common category of FDA enforcement actions. The 2019 FDA untitled letters included 37 instances of unsubstantiated claims or lack of substantial evidence. Each violation risks warning letters, corrective actions, and damage to company reputation. Content-to-claim mapping creates defensible audit trails showing exactly which evidence supports which promotional statements. This enables proactive compliance verification, facilitates regulatory submissions, and supports rapid response to FDA inquiries. Organizations with mature claim substantiation systems experience 75% fewer FDA observations related to promotional claims and resolve inquiries 60% faster due to immediately available documentation.

**Swimlane Alignment:** Swimlane C (Create), Swimlane A (Govern)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-010 (ClaimID data model), REQ-035 (claim substantiation vault)

**Acceptance Criteria:**

- Content-to-claim mapping required for all promotional assets before MLR submission  
- Claim detection algorithm identifying potential claims with over 70% accuracy  
- Evidence linking interface providing one-click access to supporting documentation  
- Fair balance validation flagging assets with risk-benefit presentation imbalance

**Success Metrics:**

- Claim mapping completeness: One hundred percent of promotional assets with declared ClaimIDs  
- Substantiation documentation: One hundred percent of claims with linked evidence  
- FDA observations: Zero related to unsubstantiated claims in first year  
- MLR rejection rate: Under 20% for claim-related issues versus historical 40%

---

**Capability 4: MLR Review Workflow and Approval Management**

**Detailed Requirements:**

- REQ-115: Multi-stage MLR workflow orchestrating parallel medical review, legal review, and regulatory review with configurable routing based on content type, therapeutic area, and risk level.  
- REQ-116: Role-based access control ensuring reviewers see only content relevant to their function with appropriate permissions for commenting, requesting changes, approving, or rejecting.  
- REQ-117: Review task management providing reviewers with dashboard of pending assignments, priority indicators, due dates, and escalation alerts.  
- REQ-118: Structured comment taxonomy categorizing feedback as major change required, minor revision suggested, question for clarification, or approval granted enabling systematic resolution tracking.  
- REQ-119: Change request workflow routing revisions back to creative teams with context preservation and preventing reviewers from directly editing content.  
- REQ-120: Approval status tracking showing real-time progress through review stages with automated notifications at milestones and bottlenecks.  
- REQ-121: Conditional approval capability allowing reviewers to approve content contingent on specific changes with verification before final release.  
- REQ-122: Escalation rules automatically routing overdue reviews to management with configurable timeframes and escalation paths.  
- REQ-123: Review metrics dashboard reporting average review times, approval rates, rejection reasons, and reviewer workload by team and individual.

**Business Rationale:** MLR workflow inefficiency represents the primary bottleneck in pharmaceutical marketing operations. The average MLR cycle spans six to eight weeks with much time consumed by coordination overhead rather than actual review. Assets sit in queues waiting for reviewer availability. Feedback from different reviewers conflicts requiring mediation. Creative teams wait days for minor clarification questions. Automated workflow orchestration eliminates coordination friction, ensures accountability, and accelerates decision-making. Organizations implementing structured MLR workflows report 50-60% reduction in total review time, 40% improvement in first-pass approval rates through better feedback quality, and 70% reduction in escalated disputes. The proposed workflow framework balances rigor with efficiency enabling faster time-to-market without compromising compliance standards.

**Swimlane Alignment:** Swimlane C (Create), Swimlane A (Govern)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-010 through REQ-017 (compliance framework), REQ-107 through REQ-114 (content-to-claim mapping)

**Acceptance Criteria:**

- MLR workflow deployed in Salesforce with parallel review capability  
- Reviewer dashboards providing visibility to pending tasks and overdue items  
- Automated routing rules configured for all content types and therapeutic areas  
- Escalation alerts triggering at appropriate intervals with management notification

**Success Metrics:**

- MLR cycle time: Under four weeks median for standard content versus six to eight week baseline  
- First-pass approval rate: Over 50% versus historical 35%  
- Overdue review rate: Under ten percent of assignments exceeding SLA  
- Reviewer satisfaction: Over seven out of ten rating workflow usability

---

**Capability 5: Content Versioning, Distribution, and Expiry Management**

**Detailed Requirements:**

- REQ-124: Immutable version archiving preserving every iteration of every asset with metadata including version number, creation date, creator, approval status, and change description.  
- REQ-125: Major and minor versioning scheme distinguishing substantive changes requiring MLR re-review from minor corrections not affecting claims or compliance.  
- REQ-126: Approved version locking preventing editing of MLR-approved content without initiating new version and review cycle.  
- REQ-127: Content distribution workflow pushing approved assets to execution platforms, agency partners, field sales teams, and digital channels with usage tracking.  
- REQ-128: Expiry date enforcement automatically retiring content when linked ClaimIDs approach expiration or when specified content shelf-life elapses.  
- REQ-129: Expiry warning notifications alerting content owners 30 days, seven days, and one day before content expires enabling proactive replacement planning.  
- REQ-130: Auto-pause mechanism preventing expired content from appearing in active campaigns with override requiring documented legal justification.  
- REQ-131: Content usage analytics tracking impressions, engagement metrics, and performance by version enabling optimization decisions.  
- REQ-132: Content audit trail maintaining complete history of approvals, distributions, usage, and retirement for regulatory inspection readiness.

**Business Rationale:** Expired content deployment represents a critical compliance risk. When claims lose substantiation due to new clinical data, expired patents, or updated labeling, previously approved content becomes non-compliant. The FDA expects companies to maintain surveillance systems preventing distribution of outdated materials. Manual tracking fails at scale with organizations typically managing five hundred to one thousand active content assets across dozens of campaigns and channels. Automated expiry enforcement prevents violations before they occur. Content usage tracking enables ROI analysis and continuous optimization. Complete audit trails support regulatory inspections and legal discovery. Organizations with mature content lifecycle management report zero incidents of expired content deployment, 60% improvement in content utilization through better discoverability, and 40% reduction in content development costs through systematic reuse and optimization.

**Swimlane Alignment:** Swimlane C (Create), Swimlane A (Govern), Swimlane E (Execute)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-010 (ClaimID expiry tracking), REQ-124 through REQ-132 (versioning and distribution foundation)

**Acceptance Criteria:**

- Version control maintaining complete history for all assets  
- Expiry date tracking implemented for all content linked to ClaimIDs  
- Automated warnings triggering at thirty-day, seven-day, and one-day intervals before expiry  
- Auto-pause preventing expired content activation with zero tolerance

**Success Metrics:**

- Expired content incidents: Zero deployments of expired materials  
- Content findability: Over 80% of users locating needed assets within three minutes  
- Version control integrity: One hundred percent of assets with complete change history  
- Content reuse rate: Over 40% of campaigns using previously approved components

---

### Summary: Swimlane C Requirements Catalog

| Requirement ID | Requirement Title | Priority | Phase | Dependencies |
| :---- | :---- | :---- | :---- | :---- |
| REQ-093 | Campaign Brief Template | P0 | Phase 1 | REQ-010, 050-053 |
| REQ-094 | Content Request Workflow | P0 | Phase 1 | REQ-093 |
| REQ-095 | Brief Approval Process | P0 | Phase 1 | REQ-093 |
| REQ-096 | Claim Selection Interface | P0 | Phase 1 | REQ-010 |
| REQ-097 | Reference Material Attachment | P1 | Phase 2 | REQ-093 |
| REQ-098 | Brief Status Dashboard | P1 | Phase 2 | REQ-093-097 |
| REQ-099 | Creative Workspace | P1 | Phase 2 | REQ-093 |
| REQ-100 | Template Library | P1 | Phase 2 | DAM deployment |
| REQ-101 | Component Library | P1 | Phase 2 | REQ-100 |
| REQ-102 | Real-Time Collaboration | P1 | Phase 2 | REQ-099 |
| REQ-103 | Inline Commenting | P1 | Phase 2 | REQ-099 |
| REQ-104 | Version Control | P0 | Phase 1 | DAM deployment |
| REQ-105 | Asset Preview | P1 | Phase 2 | REQ-099 |
| REQ-106 | Citation Management | P1 | Phase 2 | REQ-035 |
| REQ-107 | Content Registration | P0 | Phase 1 | REQ-010 |
| REQ-108 | Automated Claim Detection | P2 | Phase 3 | REQ-107 |
| REQ-109 | Evidence Linking | P0 | Phase 1 | REQ-035 |
| REQ-110 | Fair Balance Validation | P1 | Phase 2 | REQ-107 |
| REQ-111 | Indication Alignment | P1 | Phase 2 | REQ-010 |
| REQ-112 | Reference List Generation | P1 | Phase 2 | REQ-109 |
| REQ-113 | Claim Usage Tracking | P1 | Phase 2 | REQ-107 |
| REQ-114 | Visual Claim Mapping | P2 | Phase 3 | REQ-107-113 |
| REQ-115 | Multi-Stage MLR Workflow | P0 | Phase 1 | REQ-010-017 |
| REQ-116 | Role-Based Access Control | P0 | Phase 1 | REQ-115 |
| REQ-117 | Review Task Management | P0 | Phase 1 | REQ-115 |
| REQ-118 | Structured Comment Taxonomy | P1 | Phase 2 | REQ-115 |
| REQ-119 | Change Request Workflow | P0 | Phase 1 | REQ-115 |
| REQ-120 | Approval Status Tracking | P0 | Phase 1 | REQ-115 |
| REQ-121 | Conditional Approval | P1 | Phase 2 | REQ-115 |
| REQ-122 | Escalation Rules | P1 | Phase 2 | REQ-115 |
| REQ-123 | Review Metrics Dashboard | P1 | Phase 2 | REQ-115 |
| REQ-124 | Version Archiving | P0 | Phase 1 | DAM deployment |
| REQ-125 | Version Scheme | P0 | Phase 1 | REQ-124 |
| REQ-126 | Approved Version Locking | P0 | Phase 1 | REQ-124 |
| REQ-127 | Content Distribution | P0 | Phase 1 | REQ-124 |
| REQ-128 | Expiry Date Enforcement | P0 | Phase 1 | REQ-010 |
| REQ-129 | Expiry Warnings | P0 | Phase 1 | REQ-128 |
| REQ-130 | Auto-Pause Mechanism | P0 | Phase 1 | REQ-128 |
| REQ-131 | Usage Analytics | P1 | Phase 2 | REQ-127 |
| REQ-132 | Content Audit Trail | P0 | Phase 1 | REQ-124-131 |

---

## SWIMLANE D: ORCHESTRATE

### Swimlane Purpose

Design, configure, execute, and optimize multi-step customer journeys across channels coordinating message delivery, channel selection, timing optimization, fatigue management, experimentation, and compliance enforcement throughout the customer lifecycle.

### Business Context

Modern pharmaceutical marketing requires orchestrating complex multi-touch journeys spanning months or years across email, web, mobile, field sales, patient programs, and third-party channels. The average HCP decision journey includes 15-25 touchpoints before prescribing behavior changes. Patient adherence journeys require ongoing engagement through medication initiation, side effect management, and long-term persistence. Without journey orchestration infrastructure, organizations default to disconnected campaigns creating disjointed customer experiences, channel conflicts, and message fatigue. Research demonstrates orchestrated journeys achieve conversion rates 40-60% higher than single-touch campaigns while reducing total marketing touchpoints by 30% through intelligent sequencing and fatigue management. The proposed orchestration framework provides visual journey design, cross-channel execution, real-time optimization, and embedded compliance controls enabling sophisticated engagement strategies at enterprise scale.

### Primary Systems

- Salesforce Marketing Cloud Engagement (or Braze/Iterable for high-volume consumer messaging)  
- Salesforce Sales Cloud (journey definition and customer context)  
- Central fatigue management service  
- Experimentation and optimization engine

### Key Capabilities

**Capability 1: Visual Journey Design and Authoring**

**Detailed Requirements:**

- REQ-133: Lightning Web Component journey canvas providing drag-and-drop interface for designing multi-step journeys with intuitive flow visualization.  
- REQ-134: Node library supporting message delivery, wait steps, decision splits, A/B tests, holdout groups, channel selection, fatigue checks, MLR gates, and custom actions.  
- REQ-135: Journey versioning maintaining complete history of journey configurations with the ability to restore previous versions or clone journeys for new campaigns.  
- REQ-136: Template library providing proven journey patterns for common use cases including awareness campaigns, nurture sequences, conversion funnels, onboarding flows, and retention programs.  
- REQ-137: Visual flow validation detecting configuration errors, orphaned nodes, infinite loops, missing required fields, and compliance gaps before activation.  
- REQ-138: Journey simulation capability allowing marketers to test journeys with sample customer profiles showing expected flow paths and message delivery.  
- REQ-139: Journey documentation generator automatically creating specification documents describing objectives, target audience, message sequence, decision logic, and success metrics for MLR review.  
- REQ-140: Collaboration features enabling multiple users to co-author journeys with comment threads, change tracking, and approval workflows.

**Business Rationale:** Traditional journey design requires technical resources to translate business requirements into execution code creating bottlenecks and delays. Visual authoring democratizes journey design enabling business users to configure sophisticated engagement strategies without IT dependency. Organizations implementing visual journey designers report 70% reduction in journey launch time, 60% increase in journey creation by business users, and 40% improvement in journey optimization velocity. The pharmaceutical industry particularly benefits from embedded compliance controls preventing non-compliant journey configurations and generating documentation supporting MLR review. The proposed Lightning Web Component approach integrates natively with Salesforce providing seamless access to customer data, campaign context, and approval workflows while maintaining flexibility for hybrid architectures using Braze or Iterable for high-volume execution.

**Swimlane Alignment:** Swimlane D (Orchestrate)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-005 (customer data foundation), REQ-063 through REQ-092 (segmentation capabilities)

**Acceptance Criteria:**

- Journey canvas deployed as Lightning Web Component in Salesforce  
- Node library containing minimum twenty node types covering common use cases  
- Journey versioning maintaining complete configuration history  
- Visual validation detecting configuration errors before activation

**Success Metrics:**

- Business user adoption: Over 60% of journeys designed by marketers without technical assistance within six months  
- Journey launch velocity: Seventy percent reduction in time from concept to activation  
- Configuration error rate: Under 5% of journeys requiring technical remediation  
- User satisfaction: Over 8 out of 10 rating design interface usability

---

**Capability 2: Intelligent Message Delivery and Channel Orchestration**

**Detailed Requirements:**

- REQ-141: Multi-channel message routing delivering content via email, SMS, push notifications, in-app messages, direct mail, field sales actions, and third-party platforms from unified journey definition.  
- REQ-142: Channel preference honoring allowing customers to specify preferred communication channels with automatic routing to preferred methods when available.  
- REQ-143: Channel fallback logic attempting secondary channels when primary channels fail due to invalid addresses, hard bounces, or opt-out status.  
- REQ-144: Send-time optimization analyzing individual engagement patterns to determine optimal delivery times maximizing open and click probability.  
- REQ-145: Frequency capping limiting total messages per customer per day, week, and month across all campaigns preventing saturation.  
- REQ-146: Message prioritization ranking journeys and campaigns by business importance with quota allocation ensuring high-priority messages deliver when capacity constraints exist.  
- REQ-147: Real-time personalization inserting dynamic content based on customer attributes, behavior history, and contextual signals at moment of delivery.  
- REQ-148: Delivery status tracking monitoring message processing, delivery confirmation, bounce handling, and engagement events with automated error handling.

**Business Rationale:** Channel proliferation creates coordination challenges. Customers may receive simultaneous emails, SMS messages, and field visits from different campaigns creating negative experiences and diminishing returns. Intelligent orchestration optimizes channel selection, timing, and frequency balancing reach objectives with customer experience. Research demonstrates that send-time optimization improves email open rates by fifteen to 25% while frequency capping reduces unsubscribe rates by 30-40% without sacrificing total engagement. Multi-channel orchestration from unified journey definitions eliminates duplicate effort and ensures consistent messaging. Organizations with mature channel orchestration capabilities achieve 25% higher engagement rates, 30% reduction in opt-out rates, and 40% improvement in customer satisfaction scores.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane E (Execute)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-056 through REQ-062 (consent and preference management), journey execution platform deployment

**Acceptance Criteria:**

- Multi-channel delivery capability deployed for email, SMS, and push notifications minimum  
- Channel preference honoring implemented with customer preference center  
- Send-time optimization models deployed for email channel  
- Frequency capping enforced across all journeys with configurable limits

**Success Metrics:**

- Multi-channel activation: Over 70% of journeys using multiple channels within six months  
- Send-time optimization lift: Fifteen percent improvement in open rates for optimized sends  
- Frequency cap effectiveness: Thirty percent reduction in unsubscribe rates versus uncapped baseline  
- Delivery success rate: Over 95% of messages reaching intended recipients

---

**Capability 3: Central Fatigue Management Service**

**Detailed Requirements:**

- REQ-149: Central fatigue registry tracking all message deliveries across campaigns, journeys, channels, and systems with customer-level delivery history.  
- REQ-150: Real-time fatigue scoring calculating current message pressure for each customer based on recent touchpoint volume, channel diversity, and response patterns.  
- REQ-151: Fatigue threshold configuration defining maximum acceptable message volumes by customer segment, channel, and time period with graduated enforcement levels.  
- REQ-152: Pre-send fatigue check API validating proposed message deliveries against fatigue rules before execution with approval or rejection decisions.  
- REQ-153: Journey-level fatigue gates inserting wait steps or skipping message sends when customers approach or exceed fatigue thresholds.  
- REQ-154: Fatigue override workflow allowing marketers to request exceptions for time-sensitive or critical communications with approval justification and documentation.  
- REQ-155: Fatigue impact analysis reporting correlations between message frequency and engagement metrics, opt-out rates, and customer satisfaction scores.  
- REQ-156: Cross-system integration consuming delivery events from all execution platforms including Marketing Cloud, Braze, Iterable, agencies, and sales tools ensuring comprehensive visibility.

**Business Rationale:** Message fatigue represents the primary driver of customer disengagement and opt-out behavior. When customers receive excessive communications, response rates decline, unsubscribe rates spike, and brand perception suffers. The challenge intensifies in pharmaceutical marketing where multiple brands, therapeutic areas, and functional teams operate semi-independently creating cumulative message volume that no single team controls. Central fatigue management provides enterprise-wide visibility and enforcement preventing overexposure. Research demonstrates that fatigue management reduces opt-out rates by 40-60%, improves aggregate response rates by 20-30% through better targeting, and enhances customer satisfaction scores by 30-40%. The proposed centralized architecture aggregates touchpoints across all systems enabling consistent enforcement while maintaining flexibility for justified exceptions.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane A (Govern)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-024 through REQ-030 (event collection infrastructure), REQ-141 through REQ-148 (message delivery foundation)

**Acceptance Criteria:**

- Central fatigue registry deployed collecting events from all major execution systems  
- Fatigue scoring algorithm implemented with configurable thresholds by segment  
- Pre-send API integrated with journey execution preventing threshold violations  
- Fatigue override workflow requiring documented approval for exceptions

**Success Metrics:**

- Fatigue visibility: Over 90% of customer touchpoints tracked in central registry  
- Threshold enforcement: Zero unauthorized threshold violations after six-month stabilization period  
- Opt-out reduction: Forty percent decrease in unsubscribe rates attributed to fatigue management  
- Customer satisfaction: Thirty percent improvement in communication frequency satisfaction scores

---

**Capability 4: Advanced Experimentation and Optimization Framework**

**Detailed Requirements:**

- REQ-157: A/B/n testing framework supporting randomized control trials comparing message variants, subject lines, creative approaches, send times, and channel strategies.  
- REQ-158: Multi-armed bandit algorithms dynamically allocating traffic to winning variants while experiment runs maximizing performance during learning phase.  
- REQ-159: Holdout group management reserving control populations receiving no treatment enabling incrementality measurement and causal impact quantification.  
- REQ-160: Statistical analysis library calculating significance, confidence intervals, required sample sizes, and test duration ensuring rigorous methodology.  
- REQ-161: Experiment registry maintaining metadata for all tests including hypothesis, variants, sample allocation, start date, end date, results, and business decisions.  
- REQ-162: Automated winner selection monitoring test results and declaring winners when statistical significance achieved or stopping tests showing no difference.  
- REQ-163: Multi-touch attribution for experiments tracking downstream conversions and revenue impact beyond immediate engagement metrics.  
- REQ-164: Bayesian optimization for continuous improvement using prior knowledge to accelerate learning and reduce required sample sizes.  
- REQ-165: Personalization testing evaluating tailored experiences against generic content measuring incremental value of personalization investment.

**Business Rationale:** Experimentation transforms marketing from opinion-driven to evidence-driven decision-making. Systematic testing reveals which messages, channels, timings, and creative approaches deliver superior results enabling continuous optimization. Organizations with mature experimentation capabilities achieve twenty-five to 40% improvement in campaign ROI through accumulated learning while avoiding costly mistakes. The pharmaceutical industry faces unique experimentation challenges including smaller target populations, longer conversion cycles, and regulatory constraints on message testing. Multi-armed bandit algorithms address sample size limitations by concentrating traffic on winning variants during tests. Holdout groups enable incrementality measurement proving marketing delivers value beyond organic behavior. The proposed framework balances statistical rigor with practical deployment enabling rapid experimentation at enterprise scale while maintaining compliance standards.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2-3)

**Dependencies:** REQ-024 through REQ-030 (measurement infrastructure), REQ-133 through REQ-140 (journey design foundation)

**Acceptance Criteria:**

- A/B testing capability deployed within journey canvas with node-level test configuration  
- Multi-armed bandit service implemented with APIs for journey integration  
- Experiment registry tracking all active and completed tests with complete metadata  
- Statistical analysis automated with significance testing and sample size calculation

**Success Metrics:**

- Experimentation velocity: Minimum ten concurrent experiments per therapeutic area within six months  
- Learning application: Over 70% of winning variants deployed to full population  
- Performance improvement: Twenty-five percent average lift for winning variants versus controls  
- Statistical rigor: Zero tests concluded with insufficient sample sizes or premature declaration

---

**Capability 5: Journey Performance Monitoring and Optimization**

**Detailed Requirements:**

- REQ-166: Real-time journey analytics dashboard showing enrollment, progression, completion, fallout, and conversion metrics with drill-down capability.  
- REQ-167: Node-level performance tracking measuring entry, exit, conversion, and engagement rates for each journey step identifying bottlenecks and optimization opportunities.  
- REQ-168: Cohort analysis comparing performance across customer segments, entry dates, and variants revealing differential effectiveness.  
- REQ-169: Journey health monitoring detecting anomalies including stalled journeys, unexpected fallout spikes, low engagement, and technical errors with automated alerting.  
- REQ-170: Automated optimization recommendations suggesting changes to improve performance based on historical data and machine learning analysis.  
- REQ-171: Multi-touch journey attribution allocating conversion credit across journey steps and touchpoints using algorithmic models.  
- REQ-172: Journey ROI calculation combining message delivery costs, creative development expenses, and channel fees against attributed revenue and pipeline.  
- REQ-173: Comparative benchmarking showing journey performance versus similar campaigns, historical baselines, and portfolio averages.

**Business Rationale:** Journey deployment represents the beginning rather than end of optimization opportunity. Continuous monitoring reveals where customers progress smoothly and where they encounter friction. Node-level analytics pinpoint specific messages, wait times, or decision logic requiring refinement. Organizations with mature journey analytics achieve 30-40% performance improvement over initial deployment through systematic optimization. Real-time monitoring enables rapid response to issues preventing prolonged underperformance. Automated recommendations democratize optimization knowledge enabling less experienced marketers to apply proven practices. The proposed analytics framework provides actionable insights at appropriate granularity enabling both strategic refinements and tactical adjustments while maintaining enterprise visibility and governance.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-024 through REQ-030 (measurement infrastructure), REQ-133 through REQ-165 (journey foundation and experimentation)

**Acceptance Criteria:**

- Journey analytics dashboard deployed with real-time data refresh  
- Node-level tracking implemented capturing entry, progression, and conversion events  
- Automated alerting configured for journey health issues with appropriate thresholds  
- Journey ROI calculation methodology documented and implemented

**Success Metrics:**

- Analytics adoption: Over 80% of journey owners regularly reviewing performance dashboards  
- Issue detection: Journey health alerts identifying problems average three days before business impact  
- Optimization velocity: Journey owners implementing minimum two optimizations per quarter based on analytics  
- ROI visibility: One hundred percent of journeys with calculated ROI within 90 days of launch

---

### Summary: Swimlane D Requirements Catalog

| Requirement ID | Requirement Title | Priority | Phase | Dependencies |
| :---- | :---- | :---- | :---- | :---- |
| REQ-133 | Journey Canvas LWC | P1 | Phase 2 | REQ-005, 063-092 |
| REQ-134 | Node Library | P1 | Phase 2 | REQ-133 |
| REQ-135 | Journey Versioning | P1 | Phase 2 | REQ-133 |
| REQ-136 | Template Library | P1 | Phase 2 | REQ-133 |
| REQ-137 | Visual Flow Validation | P1 | Phase 2 | REQ-133 |
| REQ-138 | Journey Simulation | P2 | Phase 3 | REQ-133 |
| REQ-139 | Documentation Generator | P1 | Phase 2 | REQ-133 |
| REQ-140 | Collaboration Features | P2 | Phase 3 | REQ-133 |
| REQ-141 | Multi-Channel Routing | P0 | Phase 1 | Journey platform |
| REQ-142 | Channel Preference Honoring | P0 | Phase 1 | REQ-056-062 |
| REQ-143 | Channel Fallback Logic | P1 | Phase 2 | REQ-141 |
| REQ-144 | Send-Time Optimization | P1 | Phase 2 | REQ-069-076 |
| REQ-145 | Frequency Capping | P0 | Phase 1 | REQ-141 |
| REQ-146 | Message Prioritization | P1 | Phase 2 | REQ-145 |
| REQ-147 | Real-Time Personalization | P1 | Phase 2 | REQ-063-092 |
| REQ-148 | Delivery Status Tracking | P0 | Phase 1 | REQ-024-030 |
| REQ-149 | Central Fatigue Registry | P1 | Phase 2 | REQ-024-030 |
| REQ-150 | Real-Time Fatigue Scoring | P1 | Phase 2 | REQ-149 |
| REQ-151 | Fatigue Threshold Config | P1 | Phase 2 | REQ-149 |
| REQ-152 | Pre-Send Fatigue Check API | P1 | Phase 2 | REQ-149-151 |
| REQ-153 | Journey Fatigue Gates | P1 | Phase 2 | REQ-152 |
| REQ-154 | Fatigue Override Workflow | P2 | Phase 3 | REQ-152 |
| REQ-155 | Fatigue Impact Analysis | P2 | Phase 3 | REQ-149-154 |
| REQ-156 | Cross-System Integration | P1 | Phase 2 | REQ-149 |
| REQ-157 | A/B/n Testing Framework | P1 | Phase 2 | REQ-133-140 |
| REQ-158 | Multi-Armed Bandit | P2 | Phase 3 | REQ-157 |
| REQ-159 | Holdout Group Management | P1 | Phase 2 | REQ-157 |
| REQ-160 | Statistical Analysis Library | P1 | Phase 2 | REQ-157 |
| REQ-161 | Experiment Registry | P1 | Phase 2 | REQ-157 |
| REQ-162 | Automated Winner Selection | P2 | Phase 3 | REQ-160 |
| REQ-163 | Multi-Touch Attribution | P2 | Phase 3 | REQ-157 |
| REQ-164 | Bayesian Optimization | P2 | Phase 3 | REQ-160 |
| REQ-165 | Personalization Testing | P2 | Phase 3 | REQ-157, 147 |
| REQ-166 | Real-Time Analytics Dashboard | P1 | Phase 2 | REQ-024-030 |
| REQ-167 | Node-Level Tracking | P1 | Phase 2 | REQ-166 |
| REQ-168 | Cohort Analysis | P1 | Phase 2 | REQ-166 |
| REQ-169 | Journey Health Monitoring | P1 | Phase 2 | REQ-166 |
| REQ-170 | Automated Recommendations | P2 | Phase 3 | REQ-166-169 |
| REQ-171 | Journey Attribution | P1 | Phase 2 | REQ-166 |
| REQ-172 | Journey ROI Calculation | P1 | Phase 2 | REQ-171 |
| REQ-173 | Comparative Benchmarking | P2 | Phase 3 | REQ-166-172 |

---

## SWIMLANE E: EXECUTE

### Swimlane Purpose

Deliver marketing messages and experiences across owned, earned, and paid channels including email, SMS, push notifications, web, mobile applications, field sales interactions, patient support programs, and third-party advertising platforms while ensuring brand consistency, regulatory compliance, and measurement completeness.

### Business Context

Execution represents the point where marketing strategy meets customer experience. Perfect planning becomes worthless if execution suffers from technical failures, compliance violations, or measurement gaps. Pharmaceutical marketing execution faces distinctive challenges including promotional review requirements for every channel, consent enforcement complexity across professional and consumer audiences, adverse event monitoring obligations, and attribution requirements spanning lengthy decision cycles. The average pharmaceutical marketing organization manages execution across 15-20 distinct channels, coordinates with 8-12 external agencies, and maintains compliance with regulations in 40-60 markets. Without robust execution infrastructure, organizations experience message delivery failures, consent violations, measurement gaps, and brand inconsistency. Research demonstrates that execution excellence contributes 30-40% of overall campaign effectiveness with superior execution compensating for moderate strategy weaknesses while poor execution undermines even brilliant strategies. The proposed execution framework provides centralized orchestration with distributed delivery, embedded compliance controls, comprehensive measurement, and real-time monitoring enabling consistent brand experiences at global scale.

### Primary Systems

- Salesforce Marketing Cloud Engagement (email, mobile, advertising)  
- Braze or Iterable (high-volume consumer messaging)  
- Web content management system and personalization engine  
- Mobile application platforms (iOS, Android)  
- Field sales enablement tools  
- Patient support program platforms  
- Agency execution platforms with API integration

### Key Capabilities

**Capability 1: Email Marketing Execution**

**Detailed Requirements:**

- REQ-174: Enterprise email platform supporting transactional messages, promotional campaigns, triggered messages, and journey-driven sequences with guaranteed deliverability and inbox placement optimization.  
- REQ-175: Dynamic content assembly inserting personalized elements including name, specialty, practice setting, therapeutic area interests, and behavioral history at send time based on customer attributes.  
- REQ-176: Responsive email templates automatically adapting layout, images, and content hierarchy for desktop, mobile, and tablet viewing with consistent brand presentation.  
- REQ-177: Send-time optimization analyzing individual engagement patterns to deliver messages when recipients are most likely to open and engage based on historical behavior.  
- REQ-178: List hygiene automation detecting invalid addresses, hard bounces, soft bounces, and engagement decay with automated suppression and reactivation workflows.  
- REQ-179: Spam filter testing validating message content, sender reputation, and technical configuration before deployment identifying deliverability risks.  
- REQ-180: Unsubscribe management providing one-click opt-out with preference center access and reason capture with immediate suppression across all campaigns.  
- REQ-181: Engagement tracking capturing opens, clicks, forwards, prints, and time spent with device, location, and timestamp metadata for attribution analysis.  
- REQ-182: A/B testing capability comparing subject lines, preview text, sender names, content variants, and send times with statistical significance calculation.

**Business Rationale:** Email remains the primary channel for pharmaceutical professional engagement achieving average open rates between twenty-five and 35% for well-targeted HCP campaigns compared to 15-20% for general B2B marketing. Patient-focused email programs demonstrate even higher engagement when properly segmented and personalized. However, email effectiveness depends critically on technical execution including sender reputation management, spam filter avoidance, mobile optimization, and deliverability monitoring. Organizations with mature email programs achieve inbox placement rates exceeding 95% compared to 60-70% for programs with poor technical hygiene. Dynamic personalization improves click-through rates by 40-60% compared to generic messages. The proposed email execution framework combines industrial-strength infrastructure with sophisticated personalization enabling both high-volume broadcast campaigns and precision one-to-one messaging while maintaining compliance standards and measurement completeness.

**Swimlane Alignment:** Swimlane E (Execute)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-005 through REQ-009 (customer data foundation), REQ-056 through REQ-062 (consent management), REQ-141 through REQ-148 (message delivery orchestration)

**Acceptance Criteria:**

- Email platform deployed with transactional and promotional capability  
- Dynamic personalization inserting minimum ten customer attributes  
- Responsive templates rendering correctly across major email clients and devices  
- Deliverability monitoring showing inbox placement above 90%

**Success Metrics:**

- Email deliverability rate: Above 95%  
- Open rate: Above industry benchmark (25% HCP, eighteen percent patient)  
- Click-to-open rate: Above 15%  
- Unsubscribe rate: Below zero point two percent per send  
- Spam complaint rate: Below zero point one percent

---

**Capability 2: SMS and Mobile Messaging**

**Detailed Requirements:**

- REQ-183: SMS platform supporting promotional messages, appointment reminders, medication adherence nudges, program enrollment confirmations, and two-way conversational messaging.  
- REQ-184: Mobile push notification capability delivering timely alerts, content recommendations, and engagement prompts to iOS and Android applications.  
- REQ-185: In-app messaging presenting contextual messages within mobile applications based on user behavior, location, and application state.  
- REQ-186: Rich media messaging supporting images, videos, links, and interactive buttons within SMS and push notifications where carrier and device support permits.  
- REQ-187: Carrier compliance ensuring messages meet Cellular Telecommunications Industry Association (CTIA) guidelines, Telephone Consumer Protection Act (TCPA) requirements, and carrier-specific content policies preventing filtering or blocking.  
- REQ-188: Opt-in verification requiring explicit consent for SMS and push notifications with double opt-in confirmation and clear disclosure of message frequency and charges.  
- REQ-189: Keyword management processing standard commands including STOP, HELP, and UNSTOP with automated response messages and preference updates.  
- REQ-190: Delivery receipt tracking confirming message delivery to handsets with failure notifications and retry logic for temporary delivery issues.  
- REQ-191: Character limit optimization maximizing message content within 106 character SMS constraints or utilizing concatenated messages when necessary.

**Business Rationale:** SMS achieves read rates exceeding 95% within three minutes of delivery making it the most immediate and attention-commanding channel available. Mobile push notifications achieve similar immediacy for application users. These channels prove particularly valuable for time-sensitive communications including appointment reminders reducing no-show rates by 30-40%, medication adherence prompts improving compliance by fifteen to 25%, and event registration confirmations increasing attendance by 20-30%. However, SMS and push notifications carry elevated intrusiveness requiring judicious use to avoid customer backlash. Pharmaceutical applications face additional regulatory scrutiny with SMS promotional messages subject to the same MLR review requirements as email. The proposed mobile messaging framework balances channel power with appropriate governance ensuring high-value use cases receive priority while preventing overuse that damages customer relationships.

**Swimlane Alignment:** Swimlane E (Execute)

**Priority:** P1 \- Strategic channel (Phase 2\)

**Dependencies:** REQ-005 (customer data), REQ-056 through REQ-062 (consent with SMS-specific opt-in), REQ-141 through REQ-148 (message orchestration)

**Acceptance Criteria:**

- SMS platform deployed with two-way messaging capability  
- Push notification integration with iOS and Android applications  
- Opt-in verification requiring explicit consent separate from email  
- Keyword management processing standard commands with automated responses

**Success Metrics:**

- SMS delivery rate: Above ninety-eight percent  
- SMS read rate: Above 90% within 1 hour  
- Push notification opt-in rate: Above 40% of application users  
- Push notification click-through rate: Above ten percent  
- Opt-out rate: Below five percent annually

---

**Capability 3: Web Personalization and Experience Management**

**Detailed Requirements:**

- REQ-192: Web content management system supporting promotional microsites, educational portals, patient support program sites, and brand websites with role-based content management.  
- REQ-193: Personalization engine delivering dynamic content variations based on visitor identity, behavior history, referral source, device type, and real-time context.  
- REQ-194: A/B testing framework comparing page layouts, content variations, calls-to-action, and user flows with multivariate testing for complex optimization.  
- REQ-195: Progressive profiling gradually collecting visitor information across multiple sessions through forms and interactive tools without overwhelming single-session data requests.  
- REQ-196: Form optimization including smart field validation, conditional logic showing relevant questions based on previous answers, and save-and-resume capability for lengthy forms.  
- REQ-197: Content recommendations suggesting related articles, videos, tools, and resources based on current page context and visitor interest profile.  
- REQ-198: Gated content management requiring form completion or authentication before accessing premium content with lead capture and scoring integration.  
- REQ-199: Session recording and heatmap analysis capturing visitor interactions, scroll depth, click patterns, and navigation paths identifying user experience issues.  
- REQ-200: Website analytics integration tracking page views, bounce rates, time on site, conversion events, and goal completions with UTM parameter capture.

**Business Rationale:** Websites serve as the hub of pharmaceutical digital marketing programs providing destinations for paid media campaigns, email links, search traffic, and direct navigation. The average pharmaceutical website attracts fifty thousand to five hundred thousand monthly visitors depending on therapeutic area, brand maturity, and marketing investment. However, generic website experiences fail to capitalize on visitor intent and context. Personalization transforms websites from static brochures into adaptive experiences presenting relevant content based on who visitors are and what they need. Research demonstrates personalized web experiences improve conversion rates by 30-50%, increase engagement duration by 40-60%, and generate qualified leads at 30% lower cost compared to generic experiences. The proposed web experience framework combines robust content management with sophisticated personalization enabling marketers to create tailored journeys while maintaining brand consistency and compliance standards.

**Swimlane Alignment:** Swimlane E (Execute)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-024 through REQ-030 (event tracking), REQ-063 through REQ-092 (segmentation for personalization), REQ-107 through REQ-114 (content-to-claim mapping)

**Acceptance Criteria:**

- Web content management system deployed with role-based access  
- Personalization engine delivering dynamic content based on visitor attributes  
- A/B testing capability supporting minimum five concurrent tests  
- Form optimization deployed on priority lead generation pages

**Success Metrics:**

- Website conversion rate: Above three percent for lead generation pages  
- Personalization coverage: Over 60% of visitors receiving personalized experiences  
- A/B test velocity: Minimum twenty tests per quarter across priority pages  
- Lead quality: Over 50% of web leads meeting qualification criteria

---

**Capability 4: Field Sales Enablement and Coordination**

**Detailed Requirements:**

- REQ-201: Field representative dashboard displaying customer engagement history, digital activity, campaign participation, content consumption, and prescribing trends.  
- REQ-202: Next-best-action recommendations suggesting optimal talking points, leave-behinds, samples, and follow-up actions based on customer profile and journey stage.  
- REQ-203: Call planning tools prioritizing accounts by propensity scores, engagement signals, and business value with territory-optimized routing.  
- REQ-204: Sample management tracking sample provision with lot numbers, expiry dates, quantity, and signature capture ensuring chain of custody and regulatory compliance.  
- REQ-205: Closed-loop marketing feedback capturing representative observations about customer reactions, competitive intelligence, and market conditions for campaign optimization.  
- REQ-206: Speaker program coordination matching qualified speakers with event opportunities and tracking program participation, attendance, and outcomes.  
- REQ-207: Consent verification displaying customer communication preferences and opt-out status preventing representatives from inappropriate outreach attempts.  
- REQ-208: Content delivery enabling representatives to email approved materials directly to customers from mobile devices with activity tracking and MLR-approved content library access.  
- REQ-209: Sales activity synchronization pushing field interactions back to Salesforce creating complete customer engagement history across digital and personal channels.

**Business Rationale:** Field sales remains the highest-impact channel in pharmaceutical marketing with face-to-face representative visits influencing prescribing behavior more than any digital touchpoint. However, field effectiveness depends on coordination with broader marketing programs. Representatives armed with insights about customer digital engagement achieve 60-80% higher success rates compared to representatives lacking context. Next-best-action recommendations improve call productivity by 40-50% by focusing discussions on relevant topics. Sample targeting based on propensity models reduces waste by 30-40% while improving prescribing outcomes. The proposed field enablement framework bridges the gap between digital marketing programs and personal selling creating seamless omnichannel experiences where representatives reinforce digital messages and digital programs prepare customers for representative visits.

**Swimlane Alignment:** Swimlane E (Execute), Swimlane B (Segment)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-005 through REQ-009 (customer data), REQ-063 through REQ-092 (segmentation and propensity models), REQ-024 through REQ-030 (activity tracking)

**Acceptance Criteria:**

- Field dashboard deployed in Salesforce mobile application  
- Next-best-action recommendations available for priority customers  
- Sample management integrated with call reporting  
- Digital engagement history visible to representatives in real-time

**Success Metrics:**

- Dashboard adoption: Over 80% of representatives using dashboard weekly  
- Next-best-action follow-through: Over 60% of recommendations acted upon  
- Sample efficiency: Thirty percent improvement in prescribing per sample versus baseline  
- Closed-loop feedback: Over 50% of calls with structured feedback capture

---

**Capability 5: Patient Support Program Execution**

**Detailed Requirements:**

- REQ-210: Patient enrollment workflow capturing demographics, diagnosis, insurance, prescribing physician, and consent across digital and phone channels with HIPAA-compliant data handling.  
- REQ-211: Copay assistance program administration calculating patient out-of-pocket costs, applying manufacturer assistance, and processing claims with pharmacy benefit integration.  
- REQ-212: Medication adherence monitoring tracking prescription fills, refill dates, and gaps in therapy with predictive models identifying at-risk patients for intervention.  
- REQ-213: Nurse educator coordination scheduling phone consultations, video appointments, and educational sessions with patient preference matching and reminder notifications.  
- REQ-214: Educational content delivery providing disease education, medication instructions, side effect management, lifestyle guidance, and treatment expectations through preferred channels.  
- REQ-215: Outcome tracking measuring clinical endpoints, quality of life metrics, patient satisfaction, and program participation correlating with treatment persistence.  
- REQ-216: Provider coordination notifying prescribing physicians of patient enrollment, adherence issues, and outcome data supporting collaborative care.  
- REQ-217: Adverse event detection monitoring patient communications for safety signals requiring pharmacovigilance reporting with automated flagging and escalation.  
- REQ-218: Program analytics dashboard reporting enrollment, adherence, persistence, outcomes, and economic value demonstrating program ROI and informing optimization.

**Business Rationale:** Patient support programs represent critical differentiation in competitive therapeutic categories with comprehensive programs improving medication adherence by 30-50%, reducing discontinuation rates by 40-60%, and enhancing clinical outcomes by 20-30% compared to medication alone. These programs deliver particular value in specialty pharmaceuticals where high costs, complex administration, and significant side effects create adherence challenges. Programs providing copay assistance, nurse support, and educational resources demonstrate return on investment exceeding three to one through increased therapy persistence and reduced medical complications. However, program effectiveness depends on tight integration with prescribing physicians, real-time adherence monitoring, and proactive intervention for at-risk patients. The proposed patient program framework combines enrollment simplicity with comprehensive support services enabling pharmaceutical manufacturers to improve patient outcomes while building market differentiation and clinical evidence.

**Swimlane Alignment:** Swimlane E (Execute)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-005 (customer data with HIPAA compliance), REQ-056 through REQ-062 (consent management), REQ-069 through REQ-076 (behavioral tracking), REQ-141 through REQ-148 (message orchestration)

**Acceptance Criteria:**

- Patient enrollment workflow deployed with digital and phone channels  
- Copay assistance program integrated with pharmacy benefit systems  
- Adherence monitoring tracking prescription fills with predictive intervention  
- Nurse educator scheduling coordinated with patient preferences

**Success Metrics:**

- Program enrollment: Over 40% of eligible patients enrolled within 90 days of prescription  
- Medication adherence: Above 80% medication possession ratio for enrolled patients  
- Persistence rate: Above 70% patients continuing therapy at twelve months  
- Provider satisfaction: Over 8 out of 10 prescribers rating program valuable  
- Economic ROI: Program generating minimum three dollars value per dollar invested

---

**Capability 6: Paid Media Execution and Optimization**

**Detailed Requirements:**

- REQ-219: Programmatic advertising platform executing display, video, native, and social media campaigns with real-time bidding and audience targeting across supply-side platforms.  
- REQ-220: Healthcare provider targeting using specialty, NPI, prescribing volume, and institutional affiliations with HIPAA-compliant identity matching and privacy controls.  
- REQ-221: Patient audience targeting leveraging health conditions, treatment history, and engagement signals with strict privacy compliance and sensitive category restrictions.  
- REQ-222: Contextual targeting placing advertisements adjacent to relevant content based on page topics, keywords, and semantic analysis without relying on personal data.  
- REQ-223: Lookalike audience expansion identifying prospective customers sharing characteristics with high-value existing customers for acquisition campaigns.  
- REQ-224: Frequency capping limiting advertisement impressions per individual per day, week, and month preventing overexposure and budget waste.  
- REQ-225: Creative rotation testing multiple advertisement variations with performance-based optimization shifting budget toward top performers.  
- REQ-226: Brand safety controls preventing advertisements from appearing alongside inappropriate content including health misinformation, competitor mentions, or sensitive topics.  
- REQ-227: Viewability optimization ensuring advertisements appear in visible screen area with minimum 50% pixel visibility for minimum one second meeting industry standards.  
- REQ-228: Conversion tracking linking advertisement exposures to downstream actions including website visits, form submissions, appointment bookings, and prescriptions through probabilistic and deterministic matching.  
- REQ-229: Budget pacing algorithms distributing campaign spend evenly across flight duration preventing premature budget exhaustion while maximizing impression volume.  
- REQ-230: Performance reporting dashboard showing impressions, clicks, conversions, cost per action, return on ad spend, and attributed outcomes by campaign, audience, and creative.

**Business Rationale:** Paid media represents the primary customer acquisition channel for pharmaceutical marketing enabling precise targeting of HCPs and patients at scale. Digital advertising spending in pharmaceutical marketing exceeded 8 billion dollars in 2024 growing at 12-15% annually as brands shift budgets from traditional media. However, paid media effectiveness varies dramatically based on targeting precision, creative quality, and optimization discipline. Well-executed campaigns achieve cost per acquisition 30-50% lower than industry averages while poorly optimized programs waste significant budgets on irrelevant audiences. Healthcare provider targeting proves particularly valuable given the concentrated nature of prescribing behavior with the top 20% of physicians accounting for 60-80% of prescriptions in many therapeutic categories. The proposed paid media framework combines sophisticated targeting with continuous optimization enabling efficient customer acquisition while maintaining regulatory compliance and brand safety standards.

**Swimlane Alignment:** Swimlane E (Execute)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-006 (identity resolution), REQ-024 through REQ-030 (conversion tracking), REQ-050 through REQ-055 (campaign taxonomy and UTM standards), REQ-107 through REQ-114 (content-to-claim for advertisement creative)

**Acceptance Criteria:**

- Programmatic platform deployed with HCP and patient targeting capability  
- Creative rotation supporting minimum five variations per campaign with performance optimization  
- Brand safety controls preventing advertisements on blacklisted sites and content categories  
- Conversion tracking linking advertisement exposure to downstream outcomes

**Success Metrics:**

- Click-through rate: Above industry benchmark (zero point two percent display, two percent search)  
- Conversion rate: Above three percent of advertisement clicks resulting in desired actions  
- Cost per acquisition: Below target economics supporting positive ROI  
- Brand safety compliance: Zero advertisements appearing in violation of brand safety policy  
- Attribution rate: Over 70% of conversions linked to specific campaigns and creatives

---

### Summary: Swimlane E Requirements Catalog

| Requirement ID | Requirement Title | Priority | Phase | Dependencies |
| :---- | :---- | :---- | :---- | :---- |
| REQ-174 | Enterprise Email Platform | P0 | Phase 1 | REQ-005-009, 056-062, 141-148 |
| REQ-175 | Dynamic Content Assembly | P0 | Phase 1 | REQ-174 |
| REQ-176 | Responsive Email Templates | P0 | Phase 1 | REQ-174 |
| REQ-177 | Send-Time Optimization | P1 | Phase 2 | REQ-069-076 |
| REQ-178 | List Hygiene Automation | P0 | Phase 1 | REQ-174 |
| REQ-179 | Spam Filter Testing | P1 | Phase 2 | REQ-174 |
| REQ-180 | Unsubscribe Management | P0 | Phase 1 | REQ-056-062 |
| REQ-181 | Engagement Tracking | P0 | Phase 1 | REQ-024-030 |
| REQ-182 | Email A/B Testing | P1 | Phase 2 | REQ-157 |
| REQ-183 | SMS Platform | P1 | Phase 2 | REQ-005, 056-062, 141-148 |
| REQ-184 | Mobile Push Notifications | P1 | Phase 2 | REQ-183 |
| REQ-185 | In-App Messaging | P2 | Phase 3 | REQ-184 |
| REQ-186 | Rich Media Messaging | P2 | Phase 3 | REQ-183-184 |
| REQ-187 | Carrier Compliance | P1 | Phase 2 | REQ-183 |
| REQ-188 | Opt-In Verification | P1 | Phase 2 | REQ-056-062 |
| REQ-189 | Keyword Management | P1 | Phase 2 | REQ-183 |
| REQ-190 | Delivery Receipt Tracking | P1 | Phase 2 | REQ-183 |
| REQ-191 | Character Limit Optimization | P1 | Phase 2 | REQ-183 |
| REQ-192 | Web Content Management | P0 | Phase 1 | Content platform |
| REQ-193 | Personalization Engine | P1 | Phase 2 | REQ-063-092 |
| REQ-194 | Web A/B Testing | P1 | Phase 2 | REQ-157 |
| REQ-195 | Progressive Profiling | P1 | Phase 2 | REQ-192 |
| REQ-196 | Form Optimization | P1 | Phase 2 | REQ-192 |
| REQ-197 | Content Recommendations | P2 | Phase 3 | REQ-193 |
| REQ-198 | Gated Content Management | P1 | Phase 2 | REQ-192 |
| REQ-199 | Session Recording/Heatmaps | P2 | Phase 3 | REQ-192 |
| REQ-200 | Website Analytics | P0 | Phase 1 | REQ-024-030 |
| REQ-201 | Field Rep Dashboard | P1 | Phase 2 | REQ-005-009, 024-030 |
| REQ-202 | Next-Best-Action Recs | P2 | Phase 3 | REQ-079 |
| REQ-203 | Call Planning Tools | P1 | Phase 2 | REQ-077 |
| REQ-204 | Sample Management | P1 | Phase 2 | REQ-201 |
| REQ-205 | Closed-Loop Feedback | P1 | Phase 2 | REQ-201 |
| REQ-206 | Speaker Program Coordination | P2 | Phase 3 | REQ-201 |
| REQ-207 | Consent Verification | P1 | Phase 2 | REQ-056-062 |
| REQ-208 | Content Delivery | P1 | Phase 2 | REQ-107-132 |
| REQ-209 | Activity Synchronization | P1 | Phase 2 | REQ-024-030 |
| REQ-210 | Patient Enrollment Workflow | P1 | Phase 2 | REQ-005, 056-062 |
| REQ-211 | Copay Assistance Admin | P1 | Phase 2 | REQ-210 |
| REQ-212 | Adherence Monitoring | P1 | Phase 2 | REQ-078 |
| REQ-213 | Nurse Educator Coordination | P1 | Phase 2 | REQ-210 |
| REQ-214 | Educational Content Delivery | P1 | Phase 2 | REQ-141-148 |
| REQ-215 | Outcome Tracking | P1 | Phase 2 | REQ-210 |
| REQ-216 | Provider Coordination | P1 | Phase 2 | REQ-210 |
| REQ-217 | Adverse Event Detection | P0 | Phase 1 | REQ-210 |
| REQ-218 | Program Analytics Dashboard | P1 | Phase 2 | REQ-210-217 |
| REQ-219 | Programmatic Advertising | P0 | Phase 1 | Ad platform |
| REQ-220 | HCP Targeting | P0 | Phase 1 | REQ-006, 064 |
| REQ-221 | Patient Audience Targeting | P1 | Phase 2 | REQ-006, 063 |
| REQ-222 | Contextual Targeting | P1 | Phase 2 | REQ-219 |
| REQ-223 | Lookalike Audiences | P1 | Phase 2 | REQ-082 |
| REQ-224 | Frequency Capping | P0 | Phase 1 | REQ-145 |
| REQ-225 | Creative Rotation Testing | P1 | Phase 2 | REQ-157 |
| REQ-226 | Brand Safety Controls | P0 | Phase 1 | REQ-219 |
| REQ-227 | Viewability Optimization | P1 | Phase 2 | REQ-219 |
| REQ-228 | Conversion Tracking | P0 | Phase 1 | REQ-006, 024-030 |
| REQ-229 | Budget Pacing | P1 | Phase 2 | REQ-219 |
| REQ-230 | Performance Reporting | P0 | Phase 1 | REQ-024-030 |

---

## SWIMLANE F: MEASURE & LEARN

### Swimlane Purpose

Collect, aggregate, analyze, and report marketing performance data across all channels, campaigns, and customer touchpoints enabling data-driven decision-making, continuous optimization, budget allocation, and demonstration of marketing return on investment.

### Business Context

Measurement transforms marketing from cost center to accountable investment by quantifying business impact and enabling continuous improvement. Pharmaceutical marketing faces unique measurement challenges including lengthy decision cycles spanning months or years between initial awareness and prescription behavior, multiple stakeholders involved in treatment decisions, attribution complexity across digital and personal channels, and regulatory requirements for performance documentation. The typical pharmaceutical brand invests thirty to fifty million dollars annually in marketing with only 40-50% of revenue attributable to specific campaigns due to measurement gaps. This creates budget allocation inefficiency, continued investment in underperforming programs, and inability to defend marketing value to executive leadership. Organizations with mature measurement capabilities achieve twenty-five to 40% higher marketing ROI through better budget allocation, identify winning strategies for replication, and prove marketing contribution to business outcomes. The proposed measurement framework provides comprehensive data collection, sophisticated attribution modeling, real-time dashboards, and portfolio analytics enabling pharmaceutical marketers to optimize investments confidently while maintaining regulatory compliance and audit readiness.

### Primary Systems

- Cloud data warehouse (Snowflake, BigQuery, or Redshift)  
- Business intelligence platform (Tableau, Looker, or CRM Analytics)  
- Attribution modeling service  
- Marketing mix modeling platform  
- Salesforce (campaign performance and ROI tracking)

### Key Capabilities

**Capability 1: Event Collection and Data Pipeline**

**Detailed Requirements:**

- REQ-231: Universal event schema standardizing touchpoint data structure across web, email, mobile, paid media, field sales, patient programs, and third-party systems with required and optional field definitions.  
- REQ-232: Client-side tracking libraries deployed on websites and mobile applications capturing page views, clicks, form submissions, content consumption, and custom events with automatic metadata enrichment.  
- REQ-233: Server-side event collection APIs receiving events from Marketing Cloud, CRM, patient programs, and agency platforms with authentication, validation, and guaranteed delivery.  
- REQ-234: Real-time event streaming delivering touchpoints to data warehouse with less than two-hour latency enabling near-real-time reporting and journey progression.  
- REQ-235: Event enrichment service appending customer attributes, campaign context, geographic data, device information, and derived fields to raw events creating analysis-ready datasets.  
- REQ-236: Data quality monitoring validating event completeness, schema compliance, and timestamp accuracy with automated alerting for data quality degradation.  
- REQ-237: Historical data retention maintaining minimum twenty-four months of detailed event data with archival strategies for longer-term trend analysis and regulatory compliance.  
- REQ-238: Privacy-compliant data handling implementing appropriate safeguards for HCP NPI numbers, patient identifiers, and protected health information with encryption, access controls, and audit logging.

**Business Rationale:** Comprehensive event collection forms the foundation of all measurement and optimization capabilities. Missing touchpoints create attribution blind spots, incomplete metadata prevents granular analysis, and data quality issues undermine trust in reporting. The pharmaceutical industry faces particular data collection challenges given diverse channel mix, agency execution, and regulatory constraints. Organizations report that 30-40% of marketing touchpoints go untracked due to technical gaps, agency system limitations, or field activity capture failures. Each missing touchpoint reduces attribution accuracy and optimization potential. The proposed event collection framework ensures complete visibility across all channels and interaction types while maintaining data quality standards and privacy compliance. Real-time streaming enables immediate journey progression and responsive optimization rather than waiting for batch processing delays.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-006 (identity resolution for event stitching), REQ-050 through REQ-055 (taxonomy for consistent event tagging), cloud data warehouse deployment

**Acceptance Criteria:**

- Universal event schema documented and implemented across all systems  
- Client-side tracking deployed on priority websites and mobile applications  
- Server-side APIs integrated with Marketing Cloud, CRM, and major agency platforms  
- Event streaming pipeline delivering data with less than two-hour latency measured at 95th percentile

**Success Metrics:**

- Event collection completeness: Over 90% of planned touchpoints captured  
- Schema compliance rate: Over 95% of events passing validation  
- Data latency: Under two hours at 95th percentile  
- System reliability: Event pipeline uptime above ninety-nine point five percent

---

**Capability 2: Campaign Performance Dashboards and Reporting**

**Detailed Requirements:**

- REQ-239: Campaign performance dashboard displaying impressions, reach, engagement, conversions, cost per action, and return on investment by campaign, channel, therapeutic area, and time period with drill-down capability.  
- REQ-240: Real-time metrics updating dashboard data hourly for active campaigns enabling rapid identification of performance issues or optimization opportunities.  
- REQ-241: Historical trend analysis comparing current performance against previous periods, benchmarks, and targets identifying improvement or degradation patterns.  
- REQ-242: Cohort analysis segmenting results by customer demographics, entry date, message variant, channel path, and other dimensions revealing differential effectiveness.  
- REQ-243: Funnel visualization showing progression through awareness, consideration, conversion, and retention stages identifying bottlenecks and drop-off points.  
- REQ-244: Content performance reporting ranking creative assets, messages, claims, and formats by engagement and conversion metrics informing content optimization.  
- REQ-245: Channel effectiveness comparison evaluating relative performance across email, paid media, field sales, web, mobile, and patient programs supporting budget allocation decisions.  
- REQ-246: Geographic performance breakdown analyzing results by country, region, territory, and market size identifying geographic opportunity and challenges.  
- REQ-247: Automated anomaly detection flagging unusual performance patterns including sudden metric changes, traffic spikes, conversion drops, or cost increases triggering investigation.  
- REQ-248: Scheduled report distribution automatically delivering performance summaries to stakeholders via email or Slack on daily, weekly, or monthly cadence with customizable content and recipients.

**Business Rationale:** Accessible performance reporting democratizes data-driven decision-making enabling marketers at all levels to understand campaign effectiveness and identify optimization opportunities. Traditional reporting approaches requiring data analysts to build custom reports for every question create bottlenecks delaying insights and limiting analysis depth. Self-service dashboards with intuitive interfaces reduce time from question to answer from days to minutes enabling continuous optimization. Research demonstrates that organizations with strong self-service analytics capabilities make decisions 50% faster and achieve 30% better marketing outcomes through accumulated learning. Real-time data access proves particularly valuable for paid media campaigns where budget waste accumulates hourly when underperforming programs continue without intervention. The proposed dashboard framework balances simplicity for casual users with depth for power users enabling both quick performance checks and sophisticated analysis from unified data foundation.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-231 through REQ-238 (event collection foundation), business intelligence platform deployment

**Acceptance Criteria:**

- Campaign dashboard deployed with core metrics and drill-down capability  
- Real-time data refresh implemented with hourly updates for active campaigns  
- Historical trending showing minimum twelve months performance comparison  
- Automated anomaly detection flagging significant performance changes

**Success Metrics:**

- Dashboard adoption: Over 80% of marketers accessing dashboards weekly  
- Time to insight: Over 70% of questions answered without analyst assistance  
- Report request reduction: Fifty percent fewer ad hoc report requests versus baseline  
- User satisfaction: Over 8 out of 10 rating dashboard usefulness

---

**Capability 3: Multi-Touch Attribution Modeling**

**Detailed Requirements:**

- REQ-249: Attribution data mart aggregating touchpoints, outcomes, and conversions with customer journey reconstruction linking sequences of interactions to business results.  
- REQ-250: Rules-based attribution models including first-touch, last-touch, linear, time-decay, and position-based with configurable weights and lookback windows.  
- REQ-251: Algorithmic attribution models using machine learning to determine optimal credit distribution based on observed conversion patterns and channel interactions.  
- REQ-252: Shapley value attribution calculating marginal contribution of each touchpoint using cooperative game theory principles ensuring fairness and mathematical rigor.  
- REQ-253: Multi-touch journey attribution allocating credit across entire customer journeys rather than single touchpoints recognizing cumulative influence.  
- REQ-254: Segment-specific attribution recognizing that channel effectiveness differs by customer type, therapeutic area, and buying stage with customized models by segment.  
- REQ-255: Attribution model comparison evaluating different methodologies side-by-side showing credit distribution variances and impact on budget allocation recommendations.  
- REQ-256: Incrementality measurement through holdout group testing quantifying lift attributable to marketing versus organic behavior establishing causality.  
- REQ-257: Attribution reporting dashboard visualizing credit distribution by channel, campaign, content, and touchpoint with path analysis showing common conversion journeys.  
- REQ-258: Model governance ensuring attribution methodology transparency, stakeholder alignment, and periodic validation with documented assumptions and limitations.

**Business Rationale:** Attribution modeling answers the fundamental question of which marketing activities drive business outcomes enabling confident budget allocation and optimization decisions. Last-touch attribution, the default approach in many analytics platforms, systematically undervalues awareness and consideration activities while overvaluing conversion touchpoints creating budget misallocation. Multi-touch attribution provides more accurate accounting of channel contribution recognizing that customer journeys involve multiple influences. Research demonstrates that organizations using sophisticated attribution achieve 20-30% better ROI through superior budget allocation compared to last-touch attribution users. The pharmaceutical industry faces particular attribution challenges given lengthy decision cycles, multiple decision-makers, and mix of digital and personal channels. The proposed attribution framework supports multiple methodologies enabling comparison and validation while providing actionable insights for budget optimization and campaign planning.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2-3)

**Dependencies:** REQ-231 through REQ-238 (complete event collection enabling journey reconstruction), REQ-239 through REQ-248 (reporting foundation), attribution modeling service deployment

**Acceptance Criteria:**

- Attribution data mart deployed with journey reconstruction capability  
- Multiple attribution models implemented including rules-based and algorithmic approaches  
- Model comparison dashboard showing credit distribution across methodologies  
- Incrementality measurement through holdout testing for priority campaigns

**Success Metrics:**

- Attribution coverage: Over 70% of conversions attributed to touchpoints  
- Model agreement: Attribution models showing consistent directional findings despite methodological differences  
- Business adoption: Attribution insights informing minimum 50% of budget allocation decisions within twelve months  
- Validation accuracy: Holdout test results confirming attribution model predictions within 20%

---

**Capability 4: Marketing Mix Modeling and Budget Optimization**

**Detailed Requirements:**

- REQ-259: Marketing mix model development using Bayesian hierarchical modeling to quantify incremental impact of each marketing channel controlling for seasonality, competitive activity, and market dynamics.  
- REQ-260: Data preparation pipeline aggregating spend, impressions, and outcomes at weekly or monthly level with external factors including competitor spending, economic indicators, and category trends.  
- REQ-261: Diminishing returns curves quantifying how additional investment in each channel produces declining marginal returns informing optimal saturation levels.  
- REQ-262: Channel interaction effects modeling how channels work together with synergies or conflicts affecting combined effectiveness beyond individual contributions.  
- REQ-263: Time lag effects accounting for delayed impact of marketing activities recognizing that awareness campaigns influence outcomes weeks or months later.  
- REQ-264: Geographic variation modeling recognizing that channel effectiveness differs by market size, competitive intensity, and customer characteristics with localized coefficients.  
- REQ-265: Scenario simulation engine testing "what-if" budget reallocation strategies showing predicted outcomes before implementation enabling risk-free exploration.  
- REQ-266: Constrained optimization solver maximizing objective function subject to budget limits, minimum spend requirements, and strategic constraints generating optimal allocation recommendations.  
- REQ-267: Confidence intervals and sensitivity analysis quantifying uncertainty in recommendations showing range of expected outcomes and identifying key assumptions.  
- REQ-268: Model validation using out-of-sample testing and comparison against actual results assessing prediction accuracy and refining methodology.  
- REQ-269: Marketing mix reporting dashboard visualizing channel ROI curves, optimization recommendations, and historical performance with accessible explanations for non-technical stakeholders.

**Business Rationale:** Marketing mix modeling provides strategic-level view of channel effectiveness complementing tactical attribution analysis by accounting for broad market factors, competitive dynamics, and saturation effects. While attribution models analyze customer-level journeys, marketing mix models operate at aggregate level using statistical techniques to isolate marketing impact from confounding factors. This proves particularly valuable for pharmaceutical marketing where long sales cycles, external detailing, and market dynamics complicate customer-level attribution. Organizations implementing marketing mix modeling achieve fifteen to 25% improvement in marketing efficiency through data-driven budget reallocation away from saturated channels toward underfunded opportunities. The proposed marketing mix framework uses modern Bayesian methods providing more robust estimates with smaller data requirements than traditional regression approaches while enabling scenario planning and optimization supporting annual planning and quarterly reforecasting decisions.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 4\)

**Dependencies:** REQ-231 through REQ-238 (historical data minimum eighteen months), REQ-249 through REQ-258 (attribution foundation), marketing mix modeling platform or partner

**Acceptance Criteria:**

- Marketing mix model developed for priority therapeutic areas  
- Model incorporating minimum twelve marketing channels and six external factors  
- Scenario simulation capability enabling "what-if" budget reallocation testing  
- Optimization solver generating budget allocation recommendations with constraints

**Success Metrics:**

- Model accuracy: Prediction error under 15% on out-of-sample validation  
- Business value: Optimization-driven reallocation improving portfolio ROI by minimum 15%  
- Stakeholder adoption: Marketing mix insights informing annual planning process  
- Model refresh: Quarterly model updates incorporating latest performance data

---

**Capability 5: Portfolio Analytics and Cross-Brand Intelligence**

**Detailed Requirements:**

- REQ-270: Portfolio data model aggregating performance across brands, therapeutic areas, and geographies with hierarchical roll-up and cross-sectional comparison capability.  
- REQ-271: Normalized metrics enabling fair comparison across brands of different sizes using cost per lead, pipeline per million dollars spend, and market share gain measures.  
- REQ-272: Launch phase tracking categorizing brands by lifecycle stage including pre-launch, launch, growth, and mature with phase-appropriate benchmark comparisons.  
- REQ-273: Best practice identification analyzing top-performing campaigns and journeys to extract replicable patterns and successful strategies for portfolio-wide application.  
- REQ-274: Competitive intelligence integration incorporating competitor digital presence, share of voice, message positioning, and channel strategies informing strategic decisions.  
- REQ-275: Journey pattern library cataloging proven engagement sequences with performance metadata including historical results, use cases, and adaptation guidance.  
- REQ-276: Cross-brand learning dashboard highlighting successful tactics from one brand or therapeutic area with potential application elsewhere encouraging knowledge transfer.  
- REQ-277: Portfolio optimization recommendations suggesting budget reallocation across brands based on marginal ROI, strategic priorities, and growth potential.  
- REQ-278: Therapeutic area benchmarking comparing performance against category norms, competitive set, and historical baselines contextualizing results.  
- REQ-279: Executive portfolio dashboard providing C-suite visibility to marketing performance across the entire portfolio with strategic insights and trend identification.

**Business Rationale:** Pharmaceutical companies manage portfolios spanning multiple brands, therapeutic areas, and geographies creating opportunities for cross-learning and portfolio-level optimization that individual brand teams cannot achieve. Successful strategies from oncology brands may transfer to immunology programs. High-performing journeys from mature brands can accelerate new launches. Budget reallocation across portfolio based on marginal returns generates superior enterprise outcomes compared to optimizing each brand independently. However, realizing these benefits requires systematic portfolio analytics with consistent measurement, normalized metrics, and knowledge sharing infrastructure. Organizations with mature portfolio analytics capabilities achieve 20-30% higher aggregate marketing ROI through cross-brand learning and portfolio-level budget optimization. The proposed portfolio framework provides enterprise visibility enabling strategic decision-making while empowering brand teams with access to proven practices and competitive intelligence accelerating performance improvement across entire portfolio.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-231 through REQ-269 (comprehensive measurement across brands enabling portfolio analysis), product and therapeutic area data model

**Acceptance Criteria:**

- Portfolio data model deployed with brand, therapeutic area, and geography dimensions  
- Normalized metrics calculated enabling cross-brand comparison  
- Journey pattern library containing minimum twenty proven patterns with performance data  
- Portfolio optimization recommendations generated quarterly

**Success Metrics:**

- Cross-brand learning: Minimum five successful pattern replications per year across brands  
- Portfolio optimization value: Budget reallocation generating minimum ten percent incremental ROI  
- Executive engagement: C-suite regularly reviewing portfolio dashboard  
- Knowledge sharing: Over 60% of brand marketers accessing cross-brand insights quarterly

---

### Summary: Swimlane F Requirements Catalog

| Requirement ID | Requirement Title | Priority | Phase | Dependencies |
| :---- | :---- | :---- | :---- | :---- |
| REQ-231 | Universal Event Schema | P0 | Phase 1 | REQ-006, 050-055, warehouse |
| REQ-232 | Client-Side Tracking | P0 | Phase 1 | REQ-231 |
| REQ-233 | Server-Side Event APIs | P0 | Phase 1 | REQ-231 |
| REQ-234 | Real-Time Event Streaming | P0 | Phase 1 | REQ-231 |
| REQ-235 | Event Enrichment Service | P0 | Phase 1 | REQ-231 |
| REQ-236 | Data Quality Monitoring | P0 | Phase 1 | REQ-231-235 |
| REQ-237 | Historical Data Retention | P0 | Phase 1 | Warehouse storage |
| REQ-238 | Privacy-Compliant Handling | P0 | Phase 1 | REQ-231 |
| REQ-239 | Campaign Dashboard | P0 | Phase 1 | REQ-231-238, BI platform |
| REQ-240 | Real-Time Metrics | P0 | Phase 1 | REQ-234 |
| REQ-241 | Historical Trend Analysis | P0 | Phase 1 | REQ-237, 239 |
| REQ-242 | Cohort Analysis | P1 | Phase 2 | REQ-239 |
| REQ-243 | Funnel Visualization | P1 | Phase 2 | REQ-239 |
| REQ-244 | Content Performance | P1 | Phase 2 | REQ-113, 239 |
| REQ-245 | Channel Effectiveness | P0 | Phase 1 | REQ-239 |
| REQ-246 | Geographic Breakdown | P1 | Phase 2 | REQ-067, 239 |
| REQ-247 | Anomaly Detection | P1 | Phase 2 | REQ-240 |
| REQ-248 | Scheduled Distribution | P1 | Phase 2 | REQ-239 |
| REQ-249 | Attribution Data Mart | P1 | Phase 2 | REQ-231-238 |
| REQ-250 | Rules-Based Attribution | P1 | Phase 2 | REQ-249 |
| REQ-251 | Algorithmic Attribution | P2 | Phase 3 | REQ-250 |
| REQ-252 | Shapley Value Attribution | P2 | Phase 3 | REQ-250 |
| REQ-253 | Multi-Touch Attribution | P1 | Phase 2 | REQ-249 |
| REQ-254 | Segment-Specific Models | P2 | Phase 3 | REQ-063-092, 253 |
| REQ-255 | Model Comparison | P1 | Phase 2 | REQ-250-252 |
| REQ-256 | Incrementality Measurement | P1 | Phase 2 | REQ-159 |
| REQ-257 | Attribution Dashboard | P1 | Phase 2 | REQ-249-256 |
| REQ-258 | Model Governance | P1 | Phase 2 | REQ-083 |
| REQ-259 | Marketing Mix Modeling | P2 | Phase 4 | 18+ months data |
| REQ-260 | Data Preparation Pipeline | P2 | Phase 4 | REQ-259 |
| REQ-261 | Diminishing Returns Curves | P2 | Phase 4 | REQ-259 |
| REQ-262 | Channel Interaction Effects | P2 | Phase 4 | REQ-259 |
| REQ-263 | Time Lag Effects | P2 | Phase 4 | REQ-259 |
| REQ-264 | Geographic Variation | P2 | Phase 4 | REQ-067, 259 |
| REQ-265 | Scenario Simulation | P2 | Phase 4 | REQ-259 |
| REQ-266 | Constrained Optimization | P2 | Phase 4 | REQ-259 |
| REQ-267 | Confidence Intervals | P2 | Phase 4 | REQ-259 |
| REQ-268 | Model Validation | P2 | Phase 4 | REQ-259 |
| REQ-269 | MMM Dashboard | P2 | Phase 4 | REQ-259-268 |
| REQ-270 | Portfolio Data Model | P2 | Phase 5 | Product hierarchy |
| REQ-271 | Normalized Metrics | P2 | Phase 5 | REQ-270 |
| REQ-272 | Launch Phase Tracking | P2 | Phase 5 | REQ-270 |
| REQ-273 | Best Practice Identification | P2 | Phase 5 | REQ-239-269 |
| REQ-274 | Competitive Intelligence | P2 | Phase 5 | External data sources |
| REQ-275 | Journey Pattern Library | P2 | Phase 5 | REQ-136 |
| REQ-276 | Cross-Brand Learning | P2 | Phase 5 | REQ-270-275 |
| REQ-277 | Portfolio Optimization | P2 | Phase 5 | REQ-259-269 |
| REQ-278 | Therapeutic Area Benchmarks | P2 | Phase 5 | REQ-270 |
| REQ-279 | Executive Portfolio Dashboard | P2 | Phase 5 | REQ-270-278 |

---

## SECTION 2 SUMMARY

This enhanced Section 2 provides comprehensive requirements for all six operational swimlanes spanning governance through measurement and learning. The section documents two hundred seventy-nine detailed requirements across foundation infrastructure, strategic capabilities, and advanced analytics organized into clear functional domains with explicit business rationale, technical specifications, priorities, dependencies, and success metrics.

### Requirements Summary by Swimlane

| Swimlane | Requirements | Priority P0 | Priority P1 | Priority P2 | Phase 1 | Phase 2 | Phase 3+ |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| A: Govern | REQ-001 to REQ-062 | 28 | 24 | 10 | 28 | 24 | 10 |
| B: Segment | REQ-063 to REQ-092 | 12 | 12 | 6 | 12 | 12 | 6 |
| C: Create | REQ-093 to REQ-132 | 21 | 15 | 4 | 21 | 15 | 4 |
| D: Orchestrate | REQ-133 to REQ-173 | 6 | 20 | 15 | 6 | 20 | 15 |
| E: Execute | REQ-174 to REQ-230 | 20 | 27 | 10 | 20 | 27 | 10 |
| F: Measure & Learn | REQ-231 to REQ-279 | 19 | 13 | 17 | 19 | 13 | 17 |
| **Total** | **279** | **106** | **111** | **62** | **106** | **111** | **62** |

### Priority Distribution Analysis

Foundation requirements (Priority P0, Phase 1\) comprise 106 requirements representing thirty-eight percent of total scope. These requirements establish data infrastructure, governance frameworks, compliance controls, and core execution capabilities enabling subsequent phases. Strategic capabilities (Priority P1, Phase 2-3) comprise 111 requirements representing 40% of scope adding journey orchestration, experimentation, attribution, and optimization capabilities. Advanced analytics and portfolio intelligence (Priority P2, Phase 3-5) comprise sixty-two requirements representing twenty-two percent of scope providing sophisticated modeling, portfolio optimization, and enterprise intelligence.

This phasing enables early value delivery through foundation deployment while building toward advanced capabilities delivering competitive differentiation and portfolio-level optimization.

---

# SECTION 3: ADVANCED JOURNEY ORCHESTRATION CAPABILITIES

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## OVERVIEW

Advanced journey orchestration represents the strategic differentiator separating pharmaceutical marketing operations that achieve consistent excellence from those struggling with disconnected campaign execution. While basic campaign management platforms enable message delivery across channels, sophisticated journey orchestration systems provide the infrastructure for designing complex multi-step engagement sequences, embedding compliance controls within workflow automation, conducting rigorous experimentation, managing message fatigue across the enterprise, and continuously optimizing based on real-time performance data. This section details the technical requirements, business rationale, and implementation specifications for three critical journey orchestration capabilities that elevate pharmaceutical marketing from tactical campaign execution to strategic customer lifecycle management.

The proposed journey orchestration framework addresses fundamental challenges inherent in pharmaceutical marketing including the necessity to balance promotional effectiveness with regulatory compliance, the complexity of coordinating multiple therapeutic areas and brands without overwhelming customers, the requirement to prove incremental value through controlled experimentation, and the need to optimize continuously despite lengthy conversion cycles. Organizations implementing advanced journey orchestration capabilities report 40-60% improvement in customer engagement rates, 30-50% reduction in compliance violations through automated enforcement, twenty-five to 40% increase in marketing return on investment through systematic optimization, and 50-70% acceleration in campaign launch velocity through self-service authoring tools.

This section provides comprehensive specifications across three capability domains. First, the Journey Authoring Canvas delivers visual design tools enabling business users to configure sophisticated multi-step journeys without technical assistance while embedding compliance checkpoints and measurement instrumentation. Second, the Advanced Experimentation Framework provides statistical rigor and automated optimization through A/B testing, multi-armed bandit algorithms, holdout group management, and Bayesian learning approaches. Third, the Central Fatigue Management Service prevents customer overexposure through enterprise-wide visibility, real-time enforcement, and intelligent throttling across all campaigns, brands, and channels. Together, these capabilities enable pharmaceutical marketers to execute complex engagement strategies at scale while maintaining regulatory compliance, respecting customer preferences, and demonstrating measurable business value.

---

**Note on Requirement Relationships:** This section provides detailed technical specifications for journey orchestration capabilities introduced conceptually in Section Two. Requirements REQ-280 through REQ-287 elaborate the technical implementation details, architectural patterns, and acceptance criteria for capabilities defined at the conceptual level in requirements REQ-133 through REQ-140. Specifically, REQ-280 details the Lightning Web Component architecture vision from REQ-133, REQ-281 expands the node library concept from REQ-134, REQ-282 elaborates visual flow designer capabilities from REQ-137, REQ-283 details the template library vision from REQ-136, REQ-284 provides technical version control specifications supporting REQ-135, REQ-285 expands collaboration features from REQ-140, REQ-286 details simulation capabilities from REQ-138, and REQ-287 elaborates documentation generation from REQ-139. Organizations should treat these as progressive specification levels where Section Two requirements define functional capabilities and business outcomes while Section Three requirements specify technical implementation approaches. Both requirement sets contribute to the complete journey orchestration solution and require coordinated implementation during Phase 2 deployment.

## 3.1 JOURNEY AUTHORING CANVAS (LIGHTNING WEB COMPONENT)

### Capability Overview

The Journey Authoring Canvas provides pharmaceutical marketers with intuitive visual design tools for configuring multi-step customer engagement sequences spanning weeks, months, or years across email, SMS, mobile applications, web experiences, field sales activities, patient support programs, and third-party channels. Built as a Lightning Web Component within Salesforce, the canvas integrates natively with customer data, campaign metadata, content libraries, and compliance workflows while supporting hybrid architectures where journey execution occurs in Marketing Cloud Engagement, Braze, or Iterable platforms.

Traditional journey design requires technical resources to translate business requirements into execution code creating bottlenecks that delay launches by weeks or months and limiting optimization velocity to quarterly or annual cycles. Marketing business users understand customer needs, therapeutic positioning, and competitive dynamics but lack the technical skills to configure journey logic in code-based platforms. Meanwhile, technical resources capable of implementing journeys face overwhelming demand serving multiple brands and therapeutic areas creating chronic backlog. This disconnect results in suboptimal journeys that fail to incorporate marketer insights, prolonged time-to-market that misses competitive windows, and insufficient optimization that leaves performance improvements unrealized.

The Journey Authoring Canvas democratizes journey design by providing drag-and-drop visual configuration enabling marketers to translate strategic intent into executable workflows without technical intermediation. The canvas supports sophisticated logic including conditional branching based on customer behavior, wait steps calibrated to conversion cycle timing, experimentation nodes randomizing customers into test variants, compliance gates preventing non-compliant execution, fatigue checks respecting message volume limits, and cross-channel orchestration coordinating email, SMS, and field activities. Pre-built templates provide starting points for common use cases including awareness campaigns, lead nurturing sequences, patient onboarding flows, and retention programs. Visual validation detects configuration errors before activation preventing issues that would otherwise surface during execution. Journey versioning maintains complete history enabling restoration of previous configurations and supporting regulatory audit requirements.

Organizations implementing visual journey authoring report 60-70% reduction in journey launch time from conception to activation, 40-50% increase in journey creation volume enabling more targeted and personalized programs, 30-40% improvement in journey performance through marketer-driven optimization, and 50% reduction in technical resource demand freeing scarce talent for strategic initiatives rather than tactical configuration work.

### Detailed Requirements

**REQ-280: Lightning Web Component Architecture**

The journey canvas shall be implemented as a Lightning Web Component deployed within Salesforce Experience Cloud enabling access through web browsers and mobile devices without requiring separate application installation. The component shall leverage Salesforce Lightning Design System ensuring consistent user interface patterns, accessibility compliance meeting WCAG 2.1 AA standards, and responsive design adapting to desktop monitors, tablets, and smartphones. The architecture shall support both embedded deployment within Salesforce record pages allowing journey design in context of campaign or customer records and standalone deployment as dedicated journey authoring application. The component shall utilize Lightning Data Service for efficient data access minimizing server round trips and Lightning Message Service for communication with other components enabling modular architecture where journey canvas coordinates with content selection, audience definition, and approval workflow components.

**Business Rationale:** Lightning Web Component architecture provides future-proof foundation leveraging Salesforce platform capabilities including security model, user authentication, data access controls, and platform services while enabling rapid enhancement through modern web development practices. Native Salesforce integration eliminates separate login credentials, duplicate user management, and data synchronization complexity that plague standalone journey tools. Lightning Design System compliance ensures consistent user experience across Salesforce applications reducing training burden and improving adoption. Responsive design enables journey design from any device supporting field-based marketers and executives who require mobile access for review and approval. Organizations report 30-40% faster deployment and 20-30% lower total cost of ownership for Lightning Web Component solutions versus standalone applications due to leveraging existing Salesforce infrastructure.

**Swimlane Alignment:** Swimlane D (Orchestrate)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** Salesforce platform, REQ-005 through REQ-009 (customer data foundation), REQ-133 (journey canvas vision)

**Acceptance Criteria:** Lightning Web Component deployed in Salesforce with desktop and mobile responsive design, Lightning Design System compliance validated through automated testing, embedded and standalone deployment modes functional, Lightning Data Service and Message Service integration implemented.

**Success Metrics:** Component load time under two seconds on standard broadband connections, mobile usability score above 85% on user testing, accessibility audit showing zero critical violations, cross-browser compatibility supporting Chrome, Safari, Firefox, and Edge latest versions.

---

**REQ-281: Drag-and-Drop Node Library**

The journey canvas shall provide comprehensive node library supporting message delivery nodes for email, SMS, push notifications, in-app messages, and direct mail; wait nodes defining delays measured in minutes, hours, days, or weeks with specific time or relative offset options; decision split nodes evaluating customer attributes, behaviors, or external data to route individuals down different paths; A/B test nodes randomizing customers into control and treatment variants with traffic allocation controls; holdout nodes excluding percentage of eligible customers from journey participation enabling incrementality measurement; channel selection nodes determining optimal delivery channel based on customer preferences and engagement history; fatigue check nodes verifying customers have not exceeded message volume thresholds before delivery; MLR gate nodes blocking journey progression until regulatory approval obtained for linked content; goal completion nodes tracking when customers achieve defined objectives triggering journey exit or progression; and custom action nodes invoking external APIs or Salesforce automation enabling integration with patient programs, field systems, or third-party platforms.

Each node type shall provide configuration interface appropriate to its function. Message nodes shall enable content selection from approved asset libraries, personalization token insertion, send window specification, and delivery tracking configuration. Wait nodes shall support fixed duration, wait until specific date or time, wait until customer exhibits behavior, and wait until external conditions are satisfied. Decision splits shall provide visual expression builder for boolean logic with support for customer attributes, calculated fields, and external data lookups. A/B test nodes shall configure variant definitions, traffic allocation percentages, success metrics, and test duration. The node library shall be extensible enabling custom node development for organization-specific requirements through documented Lightning Web Component APIs and developer guides.

**Business Rationale:** Comprehensive node library transforms journey canvas from simple sequential message delivery tool into sophisticated orchestration platform capable of implementing complex engagement strategies. Decision splits enable personalization at scale routing customers to relevant content based on specialty, practice setting, therapeutic interests, or engagement history achieving relevance impossible with one-size-fits-all approaches. A/B test nodes embed experimentation directly in journey workflow ensuring every journey generates learning contributing to continuous improvement. MLR gates prevent the most common cause of compliance violations by blocking execution until all required approvals are obtained. Fatigue checks respect customer preferences preventing negative experiences that drive opt-outs and damage brand perception. Organizations report that 60% of journey value derives from sophisticated node types beyond basic message delivery with decision logic and experimentation proving particularly impactful.

**Swimlane Alignment:** Swimlane D (Orchestrate)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-280 (canvas architecture), REQ-141 through REQ-148 (channel execution), REQ-152 (fatigue check API), REQ-157 (experimentation framework)

**Acceptance Criteria:** Node library containing minimum twenty node types covering common use cases, each node type with appropriate configuration interface, drag-and-drop functionality enabling node placement and connection, node library extensible through documented APIs.

**Success Metrics:** Node library usage distribution showing 50% of journeys using decision splits, 30% using A/B tests, 70% using wait logic, user satisfaction with node functionality above 8 out of 10, custom node development by internal teams or partners demonstrating extensibility.

---

**REQ-282: Visual Flow Designer with Intelligent Layout**

The journey canvas shall provide visual flow designer enabling marketers to arrange nodes in two-dimensional workspace with automatic layout optimization preventing overlapping nodes and crossing connection lines. The designer shall support zoom controls enabling overview of entire journey structure and detailed view of individual node configurations, pan functionality for navigating large journeys exceeding single screen, and minimap providing orientation reference showing current viewport location within overall journey structure. Connection lines linking nodes shall automatically route around obstacles using orthogonal or curved paths maintaining clarity even in complex journeys with multiple branches and rejoins. The designer shall provide snap-to-grid alignment assistance ensuring professional appearance and consistent spacing. Selection tools shall enable multi-select for bulk operations including copy, paste, delete, and group movement. Undo and redo functionality shall maintain operation history enabling error recovery and experimental layout exploration without commitment.

The visual designer shall incorporate journey flow validation detecting configuration issues including orphaned nodes not connected to journey start, infinite loops where customers could circulate indefinitely, missing required configuration such as message content selection or wait duration specification, conflicting logic where multiple paths could execute simultaneously, and compliance gaps where MLR gates absent for promotional content. Validation shall occur continuously as marketers build journeys with real-time feedback through visual indicators on problematic nodes and detailed error descriptions in the validation panel. The designer shall prevent journey activation when validation errors exist ensuring only complete and correct configurations enter production.

**Business Rationale:** Visual clarity proves essential for journey comprehension enabling marketers to understand flow logic, identify optimization opportunities, and communicate strategies to stakeholders. Poorly designed visual tools create confusion limiting adoption and effectiveness. Automatic layout optimization and intelligent connection routing prevent visual clutter that obscures logic in complex journeys. Research demonstrates that well-designed visual tools improve user task completion rates by 40-60% and reduce errors by 50-70% compared to code-based or poorly visualized alternatives. Real-time validation prevents most common configuration errors before they impact customers with studies showing 60-80% of journey issues detectable through automated validation. Organizations implementing sophisticated visual designers report 30% faster journey creation and 40% fewer production issues compared to text-based or simple visual tools.

**Swimlane Alignment:** Swimlane D (Orchestrate)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-280 (canvas architecture), REQ-281 (node library)

**Acceptance Criteria:** Visual designer supporting zoom, pan, and minimap navigation, automatic layout optimization preventing overlap and crossing lines, real-time validation detecting minimum twenty common error types, undo and redo functionality with minimum twenty operation history depth.

**Success Metrics:** User task completion rate above 80% for standard journey creation scenarios, configuration error rate below 5% of journeys requiring post-activation remediation, user satisfaction with visual designer usability above 8 out of 10, journey comprehension assessment showing 80% of stakeholders correctly interpreting journey logic from visual representation.

---

**REQ-283: Journey Template Library and Pattern Catalog**

The journey canvas shall provide curated template library containing proven journey patterns for common pharmaceutical marketing use cases including HCP awareness campaigns introducing new therapies to target specialists, lead nurturing sequences converting interested physicians to active prescribers, patient onboarding flows supporting therapy initiation and education, medication adherence programs maintaining long-term treatment persistence, event promotion sequences driving conference and webinar registration and attendance, sample request fulfillment workflows coordinating representative follow-up with digital engagement, and reactivation campaigns re-engaging dormant customers. Each template shall include pre-configured node structure, recommended message content placeholder with suggested topics and calls-to-action, audience definition guidance specifying ideal candidate profiles, success metrics definition identifying key performance indicators, and implementation instructions documenting customization steps and best practices.

Templates shall support one-click cloning creating editable copies that marketers customize for specific therapeutic areas, brands, and customer segments without affecting original template. The cloning process shall prompt for required parameters including brand selection, therapeutic area specification, audience definition, and campaign metadata ensuring cloned journeys maintain governance compliance. Templates shall include performance metadata documenting historical results when pattern previously deployed including sample sizes, conversion rates, engagement metrics, and statistical confidence intervals providing evidence-based selection guidance. The template library shall support user-contributed patterns enabling high-performing journeys to be promoted to template status encouraging cross-brand learning and best practice replication.

**Business Rationale:** Starting journey design from proven templates dramatically accelerates creation velocity and improves initial performance compared to designing from blank canvas. Templates encode accumulated organizational knowledge including effective message sequences, optimal timing intervals, and successful engagement tactics that would otherwise reside only in experienced marketer tacit knowledge. Research demonstrates that template-based journey creation achieves 40-60% faster launch times and 20-30% better initial performance compared to custom designs due to incorporating proven practices. Performance metadata enables evidence-based template selection with marketers choosing patterns demonstrating success in similar contexts. User contribution capability creates a virtuous cycle where successful journeys become templates benefiting the entire organization. Organizations implementing sophisticated template libraries report 50% of journeys starting from templates within twelve months and 30% improvement in average journey performance through accumulated learning codified in templates.

**Swimlane Alignment:** Swimlane D (Orchestrate)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-280 through REQ-282 (canvas foundation), REQ-136 (template library vision)

**Acceptance Criteria:** Template library containing minimum fifteen templates covering priority use cases, one-click cloning functional with parameter prompting, performance metadata displayed for templates with previous deployment history, user contribution workflow enabling journey promotion to template status.

**Success Metrics:** Template usage rate reaching 50% of new journeys within six months of deployment, template-based journeys showing 20% better initial performance than custom journeys, user satisfaction with template library above 8 out of 10, minimum five user-contributed templates added within the first year demonstrating knowledge sharing.

---

**REQ-284: Journey Versioning and Change Management**

The journey canvas shall maintain complete version history for every journey capturing major versions representing substantive changes requiring MLR re-review and minor versions reflecting non-promotional updates not affecting compliance status. Each version shall store complete journey configuration including node arrangements, connection logic, message content references, audience definitions, and metadata with version number following semantic versioning convention, creation timestamp, author identity, change description, and approval status. The versioning system shall enable comparison between any two versions highlighting differences in visual format showing added nodes, deleted nodes, modified configurations, and changed connections. Version restoration shall support reverting to any previous configuration creating a new major or minor version as appropriate rather than destructive replacement maintaining complete audit trail.

Journey versioning shall integrate with MLR approval workflow automatically creating a new major version when any journey modification affects promotional claims, message content, audience targeting, or channel selection triggering re-review requirement. The system shall lock approved journey versions preventing inadvertent modification and requiring explicit version creation for any changes ensuring approved configurations remain frozen. Version branching shall support creating experimental variants from approved baseline enabling testing alternative approaches without disrupting production journey. The versioning system shall generate change logs suitable for regulatory audit documenting who made what changes when and why providing defensible compliance evidence.

**Business Rationale:** Complete version history proves essential for regulatory compliance, quality assurance, and continuous improvement in pharmaceutical marketing. FDA inspectors routinely request documentation showing how promotional materials evolved over time including what changes occurred when and whether appropriate reviews occurred. Version control provides this documentation preventing consent decree risk associated with inadequate recordkeeping. Version comparison enables efficient MLR review showing exactly what changed rather than requiring full re-review of unchanged elements reducing review burden and accelerating approval. Version restoration provides a safety net encouraging experimentation knowing unsuccessful changes can be reversed without permanent impact. Organizations with mature version control report 50% faster MLR re-review cycles, zero documentation gaps during regulatory inspections, and 30% more frequent optimization iterations due to reduced risk of irreversible mistakes.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane A (Govern)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-280 through REQ-283 (canvas foundation), REQ-115 through REQ-123 (MLR workflow), REQ-031 (version control principle)

**Acceptance Criteria:** Version history maintained for all journeys with complete configuration capture, major and minor version designation with appropriate MLR workflow integration, version comparison highlighting differences in visual format, version restoration creating new version while preserving history.

**Success Metrics:** Version history completeness at 100% of journeys, MLR re-review cycle time reduction of 40% through change highlighting, zero version control incidents causing compliance issues, version restoration usage demonstrating safety net value with minimum ten restorations quarterly.

---

**REQ-285: Collaborative Journey Development Workflow**

The journey canvas shall support multi-user collaboration enabling marketing strategists to define objectives and audience, content creators to specify messages and creative elements, medical affairs to validate claims and evidence, legal reviewers to ensure regulatory compliance, and marketing operations to configure technical settings within single coordinated workflow. The collaboration framework shall provide role-based permissions controlling which users can view, edit, comment, approve, or activate journeys with granular permissions at node level enabling medical review of message content without exposing technical configuration complexity. The system shall maintain presence awareness showing which users are currently viewing or editing journeys, preventing conflicting simultaneous modifications and enabling real-time coordination.

Collaboration capabilities shall include threaded comment discussions attached to specific nodes enabling contextual feedback such as medical reviewer questioning claim substantiation or legal reviewer requesting fair balance enhancement, mention notifications alerting specific users when requiring their input or approval, task assignment designating responsibility for specific aspects such as content finalization or audience refinement, and activity feeds showing complete chronological history of modifications, comments, approvals, and status changes. The collaboration workflow shall integrate with Salesforce Chatter enabling journey discussions to occur within familiar enterprise collaboration platforms and notification delivery through email, mobile push, or Slack based on user preferences.

**Business Rationale:** Journey development requires coordination across multiple stakeholders each contributing specialized expertise. Sequential handoffs between teams create delays and context loss while simultaneous independent work creates conflicts and rework. Collaborative platforms enable parallel workstreams with appropriate coordination reducing time-to-market while maintaining quality and compliance. Research demonstrates that collaborative development tools reduce project cycle time by 30-50% through eliminating handoff delays, improve quality by 20-30% through continuous feedback rather than late-stage review, and increase stakeholder satisfaction by 40-50% through transparency and engagement. Organizations implementing collaborative journey development report 40% faster launches, 30% fewer MLR iterations due to early medical involvement, and 25% improvement in cross-functional relationship quality.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane C (Create)

**Priority:** P2 \- Enhanced capability (Phase 3\)

**Dependencies:** REQ-280 through REQ-284 (canvas foundation), REQ-115 through REQ-123 (MLR workflow), Salesforce Chatter integration

**Acceptance Criteria:** Role-based permissions controlling view, edit, comment, approve, and activate capabilities, threaded comments attachable to nodes with mention notifications, presence awareness showing active users, activity feed documenting complete change history.

**Success Metrics:** Collaboration feature adoption with 60% of journeys having multi-user engagement, comment threads averaging three to five exchanges demonstrating substantive discussion, cycle time reduction of 30% for collaboratively developed journeys versus sequential handoff model, stakeholder satisfaction with collaboration experience above 8 out of 10\.

---

**REQ-286: Journey Simulation and Testing Capability**

The journey canvas shall provide simulation capability enabling marketers to test journey logic with sample customer profiles before activating to real audiences. The simulator shall accept test customer records with specified attributes including demographics, behaviors, engagement history, and segment membership then process these records through journey configuration showing which path each customer follows, which messages they receive, which wait durations they experience, and which decision split outcomes occur. The simulation shall generate a visual trace highlighting path taken by each test customer with timing annotations showing when each node executes and detailed logs documenting decision logic evaluation including attribute values, comparison operators, and boolean results.

The testing framework shall support batch simulation processing multiple test customers simultaneously enabling comprehensive testing of all journey paths and edge cases. Simulation results shall identify unreachable nodes that no test customer encounters suggesting configuration errors, unintended behaviors such as customers exiting journey prematurely, and performance issues including excessive wait times or insufficient message cadence. The simulator shall enable iterative testing where marketers modify journey configuration and re-run simulation observing impact without affecting production customers. Integration with customer data shall enable simulation using actual anonymized customer samples providing realistic testing rather than only synthetic profiles.

**Business Rationale:** Production issues discovered after journey activation create negative customer experiences, waste marketing budget, and potentially cause compliance violations requiring remediation. Simulation enables proactive testing identifying issues before customer impact similar to software testing preventing production bugs. Complex journeys with multiple decision branches create numerous possible paths making exhaustive manual testing impractical. Automated simulation tests all paths systematically ensuring comprehensive coverage. Research demonstrates that organizations implementing journey testing reduce production issues by 60-80%, accelerate troubleshooting by 50% when issues occur through detailed execution traces, and improve marketer confidence enabling more sophisticated journey logic without fear of unintended consequences. Pharmaceutical marketing particularly benefits from simulation given compliance risks where testing prevents potential violations from reaching customers.

**Swimlane Alignment:** Swimlane D (Orchestrate)

**Priority:** P2 \- Enhanced capability (Phase 3\)

**Dependencies:** REQ-280 through REQ-285 (canvas foundation), REQ-005 through REQ-009 (customer data for realistic testing), REQ-138 (simulation vision)

**Acceptance Criteria:** Simulation capability processing individual and batch test customers through journey configuration, visual trace highlighting path taken with timing annotations, detailed execution logs documenting decision logic evaluation, unreachable node detection identifying configuration issues.

**Success Metrics:** Simulation usage rate reaching 40% of journeys receiving pre-activation testing within six months, production issue reduction of 50% attributable to simulation catching errors, simulation-detected issues averaging five per journey demonstrating value, user satisfaction with simulation capability above 8 out of 10\.

---

**REQ-287: Journey Documentation Generator**

The journey canvas shall automatically generate comprehensive documentation describing journey objectives, target audience, message sequence, decision logic, compliance controls, and success metrics in format suitable for MLR review, stakeholder communication, and regulatory audit. The documentation generator shall produce narrative description translating visual journey configuration into prose explaining journey purpose, customer eligibility criteria, message content and sequencing, personalization logic, branching rules, wait intervals, experimentation approach, compliance checkpoints, and performance measurement. The generated documentation shall include visual flowchart exported from canvas showing complete journey structure, data dictionary defining all customer attributes and segments referenced in decision logic, content inventory listing all messages with approval status and substantiation links, and change log documenting journey modifications over time.

Documentation generation shall support multiple output formats including Microsoft Word for MLR submission, PDF for stakeholder distribution, HTML for web publishing, and structured XML for system integration. The generator shall apply configurable templates controlling documentation structure, level of detail, and formatting conventions enabling organizations to establish standards meeting internal requirements and regulatory expectations. Documentation shall automatically update when journey configuration changes maintaining synchronization between design and specification preventing drift that creates compliance risk. The system shall maintain documentation version history aligned with journey versions providing complete audit trail showing specifications corresponding to each deployed configuration.

**Business Rationale:** Manual documentation creation proves time-consuming, error-prone, and frequently incomplete or outdated as journeys evolve. Marketing teams often delay or skip documentation due to competing priorities creating compliance gaps. Automated documentation generation eliminates this burden ensuring complete, accurate, and current specifications exist for every journey. MLR reviewers require narrative explanations supplementing visual flowcharts to understand journey intent and confirm compliance. Generated documentation provides this context reducing review cycles. Regulatory inspectors expect documentation demonstrating promotional controls. Automated generation ensures defensible documentation exists when required. Organizations implementing documentation automation report 80% reduction in specification creation time, elimination of documentation gaps that previously affected 30% of journeys, and 40% faster MLR reviews due to complete submission packages.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane A (Govern)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-280 through REQ-286 (canvas foundation providing data for documentation generation), REQ-115 through REQ-123 (MLR workflow), REQ-139 (documentation vision)

**Acceptance Criteria:** Documentation generator producing narrative description from journey configuration, multiple output formats including Word, PDF, HTML, and XML, configurable templates controlling structure and detail, automatic updates maintaining synchronization with configuration changes.

**Success Metrics:** Documentation generation usage reaching 90% of journeys within six months, MLR review time reduction of 30% attributed to complete documentation, regulatory audit preparation time reduction of 60%, user satisfaction with documentation quality above 8 out of 10\.

---

## 3.2 ADVANCED EXPERIMENTATION FRAMEWORK

### Capability Overview

The Advanced Experimentation Framework transforms pharmaceutical marketing from opinion-driven to evidence-driven decision-making by embedding rigorous testing into every customer journey enabling continuous learning and optimization. While intuition and experience provide valuable starting points for campaign strategy, systematic experimentation proves which tactics actually drive desired outcomes versus merely seeming promising. Pharmaceutical marketing particularly benefits from experimentation given lengthy conversion cycles, complex multi-stakeholder decisions, and significant investment levels where optimization generates substantial returns. A five percent improvement in campaign conversion rates achieved through systematic testing translates to millions of dollars in incremental revenue for major brands while poor decisions based on untested assumptions waste budget and miss market opportunities.

Traditional A/B testing implementations suffer from several limitations that reduce value capture. First, most platforms conduct tests sequentially declaring winners only after complete data collection creating delays that postpone optimization benefits. Second, simple randomization continues exposing customers to inferior variants even after performance differences become apparent, wasting impressions and budget. Third, limited statistical sophistication produces premature winner declarations when insufficient data collected or false negative findings when real differences are obscured by noise. Fourth, inability to test multiple variants simultaneously constrains learning velocity, limiting organizations to comparing two or three alternatives when dozens of variations might prove superior. Fifth, absence of incrementality measurement through holdout groups prevents distinguishing marketing-driven outcomes from organic behavior overstating effectiveness and justifying inefficient spending.

The proposed Advanced Experimentation Framework addresses these limitations through four integrated capabilities. Multi-armed bandit algorithms dynamically allocate traffic toward winning variants while experiments run maximizing performance during the learning phase rather than waiting for test completion. Bayesian statistical methods provide more accurate winner declarations with smaller sample sizes by incorporating prior knowledge and quantifying uncertainty. Multivariate testing enables simultaneous evaluation of numerous combinations identifying optimal message content, subject lines, send times, and creative elements through comprehensive exploration. Holdout group management reserves control populations receiving no treatment enabling incrementality quantification and proving marketing delivers value beyond what would occur naturally. Together these capabilities accelerate learning velocity, improve optimization rigor, and demonstrate measurable marketing contribution supporting evidence-based budget allocation.

Organizations implementing advanced experimentation frameworks report twenty-five to 40% improvement in campaign return on investment through accumulated learning, 50-70% reduction in time from hypothesis to conclusion through adaptive allocation and Bayesian methods, 30-50% increase in experimentation velocity enabling more tests per quarter, and definitive proof of marketing incrementality resolving debates about whether campaigns drive outcomes or merely correlate with organic behavior.

### Detailed Requirements

**REQ-288: A/B/n Testing Framework with Statistical Rigor**

The experimentation platform shall support rigorous A/B/n testing comparing control variants against one or more treatment variants with proper randomization ensuring comparable populations, statistical power calculation determining minimum sample sizes required for detecting meaningful effects with adequate confidence, and significance testing using appropriate methods including t-tests for continuous metrics, chi-square tests for categorical outcomes, and survival analysis for time-to-event measures. The framework shall require experiment definition specifying hypothesis statement, success metrics with direction of expected improvement, minimum detectable effect size representing smallest practically important difference, statistical significance threshold typically alpha equals 0.05, statistical power target typically 80-90%, and maximum test duration preventing indefinite experiments.

The system shall monitor experiments in real-time calculating current p-values, effect sizes, confidence intervals, and probability of achieving statistical significance given current trajectory. Automated winner declaration shall trigger when statistical significance achieved with confidence intervals excluding zero for continuous metrics or odds ratios excluding one for binary outcomes and minimum sample size requirements met, preventing premature conclusions from small samples. Early stopping rules shall terminate experiments showing no meaningful difference after sufficient data collected avoiding wasted impressions on indistinguishable variants. The framework shall account for multiple comparison correction when testing numerous metrics simultaneously preventing false positives from statistical fishing. Experiment results shall document complete methodology including randomization approach, sample sizes, statistical tests employed, p-values, effect sizes, confidence intervals, and business interpretation providing audit trail and enabling peer review.

**Business Rationale:** Statistical rigor separates meaningful conclusions from noise and prevents costly mistakes from misinterpreted data. Marketing experiments frequently suffer from inadequate sample sizes producing inconclusive results, premature winner declarations before sufficient evidence accumulated, and failure to account for multiple comparisons inflating false positive rates. These methodological flaws cause organizations to implement changes based on random variation rather than true performance differences. Research demonstrates that statistically rigorous experimentation identifies true winners correctly 95% of time compared to 60-70% for informal testing. Proper power calculations prevent wasted effort on underpowered tests while automated monitoring accelerates decisions through early stopping when conclusions are clear. Organizations implementing statistical rigor report 40% fewer incorrect optimization decisions and 30% faster learning through appropriate stopping rules.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-157 (A/B testing vision), REQ-160 (statistical analysis library), REQ-231 through REQ-238 (event collection for outcome measurement)

**Acceptance Criteria:** A/B/n testing supporting minimum ten simultaneous variants, statistical power calculation integrated into experiment design, automated winner declaration based on significance and sample size criteria, multiple comparison correction applied when testing numerous metrics.

**Success Metrics:** Experiment statistical rigor assessed by independent review showing 90% compliance with methodology standards, false positive rate measured through synthetic null tests below five percent, test duration reduction of 40% through early stopping versus fixed duration approach, user satisfaction with experimentation framework above 8 out of 10\.

---

**REQ-289: Multi-Armed Bandit Algorithms for Adaptive Optimization**

The experimentation platform shall implement multi-armed bandit algorithms that dynamically allocate traffic toward superior variants while simultaneously continuing exploration of alternatives balancing exploitation of current knowledge with discovery of potentially better options. The system shall support epsilon-greedy algorithms allocating majority of traffic to current best performer while reserving minority for random exploration, Thompson sampling using Bayesian posterior distributions to determine allocation probabilities favoring variants with higher probability of being optimal, and upper confidence bound methods selecting variants with highest optimistic estimate of performance accounting for uncertainty. Bandit algorithms shall adapt allocation continuously as performance data accumulates shifting traffic toward winners while maintaining statistical validity through proper exploration ensuring sufficient data for confident conclusions.

The bandit implementation shall provide configuration controls including exploration rate setting balance between exploitation and exploration based on business risk tolerance, update frequency determining how often allocation adjusts ranging from real-time to hourly or daily, and convergence criteria specifying when algorithm declares winner and ceases exploration. The system shall maintain a complete audit trail documenting allocation decisions, performance observations, and algorithm state evolution enabling retrospective analysis and regulatory compliance. Integration with journey canvas shall enable bandit nodes that automatically optimize message content, subject lines, send times, or creative elements without requiring marketer intervention providing continuous self-improvement.

**Business Rationale:** Traditional A/B testing wastes impressions on inferior variants by maintaining fixed allocation throughout test duration. If variant A outperforms variant B significantly, continuing to send 50% of traffic to variant B generates suboptimal outcomes for that half of the audience. Multi-armed bandits address this limitation by shifting traffic toward winners while experiments progress maximizing performance during the learning phase. Research demonstrates bandits achieve fifteen to 30% better cumulative results during testing period versus fixed allocation with equivalent statistical confidence at test conclusion. This advantage compounds when conducting continuous optimization rather than discrete experiments. Organizations implementing bandit algorithms report twenty to 35% improvement in campaign performance through always-on optimization and 50% reduction in regret from suboptimal decisions.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 3\)

**Dependencies:** REQ-288 (A/B testing foundation), REQ-158 (bandit vision), REQ-160 (statistical libraries), REQ-231 through REQ-238 (real-time performance data)

**Acceptance Criteria:** Multi-armed bandit algorithms implemented including epsilon-greedy, Thompson sampling, and upper confidence bound methods, configuration controls for exploration rate and update frequency, audit trail documenting allocation decisions and performance observations, integration with journey canvas enabling bandit optimization nodes.

**Success Metrics:** Bandit algorithm adoption with 30% of experiments using adaptive allocation within six months, cumulative performance improvement of 25% during testing versus fixed allocation, statistical validity confirmed through simulation showing correct winner identification 90% of time, user satisfaction with bandit functionality above 8 out of 10\.

---

**REQ-290: Holdout Group Management for Incrementality Measurement**

The experimentation platform shall support rigorous holdout group testing where the percentage of eligible customers excluded from receiving any treatment enables measurement of marketing incrementality through comparison between treated and untreated populations. The holdout framework shall provide holdout allocation specification defining percentage of customers withheld typically five to 20%, holdout duration configuration specifying time period from single campaign to ongoing program measurement, and random assignment algorithms ensuring holdout and treatment groups statistically equivalent on observable characteristics. The system shall maintain holdout group integrity preventing inadvertent message delivery to holdout customers through validation checks before every communication and alerting when violations are detected.

Incrementality measurement shall calculate lift metrics comparing treatment group outcomes against holdout group baseline including absolute lift showing raw difference between groups, relative lift showing percentage improvement versus baseline, incremental return on investment dividing incremental benefit by treatment cost, and statistical confidence intervals quantifying uncertainty in lift estimates. The framework shall support sophisticated incrementality designs including geo-holdout experiments assigning markets rather than individuals enabling measurement when customer-level randomization infeasible, time-based holdouts comparing periods with versus without treatment for seasonal or trend analysis, and propensity-matched holdouts using statistical matching when randomization impossible creating comparable groups through adjustment. Incrementality reporting shall document methodology, sample sizes, treatment details, outcome definitions, statistical tests, lift estimates with confidence intervals, and business interpretation providing complete audit trail and enabling stakeholder communication.

**Business Rationale:** Marketing effectiveness claims frequently conflate correlation with causation measuring outcomes among message recipients without accounting for what would have occurred absent marketing intervention. Customers interested in therapy may prescribe regardless of marketing, making observed prescriptions poor proxy for marketing impact. Holdout groups provide causal evidence by measuring outcomes in absence of treatment revealing true incremental contribution. Research demonstrates that 50-70% of measured outcomes typically occur organically in holdout groups meaning marketing incrementality substantially lower than naive measurement suggests. This insight proves critical for budget justification and resource allocation. Organizations implementing holdout testing report 30-50% more accurate ROI estimates, improved executive confidence in marketing value, and better budget allocation through understanding true incremental returns versus overstated correlational measures.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-159 (holdout vision), REQ-288 (experimentation foundation), REQ-063 through REQ-092 (segmentation for holdout assignment), REQ-231 through REQ-238 (outcome measurement)

**Acceptance Criteria:** Holdout group management supporting customer-level and geo-level randomization, holdout integrity validation preventing inadvertent treatment delivery, incrementality calculation including absolute lift, relative lift, incremental ROI, and confidence intervals, sophisticated designs including geo-holdout and propensity-matched approaches.

**Success Metrics:** Holdout testing adoption with 50% of major campaigns including holdout groups within twelve months, incrementality findings showing marketing typically drives 40-60% of observed outcomes with remainder organic, executive awareness of incrementality concept reaching 90% measured through survey, budget allocation decisions explicitly considering incrementality evidence.

---

**REQ-291: Bayesian Optimization for Accelerated Learning**

The experimentation platform shall implement Bayesian optimization methods that incorporate prior knowledge and beliefs into statistical inference enabling faster conclusions with smaller sample sizes compared to frequentist approaches. The Bayesian framework shall support prior specification encoding existing knowledge about expected performance through probability distributions including informative priors when substantial historical evidence exists and non-informative priors when exploring novel approaches. As experiment data accumulates, the system shall update posterior distributions combining prior beliefs with observed evidence using Bayes theorem calculating probability that each variant represents the best option given all available information. Decision-making shall use posterior probabilities directly declaring winners when probability exceeds threshold such as 95% confident that variant A is superior to all alternatives rather than relying solely on p-values.

The Bayesian implementation shall provide credible intervals representing ranges containing true parameter values with specified probability such as 95% credible interval, expected loss calculations quantifying anticipated regret from each decision option informing risk-aware choices, and value of information estimates determining benefit from collecting additional data guiding sample size decisions. The framework shall support sequential Bayesian analysis enabling interim looks at accumulating data without inflating false positive rates like frequentist interim analyses. Visualization shall display posterior distributions showing probability densities across possible parameter values making uncertainty transparent and supporting intuitive interpretation compared to abstract p-values. Integration with multi-armed bandits shall enable Thompson sampling that naturally incorporates Bayesian reasoning for allocation decisions.

**Business Rationale:** Frequentist statistics require relatively large samples for reliable conclusions and provide binary significant versus not significant answers without quantifying probability of competing hypotheses. Bayesian methods accelerate learning by incorporating prior knowledge, reducing sample size requirements and providing intuitive probability statements directly answering business questions like what is probability this variant best option. Research demonstrates Bayesian approaches achieve conclusions with 30-50% smaller samples versus frequentist equivalents through efficient incorporation of prior information. This sample size reduction translates to faster decisions enabling more optimization iterations within fixed time. Organizations implementing Bayesian optimization report 40-60% acceleration in experimentation velocity, improved decision quality through probability-based rather than binary thinking, and better stakeholder communication through intuitive probability interpretation.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 3\)

**Dependencies:** REQ-288 (experimentation foundation), REQ-164 (Bayesian optimization vision), REQ-160 (statistical libraries with Bayesian capabilities), REQ-289 (bandit algorithms for Thompson sampling integration)

**Acceptance Criteria:** Bayesian optimization framework supporting prior specification, posterior distribution calculation and visualization, decision-making based on posterior probabilities, credible intervals and expected loss calculations, sequential analysis without p-value inflation.

**Success Metrics:** Bayesian method adoption with 20% of experiments using Bayesian analysis within twelve months, sample size reduction of 40% versus frequentist equivalents achieving equivalent decision quality, decision quality assessed through out-of-sample validation showing correct winner identification 90% of time, user satisfaction with Bayesian approach above 8 out of 10 among trained users.

---

**REQ-292: Experiment Registry and Knowledge Management**

The experimentation platform shall maintain a comprehensive experiment registry documenting all tests conducted across organization including hypothesis statement, variant descriptions, success metrics, sample allocation, start date, end date, results, statistical analysis, and business decisions. The registry shall capture metadata enabling filtering and search including therapeutic area, brand, campaign type, customer segment, channel, and hypothesis category. Each experiment record shall store complete methodology specification including randomization approach, statistical methods employed, power calculation assumptions, and analysis code ensuring reproducibility and supporting regulatory audit requirements. Results documentation shall include summary statistics, effect sizes, confidence intervals, p-values, and business interpretation making findings accessible to non-technical stakeholders. The registry shall link experiments to resulting business actions documenting whether findings implemented, deferred, or rejected with rationale.

The knowledge management framework shall identify cross-cutting insights that generalize beyond individual experiments such as consistent finding that personalized subject lines improve open rates by 20% across multiple tests suggesting organizational best practice. Pattern detection algorithms shall highlight recurring findings enabling codification of learnings into guidelines and templates. The registry shall support tagging and categorization enabling discovery of relevant historical experiments when planning new tests, preventing duplicative effort and enabling meta-analysis combining multiple studies for stronger conclusions. Integration with journey canvas shall suggest relevant historical experiments when marketers design new journeys prompting consideration of prior learnings. Executive reporting shall aggregate experimentation activity showing test velocity, win rate, average effect size, and cumulative business impact demonstrating continuous improvement culture and marketing sophistication.

**Business Rationale:** Experiments generate valuable knowledge but value dissipates without systematic capture and dissemination. Marketing teams frequently repeat tests addressing questions already answered elsewhere in organization or fail to leverage insights from parallel brands and markets. Comprehensive registries prevent duplicative effort, accelerate learning through meta-analysis of similar experiments, and demonstrate rigor to executives and regulators. Research demonstrates that organizations with mature experiment registries achieve 30-40% higher learning velocity through leveraging historical insights, reduce duplicative testing by 50-60%, and improve cross-functional collaboration through shared learning. Regulatory inspections increasingly focus on promotional testing practices making defensible documentation essential for compliance. Organizations implementing experiment registries report 40% faster experiment planning through access to relevant precedents and 60% improvement in stakeholder confidence in optimization capabilities.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-288 through REQ-291 (experimentation foundation generating data for registry), REQ-161 (registry vision), REQ-083 (model registry providing similar pattern for experiments)

**Acceptance Criteria:** Experiment registry capturing all tests with complete methodology and results documentation, metadata enabling filtering and search by therapeutic area, brand, segment, channel, pattern detection identifying cross-cutting insights, integration with journey canvas surfacing relevant historical experiments.

**Success Metrics:** Registry completeness reaching 100% of experiments documented within six months, historical experiment reference rate showing 50% of new experiments referencing prior work, cross-cutting insight identification producing minimum ten organization-wide guidelines annually, executive engagement with experimentation dashboards showing regular review.

---

## 3.3 CENTRAL FATIGUE MANAGEMENT SERVICE

### Capability Overview

The Central Fatigue Management Service provides enterprise-wide visibility and enforcement of message volume limits preventing customer overexposure that drives negative experiences, opt-out behavior, and brand damage. Message fatigue represents the primary controllable driver of customer disengagement with research demonstrating a clear negative relationship between communication frequency and engagement rates beyond optimal thresholds. Customers who receive excessive messages exhibit declining response rates, elevated unsubscribe rates, increased spam complaints, and deteriorating brand perception. The challenge intensifies in pharmaceutical marketing where multiple brands, therapeutic areas, and functional teams operate semi-independently each believing their messages merit delivery but collectively overwhelming customers.

Traditional fatigue management approaches implement channel-specific or campaign-specific limits lacking visibility to total customer message volume. Email platform may enforce weekly cap while SMS platform applies independent limit and field representatives schedule visits without considering digital touchpoints. The result resembles the tragedy of the commons where each team acting rationally within their domain creates a collectively suboptimal outcome. Customers perceive total message volume not distinguishing between brands or channels yet no single system controls aggregate exposure. This structural gap allows message proliferation until customers opt out or disengage protecting themselves through exit.

The Central Fatigue Management Service solves this coordination problem through three integrated capabilities. First, the central fatigue registry aggregates all customer touchpoints across campaigns, journeys, channels, brands, and systems providing comprehensive visibility to total message volume that no individual platform possesses. Second, real-time fatigue scoring calculates current message pressure for each customer incorporating recency, channel diversity, and response patterns identifying individuals approaching or exceeding healthy thresholds. Third, pre-send validation integrates with all execution systems checking proposed message deliveries against fatigue rules before sending with approval or rejection decisions and suggested alternatives when limits are reached. Together these capabilities transform fatigue from abstract concern to concrete operational control with measurable impact on customer experience and business outcomes.

Organizations implementing central fatigue management report 40-60% reduction in opt-out rates attributed directly to reduced message volume, 20-30% improvement in aggregate engagement rates through focusing touches on receptive moments, 30-40% enhancement in customer satisfaction scores related to communication frequency, and fifteen to 25% improvement in marketing efficiency through eliminating wasted impressions on saturated customers.

### Detailed Requirements

**REQ-293: Central Fatigue Registry Architecture**

The central fatigue management service shall implement a unified message registry collecting touchpoint data from all execution platforms including Salesforce Marketing Cloud, Braze, Iterable, email service providers, SMS gateways, mobile application platforms, field sales systems, patient program platforms, and agency execution tools. The registry architecture shall consume events through multiple integration patterns including real-time streaming APIs for platforms supporting event-driven architecture, periodic batch synchronization for systems requiring polling, and webhook callbacks for platforms providing push notifications. Event collection shall capture message deliveries with complete metadata including customer identifier, brand, therapeutic area, campaign, channel, content type, timestamp, and response indicators enabling comprehensive analysis.

The registry data model shall maintain customer-level delivery history with rolling retention period typically twelve months enabling trend analysis while managing storage costs. Storage shall use time-series optimized databases such as TimescaleDB or InfluxDB providing efficient queries across large event volumes. The registry shall support multiple customer identifier schemes including email address, phone number, CRM record ID, and universal person identifier with identity resolution linking identifiers to unified customer profiles. Data quality monitoring shall validate incoming events checking for required fields, reasonable values, and schema compliance with alerting when data quality degrades. Privacy controls shall implement appropriate safeguards for protected health information with encryption, access controls, and audit logging meeting HIPAA requirements.

**Business Rationale:** Comprehensive visibility represents a prerequisite for effective fatigue management as gaps in data collection create blind spots where over-messaging occurs undetected. Organizations report that 50-70% of customer touchpoints initially escape central tracking due to fragmented execution platforms and incomplete integration. Each untracked touchpoint undermines fatigue management allowing volume creep that gradually exceeds healthy thresholds. Complete data collection proves challenging given diverse execution platforms, agency partners with independent systems, and field activities recorded in separate tools. The proposed architecture addresses these challenges through flexible integration supporting multiple ingestion patterns and identity resolution linking fragmented identifiers. Organizations implementing comprehensive registries report 80-90% visibility improvement within six months enabling meaningful fatigue enforcement.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane A (Govern)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-024 through REQ-030 (event collection foundation), REQ-006 (identity resolution), REQ-149 (fatigue registry vision), time-series database deployment

**Acceptance Criteria:** Central registry collecting events from all major execution platforms through real-time streaming or batch synchronization, customer-level delivery history with twelve-month retention, identity resolution linking multiple identifiers to unified profiles, data quality monitoring validating incoming events.

**Success Metrics:** Message capture completeness reaching 85% of all customer touchpoints within six months and 95% within twelve months measured through reconciliation with platform sending volumes, data latency averaging under 15 minutes for real-time streams, data quality validation passing ninety-eight percent of events, system reliability maintaining uptime above ninety-nine point five percent.

---

**REQ-294: Real-Time Fatigue Scoring Algorithm**

The central fatigue service shall calculate real-time fatigue scores for each customer quantifying current message pressure on scale from zero representing minimal recent communication to one hundred indicating heavy saturation. The scoring algorithm shall incorporate multiple factors including absolute message volume counting total touches within rolling time windows such as past seven days and 30 days, recency weighting emphasizing recent messages more heavily than older communications with exponential decay, channel diversity recognizing that cross-channel coordination indicating higher sophistication than single-channel bombardment, response patterns considering customers who engage regularly can sustain higher volumes than those ignoring messages, and segment-specific baselines acknowledging that HCPs and patients have different tolerance thresholds.

The algorithm shall update fatigue scores continuously as new messages deliver and old messages age out of rolling windows ensuring current assessment at every moment. Score calculation shall execute with sub-second latency enabling real-time validation at moment of message send without introducing unacceptable delays. The scoring logic shall be transparent and configurable with documented formulas and tunable parameters enabling organizations to customize based on empirical findings from their customer base. Score attribution shall decompose total fatigue into contributions from different brands, therapeutic areas, campaigns, and channels helping teams understand their impact on shared customer resource. Historical score trends shall track evolution over time identifying customers experiencing escalating pressure versus those maintaining healthy engagement levels.

**Business Rationale:** Simple message counting proves insufficient for sophisticated fatigue management as not all messages create equal impact and customer tolerance varies by context. A customer receiving daily highly relevant educational emails may remain engaged while another receiving weekly irrelevant promotions becomes saturated. Sophisticated scoring incorporating multiple factors better predicts disengagement risk than crude volume metrics. Research demonstrates that multifactor scoring algorithms predict opt-out behavior with sixty to 75% accuracy compared to 30-40% for simple counting enabling targeted intervention before damage occurs. Real-time calculation enables immediate enforcement preventing violations rather than detecting them retrospectively. Organizations implementing sophisticated scoring report 40% improvement in predictive accuracy and 30% better resource allocation focusing retention efforts on highest-risk customers.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane A (Govern)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-293 (fatigue registry providing data for scoring), REQ-069 through REQ-076 (engagement data for response patterns), REQ-150 (fatigue scoring vision)

**Acceptance Criteria:** Fatigue scoring algorithm incorporating message volume, recency, channel diversity, response patterns, and segment-specific baselines, real-time score calculation with sub-second latency, transparent and configurable scoring logic with documented formulas, score attribution decomposing contributions by brand and campaign.

**Success Metrics:** Scoring algorithm predictive accuracy measured through holdout testing showing 65% or better prediction of opt-out behavior within 60 days, score calculation latency averaging under 200 milliseconds at 95th percentile, algorithm calibration showing monotonic relationship between fatigue score and actual opt-out rate, user comprehension of scoring methodology demonstrated through 80% correct interpretation in user testing.

---

**REQ-295: Pre-Send Fatigue Validation API**

The central fatigue service shall provide real-time validation API that execution platforms invoke before every message delivery receiving approval or rejection decisions based on current customer fatigue status. The API shall accept validation requests including customer identifier, proposed message metadata such as brand, campaign, channel, and content type, and urgency indicator flagging time-sensitive communications requiring expedited handling. Validation logic shall retrieve current fatigue score, evaluate against applicable thresholds considering customer segment and message priority, and return decision within acceptable latency budget typically under five hundred milliseconds ensuring validation does not create user-perceivable delays.

API responses shall include approval decision indicating whether message may deliver, rejection reason providing clear explanation when delivery blocked such as customer exceeded weekly limit or approaching monthly threshold, alternative timing suggestion recommending future delivery window when customer fatigue permits, and next available slot showing the earliest customer eligible for this message type. The API shall support override requests for exceptional circumstances such as critical safety communications or regulatory-required notifications with override requiring documented justification and appropriate approval authority. Integration patterns shall accommodate both real-time point-to-point validation for individual sends and batch pre-validation for bulk campaigns enabling platforms to filter suppression lists before initiating sending.

**Business Rationale:** Fatigue visibility proves valueless without enforcement as teams possessing override authority routinely justify exceptions believing their messages merit delivery regardless of limits. Pre-send validation transforms fatigue rules from advisory guidelines into hard constraints preventing violations before customer impact. API-based enforcement integrates seamlessly with existing execution platforms requiring minimal changes to established workflows while delivering material improvements. Rejection reasons and alternative timing create constructive feedback enabling teams to adapt rather than simply blocking messages. Research demonstrates that automated enforcement achieves 95% compliance compared to twenty to 40% for manual policies relying on voluntary adherence. Organizations implementing pre-send validation report 50% reduction in limit violations and 30% improvement in customer satisfaction with message frequency.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane A (Govern)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-293 (fatigue registry), REQ-294 (fatigue scoring), REQ-141 through REQ-148 (execution platforms requiring integration), REQ-152 (pre-send API vision)

**Acceptance Criteria:** Pre-send validation API processing approval and rejection decisions with sub five hundred millisecond latency, rejection responses including clear reasons and alternative timing suggestions, override workflow supporting exceptional circumstances with documented justification, batch pre-validation supporting bulk campaign filtering.

**Success Metrics:** API adoption reaching 90% of message volume validated within six months, API latency averaging under three hundred milliseconds at 95th percentile maintaining under five hundred millisecond at ninety-ninth percentile, API reliability maintaining uptime above ninety-nine point nine percent, compliance rate reaching 95% of messages respecting fatigue limits measured through post-hoc audit.

---

**REQ-296: Fatigue Threshold Configuration and Segment Customization**

The central fatigue service shall provide flexible threshold configuration enabling organizations to define maximum acceptable message volumes by customer segment, channel, time period, and message priority with graduated enforcement levels. Threshold configuration shall support absolute limits specifying maximum touches such as no more than seven emails per week or three SMS messages per month, rate limits constraining average frequency such as maintaining minimum forty-eight-hour spacing between messages, and saturation curves specifying acceptable volume trajectories over time enabling seasonal variation. Each threshold shall designate enforcement approach including hard block preventing any messages exceeding limit, soft warning alerting teams but permitting override with justification, and advisory notification informing teams without blocking providing transparency without constraint.

Segment-specific customization shall enable different thresholds for distinct customer populations recognizing that HCPs and patients have different tolerance levels and channels have varying intrusiveness. High-engagement customers demonstrating consistent interaction may receive elevated limits while low-engagement customers subject to more restrictive controls preventing further alienation. Therapeutic area customization shall accommodate situations where certain conditions require more frequent communication such as patient adherence programs for complex therapies. Channel hierarchies shall define relative intrusiveness with SMS typically more constrained than email reflecting immediacy and interruption characteristics. Threshold governance shall require appropriate approval for changes with audit trail documenting who modified what thresholds when and why supporting compliance oversight.

**Business Rationale:** Universal thresholds prove suboptimal given heterogeneous customer populations with varying receptivity and different communication contexts. One-size-fits-all limits either become so restrictive they prevent valuable communication or so permissive they fail to prevent saturation. Segment-specific customization enables precision balancing protection and promotion. Research demonstrates that segmented thresholds improve outcomes by 20-30% versus universal limits achieving higher engagement among receptive audiences while better protecting at-risk customers. Graduated enforcement approaches enable appropriate risk management with hard blocks for egregious violations and soft warnings for edge cases. Organizations implementing sophisticated threshold frameworks report 40% better balance between reach and customer experience as measured by engagement rates and opt-out rates simultaneously improving.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane A (Govern)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-293 through REQ-295 (fatigue foundation), REQ-063 through REQ-092 (segmentation enabling threshold customization), REQ-151 (threshold configuration vision)

**Acceptance Criteria:** Threshold configuration supporting absolute limits, rate limits, and saturation curves with hard block, soft warning, and advisory enforcement modes, segment-specific customization enabling different limits by customer type, channel hierarchies reflecting relative intrusiveness, threshold governance requiring approval for changes with audit trail.

**Success Metrics:** Threshold customization adoption with 60% of customer segments having tailored limits within twelve months, threshold effectiveness measured through opt-out rate differential showing customized limits achieving 30% better outcomes than default thresholds, governance compliance showing 100% of threshold changes approved and documented, stakeholder satisfaction with threshold flexibility above 8 out of 10\.

---

**REQ-297: Fatigue Impact Analysis and Reporting**

The central fatigue service shall provide comprehensive analytics quantifying relationships between message frequency and customer outcomes enabling data-driven threshold optimization and demonstrating business impact. Impact analysis shall correlate fatigue scores with engagement metrics showing how open rates, click rates, and conversion rates vary across fatigue levels, churn metrics tracking how opt-out rates, spam complaints, and customer service contacts relate to message volume, and satisfaction scores when available from surveys or feedback mechanisms. Statistical analysis shall employ regression models controlling for confounding factors such as customer demographics, product interest, and lifecycle stage isolating causal impact of message frequency from correlational patterns.

Reporting shall segment analysis by customer type, therapeutic area, brand, channel, and time period identifying where fatigue issues concentrate and which teams contribute disproportionately to problems. Threshold optimization recommendations shall emerge from empirical analysis suggesting adjustments based on observed relationships between volume and outcomes. Return on communication analysis shall estimate incremental value of each message accounting for both positive effects from information delivery and negative effects from fatigue accumulation determining optimal frequency maximizing net benefit. Executive dashboards shall track portfolio-level fatigue metrics including average customer fatigue score distribution, message volume trends over time, threshold compliance rates, and business impact metrics providing leadership visibility to program effectiveness.

**Business Rationale:** Fatigue management requires continuous refinement as customer tolerance evolves, competitive intensity changes, and organizational priorities shift. Empirical analysis enables evidence-based threshold optimization replacing subjective judgment with data-driven decisions. Impact quantification demonstrates business value justifying investment in fatigue management infrastructure and motivating organizational commitment to discipline. Research demonstrates that organizations conducting systematic impact analysis achieve 25-35% better threshold calibration measured through improved engagement and reduced churn compared to organizations setting limits through intuition. Return on communication analysis reveals optimal frequency often below what teams desire, creating tension between individual team objectives and collective customer welfare that executive visibility helps resolve.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 3\)

**Dependencies:** REQ-293 through REQ-296 (fatigue foundation generating data for analysis), REQ-069 through REQ-076 (engagement data for correlation analysis), REQ-239 through REQ-248 (reporting infrastructure), REQ-155 (impact analysis vision)

**Acceptance Criteria:** Fatigue impact analysis correlating fatigue scores with engagement, churn, and satisfaction metrics using regression models controlling for confounding factors, threshold optimization recommendations based on empirical findings, return on communication analysis estimating incremental value accounting for fatigue costs, executive dashboard tracking portfolio-level fatigue metrics.

**Success Metrics:** Impact analysis adoption with quarterly refresh demonstrating organizational commitment to evidence-based management, threshold adjustments based on empirical findings showing continuous optimization, executive engagement with fatigue dashboards indicating leadership attention, measurable improvement in engagement and churn metrics attributed to fatigue management achieving minimum 20% impact.

---

## SECTION 3 SUMMARY

This enhanced Section 3 provides comprehensive specifications for Advanced Journey Orchestration Capabilities spanning visual journey authoring, rigorous experimentation, and enterprise fatigue management. The section documents eighteen new detailed requirements (REQ-280 through REQ-297) with extensive business rationale, technical specifications, priorities, dependencies, and success metrics.

### Requirements Summary

| Capability Domain | Requirements | Priority P1 | Priority P2 | Phase 2 | Phase 3 |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Journey Authoring Canvas | REQ-280 to REQ-287 | 6 | 2 | 6 | 2 |
| Advanced Experimentation | REQ-288 to REQ-292 | 3 | 2 | 3 | 2 |
| Central Fatigue Management | REQ-293 to REQ-297 | 4 | 1 | 4 | 1 |
| **Total Section 3** | **18** | **13** | **5** | **13** | **5** |

---

# SECTION 4: CLAIMID FRAMEWORK AND MLR WORKFLOW

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## OVERVIEW

The ClaimID Framework and MLR Workflow constitute the regulatory compliance backbone of pharmaceutical marketing operations, transforming abstract compliance requirements into concrete operational controls embedded within marketing technology infrastructure. Unlike consumer marketing where creative freedom reigns and regulatory constraints remain minimal, pharmaceutical marketing operates under strict FDA oversight requiring that every promotional claim be truthful, balanced, and substantiated by adequate evidence. The consequences of non-compliance prove severe, ranging from FDA warning letters and consent decrees to criminal prosecution and multi-billion dollar settlements. The 2012 GlaxoSmithKline settlement of three billion dollars for improper promotion and the 2013 Johnson & Johnson settlement of 2.2 billion dollars for off-label marketing demonstrate the existential risks facing organizations with inadequate compliance infrastructure.

Traditional pharmaceutical marketing compliance relies heavily on manual processes where medical, legal, and regulatory reviewers examine creative materials submitted through email or document management systems, provide feedback through separate communication channels, and track approval status using spreadsheets or task management tools. This fragmented approach creates multiple failure modes including incomplete claim substantiation where promotional statements lack documented evidence, expired content deployment where materials approved based on time-limited data continue circulating after evidence expires, off-label promotion where claims inadvertently suggest uses beyond FDA-approved indications, delayed time-to-market where lengthy review cycles postpone campaign launches, and incomplete audit trails where documentation gaps undermine regulatory inspection readiness. Industry surveys indicate that the average pharmaceutical marketing organization experiences four to six compliance near-misses annually where materials nearly reached market without appropriate approvals, with actual violations occurring in ten to 15% of organizations each year despite substantial compliance investment.

The proposed ClaimID Framework addresses these challenges through systematic digitization of claim management and approval workflows. At the foundation lies the ClaimID data model establishing claims as first-class objects within the marketing technology architecture with unique identifiers, substantiating evidence links, approval metadata, expiry dates, and indication associations. Building on this foundation, automated content-to-claim mapping requires every marketing asset to declare which claims it references, enabling systematic validation that substantiation exists and remains current. The MLR approval workflow orchestrates parallel and sequential review activities across medical affairs, legal counsel, and regulatory specialists with clear accountability, defined service-level agreements, and comprehensive audit trails. Expiry enforcement automatically pauses campaigns when linked claims approach expiration preventing non-compliant deployment. Off-label detection algorithms analyze claim-to-indication mappings identifying potential violations before they reach customers. Together these capabilities transform compliance from reactive problem-solving to proactive risk prevention while accelerating time-to-market through workflow automation and reducing review burden through intelligent routing and change highlighting.

Organizations implementing comprehensive ClaimID frameworks report sixty to 75% reduction in compliance violations as measured by internal audit findings and regulatory inspection observations, 40-50% acceleration in MLR cycle time through workflow automation and parallel review, 30-40% improvement in claim substantiation completeness ensuring every promotional statement links to documented evidence, and elimination of expired content deployment incidents through automated enforcement. These improvements deliver direct business value through reduced regulatory risk, faster campaign launches, and lower compliance overhead while enhancing organizational reputation with regulators and building stakeholder confidence in promotional practices.

---

## 4.1 CLAIMID DATA MODEL AND CLAIM REGISTRY

### Capability Overview

The ClaimID data model establishes claims as discrete, manageable entities within pharmaceutical marketing infrastructure enabling systematic tracking, validation, and governance. A claim represents any factual statement about product safety, efficacy, mechanism of action, patient outcomes, comparative effectiveness, or clinical characteristics that appears in promotional materials and requires substantiation through clinical evidence, regulatory approvals, or published literature. Traditional approaches treat claims as embedded text within creative assets making them difficult to track, validate, and update. When the same claim appears across dozens of materials spanning multiple channels and agencies, organizations struggle to determine which assets contain which claims, verify that substantiation remains current, and update materials when evidence changes or expires. This fragmentation creates significant compliance risk and operational inefficiency.

The proposed ClaimID architecture treats claims as independent objects with unique identifiers, comprehensive metadata, and relationships to substantiating evidence, approved indications, and content assets. Each claim receives a human-readable identifier enabling cross-system reference and stakeholder communication. Claim attributes capture the statement text, evidence source such as pivotal trial results or FDA-approved labeling, approval date showing when regulatory review concluded, expiry date specifying when evidence loses validity, therapeutic indication defining approved use, product association linking claim to specific medications, and approval status indicating whether claim currently available for promotional use. Relationships connect claims to content assets that reference them, clinical studies that substantiate them, and regulatory submissions that approve them creating a comprehensive network revealing impact when claims require updates.

The claim registry serves as a centralized repository for all approved promotional claims across the organization providing a single source of truth for content creators, medical reviewers, and regulatory affairs specialists. Registry functions include claim authoring supporting creation of new claim proposals with required substantiation, claim review routing proposals through medical-legal-regulatory approval workflow, claim approval capturing reviewer decisions and approval metadata, claim search enabling content creators to discover available claims by therapeutic area, indication, or keyword, claim usage tracking showing which assets reference which claims, and claim lifecycle management handling updates, renewals, and retirements as evidence evolves. Integration with content management systems ensures that creative materials can only reference approved claims from the registry preventing inadvertent use of unsubstantiated or expired statements.

Organizations implementing ClaimID registries report ninety-five to 100% improvement in claim substantiation completeness measured as percentage of promotional statements with documented evidence links, 60-70% reduction in time spent searching for approved claims through centralized discovery, 40-50% faster claim approval cycles through workflow automation, and elimination of unauthorized claim usage through system-enforced validation. These operational improvements translate to reduced compliance risk, accelerated campaign launches, and lower regulatory overhead.

### Detailed Requirements

**REQ-298: ClaimID Data Model and Schema**

The system shall implement a comprehensive ClaimID data model with each claim represented as a distinct object possessing a unique identifier following naming conventions such as CLAIM-BRAND-INDICATION-SEQUENCE for human readability and cross-system reference. The data schema shall capture claim statement text representing exact wording approved for promotional use including any required qualifiers or caveats, claim type classification such as efficacy claim, safety claim, mechanism of action, patient reported outcome, or comparative claim, therapeutic indication specifying FDA-approved use to which claim applies, product association identifying specific medication including formulation and strength, evidence source documenting substantiation basis such as pivotal trial identifier, FDA labeling section, or published literature citation, evidence strength rating indicating quality level such as Level 1A for randomized controlled trials or Level 3 for observational studies, approval date timestamp recording when claim received regulatory clearance, expiry date specification defining when substantiation loses validity requiring renewal, approval status flag indicating active, pending, expired, or retired, restrictive use conditions documenting any limitations such as audience restrictions or channel constraints, and version history tracking all modifications to claim attributes over time.

The data model shall support hierarchical relationships enabling parent-child structures where broad claims spawn more specific sub-claims, equivalence relationships linking alternative phrasings that convey identical meaning, and supersession relationships documenting when new claims replace outdated predecessors. Metadata tagging shall enable multi-dimensional classification by therapeutic area, target audience such as HCP versus patient, promotional intensity level distinguishing conservative from aggressive statements, and custom attributes supporting organization-specific requirements. The schema shall enforce referential integrity ensuring that claims cannot exist without linked evidence sources, indications must match product approved uses, and expiry dates cannot precede approval dates preventing logically inconsistent states.

**Business Rationale:** Comprehensive data model provides foundation for all subsequent claim management capabilities. Rich metadata enables sophisticated querying, filtering, and analysis supporting content creation, compliance verification, and regulatory reporting. Hierarchical and equivalence relationships reduce duplication by establishing canonical claims with approved variations rather than proliferating near-identical statements requiring separate reviews. Version history proves essential for regulatory inspections demonstrating how claims evolved and whether appropriate reviews occurred. Organizations report that systematic claim modeling improves discoverability by 60-70% as measured by time to locate relevant claims, reduces duplication by 40-50% through canonical claim establishment, and accelerates regulatory responses by 50-60% through immediate access to complete claim history.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-005 (Salesforce data foundation), REQ-010 (ClaimID vision from Section 1\)

**Acceptance Criteria:** ClaimID data model implemented in Salesforce with custom objects and fields capturing all required attributes, unique identifier generation following established naming convention, referential integrity enforcement preventing invalid data states, version history automatically capturing all attribute changes with timestamp and user identification.

**Success Metrics:** Data model completeness measured through schema audit showing all required attributes present and properly typed, data quality assessment showing greater than 95% of claims with complete required fields, referential integrity validation showing zero orphaned references or logically inconsistent states, user satisfaction with data model expressiveness rated above 8 out of 10 by claim administrators.

---

**REQ-299: Claim Substantiation Evidence Management**

The system shall provide comprehensive evidence management capabilities linking each claim to substantiating documentation including clinical trial results, FDA-approved product labeling, published peer-reviewed literature, regulatory correspondence, and internal scientific analyses. Evidence storage shall support multiple formats including PDF documents, Word files, Excel spreadsheets, and web links to external sources with version control maintaining complete history of evidence updates. Each evidence item shall possess metadata including evidence type classification, publication date, author attribution, study design characteristics such as randomized controlled trial or observational study, patient population descriptions, primary and secondary endpoints, statistical significance levels, confidence intervals, and quality assessment ratings following established frameworks such as GRADE or Cochrane risk of bias tools.

The evidence linking interface shall enable claim administrators to associate multiple evidence sources with each claim recognizing that robust substantiation often requires convergent evidence from multiple studies. Link types shall distinguish between primary evidence providing direct substantiation versus supporting evidence offering contextual background. Evidence assessment workflows shall route new evidence through medical affairs review ensuring quality evaluation before acceptance into substantiation repository. The system shall validate that evidence publication dates precede claim approval dates preventing claims from being approved before substantiating evidence existed. Expiry logic shall automatically flag claims when underlying evidence approaches the end of relevance such as studies conducted more than five years ago in rapidly evolving therapeutic areas requiring periodic renewal.

**Business Rationale:** The FDA requires that promotional claims possess adequate substantiation at time of dissemination and that substantiation meet scientific standards appropriate to claim significance. Warning letters frequently cite inadequate substantiation where promotional statements lack documented support or evidence proves insufficient given claim magnitude. Systematic evidence management ensures that substantiation exists, meets quality standards, and remains accessible during regulatory inspections. Research demonstrates that organizations with mature evidence management practices receive 75% fewer FDA observations related to substantiation compared to organizations relying on informal documentation. Evidence quality assessment using established frameworks provides defensible methodology demonstrating scientific rigor. Organizations implementing systematic evidence management report ninety-five to 100% substantiation completeness compared to 60-70% for informal approaches and 50% reduction in time responding to regulatory evidence requests.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-298 (ClaimID data model), REQ-035 (substantiation vault from Section 1), document management system or Salesforce Files integration

**Acceptance Criteria:** Evidence management system supporting multiple document formats with version control, evidence metadata capture including study characteristics and quality assessment, multiple evidence linking to claims with primary versus supporting designation, evidence assessment workflow routing new submissions through medical review, expiry validation flagging outdated evidence.

**Success Metrics:** Evidence linking completeness showing 100% of active claims with documented substantiation, evidence quality assessment completion for 90% of evidence items within six months, evidence accessibility measured through retrieval time averaging under two minutes, regulatory inspection evidence production time under four hours for complete claim substantiation package.

---

**REQ-300: Claim-to-Indication Mapping and Off-Label Detection**

The system shall maintain explicit mappings between claims and FDA-approved indications enabling automated detection of potential off-label promotion. The indication data model shall capture FDA-approved uses from product labeling including specific disease or condition, patient population characteristics such as age, disease severity, or prior treatment history, dosing regimen, route of administration, and any restrictions or warnings. Each claim shall link to one or more approved indications representing valid contexts for promotional use. The mapping interface shall display indications clearly during claim creation and content development ensuring that marketers understand appropriate usage boundaries.

Off-label detection algorithms shall analyze claim-to-indication mappings identifying potential violations through pattern matching and semantic analysis. Detection rules shall flag claims used in content targeting patient populations outside approved indications, claims suggesting benefits in unapproved disease states even when not explicitly stated, claims emphasizing dosing regimens not included in FDA labeling, claims appearing in channels or formats targeting audiences for whom product not indicated, and claims modified or combined in ways that alter intended meaning creating off-label implications. The system shall generate risk scores quantifying off-label promotion likelihood based on number and severity of potential issues. High-risk scenarios shall trigger automatic escalation to medical-legal review preventing deployment without explicit approval.

**Business Rationale:** Off-label promotion represents the most serious category of FDA enforcement actions resulting in criminal prosecution, multi-billion dollar settlements, and corporate integrity agreements restricting business operations. The challenge lies in subtle scenarios where materials do not explicitly promote off-label uses but create impressions through selective emphasis, audience targeting, or contextual placement. Explicit claim-to-indication mapping provides clear documentation of appropriate usage while automated detection identifies edge cases requiring additional scrutiny. Research demonstrates that systematic off-label detection reduces violations by seventy to 85% compared to relying solely on human review, identifies fifteen to 25% more potential issues through algorithmic pattern matching, and accelerates risk assessment from days to minutes. Organizations implementing off-label detection report zero FDA observations related to off-label promotion in controlled studies and 70% improvement in medical-legal confidence in promotional materials.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-298 (ClaimID data model), REQ-299 (evidence management), product indication data from regulatory affairs systems

**Acceptance Criteria:** Indication data model implemented with FDA-approved uses and patient population characteristics, claim-to-indication mapping interface requiring explicit association during claim creation, off-label detection algorithms implementing pattern matching and semantic analysis with risk scoring, automatic escalation workflow triggering medical-legal review for high-risk scenarios.

**Success Metrics:** Mapping completeness showing 100% of claims linked to appropriate indications, detection algorithm validation through retrospective analysis showing identification of 90% of known off-label cases in historical data, false positive rate under 20% requiring human review, risk score calibration demonstrating monotonic relationship between scores and actual off-label probability confirmed through expert evaluation.

---

**REQ-301: Claim Lifecycle Management and Renewal Workflow**

The system shall implement comprehensive lifecycle management for claims spanning creation, approval, active use, expiry warning, renewal, and retirement phases. Lifecycle automation shall trigger appropriate workflows based on claim status and dates ensuring proactive management rather than reactive problem-solving. For claims approaching expiry within 90 days, the system shall automatically generate renewal tasks assigned to appropriate medical affairs personnel with reminders escalating at 60 days, 30 days, and seven days before expiration. Renewal workflows shall route claims through abbreviated review assessing whether substantiation remains current or requires updating based on new clinical evidence, competitive developments, or regulatory guidance changes.

The system shall support multiple renewal outcomes including simple extension where claim remains valid with updated expiry date, revision where statement requires modification reflecting new evidence, replacement where new claim supersedes outdated predecessor, and retirement where claim no longer supportable or strategically relevant. Upon retirement, the system shall automatically identify all content assets referencing retired claims and generate remediation tasks ensuring that materials receive updates or removal. Version control shall maintain complete history showing original claim, all revisions, renewal decisions, and retirement rationale providing audit trail demonstrating ongoing compliance vigilance. Lifecycle dashboards shall provide visibility to claims by status showing counts of active, expiring soon, pending renewal, and retired claims by therapeutic area and brand enabling proactive capacity planning.

**Business Rationale:** Claims do not remain valid indefinitely as clinical evidence evolves, competitive landscapes shift, and regulatory expectations change. Organizations must systematically reassess claim validity and update or retire outdated statements preventing non-compliant promotion. Manual lifecycle management proves challenging at scale with pharmaceutical companies typically maintaining two hundred to five hundred active claims across portfolios. Automated workflows ensure that renewal assessments occur timely while dashboards enable portfolio-level visibility and capacity planning. Research demonstrates that automated lifecycle management reduces expired claim incidents by ninety to 95%, decreases administrative burden by 60% through workflow automation, and improves renewal cycle time by 40% through proactive scheduling. Organizations report that systematic lifecycle management prevents the most common compliance issue identified in internal audits and regulatory inspections.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-298 (ClaimID data model with expiry dates), REQ-299 (evidence management), REQ-011 (MLR workflow for renewal approvals)

**Acceptance Criteria:** Lifecycle automation triggering renewal workflows at ninety, sixty, thirty, and seven days before claim expiry, renewal workflow supporting extension, revision, replacement, and retirement outcomes, automatic content asset identification and remediation task generation upon claim retirement, lifecycle dashboards providing visibility to claims by status and therapeutic area.

**Success Metrics:** Automated renewal task generation achieving 100% coverage of expiring claims, renewal completion rate above 90% before expiration date, expired claim incidents measured as zero unauthorized use of expired claims in six-month period following implementation, administrative time reduction of 50% measured through task tracking, user satisfaction with lifecycle management rated above 8 out of 10\.

---

**REQ-302: Claim Usage Tracking and Impact Analysis**

The system shall maintain comprehensive tracking of claim usage across all content assets and marketing campaigns enabling impact analysis when claims require updates or retirement. Usage tracking shall record every reference to each claim including content asset identifier, asset type such as email, detail aid, or web page, channel distribution, publication date, audience size, and engagement metrics. The tracking database shall support queries answering questions such as which assets reference specific claim, how many customers exposed to claim, which campaigns would require updating if claim changed, and what downstream impact would result from claim retirement. Real-time usage dashboards shall display claim utilization showing most frequently referenced claims, claims referenced by multiple therapeutic areas suggesting broad applicability, and unused approved claims representing potential opportunities.

Impact analysis capabilities shall simulate scenarios such as claim revision estimating number of assets requiring updates and effort required for remediation, claim retirement identifying affected campaigns and calculating business disruption, and claim expiry forecasting content update requirements over next six to twelve months enabling resource planning. The system shall generate stakeholder notifications when high-usage claims approach expiry or require revision alerting brand teams and agencies to prepare for updates. Integration with content management systems shall enable one-click identification of all assets referencing specific claims with batch update workflows reducing remediation effort. Usage analytics shall inform claim development priorities by revealing gaps where approved claims prove insufficient requiring new substantiation efforts.

**Business Rationale:** Understanding claim usage patterns proves essential for efficient compliance operations and strategic claim development. When claims require updates, organizations must identify affected materials quickly to ensure complete remediation. High-usage claims merit more proactive lifecycle management given broader potential impact if issues arise. Usage gaps reveal opportunities for new claim development addressing unmet content needs. Research demonstrates that systematic usage tracking reduces claim update cycle time by 50-60% through rapid asset identification, improves remediation completeness from 70% to 95% through systematic enumeration, and enhances strategic claim planning by revealing high-value opportunities. Organizations implementing usage tracking report 40% reduction in compliance remediation costs and 30% improvement in claim portfolio strategic alignment.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane C (Create), Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-298 through REQ-301 (claim management foundation), REQ-107 (content-to-claim mapping from Section 2), content management system integration

**Acceptance Criteria:** Usage tracking recording all claim references across content assets with comprehensive metadata, usage dashboard displaying claim utilization patterns and statistics, impact analysis simulating update and retirement scenarios with effort estimates, stakeholder notification system alerting teams when high-usage claims approach expiry, batch update workflow enabling efficient remediation when claims change.

**Success Metrics:** Usage tracking completeness showing 95% of content assets with claim references recorded, impact analysis accuracy validated through comparison of estimates versus actual remediation effort showing correlation coefficient above 0.7, remediation cycle time reduction of 50% measured from claim change to complete content update, strategic alignment improvement measured through reduction in unapproved claim requests by 30%.

---

## 4.2 MLR APPROVAL WORKFLOW AUTOMATION

### Capability Overview

The Medical-Legal-Regulatory (MLR) approval workflow represents the critical control point ensuring that all promotional materials receive appropriate expert review before customer deployment. Medical affairs evaluates scientific accuracy and clinical appropriateness, legal counsel assesses regulatory compliance and liability risks, and regulatory affairs confirms alignment with FDA guidance and agency expectations. Traditional MLR processes suffer from coordination complexity, accountability ambiguity, status opacity, and cycle time unpredictability. Materials submitted for review disappear into email chains with unclear ownership, reviews occur sequentially creating unnecessary delays when parallel evaluation would suffice, feedback from different reviewers conflicts requiring mediation, status inquiries burden coordinators, and cycle times vary unpredictably from two weeks to three months creating planning challenges.

The proposed MLR workflow automation transforms this fragmented manual process into systematic orchestrated operation with clear accountability, service-level agreements, progress transparency, and performance measurement. Built within Salesforce using Flow and Approval Process capabilities, the automated workflow routes submissions through appropriate review paths based on content type, therapeutic area, promotional risk level, and prior approval history. Standard materials with low risk and minor changes receive expedited single-reviewer approval, while novel high-risk materials undergo comprehensive multi-stage review with sequential escalation. The workflow manages task assignments, deadline tracking, reminder notifications, escalation protocols, comment consolidation, approval documentation, and performance reporting creating end-to-end visibility and control.

Workflow intelligence enables sophisticated routing decisions such as bypassing legal review for minor updates to previously approved materials, requiring regulatory affairs sign-off only for direct-to-consumer advertising, and mandating senior leadership approval for comparative claims. Version comparison capabilities highlight specific changes requiring review attention rather than forcing complete re-review of unchanged elements, accelerating cycles for revisions. Parallel review where appropriate enables simultaneous evaluation by multiple reviewers reducing sequential handoff delays. Conditional approvals allow reviewers to approve contingent on specific changes with automated verification before final release. Comprehensive audit trails document complete review history showing who reviewed what content when providing defensible compliance evidence.

Organizations implementing automated MLR workflows report 50-60% reduction in median review cycle time from six to eight weeks to three to four weeks, 40-50% improvement in on-time delivery against service-level agreements, 30-40% increase in reviewer productivity through workflow automation and intelligent routing, and elimination of accountability gaps where materials awaited review without clear ownership. These improvements accelerate time-to-market, reduce coordination overhead, and enhance compliance documentation quality.

### Detailed Requirements

**REQ-303: Multi-Stage Workflow Orchestration Engine**

The system shall implement sophisticated workflow orchestration supporting multiple approval paths tailored to content characteristics. The workflow engine shall enable configuration of distinct approval processes by content type such as email campaigns, landing pages, detail aids, patient brochures, social media posts, and television advertisements with each type possessing unique review requirements. Routing logic shall evaluate submission characteristics including promotional intensity level determined by claim types and messaging approach, therapeutic area determining appropriate medical reviewers with relevant expertise, content novelty distinguishing first-time materials requiring comprehensive review from minor updates to approved content, channel risk assessment recognizing that broadcast media and social platforms warrant additional scrutiny, and target audience considering whether content intended for HCPs, patients, caregivers, or general public.

The orchestration engine shall support serial review stages where approval at one stage triggers progression to subsequent stage, parallel review where multiple reviewers evaluate simultaneously with workflow advancing when all approvals received, and conditional branching where review outcomes determine next steps such as medical rejection triggering return to content creator while medical approval advances to legal review. The engine shall enforce service-level agreements with configurable timeframes such as three business days for medical review, two business days for legal review, and one business day for regulatory affairs sign-off. Automatic escalation shall trigger when reviews exceed SLAs notifying management and providing visibility to bottlenecks. The workflow shall maintain state persistence surviving system outages and resuming seamlessly without data loss.

**Business Rationale:** Standardized workflow orchestration eliminates ad hoc coordination replacing informal processes with systematic operations. Intelligent routing ensures appropriate expertise matches content requirements while avoiding unnecessary review overhead for low-risk materials. Parallel review where appropriate eliminates sequential delays that extend cycles unnecessarily. Service-level agreement enforcement creates accountability and predictability enabling reliable launch planning. Research demonstrates that workflow orchestration reduces median cycle time by forty-five to 55% primarily through eliminating coordination delays, improves schedule predictability enabling 90% of materials to launch within planned window compared to 60% for informal processes, and reduces coordination overhead by 60% measured through administrative task tracking. Organizations implementing orchestration report that predictability improvements prove equally valuable as speed gains enabling confident campaign planning.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-298 through REQ-302 (claim management foundation), REQ-115 (MLR workflow vision from Section 2), Salesforce Flow or equivalent workflow engine

**Acceptance Criteria:** Workflow orchestration supporting minimum five distinct approval paths configured by content type and characteristics, routing logic evaluating promotional intensity, therapeutic area, novelty, channel, and audience with appropriate path selection, serial, parallel, and conditional review stages implemented, service-level agreement enforcement with automatic escalation when thresholds exceeded, state persistence surviving interruptions.

**Success Metrics:** Workflow coverage reaching 95% of MLR submissions within six months, routing accuracy validated through retrospective analysis showing appropriate path selection 90% of time, service-level agreement compliance achieving 85% of reviews completing within target timeframe within six months of implementation, state persistence validated through failover testing showing zero data loss during simulated outages.

---

**REQ-304: Role-Based Review Task Management**

The system shall provide comprehensive task management for reviewers organizing assignments by urgency, workload balancing across team members, and progress tracking toward completion. Task assignment shall automatically route submissions to appropriate reviewers based on therapeutic area expertise, functional role such as medical versus legal versus regulatory, workload availability considering current pending reviews, and reviewer preferences reflecting individual strengths and interests. The system shall support both individual assignment to specific reviewers and team assignment to functional groups with first available team member claiming tasks. Task prioritization shall consider submission date with older requests receiving higher priority, service-level agreement urgency flagging reviews approaching deadline, strategic importance designating high-priority campaigns, and submitter escalation requests when business urgency warrants expedited handling.

Reviewer dashboards shall display pending tasks with sortable columns showing submission date, content type, submitter, priority level, days remaining until SLA breach, and estimated effort. Task details shall provide one-click access to content requiring review, previous version for comparison when applicable, submission notes explaining review purpose and specific questions, claims referenced enabling quick substantiation verification, and prior review comments when material previously evaluated. Batch operations shall enable reviewers to manage multiple similar items efficiently such as approving twenty email variations simultaneously when differences prove minor. Task delegation shall allow reviewers to reassign items to colleagues when expertise gaps arise or workload proves overwhelming. Task history shall document all assignments, reassignments, and completion events providing complete audit trail of accountability chain.

**Business Rationale:** Effective task management dramatically influences reviewer productivity and satisfaction. Clear prioritization prevents low-value work from crowding out urgent business needs. Workload balancing ensures equitable distribution preventing burnout and bottlenecks. One-click access to all relevant context eliminates time wasted searching for materials and substantiation. Research demonstrates that sophisticated task management improves reviewer productivity by 30-40% measured through reviews completed per week, reduces review cycle time by 25-35% through eliminating delays and interruptions, and enhances reviewer satisfaction by 40-50% based on engagement surveys. Organizations implementing task management report that productivity gains primarily result from reducing context switching and search time rather than faster individual review speeds.

**Swimlane Alignment:** Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-303 (workflow orchestration), REQ-116 and REQ-117 (role-based access and task management from Section 2), Salesforce or task management platform integration

**Acceptance Criteria:** Task assignment routing based on expertise, role, workload, and preferences with individual and team assignment modes, task prioritization considering age, SLA urgency, strategic importance, and escalation requests, reviewer dashboard displaying pending tasks with comprehensive filtering and sorting, one-click context access including content, prior versions, submission notes, referenced claims, and prior comments, batch operations and task delegation capabilities.

**Success Metrics:** Task assignment accuracy validated through reviewer expertise matching showing appropriate specialist assignment 90% of time, workload balancing achieving coefficient of variation under zero point three indicating equitable distribution, reviewer productivity improvement measured through reviews per week increasing 30% within six months, reviewer satisfaction with task management rated above 8 out of 10\.

---

**REQ-305: Structured Comment and Feedback Framework**

The system shall implement structured feedback mechanisms enabling reviewers to provide clear, actionable, and trackable comments on materials under review. Comment types shall distinguish between major change required indicating substantive issues requiring revision before approval consideration, minor change suggested recommending improvements but not blocking approval, question needing clarification requesting information from submitter, and approval granted confirming material meets standards. Each comment shall attach to specific content elements such as particular claim statement, image, or disclaimer enabling precise feedback location. Comment metadata shall capture reviewer identity, timestamp, comment type, severity if applicable, and resolution status tracking whether submitter addressed feedback.

Threaded discussions shall enable conversations between submitters and reviewers clarifying questions and negotiating resolutions without resorting to email. Comment templates shall provide standardized feedback for common issues such as inadequate fair balance, missing safety information, unsubstantiated claims, and off-label implications ensuring consistent communication and reducing repetitive typing. Comment analytics shall aggregate feedback patterns identifying most frequent rejection reasons, reviewers with highest revision request rates, and content types with most issues informing process improvements and training priorities. Comment resolution workflow shall require submitters to explicitly address each comment documenting either implementation of requested changes or rationale for declining suggestions before resubmission. Approval decisions shall consider comment resolution status preventing materials from advancing with unresolved major issues.

**Business Rationale:** Clear, structured feedback accelerates resolution by eliminating ambiguity about reviewer expectations and required actions. Attaching comments to specific content elements focuses attention on problematic areas avoiding confusion about which parts require changes. Threaded discussions resolve questions efficiently compared to email exchanges that fragment across multiple threads. Comment analytics reveal systematic issues enabling root cause remediation through training or process changes. Research demonstrates that structured feedback reduces rework cycles by 40-50% through clearer initial guidance, accelerates issue resolution by 30-40% through threaded discussions, and improves submitter satisfaction by 50-60% measured through surveys asking about clarity and helpfulness of reviewer feedback. Organizations report that comment analytics frequently reveal a small number of recurring issues causing disproportionate rework enabling targeted training interventions.

**Swimlane Alignment:** Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-303 and REQ-304 (workflow and task management foundation), REQ-118 (structured comment taxonomy from Section 2\)

**Acceptance Criteria:** Structured comment framework supporting major change, minor change, question, and approval types with attachment to specific content elements, threaded discussion capability enabling conversations between submitters and reviewers, comment templates for common feedback patterns, comment analytics aggregating patterns and identifying improvement opportunities, resolution workflow requiring explicit comment addressing before resubmission.

**Success Metrics:** Comment usage adoption reaching 90% of reviews using structured framework rather than unstructured notes within three months, rework cycle reduction measured through average resubmissions per approval decreasing from current baseline by 40%, issue resolution time for questions averaging under 24 hours through threaded discussions, submitter satisfaction with feedback clarity rated above 8 out of 10, comment analytics identifying minimum ten actionable process improvements within first year.

---

**REQ-306: Version Comparison and Change Highlighting**

The system shall provide sophisticated version comparison capabilities enabling reviewers to focus attention on changes rather than re-reviewing entire materials when minor revisions occur. Version comparison shall support multiple content formats including Word documents showing track changes and deletions with inline annotations, PowerPoint presentations highlighting modified slides and indicating unchanged sections, PDF files displaying side-by-side comparison with change markup, HTML web pages showing textual differences and layout modifications, and email templates comparing subject lines, preview text, and body content. The comparison engine shall identify substantive changes affecting claims, messaging, images, or compliance elements while filtering cosmetic adjustments such as font changes, color variations, or spacing modifications that do not warrant review attention.

Change summary reports shall provide high-level overview listing all modifications with categorization by significance such as claim additions or removals, message tone shifts, audience targeting changes, and technical corrections. Reviewers shall configure comparison sensitivity determining whether to highlight all changes or only substantive modifications based on personal preference and review context. The system shall automatically determine whether changes trigger full re-review versus abbreviated evaluation based on modification scope with minor updates receiving expedited processing. Change history visualization shall display version timeline showing all previous iterations with ability to compare any two versions not just consecutive pairs. Integration with MLR workflow shall use version comparison to route appropriately with materials showing only minor changes bypassing certain review stages.

**Business Rationale:** Re-reviewing entire materials when only small sections changed wastes reviewer time and delays approvals unnecessarily. Version comparison focuses attention on modifications enabling efficient evaluation of whether changes maintain compliance and strategic alignment. Automatic routing based on change scope ensures that truly novel content receives comprehensive review while minor updates progress expeditiously. Research demonstrates that version comparison reduces review time by 50-70% for revised materials, improves review quality by focusing attention on relevant changes rather than scattering across unchanged content, and accelerates approval cycles for revisions by 40-60%. Organizations implementing version comparison report that efficiency gains prove most substantial for materials undergoing multiple revision cycles where incremental improvements occur across several review iterations.

**Swimlane Alignment:** Swimlane C (Create)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-303 through REQ-305 (workflow and review foundation), REQ-104 (version control from Section 2), document comparison service or libraries

**Acceptance Criteria:** Version comparison supporting Word, PowerPoint, PDF, HTML, and email formats with change highlighting and track changes display, substantive change identification filtering cosmetic modifications, change summary reports categorizing modifications by significance, comparison sensitivity configuration enabling reviewer preferences, version history visualization showing complete timeline with any-to-any comparison.

**Success Metrics:** Version comparison adoption with 70% of resubmissions using comparison feature within six months, review time reduction for revised materials measured through timestamps showing 60% decrease versus full re-review, reviewer satisfaction with comparison functionality rated above 8 out of 10, routing accuracy showing appropriate expedited processing for minor changes validated through retrospective audit.

---

**REQ-307: Approval Documentation and Audit Trail**

The system shall generate comprehensive approval documentation providing defensible evidence that materials received appropriate review before deployment. Approval records shall capture complete metadata including submission details such as content title, version number, submission date, and submitter identity; review activities documenting which reviewers evaluated material, review completion timestamps, time spent in review calculated from task assignment to completion, and review outcomes including approval, rejection, or conditional approval; comments and feedback preserving all reviewer comments with resolution documentation showing how submitters addressed concerns; and final approval decision indicating ultimate disposition with approval authority identification.

The audit trail shall maintain an immutable record of all workflow events including submission creation, task assignments, reassignments, review completions, resubmissions, escalations, and final approvals with timestamps and user attribution. Cryptographic hashing shall ensure trail integrity preventing tampering with compliance records. Approval certificates shall be generated as PDF documents suitable for regulatory inspection showing material thumbnails, approval metadata, reviewer signatures or electronic equivalent, and substantiation references for all claims. The system shall support bulk audit trail export enabling efficient response to regulatory requests for documentation covering specific time periods, therapeutic areas, or content types. Retention policies shall maintain approval records for a minimum seven years or longer as required by applicable regulations with secure archival storage and retrieval capabilities.

**Business Rationale:** Complete, defensible documentation proves essential during regulatory inspections, legal discovery, and internal audits. FDA inspectors routinely request evidence demonstrating that promotional materials received appropriate review including reviewer qualifications, review scope, identified issues, and resolution documentation. Incomplete or inconsistent records create compliance liability suggesting inadequate controls. Immutable audit trails prevent documentation manipulation ensuring evidence integrity. Research demonstrates that comprehensive approval documentation reduces regulatory inspection duration by 40-50% through efficient evidence production, improves inspection outcomes with 60% fewer observations related to promotional controls, and accelerates legal discovery response by 70%. Organizations implementing systematic documentation report that record completeness proves as important as approval rigor itself when demonstrating compliance culture to regulators.

**Swimlane Alignment:** Swimlane A (Govern), Swimlane C (Create)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-303 through REQ-306 (workflow generating events for audit trail), REQ-033 (approval record repository from Section 1), REQ-132 (content audit trail from Section 2\)

**Acceptance Criteria:** Approval record generation capturing complete submission metadata, review activities, comments, and final decisions with immutable audit trail of all workflow events, cryptographic hashing ensuring trail integrity, approval certificate generation as PDF with material thumbnails and substantiation references, bulk export capability for regulatory requests, retention policies maintaining records minimum seven years.

**Success Metrics:** Documentation completeness achieving 100% of approved materials with complete approval records within three months of implementation, audit trail integrity validated through cryptographic verification showing zero tampering incidents, regulatory inspection evidence production time averaging under four hours for complete documentation package, internal audit findings showing zero critical gaps in approval documentation, retention compliance verified through quarterly validation.

---

**REQ-308: MLR Performance Analytics and Continuous Improvement**

The system shall provide comprehensive analytics enabling continuous workflow optimization and performance management. Performance dashboards shall track key metrics including median and 95th percentile cycle times showing distribution of review durations by content type and therapeutic area, service-level agreement compliance rates measuring percentage of reviews completing within target timeframes, throughput metrics counting reviews completed per week or month showing capacity utilization, rejection and rework rates indicating percentage of submissions requiring multiple iterations, and reviewer productivity showing completions per reviewer normalized by effort and complexity. Trend analysis shall compare current performance against historical baselines identifying improvements or degradations requiring attention.

Bottleneck identification shall pinpoint workflow stages or individuals creating delays through analysis showing which review stages consume disproportionate time, which reviewers have highest pending task counts suggesting workload imbalance, which content types require most cycles indicating systematic issues, and which therapeutic areas show longest cycles suggesting capacity constraints. Root cause analysis shall investigate outlier cases taking excessively long to complete understanding whether delays result from reviewer unavailability, unclear submission requirements, complex scientific questions, or systemic process gaps. Continuous improvement initiatives shall target identified bottlenecks through process redesign, staffing adjustments, training programs, or technology enhancements with measurable impact assessment. Executive reporting shall aggregate portfolio-level metrics showing organizational MLR maturity and improvement trajectory with peer benchmarking when available.

**Business Rationale:** Measurement enables management as workflow analytics transform qualitative impressions about performance into quantitative evidence supporting improvement initiatives. Bottleneck identification directs improvement efforts toward highest-impact opportunities rather than diffuse interventions with modest returns. Trend analysis reveals whether interventions deliver intended benefits enabling course correction when initiatives underperform. Research demonstrates that organizations implementing workflow analytics achieve 25-35% additional cycle time improvements beyond initial workflow automation through systematic optimization targeting revealed bottlenecks, improve service-level agreement compliance by 40-50 percentage points through performance management and accountability, and enhance reviewer satisfaction by 30-40% through workload balancing and process improvements addressing pain points. Organizations report that analytics frequently reveal counterintuitive improvement opportunities such as legal review proving faster than medical despite assumptions to contrary suggesting medical staffing constraints require attention.

**Swimlane Alignment:** Swimlane C (Create), Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-303 through REQ-307 (workflow generating performance data), REQ-123 (review metrics dashboard from Section 2), REQ-239 through REQ-248 (reporting infrastructure)

**Acceptance Criteria:** Performance dashboard tracking cycle times, SLA compliance, throughput, rejection rates, and reviewer productivity with trend analysis comparing current versus historical performance, bottleneck identification analyzing stages, individuals, content types, and therapeutic areas consuming disproportionate time, root cause analysis investigating outlier cases, continuous improvement framework with measurable impact assessment, executive reporting showing portfolio-level metrics.

**Success Metrics:** Analytics adoption with monthly dashboard review by MLR leadership demonstrating organizational commitment to data-driven management, improvement initiatives launched based on analytics insights averaging two per quarter, measurable impact from improvements showing cycle time reductions or SLA compliance improvements within six months of intervention, stakeholder satisfaction with analytics capability rated above 8 out of 10\.

---

## SECTION 4 SUMMARY

This enhanced Section 4 provides comprehensive specifications for ClaimID Framework and MLR Workflow capabilities addressing pharmaceutical regulatory compliance requirements. The section documents eleven new detailed requirements spanning REQ-298 through REQ-308 covering claim data modeling, substantiation evidence management, lifecycle automation, usage tracking, workflow orchestration, task management, structured feedback, version comparison, approval documentation, and performance analytics. These capabilities transform abstract compliance obligations into concrete operational controls embedded within marketing technology infrastructure reducing regulatory risk while accelerating time-to-market.

### Requirements Summary

| Capability Domain | Requirements | Priority P0 | Priority P1 | Phase 1 | Phase 2 |
| :---- | :---- | :---- | :---- | :---- | :---- |
| ClaimID Data Model and Registry | REQ-298 to REQ-302 | 4 | 1 | 4 | 1 |
| MLR Workflow Automation | REQ-303 to REQ-308 | 4 | 2 | 4 | 2 |
| **Total Section 4** | **11** | **8** | **3** | **8** | **3** |

---

# SECTION 5: MARKETING MIX MODELING AND OPTIMIZATION

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## OVERVIEW

Marketing Mix Modeling and Optimization capabilities represent the strategic analytics layer that transforms pharmaceutical marketing from intuition-driven budget allocation to evidence-based investment optimization. While tactical performance dashboards reveal which individual campaigns perform well or poorly, marketing mix modeling addresses the more fundamental strategic questions about optimal channel investment levels, diminishing returns thresholds, cross-channel synergies, and portfolio-level budget allocation. These strategic insights prove particularly valuable in pharmaceutical marketing where annual marketing investments frequently reach thirty to fifty million dollars per brand creating substantial opportunity for optimization while lengthy sales cycles and complex multi-stakeholder decisions complicate attribution making causal impact measurement essential rather than optional.

Traditional pharmaceutical marketing budget allocation relies heavily on historical precedent modified by executive judgment and political negotiation across brand teams. Media planning agencies recommend channel investments based on reach and frequency models that ignore downstream business outcomes. Field sales receives budget based on physician counts and territory potential without considering digital marketing effectiveness. Email campaigns continue year after year because they seem inexpensive without rigorous measurement of incremental value. Patient support programs expand based on enrollment rather than adherence improvement or persistence outcomes. This approach perpetuates suboptimal allocations where saturated channels receive excessive investment generating minimal incremental returns while underfunded opportunities with high marginal returns remain unexploited. Industry research suggests that typical pharmaceutical marketing portfolios could achieve fifteen to 30% higher return on investment through optimized reallocation without requiring additional total budget.

The proposed Marketing Mix Modeling framework addresses these challenges through four integrated analytical capabilities that collectively enable data-driven strategic decision making. Multi-touch attribution models reconstruct customer journeys linking touchpoints to outcomes using sophisticated algorithms that distribute credit appropriately across awareness, consideration, and conversion interactions rather than naive last-touch attribution that systematically undervalues early-stage activities. Marketing mix models employ Bayesian hierarchical regression techniques to quantify incremental impact of each channel controlling for seasonality, competitive activity, and market dynamics while capturing diminishing returns curves and cross-channel interaction effects. Scenario simulation engines enable risk-free exploration of alternative budget allocations showing predicted outcomes before implementation eliminating guesswork from strategic planning. Constrained optimization solvers identify mathematically optimal budget allocations that maximize defined objectives subject to business constraints such as minimum spend commitments and strategic priorities providing concrete actionable recommendations.

Organizations implementing comprehensive marketing mix modeling capabilities report twenty-five to 40% improvement in marketing return on investment achieved through systematic reallocation away from saturated low-return channels toward underfunded high-return opportunities, fifteen to 25% reduction in wasted spending on ineffective activities identified through incrementality measurement, 30-40% improvement in forecast accuracy enabling better business planning and resource allocation, and transformation of marketing leadership credibility with chief financial officers and boards through demonstrated ability to quantify and optimize investment returns. These benefits compound annually as accumulated learning refines models and successive optimization cycles drive continuous improvement.

---

## 5.1 ATTRIBUTION MODEL FRAMEWORK AND IMPLEMENTATION

### Capability Overview

Attribution modeling quantifies which marketing activities drive business outcomes by analyzing customer journeys and allocating conversion credit across touchpoints using methodologically rigorous approaches. The fundamental attribution challenge lies in determining causality rather than mere correlation when customers exposed to marketing campaigns subsequently take desired actions. Did the marketing cause the outcome or would the customer have converted anyway based on organic need, competitive factors, or other influences beyond marketing control? Would different marketing have produced better results? These questions prove difficult to answer definitively yet prove essential for optimizing investment allocation.

Traditional last-touch attribution assigns full credit to the final marketing interaction before conversion such as the last email clicked or last advertisement viewed. This approach systematically undervalues awareness and consideration activities that initiate customer interest and nurture relationships over time while overvaluing late-stage conversion tactics. An HCP may attend conferences, download clinical guidelines, and engage with field representatives over six months before prescribing a medication yet last-touch attribution credits only the final detail aid that immediately preceded the prescription. This distortion leads to chronic underinvestment in awareness building and overinvestment in conversion tactics creating imbalanced portfolios that struggle to generate sufficient qualified prospects for conversion activities to address.

The proposed attribution framework implements multiple methodologies ranging from simple rules-based approaches to sophisticated algorithmic models enabling comparison and validation while supporting different analytical purposes. Rules-based models including first-touch, last-touch, linear, time-decay, and position-based attribution provide transparent starting points with clearly understood limitations. Algorithmic models employ machine learning to determine optimal credit distribution based on observed conversion patterns across thousands of customer journeys revealing which touchpoint sequences correlate most strongly with desired outcomes. Shapley value attribution applies cooperative game theory principles to calculate each touchpoint's marginal contribution ensuring mathematically fair credit allocation. Incrementality measurement through holdout group testing establishes causal impact by comparing outcomes between customers who received marketing versus control groups who did not providing definitive evidence of marketing value.

Together these methodologies provide comprehensive view of marketing effectiveness suitable for different decision contexts. Rules-based attribution supports rapid operational analysis and channel performance monitoring. Algorithmic attribution reveals optimization opportunities by identifying high-performing touchpoint combinations. Shapley values provide equitable budget allocation when multiple teams share responsibility for customer outcomes. Incrementality testing resolves debates about marketing value by proving causal impact rather than merely correlation. Organizations implementing multi-methodology attribution frameworks report 30-40% improvement in budget allocation quality measured through subsequent campaign performance, 25-35% better alignment between marketing investment and business outcomes, and 50-60% reduction in time spent debating attribution methodology as multiple approaches converge on similar directional findings building stakeholder confidence.

### Detailed Requirements

**REQ-309: Attribution Data Mart and Journey Reconstruction**

The system shall implement specialized attribution data mart aggregating touchpoint events, customer attributes, and business outcomes enabling efficient journey analysis and attribution modeling. The data mart architecture shall organize data around customer journeys representing complete sequences of marketing interactions from initial awareness through conversion and beyond. Journey reconstruction algorithms shall link touchpoints to individual customers using deterministic identifiers such as email address and CRM record identifier supplemented by probabilistic matching for anonymous sessions before authentication. The reconstruction process shall handle common data quality challenges including duplicate event recording requiring deduplication logic, timestamp inconsistencies necessitating temporal ordering validation, and cross-device tracking linking desktop and mobile interactions to unified customer profiles.

The attribution schema shall capture essential touchpoint attributes including channel classification such as email, paid search, display advertising, organic social, field sales, or patient program, campaign identification linking interactions to specific marketing initiatives, content type describing asset format such as whitepaper, video, webinar, or detail aid, touchpoint timestamp recording when interaction occurred, engagement depth quantifying intensity from simple impression through active participation, and cost allocation assigning marketing investment to individual touchpoints enabling return on investment calculation. Outcome definitions shall specify conversion events such as prescription written, trial enrollment, speaker program participation, or patient adherence milestone with attributed revenue or pipeline value. Customer attributes shall include segment membership, lifecycle stage, geographic location, and demographic characteristics enabling cohort analysis revealing differential channel effectiveness across populations.

The data mart shall maintain historical journey data spanning minimum eighteen months providing sufficient observations for model training while managing storage costs through compression and archival strategies. Query optimization shall support common attribution analyses including journey path analysis showing frequent sequences, conversion rate calculation by touchpoint combinations, and time-to-conversion measurement revealing typical decision cycles. Data quality monitoring shall validate incoming data checking for completeness, consistency, and reasonable values with automated alerting when quality degrades. Privacy controls shall implement appropriate safeguards protecting customer identifiers and behavioral data with access controls limiting visibility to authorized analysts.

**Business Rationale:** Comprehensive journey data represents the essential foundation for all attribution modeling approaches as models require complete touchpoint histories to determine which interactions influenced outcomes. Fragmented or incomplete data creates attribution blind spots where missing touchpoints prevent accurate credit allocation. Industry research demonstrates that typical organizations capture only 60-70% of marketing touchpoints due to tracking gaps, agency system disconnects, and field activity recording challenges. Each missing touchpoint reduces attribution accuracy and optimization potential. The proposed data mart architecture addresses these challenges through systematic integration across all marketing systems ensuring comprehensive journey visibility. Organizations implementing attribution data marts report 40-50% improvement in journey completeness measured through touchpoint coverage, 30-40% reduction in data preparation effort for analysis through purpose-built schema design, and 25-35% faster query performance enabling interactive analysis.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-231 through REQ-238 (event collection infrastructure providing source data), REQ-006 (identity resolution enabling journey reconstruction), REQ-249 (attribution data mart vision from Section 2), cloud data warehouse deployment

**Acceptance Criteria:** Attribution data mart implemented with journey-centric schema capturing touchpoints, customer attributes, and outcomes, journey reconstruction algorithms linking events to customers with deduplication and temporal ordering, eighteen-month historical retention with compression and archival management, query optimization supporting common attribution analyses with sub-minute response times, data quality monitoring validating completeness and consistency.

**Success Metrics:** Journey completeness reaching 85% of marketing touchpoints captured within six months measured through reconciliation against source system volumes, data quality assessment showing greater than 95% of journeys with complete required attributes, query performance achieving sub-minute response for 95th percentile of attribution analyses, analyst satisfaction with data mart usability rated above 8 out of 10\.

---

**REQ-310: Rules-Based Attribution Models**

The system shall implement comprehensive suite of rules-based attribution models providing transparent, understandable starting points for attribution analysis. First-touch attribution shall assign 100% of conversion credit to the initial marketing touchpoint that began customer relationship enabling measurement of top-of-funnel awareness activities. Last-touch attribution shall allocate full credit to the final marketing interaction before conversion supporting evaluation of close tactics and conversion optimization. Linear attribution shall distribute credit equally across all journey touchpoints recognizing that each interaction contributed to outcome without attempting to weight relative importance. Time-decay attribution shall apply exponentially increasing weights to more recent touchpoints reflecting hypothesis that interactions closer to conversion exert stronger influence. Position-based attribution shall assign 40% credit each to first and last touches with remaining 20% distributed across middle interactions acknowledging special importance of awareness and conversion moments.

Each attribution model shall generate consistent output formats enabling comparison including channel-level credit allocation showing how conversion credit distributes across email, paid media, field sales, and other channels, campaign-level attribution revealing which specific initiatives drive outcomes, content-level analysis identifying high-performing asset types and messages, and temporal patterns showing credit distribution over customer lifecycle stages. The system shall support configurable lookback windows defining relevant time periods for attribution such as 30 days for tactical campaigns or twelve months for strategic relationship building. Attribution results shall aggregate across customer populations showing portfolio-level channel effectiveness while supporting drill-down to individual journey analysis.

Model comparison capabilities shall enable side-by-side evaluation of different attribution methodologies revealing how credit allocation varies with methodological choices. Visualization shall display channel credit across models using grouped bar charts or heatmaps making differences immediately apparent. The system shall calculate methodological agreement metrics quantifying similarity between approaches such as rank correlation showing whether models agree on relative channel importance despite absolute credit differences. Documentation shall clearly communicate each model's assumptions, strengths, and limitations enabling informed interpretation rather than uncritical acceptance of results.

**Business Rationale:** Rules-based attribution provides accessible starting point for organizations beginning attribution journey with transparent methodologies that stakeholders readily understand. Simple models enable rapid implementation generating immediate value while more sophisticated approaches develop. Model comparison reveals whether strategic conclusions prove robust across methodologies building confidence in findings. Research demonstrates that rules-based attribution typically identifies directionally correct opportunities improving decision quality by 20-30% versus no attribution despite methodological limitations. Organizations report that rules-based models frequently reveal obvious misallocations such as excessive last-touch focus driving rebalancing toward awareness activities even before algorithmic approaches become available. Transparency proves particularly valuable in pharmaceutical contexts where cross-functional stakeholders require clear explanation of analytical approaches.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-309 (attribution data mart providing journey data), REQ-250 (rules-based attribution vision from Section 2\)

**Acceptance Criteria:** Complete suite of rules-based models implemented including first-touch, last-touch, linear, time-decay, and position-based attribution with configurable lookback windows, consistent output formats enabling channel, campaign, and content-level analysis, model comparison capabilities showing side-by-side credit allocation with agreement metrics, comprehensive documentation explaining assumptions, strengths, and limitations.

**Success Metrics:** Model implementation completeness achieving all five rules-based approaches deployed and validated, analytical adoption measured through monthly usage by marketing analysts reaching 80% within six months, methodological agreement assessment showing rank correlation above 0.6 across models suggesting convergent findings, stakeholder comprehension validated through testing showing 90% correct interpretation of model outputs.

---

**REQ-311: Algorithmic Attribution Using Machine Learning**

The system shall implement sophisticated algorithmic attribution models employing machine learning techniques to determine optimal credit distribution based on observed conversion patterns across large populations of customer journeys. The algorithmic framework shall support multiple machine learning approaches including logistic regression predicting conversion probability as function of touchpoint exposure with coefficients revealing relative impact, random forests capturing non-linear relationships and interaction effects between touchpoints through ensemble decision trees, gradient boosting machines achieving high predictive accuracy through iterative refinement, and neural networks modeling complex patterns when sufficient training data exists. Model training shall use historical journey data with proper train-test splits ensuring evaluation on held-out data preventing overfitting that would compromise generalization.

Feature engineering shall transform raw touchpoint sequences into model inputs including channel exposure counts tallying interactions by marketing channel, touchpoint sequencing capturing order dependencies, time-since-exposure calculating recency, interaction effects representing cross-channel combinations, and customer context incorporating segment membership and lifecycle stage. The system shall handle class imbalance where conversions prove relatively rare compared to non-conversions through techniques such as stratified sampling, cost-sensitive learning, or synthetic minority oversampling ensuring models learn from positive examples rather than merely predicting majority class. Credit allocation shall derive from model coefficients or feature importance scores translated into percentage allocations across touchpoints ensuring credit sums to 100%.

Model evaluation shall employ multiple performance metrics including area under receiver operating characteristic curve measuring discriminative ability to distinguish converters from non-converters, precision and recall assessing prediction accuracy, and calibration plots showing whether predicted probabilities match observed conversion rates. The framework shall support model comparison selecting best-performing approach for production deployment. Model updates shall occur periodically such as quarterly refreshes incorporating recent data preventing staleness as market conditions and customer behaviors evolve. The system shall provide model explainability features showing which touchpoint patterns most strongly predict conversion supporting business interpretation and trust building.

**Business Rationale:** Algorithmic attribution overcomes rules-based limitations by learning optimal credit distribution from data rather than imposing arbitrary rules. Machine learning discovers patterns that human analysts might miss such as specific touchpoint sequences that prove particularly effective or cross-channel synergies that amplify impact. Research demonstrates that algorithmic approaches typically improve prediction accuracy by 30-50% versus rules-based models measured through out-of-sample testing, reveal non-obvious optimization opportunities such as undervalued mid-funnel tactics, and provide more accurate budget allocation guidance. Organizations implementing machine learning attribution report twenty to 35% improvement in campaign return on investment through identifying and scaling high-performing patterns while reducing investment in revealed low-impact activities. Pharmaceutical applications benefit particularly from handling complex multi-stakeholder journeys where simple rules prove inadequate.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 3\)

**Dependencies:** REQ-309 (attribution data mart with sufficient historical data for model training), REQ-310 (rules-based attribution providing baseline comparison), REQ-251 (algorithmic attribution vision from Section 2), machine learning platform or libraries

**Acceptance Criteria:** Machine learning attribution framework supporting logistic regression, random forests, gradient boosting, and neural networks with proper train-test evaluation, feature engineering transforming journey sequences into model inputs with channel exposure, sequencing, recency, interactions, and context, class imbalance handling through appropriate techniques, model evaluation using AUC, precision, recall, and calibration metrics, periodic model updates incorporating recent data, explainability features showing predictive patterns.

**Success Metrics:** Model performance achieving area under curve above 0.7 on out-of-sample test data indicating strong discriminative ability, prediction accuracy improvement of 30% versus rules-based attribution measured through correlation with actual outcomes, business value demonstration showing campaigns optimized using algorithmic attribution achieving 25% higher return versus baseline, stakeholder trust validated through survey showing 70% confidence in model recommendations.

---

**REQ-312: Shapley Value Attribution for Fair Credit Allocation**

The system shall implement Shapley value attribution applying cooperative game theory principles to calculate each touchpoint's marginal contribution to conversion ensuring mathematically fair and defensible credit distribution. Shapley value methodology considers all possible orderings of touchpoints within customer journey calculating each touchpoint's average marginal contribution across orderings. The calculation process shall enumerate permutations of journey touchpoints, compute incremental conversion probability from adding each touchpoint to existing sets, and average marginal contributions across all orderings producing unique credit allocation satisfying fairness axioms including efficiency where total credit equals actual outcome, symmetry where equivalent touchpoints receive equal credit, and additivity where credit for combined outcomes equals sum of individual credits.

The implementation shall employ computational approximations for long journeys where exact enumeration proves intractable due to combinatorial explosion. Monte Carlo sampling shall estimate Shapley values through random permutation sampling achieving statistically valid approximations with controllable precision. The system shall support configurable sample sizes balancing computational cost against estimation accuracy with larger samples for high-stakes analyses and smaller samples for exploratory work. Convergence monitoring shall track estimate stability ensuring sufficient sampling before reporting results. The framework shall parallelize calculations across multiple processors enabling reasonable computation times for large journey datasets.

Shapley attribution output shall provide channel-level, campaign-level, and touchpoint-level credit allocations with confidence intervals quantifying estimation uncertainty. Comparison with rules-based and algorithmic approaches shall reveal whether Shapley values yield materially different conclusions or converge with other methodologies. The system shall support counterfactual analysis answering questions such as what credit allocation would result if specific touchpoints removed or replaced enabling optimization scenario evaluation. Documentation shall explain game theory foundation, fairness properties, and interpretation guidance enabling stakeholder comprehension despite mathematical sophistication.

**Business Rationale:** Shapley value attribution provides mathematically rigorous fair allocation addressing common criticism that attribution methods impose arbitrary rules. Fairness axioms create defensible methodology particularly valuable when multiple teams share responsibility for customer outcomes and credit allocation influences budget allocation or performance evaluation. Game theory foundation enables sophisticated counterfactual analysis supporting strategic planning scenarios. Research demonstrates that Shapley attribution often produces materially different results versus simple rules revealing undervalued touchpoints that contribute significantly but rarely occur as last touches. Organizations implementing Shapley attribution report improved cross-functional collaboration as teams accept fair methodology reducing political disputes about credit allocation, 30-40% better alignment between touchpoint investment and actual contribution, and enhanced analytical credibility with technical stakeholders who recognize mathematical rigor.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 3\)

**Dependencies:** REQ-309 (attribution data mart), REQ-310 and REQ-311 (baseline attribution approaches for comparison), REQ-252 (Shapley attribution vision from Section 2), computational resources for intensive calculations

**Acceptance Criteria:** Shapley value calculation implementing marginal contribution methodology with fairness axioms, computational approximations using Monte Carlo sampling with convergence monitoring, parallel processing enabling reasonable computation times for large datasets, output providing channel, campaign, and touchpoint credit with confidence intervals, counterfactual analysis supporting optimization scenarios.

**Success Metrics:** Computational performance achieving Shapley calculation completion within four hours for typical monthly journey volume using Monte Carlo approximation, estimation accuracy validated through convergence testing showing coefficient of variation below ten percent, methodological agreement with other approaches measured through rank correlation showing directional consistency, stakeholder acceptance validated through cross-functional endorsement for budget allocation decisions.

---

**REQ-313: Incrementality Measurement Through Holdout Testing**

The system shall support rigorous incrementality measurement quantifying causal marketing impact through controlled experimentation comparing outcomes between treatment groups receiving marketing versus holdout groups receiving no marketing intervention. The holdout framework shall enable multiple experimental designs including customer-level randomization splitting eligible population into treatment receiving normal marketing and control receiving no marketing communications, geographic holdouts assigning markets or territories to treatment versus control conditions enabling measurement when customer-level randomization proves infeasible, and time-based holdouts comparing periods with marketing activity versus periods without treatment suitable for seasonal analysis or trend evaluation. Randomization procedures shall ensure treatment and control groups possess equivalent characteristics on observable attributes preventing selection bias that would confound causal inference.

Sample size calculations shall determine minimum group sizes required for detecting meaningful effects with adequate statistical power considering baseline conversion rates, expected lift magnitude, and desired confidence levels. The framework shall support power analysis across multiple scenarios enabling tradeoff evaluation between sample size costs and measurement precision. Holdout duration planning shall consider typical conversion lag times ensuring sufficient observation period for outcomes to manifest. The system shall implement holdout integrity monitoring validating that control customers do not inadvertently receive marketing interventions through execution errors with alerting and remediation when violations detected.

Analysis methodologies shall employ appropriate statistical techniques for causal inference including difference-in-differences comparing outcome changes between treatment and control groups accounting for time trends, regression adjustment controlling for covariates that explain outcome variation improving precision, and propensity score matching creating comparable groups when randomization imperfect through statistical adjustment. Effect estimation shall quantify absolute lift showing raw difference between groups, relative lift calculating percentage improvement versus control, incremental return on investment dividing incremental benefit by treatment cost, and confidence intervals representing estimation uncertainty. Subgroup analysis shall reveal whether effects vary across customer segments, geographic regions, or time periods informing targeting optimization.

**Business Rationale:** Incrementality testing provides definitive causal evidence resolving debates about whether marketing drives outcomes or merely correlates with organic behavior. Holdout groups reveal the counterfactual showing what would happen without marketing intervention enabling true incremental impact quantification. Research consistently demonstrates that 50-70% of measured outcomes typically occur organically in holdout groups meaning naive measurement overstates marketing contribution by two to three times. This insight proves critical for accurate return on investment calculation and defending marketing budgets to skeptical finance partners. Organizations implementing systematic incrementality testing report 30-50% more accurate return on investment estimates, improved executive confidence in marketing value enabling budget increases for proven effective programs, and better strategic decisions about channel investments informed by causal evidence rather than correlational assumptions.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P1 \- Strategic capability (Phase 2\)

**Dependencies:** REQ-309 (attribution data mart for outcome measurement), REQ-159 (holdout group management from Section 2), REQ-256 (incrementality measurement vision from Section 2), REQ-063 through REQ-092 (segmentation for holdout assignment)

**Acceptance Criteria:** Holdout framework supporting customer-level, geographic, and time-based experimental designs with randomization procedures ensuring group equivalence, sample size calculations determining minimum requirements for adequate statistical power, holdout integrity monitoring validating control group isolation with violation alerting, analysis methodologies employing difference-in-differences, regression adjustment, and propensity matching, effect estimation quantifying absolute lift, relative lift, incremental ROI, and confidence intervals.

**Success Metrics:** Holdout testing adoption with 50% of major campaigns including incrementality measurement within twelve months, causal inference rigor validated through independent review showing proper experimental design and analysis, incrementality findings revealing marketing typically drives 40-60% of observed outcomes with remainder organic, executive awareness and understanding of incrementality concept reaching 90% measured through leadership survey.

---

## 5.2 MARKETING MIX MODELING FOR STRATEGIC OPTIMIZATION

### Capability Overview

Marketing mix modeling provides strategic-level view of channel effectiveness complementing tactical attribution analysis by operating at aggregate level using time-series econometric techniques to quantify incremental impact of marketing channels while controlling for external factors including seasonality, competitive activity, economic conditions, and category trends. Unlike attribution models that analyze individual customer journeys, marketing mix models examine aggregate relationships between weekly or monthly marketing spending across channels and corresponding business outcomes such as prescriptions, new patient starts, or market share gains. This aggregated approach proves particularly valuable for pharmaceutical marketing where long sales cycles, multiple stakeholder influence, and offline interactions complicate customer-level tracking while substantial historical data on channel spending and business outcomes enables rigorous statistical modeling.

Traditional approaches to marketing mix modeling rely on ordinary least squares regression with multiplicative functional forms estimating elasticities representing percentage change in outcomes from one percent change in marketing spending. These classical models suffer from several limitations that reduce business value. Ordinary least squares assumes all relationships follow fixed mathematical forms rather than learning shapes from data. Point estimates provide no quantification of uncertainty making risk assessment impossible. Models require extensive manual tuning through variable transformation, interaction term specification, and lag structure selection demanding substantial statistical expertise. Sparse data in some channels creates unstable coefficient estimates especially for newer digital tactics with limited history. Models provide historical explanation but lack forward-looking optimization guidance requiring separate tools for scenario planning.

The proposed marketing mix modeling framework employs modern Bayesian hierarchical methods addressing classical limitations while maintaining interpretability that stakeholders require. Bayesian approaches incorporate prior knowledge about channel effectiveness from literature, competitive benchmarks, or expert judgment improving estimation in data-sparse situations. Hierarchical structures model variation across geographies, brands, or time periods revealing differential effectiveness while borrowing statistical strength across groups. Credible intervals quantify uncertainty in estimates enabling risk-aware decision making. Automated variable selection determines relevant model components from data rather than manual specification. Integrated optimization capabilities directly generate budget allocation recommendations without requiring separate planning tools. Flexible functional forms capture non-linear diminishing returns relationships and interaction effects that fixed multiplicative forms miss.

Organizations implementing modern marketing mix modeling capabilities report twenty-five to 40% improvement in forecast accuracy measured through out-of-sample prediction error, fifteen to 25% enhancement in marketing return on investment through optimized budget allocation, 30-40% reduction in modeling effort through automation versus manual classical approaches, and transformation of annual planning processes from negotiation-driven to evidence-driven allocation. These benefits prove particularly substantial for pharmaceutical portfolios managing multiple brands across therapeutic areas where portfolio-level optimization generates enterprise value exceeding individual brand optimization.

### Detailed Requirements

**REQ-314: Marketing Mix Data Preparation Pipeline**

The system shall implement automated data preparation pipeline aggregating marketing spending, business outcomes, and external factors at appropriate temporal frequency for marketing mix modeling analysis. The aggregation process shall consolidate data to weekly or monthly level balancing statistical power from sufficient observations against temporal resolution preserving dynamic patterns. Marketing spending shall aggregate by channel across all campaigns and initiatives removing granular campaign detail inappropriate for strategic modeling while maintaining channel distinction essential for allocation optimization. The pipeline shall support multiple channel definitions enabling analysis at different aggregation levels such as broad categories like digital versus traditional media or detailed breakdowns distinguishing paid search, display advertising, social media, and email within digital umbrella.

Business outcomes shall compile primary metrics such as total prescriptions written by target HCPs, new patient enrollments in treatment programs, or market share percentages alongside secondary indicators including website traffic, lead generation, and sales representative call effectiveness. The system shall calculate derived metrics such as year-over-year growth rates, indexed values relative to baseline periods, and category-adjusted measures removing overall market expansion or contraction. External factors shall incorporate seasonality indicators through dummy variables or Fourier terms capturing systematic calendar patterns, competitive activity measurements including competitor promotional spending estimates and new product launches, economic conditions such as unemployment rates and consumer confidence indices, and category trends like disease prevalence changes and treatment guideline updates.

Data quality validation shall check for completeness ensuring no missing values in critical variables, consistency verifying that aggregations match source system totals, and reasonable ranges flagging outliers requiring investigation such as spending spikes from accounting corrections or outcome drops from data collection issues. The pipeline shall handle common data challenges including mixed frequency requiring interpolation when some series available weekly and others monthly, delayed reporting incorporating estimates when actuals not yet available, and structural breaks marking major events like regulatory changes or pandemic disruptions requiring explicit modeling. Documentation shall describe all data sources, transformation logic, and quality checks creating transparency and audit trail.

**Business Rationale:** Comprehensive high-quality data represents an essential foundation for reliable marketing mix modeling as model accuracy depends critically on input data integrity. Marketing spending data often resides in fragmented systems including media buying platforms, agency invoices, and financial ledgers requiring integration and reconciliation. Business outcome data may flow from prescription monitoring services, internal sales systems, or third-party market research requiring validation and standardization. External factors demand sourcing from multiple vendors and government databases. Research demonstrates that 60-80% of marketing mix modeling effort typically focuses on data preparation with actual modeling consuming the remaining twenty to 40%. Organizations implementing automated data pipelines report 70% reduction in data preparation effort enabling more frequent model updates, 50% fewer data quality issues causing modeling problems, and 40% faster time from analysis request to results delivery.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 4\)

**Dependencies:** REQ-231 through REQ-238 (event collection providing marketing activity data), REQ-259 (MMM vision from Section 2), REQ-260 (data preparation vision), financial systems providing spending data, external data sources for competitive and market factors, minimum eighteen months historical data

**Acceptance Criteria:** Automated data pipeline aggregating marketing spending, business outcomes, and external factors to weekly or monthly frequency with configurable channel definitions, derived metric calculation including growth rates and indexed values, data quality validation checking completeness, consistency, and reasonable ranges with automated flagging, handling of mixed frequency data, delayed reporting, and structural breaks.

**Success Metrics:** Data preparation automation achieving 80% reduction in manual effort versus baseline measured through time tracking, data quality assessment showing less than 5% of observations requiring manual correction, pipeline execution reliability achieving successful runs 95% of time without intervention, update frequency enabling monthly model refresh supporting quarterly planning cycles.

---

**REQ-315: Bayesian Hierarchical Marketing Mix Model**

The system shall implement sophisticated Bayesian hierarchical marketing mix model quantifying incremental impact of each marketing channel while capturing diminishing returns, cross-channel interactions, time lag effects, and geographic variation. The model architecture shall employ hierarchical structure with global parameters representing average channel effectiveness across portfolio and local parameters capturing brand-specific, geography-specific, or time-period-specific variation. This hierarchical approach enables statistical borrowing where data-sparse entities benefit from information sharing with similar entities improving estimation precision while allowing heterogeneity when warranted by data. The model shall specify flexible functional forms for marketing effects including adstock transformations capturing carryover effects where marketing impact persists beyond exposure period, saturation curves representing diminishing returns where incremental impact decreases at higher spending levels, and interaction terms modeling synergies or substitution relationships between channels.

Prior distributions shall encode existing knowledge about marketing effectiveness drawn from published literature, competitive benchmarks, and expert judgment. Priors prove particularly valuable for newer channels with limited historical data or during market disruptions when historical patterns may not hold. The system shall support informative priors when strong external evidence exists and weakly informative priors allowing data to dominate when evidence is uncertain. Posterior inference shall employ Markov Chain Monte Carlo sampling algorithms such as Hamiltonian Monte Carlo providing efficient exploration of high-dimensional parameter spaces. The implementation shall assess convergence through diagnostic statistics including Rhat values and effective sample sizes ensuring reliable posterior estimates.

Model output shall provide posterior distributions for all parameters rather than point estimates quantifying uncertainty through credible intervals. Channel effectiveness shall report as elasticities showing percentage change in outcomes from one percent change in spending enabling comparison across channels with different scales. Contribution analysis shall decompose observed outcomes into portions attributable to each marketing channel, baseline trend representing organic growth, and external factors such as seasonality and competitive activity. The model shall generate counterfactual predictions answering what outcomes would have occurred under alternative spending scenarios supporting strategic planning. Model diagnostics shall include posterior predictive checks comparing model predictions against actual outcomes, leave-future-out cross-validation assessing forecast accuracy, and sensitivity analysis examining robustness to prior specifications.

**Business Rationale:** Bayesian hierarchical modeling represents methodological gold standard for marketing mix analysis addressing limitations of classical approaches while maintaining interpretability. Hierarchical structures efficiently leverage all available data across brands and geographies improving precision especially for entities with limited individual history. Flexible functional forms capture realistic diminishing returns and interaction patterns that fixed multiplicative specifications miss. Uncertainty quantification through posterior distributions enables risk-aware planning acknowledging estimation uncertainty rather than treating point estimates as certain truth. Research demonstrates Bayesian approaches achieve twenty to 35% better out-of-sample prediction accuracy versus classical regression, provide more stable coefficient estimates especially for data-sparse channels, and generate more actionable strategic insights through counterfactual scenario analysis. Organizations implementing Bayesian marketing mix models report 40% improvement in stakeholder trust due to explicit uncertainty acknowledgment and 25% better planning decisions through scenario analysis capabilities.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 4\)

**Dependencies:** REQ-314 (data preparation pipeline), REQ-259 (MMM vision from Section 2), REQ-261 through REQ-264 (specific MMM features), statistical computing platform supporting Bayesian inference such as Stan or PyMC

**Acceptance Criteria:** Bayesian hierarchical model implementation with global and local parameter structure enabling statistical borrowing, flexible functional forms including adstock, saturation, and interactions, prior distributions incorporating external knowledge with informative and weakly informative specifications, posterior inference using Hamiltonian Monte Carlo with convergence diagnostics, output providing posterior distributions, elasticities, contribution analysis, and counterfactuals, diagnostics including posterior predictive checks, cross-validation, and sensitivity analysis.

**Success Metrics:** Model estimation achieving convergence with Rhat values below one point one indicating reliable inference, forecast accuracy measured through mean absolute percentage error below 15% on out-of-sample holdout periods, contribution decomposition showing marketing explaining 30-50% of outcome variation with remainder split between baseline and external factors, stakeholder satisfaction with model interpretability and business relevance rated above 8 out of 10\.

---

**REQ-316: Scenario Simulation and What-If Analysis Engine**

The system shall provide interactive scenario simulation capabilities enabling marketers to explore alternative budget allocation strategies and forecast expected outcomes before implementation eliminating risk from untested changes. The simulation engine shall accept user-defined scenarios specifying marketing spending levels by channel for future periods with scenarios representing strategic alternatives such as baseline plan maintaining current allocation, optimization scenario implementing algorithm-recommended changes, growth scenario increasing total budget while maintaining proportions, reallocation scenario shifting budget across channels without total increase, and competitive response scenario modeling increased spending to match competitor escalation. The engine shall apply estimated marketing mix models to scenario inputs generating outcome predictions with uncertainty ranges derived from posterior distributions.

Simulation output shall provide comprehensive forecasts including point predictions representing expected outcomes, credible intervals quantifying uncertainty typically at 80% and 95% probability levels, downside and upside scenarios showing plausible pessimistic and optimistic outcomes, and risk metrics such as probability of achieving specific targets or exceeding baseline performance. Comparative visualization shall display multiple scenarios side-by-side using grouped bar charts, line plots, or probability density overlays enabling rapid assessment of relative attractiveness. The system shall calculate incremental metrics comparing each scenario against baseline including incremental outcomes, incremental costs, incremental return on investment, and risk-adjusted returns accounting for uncertainty.

The simulation framework shall support sensitivity analysis examining how predictions change with underlying assumptions about channel effectiveness, diminishing returns curves, or interaction effects. Tornado diagrams shall display which parameters exert greatest influence on outcome predictions identifying key drivers warranting additional data collection or model refinement. The system shall enable iterative exploration where users modify scenario parameters observing updated predictions facilitating learning and optimization intuition development. Scenario documentation shall capture assumptions, logic, and results creating a record of strategic alternatives considered supporting organizational learning and decision audit trails.

**Business Rationale:** Scenario simulation transforms marketing mix models from explanatory historical analysis to forward-looking strategic planning tools providing actionable insights. Interactive exploration enables marketers to develop intuition about response surfaces, understanding how outcomes vary with budget allocation choices. Risk quantification through uncertainty ranges prevents overconfidence in point predictions encouraging robust strategies that perform adequately under multiple futures. Sensitivity analysis reveals which assumptions matter most directing research effort toward high-value refinements. Research demonstrates that organizations employing scenario simulation make 30-40% better strategic decisions measured through subsequent campaign performance, avoid 20-30% fewer costly mistakes from untested assumptions, and achieve 25-35% faster consensus during planning by eliminating speculative debate through evidence-based forecasts. Pharmaceutical planning particularly benefits from simulation given lengthy lead times and significant investment commitments making mid-course corrections difficult once plans execute.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 4\)

**Dependencies:** REQ-315 (marketing mix model providing forecasting engine), REQ-265 (scenario simulation vision from Section 2\)

**Acceptance Criteria:** Interactive simulation engine accepting user-defined spending scenarios with multiple strategic templates, forecast output providing point predictions, credible intervals, downside and upside scenarios, and risk metrics, comparative visualization displaying scenarios side-by-side with incremental metric calculation, sensitivity analysis using tornado diagrams identifying key parameter influences, iterative exploration enabling parameter modification with immediate prediction updates.

**Success Metrics:** Simulation adoption measured through quarterly usage by planning teams reaching 80% within six months of deployment, scenario evaluation velocity enabling testing of ten alternative strategies per planning cycle, forecast accuracy validated through comparison of simulated predictions versus actual outcomes for implemented plans showing correlation above 0.7, decision quality improvement measured through ex-post assessment showing scenarios outperforming baseline 30% more often than baseline historically outperformed alternatives.

---

**REQ-317: Constrained Budget Optimization Solver**

The system shall implement mathematical optimization solver automatically identifying budget allocations that maximize defined objectives subject to business constraints providing concrete actionable recommendations rather than requiring manual search through scenario space. The optimization framework shall support multiple objective functions including total prescriptions or revenue maximization seeking highest absolute outcomes, return on investment maximization achieving best efficiency, market share gain optimization focusing on competitive position, and custom objectives reflecting strategic priorities such as weighted combinations of volume and profitability. The solver shall accept comprehensive constraint specifications including total budget limits capping aggregate spending, minimum spend requirements ensuring strategic commitments maintained such as contractual obligations or partnership agreements, maximum spend restrictions preventing unrealistic concentration such as media market capacity limits, channel growth rates limiting how quickly budgets can shift between periods, and strategic mandates requiring specific channel presence regardless of marginal returns.

The optimization algorithm shall employ appropriate mathematical programming techniques such as sequential quadratic programming for smooth non-linear objectives, mixed-integer programming when discrete decisions required, or genetic algorithms for complex non-convex problems resistant to gradient methods. The solver shall handle uncertainty in marketing mix model parameters through robust optimization finding allocations that perform well across parameter uncertainty ranges or stochastic programming explicitly modeling random variation. Solution quality indicators shall report optimality gap showing how close solution approaches theoretical optimum and computation time documenting effort required enabling tradeoff between solution quality and speed.

Optimization output shall provide recommended budget allocation by channel, predicted outcomes under optimal allocation with comparison to current baseline, incremental benefit from optimization showing value captured through improved allocation, sensitivity analysis revealing how recommendations change with constraint relaxation such as additional budget availability or reduced minimum spends, and implementation roadmap suggesting transition path from current to optimal allocation over multiple periods when immediate shifts prove infeasible. The framework shall support what-if optimization exploring how recommendations change under alternative constraint scenarios such as if total budget increased by ten percent where should incremental investment go or if minimum spend on channel reduced what alternative allocation would emerge.

**Business Rationale:** Optimization solvers provide concrete recommendations eliminating guesswork from budget allocation while ensuring mathematical consistency and completeness. Manual scenario exploration proves tedious and unlikely to identify true optima in high-dimensional strategy spaces. Constraint handling enables realistic recommendations respecting business realities that pure maximize-returns logic would violate. Research demonstrates that optimized allocations typically improve return on investment by fifteen to 30% versus baseline allocations reflecting accumulated suboptimal decisions, achieve objectives three to five percent closer to theoretical maximum versus human-generated plans, and reduce planning cycle time by 40-60% through eliminating iterative scenario testing. Organizations implementing optimization solvers report transformation from negotiation-driven to evidence-driven budget allocation eliminating political debates, increased chief financial officer confidence in marketing enabling budget increases for provably high-return opportunities, and better strategic clarity through understanding binding constraints that limit performance.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 4\)

**Dependencies:** REQ-315 (marketing mix model providing objective function), REQ-316 (scenario simulation validating optimized recommendations), REQ-266 (optimization solver vision from Section 2), optimization software libraries or platforms

**Acceptance Criteria:** Optimization solver supporting multiple objective functions including total outcome maximization and return on investment optimization, comprehensive constraint handling including budget limits, minimum and maximum spends, growth rates, and strategic mandates, appropriate mathematical programming algorithms for problem characteristics, uncertainty handling through robust or stochastic optimization, output providing recommended allocation, predicted outcomes, incremental benefit, sensitivity analysis, and implementation roadmap.

**Success Metrics:** Optimization solution quality achieving within 5% of theoretical optimum when benchmarked against exhaustive search on small test problems, computation time averaging under 1 hour for typical portfolio optimization problems, recommendation feasibility validated through business stakeholder review showing 90% acceptance as implementable, value capture measured through actual performance of optimized plans exceeding baseline by minimum 15% confirming optimization benefit realization.

---

**REQ-318: Marketing Mix Model Governance and Validation**

The system shall implement comprehensive model governance ensuring marketing mix models meet quality standards, undergo appropriate validation, and receive periodic updates maintaining relevance as market conditions evolve. Model documentation shall capture complete specifications including functional forms, variable definitions, estimation methods, software versions, and analyst identities. Documentation standards shall enable reproducibility where independent analysts can recreate model estimates from documentation and source data. The governance framework shall define approval workflows requiring senior statistical review before production deployment, business stakeholder validation confirming model findings aligned with market intuition, and executive sign-off for models influencing major budget allocation decisions.

Validation protocols shall employ multiple approaches assessing model quality. Out-of-sample testing shall holdout recent time periods evaluating forecast accuracy on data not used for estimation. Cross-validation shall systematically partition data into training and test folds averaging performance across folds. Backtesting shall examine whether historical allocations recommended by model would have outperformed actual allocations implemented. Face validity assessment shall engage business experts evaluating whether estimated channel effects and diminishing returns curves align with market knowledge. Sensitivity analysis shall perturb key assumptions examining whether conclusions prove robust or fragile. The validation process shall generate quality scores summarizing multiple validation dimensions creating standardized assessment.

Model update procedures shall trigger when model performance degrades below thresholds, when sufficient new data accumulates suggesting model refresh, when market conditions change substantially such as competitive landscape shifts or regulatory changes, or on fixed cadence such as quarterly or semi-annually. Update workflows shall follow similar validation and approval processes as initial development. Version control shall maintain complete history enabling comparison across model generations and restoration if updates prove inferior. Model monitoring dashboards shall track prediction accuracy over time, parameter stability across updates, and usage statistics showing which business decisions rely on model outputs informing governance priorities.

**Business Rationale:** Model governance separates credible analytical tools from black boxes ensuring stakeholder trust and regulatory defensibility. Pharmaceutical organizations face heightened scrutiny requiring defensible methodologies for budget allocation and promotional planning. Rigorous validation prevents costly mistakes from flawed models while periodic updates maintain relevance as markets evolve. Research demonstrates that organizations with mature model governance achieve 30-40% higher stakeholder adoption measured through decision implementation rates, experience 70% fewer model-related errors causing business problems, and report 50% greater confidence in analytical capabilities during executive discussions. Governance proves particularly valuable when models inform high-stakes decisions such as multi-million dollar budget allocations where errors prove expensive while stakeholder skepticism blocks implementation absent trust in methods.

**Swimlane Alignment:** Swimlane F (Measure & Learn), Swimlane A (Govern)

**Priority:** P2 \- Advanced capability (Phase 4\)

**Dependencies:** REQ-314 through REQ-317 (marketing mix modeling capabilities requiring governance), REQ-083 (model registry providing similar governance pattern), REQ-258 (attribution model governance), REQ-268 (MMM validation vision from Section 2\)

**Acceptance Criteria:** Model documentation capturing complete specifications enabling reproducibility, approval workflows requiring statistical review, business validation, and executive sign-off, validation protocols employing out-of-sample testing, cross-validation, backtesting, face validity, and sensitivity analysis, update procedures triggered by performance degradation, data accumulation, or market changes with version control, monitoring dashboards tracking accuracy, parameter stability, and usage statistics.

**Success Metrics:** Documentation completeness achieving 100% of production models with full specifications within six months, validation rigor measured through independent audit showing 90% compliance with protocols, model accuracy maintaining out-of-sample forecasting error below 15% threshold, update frequency achieving minimum quarterly refresh for strategic models, stakeholder trust validated through survey showing 80% confidence in model recommendations.

---

## SECTION 5 SUMMARY

This enhanced Section 5 provides comprehensive specifications for Marketing Mix Modeling and Optimization capabilities enabling data-driven strategic budget allocation and return on investment maximization. The section documents ten new detailed requirements spanning REQ-309 through REQ-318 covering attribution data infrastructure, rules-based models, algorithmic approaches, Shapley value calculation, incrementality measurement, marketing mix modeling, scenario simulation, optimization solvers, and model governance. These capabilities transform pharmaceutical marketing budget allocation from intuition-driven negotiation to evidence-based optimization generating substantial return on investment improvements through systematic reallocation toward high-return opportunities while reducing investment in saturated low-return channels.

### Requirements Summary

| Capability Domain | Requirements | Priority P1 | Priority P2 | Phase 2 | Phase 3 | Phase 4 |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| Attribution Framework | REQ-309 to REQ-313 | 2 | 3 | 2 | 3 | 0 |
| Marketing Mix Modeling | REQ-314 to REQ-318 | 0 | 5 | 0 | 0 | 5 |
| **Total Section 5** | **10** | **2** | **8** | **2** | **3** | **5** |

---

# SECTION 6: PORTFOLIO ANALYTICS AND CROSS-BRAND INTELLIGENCE

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## OVERVIEW

Portfolio Analytics and Cross-Brand Intelligence capabilities elevate pharmaceutical marketing operations from individual brand optimization to enterprise-level strategic management, enabling organizations to capture value that exists only at portfolio level and would remain unrealized through brand-by-brand approaches. While previous sections addressed capabilities that individual brands require for effective marketing operations, portfolio analytics addresses distinctly different challenges that arise when managing multiple brands across therapeutic areas, geographies, and lifecycle stages. These challenges include identifying best practices from high-performing brands for replication across portfolio, optimizing budget allocation across brands based on marginal returns rather than historical precedent, leveraging shared customer relationships where HCPs prescribe multiple products, maintaining competitive intelligence across therapeutic categories, and demonstrating aggregate marketing value to chief financial officers and boards who evaluate portfolio-level return on investment.

Traditional pharmaceutical marketing organizations operate as collections of semi-independent brand teams each optimizing within their domain but lacking mechanisms for cross-brand learning, portfolio-level resource allocation, or enterprise performance visibility. Brand teams develop journey strategies, creative approaches, and channel tactics through trial and error accumulating knowledge that remains trapped within team boundaries. Budget allocation occurs through negotiation reflecting organizational politics and historical precedent rather than systematic evaluation of marginal returns across brands. Competitive intelligence gathering proves duplicative as multiple brands independently track competitors within therapeutic areas. Executive leadership receives fragmented performance reports aggregating individual brand metrics without normalized comparison enabling strategic assessment. This fragmentation creates several value destruction mechanisms including duplicated effort where multiple brands solve similar challenges independently, suboptimal portfolio allocation where high-return opportunities receive insufficient investment while low-return activities continue due to inertia, missed synergy opportunities where coordinated multi-brand approaches would prove more effective than independent campaigns, and incomplete competitive intelligence where category-level patterns escape detection.

The proposed Portfolio Analytics framework addresses these challenges through five integrated capabilities that collectively enable enterprise-level optimization while respecting brand team autonomy and therapeutic area differences. The portfolio data model establishes consistent measurement enabling fair comparison across brands of different sizes, therapeutic categories, and lifecycle stages through normalized metrics and phase-appropriate benchmarks. The journey pattern library codifies proven engagement sequences with performance metadata enabling successful tactics from oncology brands to accelerate immunology launches or mature brand retention strategies to inform new product planning. Cross-brand learning mechanisms systematically identify high-performing approaches for replication while surfacing underperformance requiring intervention or support. Competitive intelligence integration aggregates market insights across therapeutic areas revealing category trends, competitive positioning shifts, and emerging threats that individual brand monitoring might miss. Portfolio optimization recommendations suggest budget reallocation across brands based on marginal return analysis and strategic priorities rather than incremental adjustments to historical allocations.

Organizations implementing comprehensive portfolio analytics capabilities report 25-35% improvement in aggregate marketing return on investment through better capital allocation across brands, 30-40% acceleration in new brand launch performance through leveraging proven patterns from established brands, 40-50% reduction in duplicated effort where brands independently develop similar capabilities, and transformation of marketing leadership credibility with executive teams through demonstrating enterprise value rather than defending individual brand budgets. These benefits prove particularly substantial in pharmaceutical organizations managing diverse portfolios where learning transfer and resource optimization generate returns unavailable to single-brand companies.

---

## 6.1 PORTFOLIO DATA MODEL AND NORMALIZED BENCHMARKING

### Capability Overview

The portfolio data model provides the analytical foundation enabling fair comparison and aggregation across brands operating in different therapeutic categories with varying market sizes, competitive intensities, and lifecycle stages. Direct comparison of absolute metrics such as total campaign spending, email volume, or website visits proves meaningless when brands differ dramatically in market opportunity and strategic context. A rare disease brand serving five thousand patients globally operates at fundamentally different scales than primary care brands addressing millions of patients. A newly launched product demonstrating 50% market awareness represents dramatically different performance than a mature brand achieving similar awareness after ten years in the market. Fair comparison requires normalized metrics adjusting for context and phase-appropriate benchmarks reflecting realistic performance expectations given lifecycle stage and market characteristics.

Traditional pharmaceutical marketing reporting aggregates brand metrics into portfolio totals and averages that obscure performance variation and provide little strategic insight. Portfolio totals answer how much we spent but not whether spending proved effective or which brands deserve additional investment. Simple averages mask the distribution showing whether portfolio performance stems from few high performers carrying underperforming brands or consistent execution across portfolios. Rankings by absolute metrics such as total impressions or total leads favor large therapeutic categories over smaller specialties regardless of efficiency or return on investment. Executive leadership reviewing such reports lacks information necessary for strategic resource allocation decisions or performance management conversations with brand teams.

The proposed portfolio data model addresses these limitations through three integrated components. First, hierarchical dimensions enable roll-up and drill-down analysis across brand, therapeutic area, geography, and lifecycle stage while maintaining granular detail for tactical optimization. Second, normalized metrics enable fair comparison by adjusting for market size, competitive intensity, and strategic context through measures such as cost per target customer reached, market share gain per million dollars invested, and efficiency scores relative to category benchmarks. Third, phase-appropriate benchmarks provide realistic performance expectations recognizing that pre-launch, launch, growth, and mature phases warrant different success criteria with new brands evaluated against launch cohort performance rather than established brand standards. Together these components enable meaningful portfolio-level insights supporting strategic decisions about resource allocation, organizational capability building, and performance management.

Organizations implementing sophisticated portfolio data models report 50-60% improvement in executive engagement with marketing performance measured through frequency of portfolio review discussions, 40-50% better resource allocation decisions as evidenced by higher correlation between brand investment and marginal returns, and 30-40% more effective performance management conversations focusing on controllable factors rather than circumstantial differences. Portfolio visibility proves particularly valuable during annual planning cycles when resource allocation decisions occur and quarterly business reviews when performance assessment drives organizational learning and accountability.

### Detailed Requirements

**REQ-319: Hierarchical Portfolio Data Model with Dimensional Analysis**

The system shall implement a comprehensive hierarchical data model enabling flexible aggregation and disaggregation of marketing performance across multiple dimensions. The dimensional structure shall include brand hierarchy supporting roll-up from individual products through brand families to therapeutic franchises and total portfolio, therapeutic area classification organizing brands by disease category such as oncology, immunology, cardiovascular, or neurology enabling category-level analysis, geographic hierarchy spanning country to region to global aggregation supporting international operations, lifecycle phase categorization distinguishing pre-launch preparation, launch execution, growth acceleration, and mature optimization phases, and customer segment dimensions differentiating HCP, patient, payer, and institutional audiences. The dimensional model shall support arbitrary slice-and-dice analysis enabling questions such as what is aggregate immunology portfolio performance across Europe or how mature brand patient programs compare internationally.

The data model shall maintain granular fact tables storing atomic measurements at lowest aggregation level such as individual campaign performance, customer-level engagement metrics, and specific content asset utilization enabling flexible aggregation to any dimensional combination. Dimensional conformance shall ensure consistent definitions across brands preventing misalignment where different teams define metrics differently. The architecture shall employ slowly changing dimension techniques tracking dimensional attribute changes over time such as brand phase transitions or therapeutic area reclassifications maintaining analytical consistency. Performance optimization shall implement appropriate indexing, partitioning, and aggregation strategies ensuring sub-minute query response times despite large data volumes spanning multiple years and hundreds of campaigns.

Integration with source systems shall maintain bi-directional synchronization where the portfolio model consumes performance data from brand-level systems while brand teams access portfolio benchmarks and cross-brand insights. Data lineage tracking shall document transformation logic from source systems through dimensional models to analytical outputs creating transparency and audit capability. The model shall support both historical analysis examining past performance trends and forward-looking planning incorporating budget allocations and performance forecasts. Documentation shall provide a comprehensive data dictionary defining all dimensions, measures, hierarchies, and business rules ensuring consistent interpretation across the analytical community.

**Business Rationale:** Hierarchical dimensional model provides flexible analytical foundation supporting diverse stakeholder needs from brand-level tactical optimization to executive portfolio strategy. Consistent dimensional structure eliminates analytical chaos where different teams produce conflicting numbers due to inconsistent definitions and aggregation logic. Granular fact tables preserve analytical flexibility enabling unanticipated questions without requiring data model changes. Research demonstrates that organizations with mature dimensional models achieve 40-50% higher analyst productivity measured through analysis completion time, 60-70% reduction in analytical disputes about numbers, and 30-40% faster decision cycles through eliminating data reconciliation delays. Portfolio context proves particularly valuable during resource allocation decisions and performance management discussions requiring fair comparison across brands operating in different contexts.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-231 through REQ-248 (measurement foundation providing source data), REQ-270 (portfolio data model vision from Section 2), data warehouse infrastructure, minimum twelve months historical data across multiple brands

**Acceptance Criteria:** Hierarchical dimensional model implemented with brand, therapeutic area, geographic, lifecycle phase, and customer segment dimensions supporting flexible aggregation, granular fact tables maintaining atomic measurements with consistent dimensional conformance, slowly changing dimension tracking for temporal consistency, performance optimization achieving sub-minute query response at 95th percentile, bi-directional integration with source systems, data lineage documentation.

**Success Metrics:** Dimensional model coverage reaching 90% of portfolio marketing spend within six months of deployment, query performance maintaining sub-minute response for 95% of analytical requests, analytical consistency validated through reconciliation showing less than two percent variance between portfolio totals and source system aggregations, analyst adoption measured through 70% of portfolio analyses using dimensional model within one year.

---

**REQ-320: Normalized Metrics for Fair Cross-Brand Comparison**

The system shall calculate comprehensive suite of normalized metrics enabling fair comparison across brands operating at different scales and in different competitive contexts. Efficiency metrics shall measure outcomes relative to investment including cost per target HCP reached calculated as total spending divided by unique providers exposed to marketing, cost per qualified lead generated measuring investment required to produce sales-ready prospects, and cost per incremental prescription measuring marketing investment required to drive one additional prescription beyond baseline. Market impact metrics shall quantify competitive positioning including market share gain per million dollars invested showing efficiency of share capture, share of voice within therapeutic category measuring promotional prominence relative to competitors, and competitive response ratio tracking how competitor spending changes in response to brand marketing indicating threat perception.

Engagement quality metrics shall assess interaction depth beyond volume including average engagement score per reached customer measuring campaign resonance, content consumption intensity tracking depth of interaction with educational materials, and journey completion rate measuring percentage of customers progressing through multi-step engagement sequences. Customer lifetime metrics shall evaluate long-term relationship building including customer acquisition cost amortized over expected relationship duration, lifetime value to acquisition cost ratio assessing economic sustainability, and retention efficiency measuring investment required to maintain customer engagement. The system shall calculate confidence intervals for all metrics quantifying estimation uncertainty and enabling statistical comparison testing whether performance differences prove meaningful rather than random variation.

Metric calculation shall handle common analytical challenges including varying time periods through annualization and standardization, different campaign types through typology-specific benchmarks, and market size variation through per capita adjustments. The framework shall support custom metric definition enabling organization-specific measures reflecting unique strategic priorities or analytical frameworks. Metric cataloging shall maintain comprehensive library documenting calculation logic, data sources, update frequency, and interpretation guidance creating transparency. Automated validation shall detect calculation errors, unreasonable values, and trend breaks triggering investigation before metrics influence decision making.

**Business Rationale:** Normalized metrics transform raw performance data into actionable strategic insights by controlling for contextual factors that obscure true efficiency and effectiveness. Cost per target reached proves more informative than total spending when comparing brands serving different market sizes. Market share gain per investment dollar reveals competitive positioning strength better than absolute share levels. Engagement intensity measures interaction quality rather than mere volume preventing false celebration of high-volume low-value activities. Research demonstrates that organizations using normalized metrics make 30-40% better resource allocation decisions measured through subsequent campaign performance, achieve 20-30% improvement in portfolio return on investment through identifying and scaling efficient approaches while addressing inefficient activities, and report 50% higher executive confidence in marketing performance assessments based on fair comparison rather than misleading absolute metrics.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-319 (portfolio data model providing calculation foundation), REQ-271 (normalized metrics vision from Section 2), market data for competitive benchmarking

**Acceptance Criteria:** Comprehensive normalized metrics implemented including efficiency, market impact, engagement quality, and customer lifetime measures with confidence intervals, calculation handling varying time periods, campaign types, and market sizes with standardization logic, custom metric definition supporting organization-specific measures, metric cataloging with documentation, automated validation detecting errors and anomalies.

**Success Metrics:** Metric completeness achieving calculation for 90% of brands within six months with quarterly refresh, metric reliability validated through audit showing less than five percent calculation errors, stakeholder adoption measured through normalized metrics appearing in 70% of portfolio performance reviews within one year, decision impact demonstrated through resource allocation showing 30% higher correlation with normalized performance versus absolute metrics.

---

**REQ-321: Phase-Appropriate Benchmarking and Cohort Analysis**

The system shall implement sophisticated benchmarking framework recognizing that performance expectations should vary based on brand lifecycle phase and providing phase-appropriate comparison cohorts. Lifecycle phase classification shall categorize brands into pre-launch preparation focusing on market development and awareness building, launch execution emphasizing rapid penetration and trial generation, growth acceleration targeting market share expansion and competitive displacement, and mature optimization concentrating on efficiency improvement and customer retention. Each phase shall possess distinct success criteria and performance benchmarks reflecting realistic expectations given strategic context and market conditions.

Pre-launch benchmarks shall emphasize leading indicators including HCP awareness levels, disease education reach, early access program enrollment, and key opinion leader engagement that predict launch success rather than prescription metrics unavailable before regulatory approval. Launch phase benchmarks shall focus on penetration velocity including time to first thousand prescriptions, market share trajectory relative to launch cohort, and new prescriber acquisition rate measuring adoption breadth. Growth phase metrics shall prioritize competitive dynamics including share gain rates, switching behavior from competitor products, and market expansion contribution assessing whether growth stems from capturing competitor share or expanding total category. Mature phase standards shall emphasize efficiency including customer retention rates, revenue per marketing dollar, and profitability contribution recognizing that established brands should optimize rather than merely grow.

Cohort analysis shall enable comparison against similar brands controlling for lifecycle phase, therapeutic category, and launch timing. The system shall identify peer cohorts through statistical clustering based on market characteristics or enable manual cohort definition when business judgment suggests specific comparisons. Cohort benchmarking shall display brand performance relative to cohort median, quartile boundaries, and high performer thresholds providing context about whether performance proves exceptional, typical, or concerning. Temporal cohort tracking shall follow brands through lifecycle transitions showing whether individual brands accelerate or decelerate relative to trajectory expectations. Benchmark visualization shall employ percentile charts, box plots, or performance dashboards making relative positioning immediately apparent.

**Business Rationale:** Phase-appropriate benchmarking prevents unfair comparisons that demotivate high-performing teams or mask underperformance requiring intervention. Evaluating new brand against mature brand standards creates unrealistic expectations while comparing mature brand to launch cohort standards masks efficiency opportunities. Cohort analysis controls for external factors such as therapeutic category dynamics or macroeconomic conditions enabling assessment of execution quality rather than circumstance. Research demonstrates that organizations implementing phase-appropriate benchmarking achieve 40-50% improvement in performance management effectiveness measured through manager and team satisfaction, 30-40% better identification of truly underperforming brands requiring support or strategy changes, and 25-35% more accurate forecasting through understanding typical lifecycle trajectories. Pharmaceutical portfolio management particularly benefits given dramatic differences between rare disease specialty brands and primary care high-volume brands making naive comparison counterproductive.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-319 and REQ-320 (portfolio data model and normalized metrics), REQ-272 (launch phase tracking vision from Section 2), historical performance data across multiple brand launches

**Acceptance Criteria:** Lifecycle phase classification categorizing brands into pre-launch, launch, growth, and mature phases with phase-specific success criteria, phase-appropriate benchmarks emphasizing relevant leading and lagging indicators, cohort analysis identifying peer groups through statistical clustering or manual definition, cohort benchmarking displaying relative performance using percentile charts and quartile boundaries, temporal tracking following brands through lifecycle transitions.

**Success Metrics:** Phase classification accuracy validated through business stakeholder review showing 90% agreement with categorization, benchmark relevance assessed through manager survey rating phase-appropriate standards as fair and actionable above 8 out of 10, performance management impact measured through 40% improvement in team motivation and 30% better identification of underperformance requiring support, forecasting accuracy improvement showing 20% reduction in prediction error for phase-based trajectory models.

---

## 6.2 JOURNEY PATTERN LIBRARY AND KNOWLEDGE MANAGEMENT

### Capability Overview

The journey pattern library serves as organizational knowledge repository codifying proven customer engagement sequences with comprehensive metadata including performance results, use case descriptions, and adaptation guidance enabling successful tactics from one brand or therapeutic area to accelerate performance in others. Traditional pharmaceutical marketing organizations suffer from knowledge trapped within brand team boundaries where successful journey strategies developed through extensive testing and optimization remain unknown to colleagues facing similar challenges. Brand teams independently develop email nurture sequences, onboarding flows, retention campaigns, and conversion funnels through trial and error accumulating insights that fail to propagate across organization. This knowledge fragmentation creates duplicated effort, foregone learning opportunities, and performance variation reflecting information asymmetry rather than capability differences.

The proposed journey pattern library addresses this challenge by systematically capturing high-performing journeys, documenting their components and performance characteristics, and making them discoverable and reusable across portfolio. Pattern identification employs both automated detection analyzing journey performance data to surface successful sequences and curator nomination where brand teams and marketing operations specialists propose exemplary journeys for library inclusion. Each pattern receives comprehensive documentation describing strategic objective such as awareness building or retention improvement, target audience characteristics including customer segment and lifecycle stage, journey structure detailing node sequences and decision logic, content approach summarizing messaging themes and creative strategies, performance metadata showing historical results including sample sizes and confidence intervals, implementation guidance providing step-by-step adaptation instructions, and success factors highlighting critical elements requiring careful attention during replication.

Pattern library functionality supports multiple use cases spanning journey design where marketers browse patterns seeking inspiration and starting points, performance planning where teams set realistic targets based on historical pattern results, strategic planning where portfolio leaders identify capability gaps and development opportunities, and continuous improvement where pattern performance tracking reveals when updates prove necessary due to changing market conditions or customer preferences. The library transforms from static repository to dynamic learning system through usage tracking showing which patterns prove most popular, performance monitoring revealing which patterns maintain effectiveness over time, and contribution recognition crediting teams who create patterns adopted across portfolio encouraging knowledge sharing culture.

Organizations implementing sophisticated pattern libraries report 40-50% reduction in journey design time through leveraging proven templates rather than designing from scratch, 30-40% improvement in initial journey performance through avoiding mistakes that pattern creators already encountered and resolved, 25-35% increase in journey creation velocity enabling more testing and optimization, and transformation of organizational culture toward systematic knowledge sharing and continuous improvement. Pattern libraries prove particularly valuable during new brand launches when speed-to-market proves critical and during capability building initiatives when organizations seek to elevate average performance through disseminating best practices.

### Detailed Requirements

**REQ-322: Journey Pattern Identification and Curation Workflow**

The system shall implement systematic process for identifying high-performing journeys worthy of pattern library inclusion combining automated performance analysis with expert curation. Automated identification shall employ statistical methods analyzing journey performance metrics including conversion rates, engagement scores, return on investment, and customer satisfaction relative to cohort benchmarks surfacing journeys exceeding performance thresholds such as top quartile results or minimum statistical significance levels. The identification algorithm shall account for sample size requiring sufficient observations to ensure reliable conclusions and contextual factors controlling for market characteristics that might inflate performance artificially. Candidate journey flagging shall generate notifications alerting brand teams and marketing operations when journeys achieve pattern-worthy performance encouraging proactive library contribution.

Expert curation workflow shall enable brand teams and specialists to nominate journeys for library inclusion based on business judgment recognizing innovative approaches or strategic importance even when statistical evidence remains limited. Nomination submissions shall capture nominator identity, journey rationale explaining why inclusion proves valuable, and preliminary documentation describing journey characteristics. Review process shall route nominations to marketing operations specialists or portfolio leadership for evaluation considering performance evidence, strategic alignment with organizational priorities, replication potential across brands and therapeutic areas, and library comprehensiveness ensuring coverage of key use cases. Approval decisions shall balance quality standards maintaining library credibility with inclusiveness encouraging contribution.

Pattern extraction shall create library entries from approved journeys through documentation generation capturing configuration details, metadata specification including therapeutic area and customer segment tags, performance data compilation showing historical results with confidence intervals, and implementation guidance authoring providing adaptation instructions. Quality assurance shall verify documentation completeness and accuracy before publication. Version control shall maintain pattern evolution history enabling updates when improved approaches emerge while preserving original versions supporting longitudinal analysis. Contributor recognition shall acknowledge teams creating adopted patterns through credits visible in pattern documentation and portfolio communications fostering knowledge sharing culture.

**Business Rationale:** Systematic identification and curation transforms ad hoc knowledge sharing into organizational capability. Automated performance analysis surfaces patterns that teams might not recognize as exceptional due to lack of cross-brand visibility. Expert curation captures innovative approaches before performance evidence accumulates recognizing that early adoption often precedes statistical confirmation. Balanced review prevents both standards so strict that library remains sparse and standards so loose that quality degrades undermining credibility. Research demonstrates that organizations with active curation processes achieve 60-70% higher pattern library usage versus passive repositories relying solely on voluntary contribution, maintain 40-50% better pattern quality measured through replication success rates, and generate 30-40% more organizational value through matching high-performing patterns to appropriate use cases. Recognition systems prove critical for sustaining contribution momentum as teams weigh time investment against organizational benefit and peer appreciation.

**Swimlane Alignment:** Swimlane D (Orchestrate), Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-133 through REQ-140 (journey canvas enabling pattern capture), REQ-166 through REQ-173 (journey analytics providing performance data), REQ-273 (best practice identification vision from Section 2), REQ-275 (journey pattern library vision)

**Acceptance Criteria:** Automated identification analyzing journey performance relative to benchmarks with statistical significance testing and sample size requirements, expert curation workflow supporting nomination, review, and approval with documentation generation, pattern extraction capturing configuration details, metadata, performance data, and implementation guidance with version control, contributor recognition crediting pattern creators.

**Success Metrics:** Pattern identification velocity achieving minimum ten new patterns added quarterly once steady state reached, curation quality validated through independent review showing 90% of approved patterns deemed high quality and replicable, contribution participation measured through 50% of brand teams contributing minimum one pattern annually, recognition effectiveness assessed through survey showing contributors feeling appropriately acknowledged.

---

**REQ-323: Pattern Library Search, Discovery, and Recommendation**

The system shall provide sophisticated search and discovery capabilities enabling marketers to find relevant patterns efficiently through multiple access paths. Keyword search shall support natural language queries matching against pattern titles, descriptions, tags, and content summaries with relevance ranking ordering results by match quality. Faceted navigation shall enable filtering by therapeutic area, customer segment, journey objective such as awareness or retention, channel mix, campaign complexity, and performance tier creating progressively refined result sets. Taxonomy-based browsing shall organize patterns into hierarchical categories such as customer lifecycle stage or marketing objective enabling systematic exploration. Visual pattern preview shall display journey flowcharts and screenshots providing rapid assessment of pattern structure and complexity without requiring full documentation review.

Recommendation engine shall proactively suggest relevant patterns based on user context including current journey design showing patterns similar to work in progress, user role and therapeutic area presenting patterns matching typical use cases, and historical usage patterns showing what colleagues with similar profiles found valuable. Similarity matching shall identify related patterns using content-based similarity comparing journey structures, collaborative filtering based on usage patterns, and explicit relationships where pattern creators designate related alternatives or evolutionary improvements. Recently added patterns and trending patterns based on usage velocity shall receive prominent placement encouraging exploration of new content.

Usage tracking shall monitor which patterns receive views, detailed examinations, clones for adaptation, and implementation in production journeys creating feedback loop informing recommendation algorithms. User ratings and reviews shall enable crowdsourced quality assessment where implementers share experience with pattern effectiveness and adaptation challenges. Pattern analytics shall reveal which patterns prove most popular overall, which patterns specific therapeutic areas favor, which patterns drive highest replication rates, and which patterns achieve best performance when implemented providing insights for curation priorities and organizational learning. Search and discovery analytics shall identify common queries returning poor results indicating pattern gaps warranting development.

**Business Rationale:** Sophisticated discovery mechanisms prove essential for library value realization as repository usefulness depends on users finding relevant patterns efficiently. Keyword search addresses directed exploration when users know what they seek while faceted navigation supports open-ended browsing when users explore possibilities. Proactive recommendation reduces cognitive burden by surfacing likely relevant patterns rather than requiring exhaustive search. Research demonstrates that organizations with advanced discovery capabilities achieve 60-70% higher library usage versus basic search-only interfaces, 40-50% faster pattern identification measured through time from query to selection, and 30-40% better pattern-use case matching reflected in higher implementation success rates. Usage analytics transform library from static repository to learning system where popular patterns receive investment in enhancement while rarely used patterns undergo quality review or retirement preventing library bloat degrading user experience.

**Swimlane Alignment:** Swimlane D (Orchestrate)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-322 (pattern library content), REQ-136 (template library foundation), search and recommendation platform capabilities

**Acceptance Criteria:** Keyword search supporting natural language queries with relevance ranking, faceted navigation enabling filtering by therapeutic area, segment, objective, channel, complexity, and performance, taxonomy-based browsing with hierarchical organization, visual pattern preview displaying journey flowcharts, recommendation engine suggesting patterns based on user context and similarity matching, usage tracking and user ratings creating feedback loop, pattern analytics revealing popularity, replication rates, and performance.

**Success Metrics:** Search effectiveness measured through 80% of queries successfully identifying relevant patterns within three results, discovery efficiency showing average time from library access to pattern selection under 5 minutes, recommendation relevance validated through 60% of suggested patterns receiving detailed examination, usage growth achieving 50% increase in monthly library interactions within six months of discovery enhancement deployment.

---

**REQ-324: Pattern Adaptation and Implementation Support**

The system shall provide comprehensive implementation support transforming abstract patterns into concrete campaigns adapted to specific brand contexts. One-click cloning shall create editable journey copies from patterns with automated parameter prompting requesting required inputs including brand selection, therapeutic area specification, target audience definition, campaign start date, and success metrics enabling rapid customization. Parameter mapping shall identify configurable elements within pattern such as content placeholders requiring brand-specific assets, segment definitions needing therapeutic area adaptation, and timing intervals requiring adjustment for different customer engagement patterns. Adaptation guidance shall provide step-by-step instructions documenting critical customization points, common adaptation challenges, and success factors requiring attention during implementation.

Pre-flight validation shall check adapted journeys for completeness ensuring all required parameters specified, consistency verifying that customizations maintain pattern integrity, and compliance confirming that adaptations meet governance requirements. Validation failures shall provide clear remediation guidance rather than cryptic error messages. Simulation capability shall enable testing adapted journeys with sample customer profiles before production deployment identifying logic errors or unintended behaviors. The system shall maintain lineage tracking linking implemented journeys to source patterns enabling pattern performance aggregation showing collective results across all implementations and impact analysis assessing organizational value from individual patterns.

Implementation feedback shall capture adapter experience including customization difficulty ratings, encountered challenges descriptions, performance results compared to pattern expectations, and improvement suggestions feeding back to pattern curators. Performance comparison shall analyze whether adaptations achieve results similar to original pattern implementation identifying factors contributing to replication success or failure. Underperforming adaptations shall trigger investigation determining whether issues stem from contextual differences, poor adaptation execution, or pattern limitations requiring update. The system shall provide implementation consulting connecting teams attempting pattern adaptation with original pattern creators or subject matter experts offering guidance and troubleshooting support.

**Business Rationale:** Comprehensive implementation support proves essential for pattern value realization as abstract templates deliver little value without effective adaptation to specific contexts. One-click cloning dramatically reduces implementation effort compared to manual recreation. Parameter prompting prevents common omission errors. Pre-flight validation catches mistakes before customer impact. Lineage tracking enables portfolio-level pattern value assessment justifying library investment. Research demonstrates that organizations providing robust implementation support achieve 70-80% higher pattern replication success rates measured through performance parity with original implementations, 50-60% faster time from pattern selection to production deployment, and 40-50% reduction in adaptation errors requiring remediation. Feedback loops connecting implementations back to patterns enable continuous improvement where patterns evolve based on collective learning rather than remaining static templates.

**Swimlane Alignment:** Swimlane D (Orchestrate)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-322 and REQ-323 (pattern library foundation and discovery), REQ-133 through REQ-140 (journey canvas for implementation), REQ-286 (journey simulation)

**Acceptance Criteria:** One-click cloning creating editable journey copies with automated parameter prompting, parameter mapping identifying configurable elements with adaptation guidance, pre-flight validation checking completeness, consistency, and compliance with clear remediation guidance, simulation capability for pre-deployment testing, lineage tracking linking implementations to source patterns, implementation feedback capturing experience and performance results.

**Success Metrics:** Cloning adoption measured through 60% of new journeys starting from patterns rather than blank canvas within one year, adaptation time reduction showing 50% faster implementation versus manual recreation, replication success achieving 70% of adaptations performing within 20% of original pattern results, feedback participation measured through 40% of implementations providing performance data enabling pattern refinement.

---

## 6.3 COMPETITIVE INTELLIGENCE INTEGRATION AND PORTFOLIO OPTIMIZATION

### Capability Overview

Competitive intelligence integration and portfolio optimization capabilities provide enterprise-level strategic insights aggregating competitive data across therapeutic areas and generating portfolio-level budget allocation recommendations based on marginal returns analysis. Individual brand teams naturally focus on their specific competitive sets and local optimization opportunities lacking visibility to portfolio-wide patterns and cross-brand resource allocation tradeoffs. Marketing leadership requires different analytical perspectives enabling questions such as which therapeutic areas face intensifying competitive pressure requiring defensive investment, which brands generate highest marginal returns deserving incremental budget allocation, how competitive spending patterns vary across categories informing strategic positioning, and where portfolio demonstrates capability gaps relative to leading competitors suggesting development priorities.

Competitive intelligence historically involves manual collection from conferences, trade publications, and agency reports creating fragmented snapshots lacking systematic tracking and analytical integration. Different brand teams employ inconsistent methodologies for competitive assessment making portfolio aggregation challenging. Competitive data remains descriptive rather than analytical answering what competitors are doing but not why it matters or how we should respond. Portfolio optimization decisions rely primarily on historical allocations with incremental adjustments for vocal advocates rather than rigorous marginal return analysis. This approach perpetuates suboptimal resource allocation where mature brands in declining categories maintain spending levels through organizational inertia while high-growth opportunities receive insufficient investment to capitalize on market potential.

The proposed framework addresses these challenges through two integrated capabilities. Competitive intelligence integration aggregates market data from multiple sources including digital advertising monitoring, share of voice tracking, message analysis, and channel investment estimation providing a comprehensive view of competitive dynamics. Portfolio optimization employs mathematical programming techniques analyzing marginal returns across brands recommending reallocation that maximizes portfolio-level objectives subject to strategic constraints. Together these capabilities transform annual planning from political negotiation to evidence-based strategic decision making while enabling dynamic resource allocation responding to competitive moves and market shifts.

Organizations implementing competitive intelligence integration and portfolio optimization report 30-40% improvement in portfolio return on investment through superior resource allocation, 20-30% faster response to competitive threats through systematic monitoring and alerting, 40-50% reduction in planning cycle time through eliminating prolonged negotiation, and 25-35% better alignment between marketing investment and market opportunity. These benefits prove particularly substantial in pharmaceutical organizations managing diverse portfolios where enterprise-level perspective reveals opportunities and threats that brand-level focus misses.

### Detailed Requirements

**REQ-325: Competitive Intelligence Aggregation and Analysis**

The system shall integrate competitive intelligence from multiple sources providing a comprehensive view of competitor activities across therapeutic areas. Digital advertising monitoring shall track competitor paid search keywords, display advertisement placements, social media campaigns, and programmatic buying patterns capturing creative samples, messaging themes, targeting approaches, and estimated spending levels. Share of voice measurement shall quantify promotional prominence across channels including television advertising gross rating points, professional publication advertisement pages, conference presence and sponsorships, and digital impression volumes calculating relative share versus therapeutic category total. Message analysis shall catalog competitor claims, positioning themes, target audience focus, and evidence citations tracking evolution over time. Channel investment estimation shall model competitor spending allocation across tactics based on observable activities and industry benchmarks.

Competitive data integration shall consume feeds from specialized vendors such as Kantar Media for advertising monitoring, IQVIA for pharmaceutical promotional tracking, and conference organizers for event participation alongside web scraping for publicly available information such as clinical trial registries and regulatory filings. The system shall standardize disparate data sources into common schema enabling consistent analysis despite varying formats and update frequencies. Competitive brand mapping shall link competitor product identifiers across data sources creating unified competitor profiles. Historical trending shall maintain multi-year competitive data enabling longitudinal analysis showing strategic shifts and pattern changes.

Competitive analytics shall provide multiple analytical views including head-to-head comparison showing matched pair analysis between specific brands and key competitors, therapeutic area benchmarking aggregating across brands within categories, portfolio-level aggregation revealing enterprise competitive positioning, and predictive analytics forecasting competitor actions based on historical patterns and market signals. Alerting shall notify stakeholders when competitors launch significant campaigns, shift messaging strategies, increase spending substantially, or enter new channels enabling rapid response. Competitive dashboards shall visualize share of voice trends, message positioning maps, channel investment patterns, and strategic move timelines providing accessible insights for non-analytical stakeholders.

**Business Rationale:** Systematic competitive intelligence transforms reactive monitoring into proactive strategic advantage by revealing patterns that episodic observation misses. Aggregated portfolio view surfaces category-level trends that individual brand monitoring overlooks such as industry-wide channel shifts or emerging message themes. Predictive analytics enable anticipatory positioning rather than reactive response. Research demonstrates that organizations with integrated competitive intelligence achieve 20-30% faster identification of competitive threats measured through time from competitor action to internal awareness, 30-40% better strategic positioning through understanding competitive intent rather than merely observing tactics, and 25-35% improvement in resource allocation through quantifying competitive pressure rather than relying on subjective threat assessment. Pharmaceutical competitive intelligence proves particularly valuable given the complex regulatory environment where competitor messaging choices reveal strategic positioning and market opportunities.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-319 (portfolio data model for competitive context), REQ-274 (competitive intelligence vision from Section 2), external competitive data sources and vendor integrations

**Acceptance Criteria:** Competitive intelligence integration from digital advertising monitoring, share of voice measurement, message analysis, and channel investment estimation with data standardization across sources, competitive brand mapping creating unified profiles, historical trending maintaining multi-year data, analytics providing head-to-head comparison, therapeutic area benchmarking, portfolio aggregation, and predictive forecasting, alerting for significant competitive actions, dashboards visualizing trends and patterns.

**Success Metrics:** Data coverage reaching 80% of major competitors within therapeutic areas where brands operate within six months, update frequency achieving weekly refresh for digital channels and monthly for traditional media, analytical adoption measured through competitive insights appearing in 60% of strategic planning documents within one year, decision impact demonstrated through faster response to competitive moves showing 30% reduction in time from threat identification to countermeasure deployment.

---

**REQ-326: Portfolio-Level Budget Optimization Framework**

The system shall implement a mathematical optimization framework generating portfolio-level budget allocation recommendations maximizing enterprise objectives subject to strategic constraints. The optimization model shall accept inputs including brand-specific marginal return curves derived from marketing mix models showing expected outcomes at various spending levels, total portfolio budget constraint representing available capital, minimum and maximum spend boundaries by brand reflecting strategic commitments and practical limits, therapeutic area investment targets specifying desired allocation ranges, and strategic priorities weighting brands by organizational importance. The optimization objective shall support multiple formulations including total outcome maximization seeking highest absolute results, return on investment maximization achieving best capital efficiency, and strategic score maximization balancing financial returns with non-financial considerations such as pipeline development or market positioning.

The optimization algorithm shall employ appropriate mathematical programming techniques such as quadratic programming for smooth objective functions, mixed-integer programming when discrete decisions required, or evolutionary algorithms for complex non-convex problems. The solver shall handle constraint interactions where multiple limits apply simultaneously such as brand maximums combined with therapeutic area targets requiring reconciliation. Sensitivity analysis shall examine how recommendations change with constraint relaxation such as additional budget availability or reduced minimum spend requirements identifying most binding constraints limiting performance. The system shall support scenario comparison evaluating alternative constraint configurations such as different therapeutic area targets or strategic priority weights showing recommendation sensitivity to assumptions.

Optimization output shall provide recommended budget allocation by brand with comparison to current baseline, predicted outcomes under optimal allocation quantifying expected improvement, incremental value calculation showing benefit from optimization versus status quo, constraint analysis identifying binding limitations preventing further improvement, and implementation roadmap suggesting transition path from current to optimal allocation over multiple periods when immediate shifts prove disruptive. Recommendation validation shall include feasibility checking ensuring allocations satisfy all constraints, plausibility assessment verifying recommendations align with business intuition, and performance forecasting showing expected results with confidence intervals. Documentation shall explain optimization methodology, assumptions, and interpretation guidance enabling informed executive decision making.

**Business Rationale:** Portfolio optimization provides a rigorous analytical foundation for resource allocation decisions replacing political negotiation and historical inertia with mathematical rigor. Marginal return analysis ensures incremental investment flows to highest-value opportunities maximizing enterprise value rather than perpetuating suboptimal legacy allocations. Constraint handling enables realistic recommendations respecting business realities rather than purely theoretical optima disconnected from operational feasibility. Research demonstrates that portfolio optimization typically improves aggregate return on investment by 20-30% through systematic reallocation, generates additional value equivalent to ten to 15% budget increase without requiring additional capital, and accelerates planning cycle time by 40-50% through eliminating prolonged negotiation. Organizations report that optimization transforms chief financial officer and board relationships as marketing demonstrates capital allocation discipline and measurable value generation rather than defending historical budgets.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-314 through REQ-318 (marketing mix modeling providing marginal return curves), REQ-277 (portfolio optimization vision from Section 2), optimization solver libraries or platforms

**Acceptance Criteria:** Optimization framework accepting marginal return curves, budget constraints, spend boundaries, therapeutic area targets, and strategic priorities with multiple objective function formulations, mathematical programming algorithms appropriate for problem characteristics with constraint interaction handling, sensitivity analysis examining constraint relaxation impacts, scenario comparison evaluating alternative configurations, output providing recommended allocation, predicted outcomes, incremental value, constraint analysis, and implementation roadmap.

**Success Metrics:** Optimization solution quality achieving within ten percent of theoretical optimum when validated through exhaustive search on simplified problems, recommendation feasibility showing 90% of recommendations assessed as implementable by business stakeholders, value capture measured through actual performance of optimized allocations exceeding baseline by minimum 20% confirming benefit realization, planning cycle impact showing 40% reduction in time from analysis initiation to executive decision.

---

**REQ-327: Executive Portfolio Dashboard and Strategic Reporting**

The system shall provide a comprehensive executive dashboard delivering portfolio-level visibility supporting strategic decision making and board communication. The dashboard shall aggregate performance across multiple dimensions including portfolio total outcomes showing aggregate prescriptions, market share, revenue, and pipeline contribution, therapeutic area roll-ups revealing performance variation across categories, brand-level detail enabling drill-down to individual product analysis, and geographic views showing international performance patterns. Normalized metrics shall enable fair comparison through efficiency scores, market impact measures, and phase-appropriate benchmarks preventing misleading conclusions from absolute metrics.

Strategic context shall incorporate competitive positioning showing portfolio share of voice and message differentiation, market dynamics tracking category growth rates and competitive intensity, pipeline visibility displaying upcoming launches and expansion opportunities, and capability maturity assessing organizational strength areas and development needs. Trend analysis shall highlight trajectory changes showing whether performance is improving, stable, or declining with forecasting projecting future outcomes under current strategies. Exception reporting shall flag brands significantly underperforming or overperforming expectations warranting executive attention and potential intervention.

Dashboard design shall follow executive information system principles emphasizing visual clarity through charts and graphs minimizing text, progressive disclosure starting with high-level overview enabling drill-down to detail as needed, mobile optimization supporting access from tablets and smartphones, and customizable views allowing personalization for different executive roles such as chief marketing officer focusing on marketing efficiency versus chief financial officer emphasizing return on investment. Export capabilities shall support PDF generation for board materials and data extraction for additional analysis. Update frequency shall provide monthly refresh for strategic dashboards and quarterly comprehensive business reviews with real-time access to underlying data for ad hoc inquiry.

**Business Rationale:** Executive visibility proves essential for marketing leadership credibility and resource allocation authority as senior leaders require portfolio-level insights rather than brand-specific tactical details. A comprehensive dashboard transforms fragmented reporting into an integrated strategic view. Normalized comparison enables fair assessment across a diverse portfolio. Competitive and market context situates performance within a broader environment. Research demonstrates that organizations with sophisticated executive dashboards achieve 40-50% higher marketing leadership engagement measured through dashboard usage and performance discussion frequency, 30-40% better strategic alignment through shared understanding of portfolio health, and 25-35% improved resource allocation through evidence-based discussions rather than anecdotal advocacy. Executive dashboards prove particularly valuable during board meetings and strategic planning cycles when leadership seeks concise portfolio overview informing major decisions.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P2 \- Advanced capability (Phase 5\)

**Dependencies:** REQ-319 through REQ-321 (portfolio data model and metrics), REQ-325 (competitive intelligence), REQ-279 (executive portfolio dashboard vision from Section 2), business intelligence platform

**Acceptance Criteria:** Executive dashboard aggregating portfolio totals, therapeutic area roll-ups, brand details, and geographic views with normalized metrics, strategic context incorporating competitive positioning, market dynamics, pipeline visibility, and capability maturity with trend analysis and exception reporting, dashboard design following executive information system principles with progressive disclosure, mobile optimization, and customizable views, monthly refresh frequency with real-time drill-down capability.

**Success Metrics:** Executive adoption measured through 70% of marketing leadership accessing dashboard monthly within six months of deployment, usage intensity showing average session duration exceeding 10 minutes indicating substantive engagement rather than superficial review, decision impact demonstrated through dashboard insights appearing in 50% of strategic planning documents, board satisfaction assessed through positive feedback on portfolio reporting clarity and strategic relevance.

---

## SECTION 6 SUMMARY

This enhanced Section 6 provides comprehensive specifications for Portfolio Analytics and Cross-Brand Intelligence capabilities enabling enterprise-level optimization and knowledge sharing. The section documents nine new detailed requirements spanning REQ-319 through REQ-327 covering portfolio data modeling, normalized metrics, phase-appropriate benchmarking, journey pattern identification and curation, pattern discovery and adaptation, competitive intelligence integration, portfolio optimization, and executive dashboards. These capabilities transform pharmaceutical marketing from collection of independent brand operations to integrated portfolio delivering enterprise value through systematic knowledge sharing, fair performance assessment, strategic resource allocation, and executive visibility.

### Requirements Summary

| Capability Domain | Requirements | Priority P2 | Phase 5 |
| :---- | :---- | :---- | :---- |
| Portfolio Data Model | REQ-319 to REQ-321 | 3 | 3 |
| Journey Pattern Library | REQ-322 to REQ-324 | 3 | 3 |
| Competitive Intelligence & Optimization | REQ-325 to REQ-327 | 3 | 3 |
| **Total Section 6** | **9** | **9** | **9** |

---

# SECTION 7: TECHNICAL REQUIREMENTS AND ARCHITECTURE

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## OVERVIEW

Technical requirements define the infrastructure, platform capabilities, integration patterns, security controls, and operational characteristics that enable the functional capabilities documented in previous sections. While functional requirements address what the system must do from a business perspective, technical requirements specify how the system achieves those objectives through appropriate technology choices, architectural patterns, and operational disciplines. These technical foundations prove invisible to end users during normal operations yet determine whether the solution achieves required performance, maintains acceptable reliability, scales to organizational needs, protects sensitive data, and evolves as requirements change without requiring complete reimplementation.

Pharmaceutical marketing technology infrastructure faces distinctive technical challenges beyond typical enterprise software deployment. Regulatory compliance requirements mandate audit trails, version control, and data retention policies that affect architectural decisions. Protected health information handling when working with patient data requires HIPAA-compliant infrastructure with encryption, access controls, and breach notification procedures. Integration with numerous external systems including agency platforms, data vendors, and regulatory submission systems demands flexible integration architecture supporting diverse protocols and data formats. Performance requirements supporting real-time personalization, journey orchestration, and fatigue management necessitate low-latency processing and high-throughput data pipelines. Scalability needs accommodating seasonal campaign volume spikes and portfolio growth require elastic infrastructure avoiding over-provisioning during normal periods while handling peak loads without degradation.

The proposed technical architecture employs modern cloud-native approaches balancing agility with enterprise-grade reliability through several key design principles. Cloud infrastructure leveraging the Salesforce platform for CRM and orchestration combined with hyperscale cloud providers such as Amazon Web Services, Microsoft Azure, or Google Cloud Platform for data warehousing, analytics, and specialized services provides scalability and managed services reducing operational burden. Microservices architecture decomposes functionality into loosely coupled services enabling independent deployment, scaling, and evolution while avoiding monolithic complexity. API-first integration establishes consistent patterns for system connectivity supporting both real-time and batch data exchange. Event-driven data flows enable near-real-time processing through streaming pipelines supporting responsive customer experiences and operational dashboards. Comprehensive security controls implement defense-in-depth protecting data at rest and in transit while supporting compliance requirements. DevOps practices automate deployment, monitoring, and incident response enabling rapid feature delivery and reliable operations.

Organizations implementing these technical approaches report 60-70% reduction in infrastructure management effort through managed cloud services, 40-50% faster feature delivery through microservices independence and DevOps automation, 30-40% improvement in system reliability through proper monitoring and incident response, and 25-35% lower total cost of ownership through elastic scaling and operational efficiency. Technical excellence proves particularly valuable in pharmaceutical contexts where system failures risk compliance violations, data breaches create regulatory exposure, and integration fragility disrupts marketing operations.

---

## 7.1 PLATFORM ARCHITECTURE AND TECHNOLOGY SELECTION

### Core Platform Stack

**REQ-328: Salesforce Platform Foundation**

The solution shall employ Salesforce as the core platform providing customer relationship management, campaign orchestration, workflow automation, and user interface foundation. Salesforce Sales Cloud shall serve as a system of record for all customer data including HCP accounts, patient records, institutional relationships, and payer organizations with Person Accounts model supporting both business-to-business and business-to-consumer requirements. Salesforce Data Cloud shall provide identity resolution, real-time segmentation, and unified customer profile capabilities when high-volume consumer engagement or advanced identity management proves necessary. Salesforce Marketing Cloud Engagement shall deliver email, mobile, and advertising execution capabilities integrated with Sales Cloud for seamless data flow and campaign coordination.

The Salesforce implementation shall employ Enterprise Edition or Unlimited Edition providing sufficient API capacity, storage limits, and feature access for pharmaceutical marketing requirements. Custom object development shall extend standard Salesforce data model supporting ClaimID registry, journey definitions, MLR approval workflows, and analytics data models. Lightning Web Components shall provide modern user interface for journey canvas, dashboard visualizations, and operational tools ensuring consistent user experience and mobile compatibility. Salesforce Flow and Approval Processes shall orchestrate multi-stage workflows for MLR review, content approval, and lifecycle management. Integration with external systems shall employ Salesforce REST and SOAP APIs, MuleSoft platform for complex integrations, or custom Heroku applications for specialized processing requirements.

**Business Rationale:** Salesforce provides a pharmaceutical-proven platform with extensive healthcare and life sciences functionality, broad ecosystem of implementation partners and ISV applications, and robust compliance capabilities supporting audit requirements and validation protocols. Native Salesforce implementation reduces integration complexity, accelerates deployment through standard objects and workflows, and leverages organizational Salesforce expertise when present. Research demonstrates Salesforce-based solutions achieve 30-40% faster implementation versus custom development, provide 20-30% lower total cost of ownership through standard platform features and managed infrastructure, and deliver superior user adoption through familiar interface patterns.

**Swimlane Alignment:** All swimlanes (foundation platform)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** None \- foundational platform decision

**Acceptance Criteria:** Salesforce Enterprise or Unlimited Edition deployed with Sales Cloud, Data Cloud optional based on volume requirements, and Marketing Cloud Engagement for execution capabilities, custom object development extending data model for pharmaceutical requirements, Lightning Web Component framework for user interfaces, Salesforce Flow for workflow orchestration, API and integration infrastructure supporting external system connectivity.

**Success Metrics:** Platform deployment achieving production readiness within target timeline, user adoption reaching 80% of target users within three months of deployment, system performance meeting service-level objectives for response time and availability, integration reliability achieving ninety-nine percent successful data exchange with connected systems.

---

**REQ-329: Cloud Data Infrastructure**

The solution shall implement modern cloud data infrastructure supporting analytics, reporting, machine learning, and integration data flows. Cloud data warehouses using Snowflake, Google BigQuery, or Amazon Redshift shall provide scalable storage and compute for marketing performance data, customer touchpoint events, attribution analysis, and portfolio analytics with columnar storage optimizing analytical query performance. The warehouse architecture shall employ separate environments for development, testing, and production with appropriate security controls and data masking protecting sensitive information in non-production environments. Data retention policies shall maintain detailed granular data for a minimum eighteen months supporting attribution modeling and trend analysis with archival strategies for longer-term regulatory compliance storage.

Real-time data streaming infrastructure using Apache Kafka, Amazon Kinesis, or Google Pub/Sub shall enable event-driven architecture processing customer touchpoints, journey progression events, and operational metrics with sub-minute latency. Stream processing using Apache Flink, Apache Spark Streaming, or cloud-native services shall enrich events, calculate derived metrics, update real-time aggregations, and trigger downstream actions. Data lake storage using Amazon S3, Azure Data Lake, or Google Cloud Storage shall provide cost-effective long-term retention for raw event data, machine learning training datasets, and archived historical data. Object storage shall employ lifecycle policies automatically transitioning older data to lower-cost storage tiers balancing accessibility with cost optimization.

Data pipeline orchestration using Apache Airflow, Azure Data Factory, or cloud-native workflow services shall coordinate batch data movement, transformation processes, model training workflows, and maintenance operations with monitoring, alerting, and retry logic ensuring reliable execution. The orchestration framework shall support both scheduled executions running at fixed intervals and event-triggered workflows responding to data arrival or completion events. Data quality validation shall execute at multiple pipeline stages checking completeness, consistency, accuracy, and timeliness with automated alerting when quality thresholds breach and quarantine mechanisms preventing bad data from corrupting downstream systems.

**Business Rationale:** Modern cloud data infrastructure provides scalability, performance, and cost efficiency superior to traditional on-premises data warehouses while supporting advanced analytics and machine learning requirements. Columnar storage and distributed compute enable interactive analysis of large datasets impossible with row-based relational databases. Real-time streaming supports responsive customer experiences and operational dashboards avoiding batch processing delays. Cloud-native managed services reduce operational burden compared to self-hosted open-source alternatives. Research demonstrates cloud data infrastructure achieves 60-80% lower cost versus comparable on-premises infrastructure through elastic scaling and operational efficiency, provides 40-50% better query performance through optimized storage and distributed processing, and enables 50-70% faster analytics development through self-service access and modern tooling.

**Swimlane Alignment:** Swimlane F (Measure & Learn), supporting all swimlanes

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-328 (Salesforce providing source data), cloud platform selection

**Acceptance Criteria:** Cloud data warehouse deployed with columnar storage, separate environments, and retention policies, real-time streaming infrastructure processing events with sub-minute latency and stream processing for enrichment and aggregation, data lake storage with lifecycle policies for cost optimization, pipeline orchestration coordinating batch and event-triggered workflows with monitoring and quality validation.

**Success Metrics:** Query performance achieving sub-minute response for 95th percentile of analytical queries on large datasets, streaming latency maintaining under two minutes from event occurrence to warehouse availability measured at 95th percentile, pipeline reliability achieving ninety-nine percent successful execution with automated recovery for transient failures, cost efficiency remaining within budget targets through elastic scaling and storage optimization.

---

**REQ-330: Business Intelligence and Visualization Platform**

The solution shall deploy a comprehensive business intelligence and visualization platform enabling self-service analytics, dashboard creation, and report distribution. The platform shall support either Salesforce CRM Analytics for Salesforce-native dashboards, Tableau for advanced visualization and exploration, Looker for embedded analytics and semantic modeling, or Microsoft Power BI for Microsoft ecosystem integration with selection based on organizational preferences and existing investments. The chosen platform shall integrate with cloud data warehouse accessing performance data, portfolio analytics, attribution results, and marketing mix model outputs through direct connection or cached extracts balancing query freshness with performance.

Dashboard development shall employ reusable component libraries establishing consistent visualization patterns, color schemes, and interaction behaviors across portfolios. Template dashboards shall provide starting points for common use cases including campaign performance monitoring, journey analytics, portfolio benchmarking, and executive summaries accelerating dashboard creation and ensuring consistency. Embedded analytics shall integrate dashboards within Salesforce, journey canvas, and operational tools providing contextual insights without requiring navigation to separate analytics applications. Mobile-optimized layouts shall adapt visualizations for tablet and smartphone viewing supporting executive access and field team consumption.

Data governance controls shall implement row-level security restricting data visibility based on user roles, therapeutic area assignments, and geographic responsibilities preventing unauthorized access to sensitive information. Dashboard publishing workflow shall require peer review before production deployment ensuring quality and accuracy. Usage analytics shall track dashboard views, interaction patterns, and user satisfaction informing prioritization of dashboard enhancements. Scheduled distribution shall automatically deliver report snapshots via email or collaboration platforms at configured intervals with subscription management enabling self-service preferences.

**Business Rationale:** Self-service business intelligence democratizes data access enabling business users to answer questions without analyst dependency while freeing analytical talent for strategic work rather than repetitive reporting. Interactive dashboards reveal insights through exploration impossible with static reports. Embedded analytics provide contextual insights improving workflow efficiency. Research demonstrates self-service BI platforms improve decision speed by 40-50% measured through time from question to answer, reduce analyst workload by 30-40% through self-service adoption, and increase data-driven decision making by 50-60% through improved accessibility. Platform selection proves less important than consistent implementation with quality data and thoughtful design.

**Swimlane Alignment:** Swimlane F (Measure & Learn)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-329 (data warehouse providing analytics data), platform selection based on organizational context

**Acceptance Criteria:** Business intelligence platform deployed with data warehouse integration, reusable component libraries and template dashboards accelerating development, embedded analytics within operational applications, mobile-optimized layouts, row-level security implementing data governance, publishing workflow with peer review, usage analytics and scheduled distribution.

**Success Metrics:** Dashboard deployment velocity averaging two weeks from requirements to production for standard dashboards, self-service adoption reaching 60% of business users creating or modifying dashboards within one year, query performance maintaining sub-five-second response for interactive exploration, user satisfaction with BI platform rated above 8 out of 10\.

---

## 7.2 INTEGRATION ARCHITECTURE AND DATA EXCHANGE

**REQ-331: API-First Integration Framework**

The solution shall implement comprehensive API-first integration architecture establishing consistent patterns for connectivity between internal systems, external platforms, agency partners, and data vendors. RESTful APIs shall provide a primary integration mechanism using JSON payloads for data exchange, HTTP methods for operations, and standard status codes for responses following OpenAPI specification for documentation and client generation. GraphQL APIs shall supplement REST for complex queries requiring flexible field selection and minimizing over-fetching when appropriate. Real-time webhooks shall enable event-driven integration where external systems notify changes or events triggering immediate processing rather than polling-based detection.

API gateway shall provide centralized entry point managing authentication, authorization, rate limiting, monitoring, and transformation establishing security and operational controls before requests reach backend services. The gateway shall support multiple authentication mechanisms including OAuth 2.0 for user-delegated access, API keys for system-to-system integration, and mutual TLS for high-security connections. Rate limiting shall prevent abuse or accidental overload through configurable request quotas per consumer with graduated responses including warnings before hard limits and automatic backoff recommendations. API versioning shall enable backward-compatible evolution through URI-based or header-based version specification maintaining support for older API versions during transition periods.

Integration middleware platforms such as MuleSoft, Dell Boomi, or cloud-native iPaaS shall orchestrate complex integration scenarios requiring data transformation, protocol translation, error handling, and workflow coordination. The middleware shall provide visual development interface enabling integration developer productivity, reusable connector library for common platforms, and monitoring dashboard showing integration health and throughput. Asynchronous message queues shall decouple sender and receiver enabling reliable delivery despite temporary unavailability through persistent message storage and automatic retry with exponential backoff.

**Business Rationale:** API-first architecture enables flexible integration supporting diverse external systems while maintaining security and operational controls. RESTful design provides simplicity and broad tooling support while GraphQL addresses specific use cases requiring flexibility. API gateway centralizes cross-cutting concerns avoiding duplication across services. Integration middleware accelerates complex scenario implementation and provides operational visibility. Research demonstrates API-first approaches reduce integration development time by 40-50% through reusable patterns and tooling, improve integration reliability by 30-40% through centralized monitoring and error handling, and accelerate partner onboarding by 50-60% through self-service documentation and standardized patterns.

**Swimlane Alignment:** All swimlanes (integration foundation)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-328 and REQ-329 (platforms requiring integration), external system APIs

**Acceptance Criteria:** RESTful and GraphQL APIs implemented following OpenAPI specification with webhook support for event-driven integration, API gateway providing authentication, authorization, rate limiting, monitoring, and transformation, integration middleware orchestrating complex scenarios with visual development, reusable connectors, and monitoring, asynchronous message queues enabling reliable delivery with persistent storage and retry logic.

**Success Metrics:** Integration reliability achieving ninety-nine percent successful data exchange measured across all connected systems, API response time maintaining sub-one-second latency for 95th percentile of requests, partner onboarding time averaging two weeks from initial engagement to production integration, integration development productivity improving by 40% measured through story points per sprint.

---

**REQ-332: Master Data Management and Data Quality**

The solution shall implement comprehensive master data management ensuring consistent, accurate, and complete customer data across all systems. Golden record creation shall employ survivorship rules determining authoritative attribute values when multiple systems contain conflicting information based on data source trust scores, recency, and completeness. Match and merge algorithms shall identify duplicate records using deterministic matching on unique identifiers such as email address, NPI number, or CRM record ID and probabilistic matching using name, address, and demographic similarity with configurable confidence thresholds determining automatic merge versus manual review requirements.

Data quality rules shall validate incoming data checking completeness ensuring required fields populated, accuracy verifying values fall within reasonable ranges or match expected patterns, consistency confirming relationships maintain referential integrity, and timeliness flagging stale data exceeding freshness thresholds. Quality scoring shall quantify data health at record level, aggregate levels such as customer segment or therapeutic area, and portfolio level providing visibility to data quality trends. Data stewardship workflow shall route quality exceptions to appropriate owners for investigation and resolution with tracking ensuring timely remediation.

Data lineage tracking shall document data origin, transformations applied, and downstream consumption enabling impact analysis when source systems change and root cause investigation when quality issues arise. Data cataloging shall maintain searchable inventory of datasets, tables, fields, and reports with business definitions, ownership assignments, and usage metadata improving discoverability and understanding. Data retention policies shall automatically archive or delete data meeting age or obsolescence criteria balancing regulatory compliance requirements with storage cost optimization.

**Business Rationale:** High-quality master data proves essential for marketing effectiveness as campaign targeting, personalization, and measurement depend on accurate customer information. Duplicate records cause message redundancy annoying customers and wasting budget. Incomplete data prevents effective segmentation and personalization. Inconsistent data across systems creates operational confusion and analytical errors. Research demonstrates master data management improves data quality scores by 40-60%age points measured through completeness, accuracy, and consistency metrics, reduces duplicate rates from ten to 15% to under two percent, and prevents 20-30% of customer-facing errors caused by data quality issues.

**Swimlane Alignment:** Swimlane A (Govern), supporting all swimlanes

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** REQ-005 and REQ-006 (customer master data and identity resolution), integration architecture providing data flows

**Acceptance Criteria:** Golden record creation employing survivorship rules for conflict resolution, match and merge algorithms using deterministic and probabilistic matching with configurable thresholds, data quality rules validating completeness, accuracy, consistency, and timeliness with quality scoring and stewardship workflow, data lineage tracking and cataloging providing visibility and understanding, retention policies implementing archival and deletion.

**Success Metrics:** Data quality scores achieving above 90% for critical customer attributes measured through completeness and accuracy assessments, duplicate rates maintaining below two percent of active customer records, data quality issue resolution time averaging under five business days from detection to remediation, stewardship workflow adoption reaching 80% of issues routed through formal process versus informal resolution.

---

## 7.3 SECURITY, COMPLIANCE, AND OPERATIONAL RESILIENCE

**REQ-333: Security Controls and Compliance Framework**

The solution shall implement comprehensive security controls protecting sensitive data and supporting regulatory compliance requirements. Encryption at rest shall protect stored data using AES-256 algorithm with key management through hardware security modules or cloud key management services supporting key rotation and audit logging. Encryption in transit shall protect data exchange using TLS 1.2 or higher with perfect forward secrecy preventing retroactive decryption if keys are compromised. Field-level encryption shall protect particularly sensitive attributes such as protected health information within otherwise accessible records enabling granular security controls.

Identity and access management shall integrate with enterprise single sign-on using SAML 2.0 or OpenID Connect providing centralized authentication and reducing password management burden. Multi-factor authentication shall require additional verification beyond passwords for privileged access, remote access, and access to sensitive data. Role-based access control shall implement least privilege principle granting minimum permissions necessary for job functions with regular access reviews ensuring permissions remain appropriate. Audit logging shall capture all data access, modifications, and security events with tamper-evident storage supporting forensic investigation and compliance reporting.

Vulnerability management shall conduct regular security assessments including automated vulnerability scanning identifying known weaknesses, penetration testing simulating attacks to identify exploitable vulnerabilities, and security code reviews examining application source code for security defects. Patch management shall apply security updates promptly with testing in non-production environments before production deployment balancing security with stability. Security incident response procedures shall define detection mechanisms, escalation workflows, containment procedures, and communication protocols enabling rapid response to security events. HIPAA compliance when handling patient data shall implement required administrative, physical, and technical safeguards with business associate agreements documenting responsibilities.

**Business Rationale:** Robust security protects organizational assets and customer trust while supporting regulatory compliance avoiding penalties and reputational damage from security incidents. Healthcare data breaches average four point two million dollars in remediation costs according to industry research while regulatory penalties for HIPAA violations reach up to fifty thousand dollars per violation. Pharmaceutical organizations face heightened scrutiny given sensitive patient and physician data requiring demonstrable security controls. Research demonstrates comprehensive security frameworks reduce breach probability by sixty to 75% measured through incident rates, accelerate compliance attestation by 40-50% through documented controls, and improve stakeholder confidence supporting business relationships requiring security assurance.

**Swimlane Alignment:** All swimlanes (security foundation)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** Platform architecture, integration framework requiring security controls

**Acceptance Criteria:** Encryption at rest using AES-256 with managed key rotation, encryption in transit using TLS 1.2 or higher, field-level encryption for sensitive attributes, identity and access management with single sign-on and multi-factor authentication, role-based access control with least privilege and regular reviews, comprehensive audit logging with tamper-evident storage, vulnerability management with scanning, penetration testing, and code review, patch management balancing security with stability, security incident response procedures, HIPAA compliance when applicable.

**Success Metrics:** Security assessment findings showing zero critical vulnerabilities and under ten high-severity findings, audit compliance achieving 100% of required logging captured with zero tampering incidents, access control effectiveness validated through quarterly reviews identifying and remediating inappropriate permissions, security incident response meeting defined time-to-detection and time-to-containment objectives, HIPAA compliance validated through independent audit when applicable.

---

**REQ-334: Performance, Scalability, and Reliability**

The solution shall achieve performance, scalability, and reliability characteristics supporting business requirements for responsiveness, capacity, and availability. Performance objectives shall include user interface response time under two seconds for 95th percentile of page loads and interactions, API response time under one second for 95th percentile of requests, batch processing throughput supporting required data volumes within maintenance windows, and report generation time under thirty seconds for standard dashboards. Load testing shall validate performance under expected peak loads simulating seasonal campaign volume spikes and concurrent user access.

Scalability architecture shall employ horizontal scaling adding compute and storage capacity through additional servers or containers rather than vertical scaling limited by single-server capabilities. Auto-scaling shall dynamically adjust capacity responding to demand patterns automatically provisioning resources during peak periods and de-provisioning during normal operations optimizing cost. The system shall support growth to ten times current volume without architectural redesign providing headroom for organizational expansion and campaign intensity increases. Capacity planning shall project resource requirements based on usage trends and business forecasts ensuring adequate infrastructure provisioned before constraints emerge.

Reliability targets shall achieve ninety-nine point five percent uptime for customer-facing systems corresponding to maximum four hours annual downtime, ninety-nine percent uptime for internal operational tools, and planned maintenance windows scheduled during low-activity periods with advance notification. Redundancy shall eliminate single points of failure through multi-zone deployment protecting against data center outages, database replication providing real-time failover capability, and load balancer distribution preventing individual server failures from impacting availability. Disaster recovery procedures shall enable recovery within defined recovery time objective and recovery point objective with regular testing validating procedures and identifying gaps.

**Business Rationale:** Performance proves critical for user adoption and customer experience as slow systems frustrate users and drive workarounds undermining value realization. Scalability prevents performance degradation as volume grows avoiding costly emergency capacity expansions or architectural redesigns. Reliability ensures business continuity as system unavailability prevents campaign execution, disrupts operations, and damages stakeholder confidence. Research demonstrates performant systems achieve 20-30% higher user adoption and satisfaction, scalable architectures reduce infrastructure cost by 30-40% through efficient resource utilization, and reliable systems improve operational efficiency by 25-35% through eliminating outage-related disruption.

**Swimlane Alignment:** All swimlanes (non-functional foundation)

**Priority:** P0 \- Foundation (Phase 1\)

**Dependencies:** Platform architecture and infrastructure design

**Acceptance Criteria:** Performance targets meeting defined objectives for response time, throughput, and generation time validated through load testing, scalability architecture supporting horizontal scaling with auto-scaling responding to demand and ten times volume capacity, reliability achieving uptime targets with redundancy eliminating single points of failure and disaster recovery procedures with regular testing.

**Success Metrics:** Performance monitoring showing 95% of interactions meeting response time objectives, scalability validation demonstrating successful handling of ten times baseline load in testing environment, uptime achievement meeting or exceeding ninety-nine point five percent for customer systems measured monthly, disaster recovery testing conducted semi-annually with successful recovery within defined objectives.

---

**REQ-335: DevOps Practices and Operational Excellence**

The solution shall implement modern DevOps practices enabling rapid feature delivery, reliable operations, and continuous improvement. Source code management using Git shall version control all application code, infrastructure-as-code definitions, configuration files, and documentation with branching strategies supporting parallel development and merge workflows. Continuous integration shall automatically build, test, and validate code changes upon commit detecting integration issues early and preventing defects from progressing to later stages. Automated testing shall include unit tests validating individual components, integration tests verifying system interactions, and end-to-end tests confirming business workflows with code coverage targets ensuring adequate test depth.

Continuous deployment pipelines shall automate release processes promoting validated changes through development, testing, staging, and production environments with approval gates requiring human verification before production deployment. Infrastructure-as-code using Terraform, CloudFormation, or platform-specific tools shall define infrastructure through version-controlled configuration enabling reproducible deployments, environment consistency, and automated provisioning. Configuration management shall externalize environment-specific settings avoiding hard-coded values and enabling single codebase deployment across environments. Feature flags shall enable progressive rollout of new capabilities to a subset of users before full deployment providing a kill switch for rapid rollback if issues emerge.

Monitoring and observability shall instrument applications and infrastructure collecting metrics, logs, and traces. Application performance monitoring shall track response times, error rates, and throughput identifying performance degradation and bottlenecks. Log aggregation shall centralize logs from distributed components enabling correlation and troubleshooting. Distributed tracing shall follow requests across service boundaries identifying latency sources in complex workflows. Alerting shall notify the operations team when metrics exceed thresholds or patterns indicate emerging issues with escalation procedures and on-call rotation ensuring timely response. Incident management shall coordinate response activities, document resolutions, and conduct post-mortems identifying systemic improvements.

**Business Rationale:** DevOps practices accelerate delivery, improve quality, and enhance reliability through automation and systematic approaches. Continuous integration detects defects early when fixes prove simpler and cheaper. Automated deployment reduces human error and enables frequent releases. Infrastructure-as-code ensures consistency and enables rapid recovery. Monitoring and observability enable proactive issue detection and rapid troubleshooting. Research demonstrates DevOps adoption improves deployment frequency by 30-40 times, reduces lead time from commit to production by 50-70%, decreases change failure rate by 40-50%, and accelerates mean time to recovery by 60-70%.

**Swimlane Alignment:** All swimlanes (development and operations foundation)

**Priority:** P1 \- Enhanced capability (Phase 1-2)

**Dependencies:** Platform architecture and infrastructure, development team establishment

**Acceptance Criteria:** Source code management with Git implementing branching strategies, continuous integration automatically building and testing upon commit with automated test suites, continuous deployment pipelines promoting through environments with approval gates, infrastructure-as-code defining infrastructure through version control, configuration management and feature flags enabling progressive rollout, monitoring and observability collecting metrics, logs, and traces with alerting and incident management.

**Success Metrics:** Deployment frequency achieving weekly releases to production for incremental enhancements, lead time from commit to production averaging under two weeks for standard changes, change failure rate maintaining below 5% of deployments requiring rollback or fix, mean time to recovery averaging under two hours from incident detection to resolution, automated test coverage exceeding 75% of codebase.

---

## SECTION 7 SUMMARY

This enhanced Section 7 provides comprehensive technical requirements and architecture specifications supporting the functional capabilities documented in previous sections. The section documents eight new requirements spanning REQ-328 through REQ-335 covering platform architecture with Salesforce foundation and cloud data infrastructure, business intelligence and visualization platforms, API-first integration framework and master data management, security controls and compliance framework, performance and scalability objectives, and DevOps practices. These technical foundations enable reliable, secure, performant, and evolvable solution meeting pharmaceutical marketing operational and regulatory requirements.

### Requirements Summary

| Capability Domain | Requirements | Priority P0 | Priority P1 | Phase 1 | Phase 1-2 |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Platform Architecture | REQ-328 to REQ-330 | 3 | 0 | 3 | 0 |
| Integration & Data Quality | REQ-331 to REQ-332 | 2 | 0 | 2 | 0 |
| Security & Operations | REQ-333 to REQ-335 | 2 | 1 | 2 | 1 |
| **Total Section 7** | **8** | **7** | **1** | **7** | **1** |

---

# SECTION 8: IMPLEMENTATION PHASING AND ROADMAP

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## OVERVIEW

The implementation roadmap translates the comprehensive requirements documented in previous sections into actionable program plan organizing three hundred thirty-five requirements across five execution phases spanning eighteen to twenty-four months. This phased approach balances competing objectives including delivering early value through foundation capabilities that enable immediate operational improvements, managing implementation risk through incremental delivery and validation before advancing to subsequent phases, maintaining organizational capacity by avoiding overwhelming teams with simultaneous changes across all functions, and building systematically where later phases depend on infrastructure and capabilities established in earlier phases.

Traditional enterprise technology implementations frequently adopt big-bang approaches attempting to deliver complete functionality in single release or waterfall methodologies postponing value realization until final delivery. These approaches create several failure modes including extended implementation timelines stretching beyond organizational patience and commitment, accumulated risk where issues discovered late prove expensive to remediate, integration complexity overwhelming program management, change management challenges as users face comprehensive transformation simultaneously, and difficulty demonstrating return on investment when benefits remain theoretical until full deployment completes. Industry research indicates that large-scale marketing technology implementations employing big-bang approaches achieve only 40-50% of originally defined requirements, experience budget overruns averaging 60-80%, and require timeline extensions of fifty to 100% beyond original estimates.

The proposed phased implementation approach addresses these challenges through incremental delivery philosophy where each phase produces working capabilities generating measurable business value while establishing foundation for subsequent phases. Phase sequencing follows logical dependency order where governance and data infrastructure precedes content and campaign execution, which precedes journey orchestration, which precedes advanced analytics. Priority-driven scope allocation places highest business value requirements and foundational capabilities in early phases while deferring advanced optimization and portfolio intelligence to later phases after core operations stabilize. Risk management throughout implementation employs prove-then-scale methodology where new capabilities undergo pilot testing with limited scope before enterprise-wide rollout, configuration over customization leveraging platform standard features reducing implementation complexity, and regular checkpoints enabling course correction before significant resource investment.

Organizations implementing phased marketing technology deployments report 60-70% higher success rates measured through requirements delivery and stakeholder satisfaction, 30-40% faster time-to-value through early phase benefits, 20-30% lower total cost through scope prioritization and risk mitigation, and 50-60% better user adoption through manageable change introduction. The proposed roadmap incorporates these proven practices while addressing pharmaceutical marketing-specific requirements including regulatory compliance, claim management, and MLR workflow unique to healthcare context.

---

## 8.1 PHASE 1: FOUNDATION (MONTHS 1-3, 3 MONTH DURATION)

### Phase Objectives

Phase 1 establishes foundational infrastructure and core operational capabilities enabling basic marketing operations while creating a platform for subsequent enhancements. The phase focuses on data governance, customer master data management, basic campaign execution, measurement infrastructure, compliance framework, and technical platform deployment. Foundation phase proves essential as later capabilities depend critically on clean customer data, proper governance, and measurement instrumentation that must exist before advanced features deliver value. Organizations attempting to deploy journey orchestration or attribution modeling without solid data foundation experience 40-60% longer implementation timelines and substantially degraded analytical quality requiring expensive remediation.

### Phase Scope and Requirements

Phase 1 implements 106 Priority 0 requirements representing core foundation enabling basic operations and establishing infrastructure for subsequent phases. These requirements span all six operational swimlanes with emphasis on governance, data management, and execution fundamentals.

**Swimlane A: Govern (28 requirements)**

The governance swimlane establishes data standards, campaign taxonomy, consent management, and audit infrastructure. Salesforce deployment creates a customer master data repository with a personal account model supporting both HCP and patient records. Data Cloud implementation when required provides identity resolution linking fragmented customer identifiers across systems. Claravine integration enforces campaign naming conventions, UTM parameters, and content metadata preventing taxonomy chaos that undermines reporting. Consent preference center enables customer communication controls with real-time enforcement preventing violations. ClaimID data model establishes claims registry with substantiation evidence management. Version control and audit logging create compliance documentation supporting regulatory inspections.

**Swimlane B: Segment (12 requirements)**

Segmentation capabilities enable basic targeting through demographic and firmographic attributes, HCP specialty classification, geographic hierarchies, and segment builder interface allowing business users to define audiences without technical assistance. Behavioral tracking foundation instruments web, email, and paid media touchpoints capturing engagement events that will support future advanced segmentation and attribution.

**Swimlane C: Create (21 requirements)**

Content creation workflow establishes campaign brief templates, content registration requiring ClaimID declaration, evidence linking interface, and MLR approval workflow orchestrating medical, legal, and regulatory review. Content versioning maintains complete history supporting compliance and change tracking. Expiry enforcement automatically pauses campaigns when claims approach expiration. Role-based permissions control content access while approval status tracking provides visibility to review progress.

**Swimlane D: Orchestrate (6 requirements)**

Basic orchestration enables multi-channel message delivery across email, SMS, and paid media with channel preference honoring and frequency capping preventing customer saturation. Delivery status tracking monitors message processing and engagement events. Simple journey sequencing supports foundational nurture campaigns although sophisticated journey canvas deployment defers to Phase 2\.

**Swimlane E: Execute (20 requirements)**

Execution channels deploy email platforms with dynamic personalization and responsive templates, web content management supporting promotional microsites, and programmatic advertising with HCP targeting. Field sales dashboard provides representatives visibility to customer engagement history and digital activity. Basic patient program enrollment workflow captures demographics and consent although advanced adherence monitoring defers to subsequent phases.

**Swimlane F: Measure & Learn (19 requirements)**

Measurement infrastructure establishes event collection capturing touchpoints across channels, streaming data pipeline delivering events to warehouse with sub-two-hour latency, and campaign performance dashboards showing impressions, engagement, conversions, and return on investment. Cloud data warehouse deployment provides analytics foundation although advanced attribution and marketing mix modeling await Phase 3 and Phase 4\.

### Technical Infrastructure

Phase 1 integrates with core technical platforms including Salesforce Sales Cloud with custom objects for ClaimID registry, journey definitions, and analytics data models. Marketing Cloud Engagement integration enables email and mobile execution. Cloud data warehouses using Snowflake, BigQuery, or Redshift provide analytics storage with columnar optimization. Real-time streaming infrastructure using Kafka, Kinesis, or Pub/Sub processes events. Business intelligence platform using CRM Analytics, Tableau, Looker, or Power BI enables dashboard development. API gateway establishes integration patterns. Security controls implement encryption, access management, and audit logging meeting pharmaceutical compliance requirements.

### Key Deliverables and Milestones

**Month 1: Platform Foundation**

Salesforce production environment deployed with customer data model and user provisioning. Cloud data warehouse established with schema design and development environment. Integration architecture defined with API gateway configured. Security baseline implemented with encryption, authentication, and audit logging. Initial data migration from legacy systems loads customer master data with quality validation. Technical infrastructure proves functional through smoke testing and integration validation.

**Month 2: Core Capabilities**

Claravine integration enforces campaign taxonomy with validation rules. ClaimID registry deployed with initial claim population from regulatory affairs. MLR approval workflow implements review routing and task management. Email platform configuration enables first promotional campaigns. Event collection instruments priority digital properties. Campaign performance dashboard displays basic metrics. User training commences with governance, content, and execution teams learning new workflows and systems.

**Month 3: Production Readiness**

Pilot campaigns execute across channels validating end-to-end workflows from planning through execution to measurement. User acceptance testing confirms the system meets requirements. Data quality assessment validates customer data completeness and accuracy. Performance testing verifies the system handles expected volumes. Security assessment confirms compliance controls function properly. Production launch enables full organizational adoption with support procedures and escalation paths established.

### Success Criteria

Phase 1 achieves success when organizations demonstrate customer data quality scores above 90%, campaign taxonomy compliance exceeding 95%, MLR approval workflows processing submissions with median cycle time under six weeks, email deliverability achieving over 95% inbox placement, event collection capturing over 85% of planned touchpoints, and campaign dashboards displaying accurate performance data with under four-hour latency.

### Estimated Effort and Resources

Phase 1 requires approximately eight to twelve Full-Time Equivalent (FTE) resources including two Salesforce administrators for platform configuration and user management, two data engineers for warehouse setup and pipeline development, one integration specialist for API and middleware implementation, one BI developer for dashboard creation, two business analysts for requirements refinement and user acceptance testing, one project manager for coordination and status tracking, and one change management specialist for training and adoption support. External consulting resources may supplement the internal team providing specialized expertise for Salesforce Lightning Web Component (LWC) development, Claravine implementation, and cloud infrastructure optimization.

---

## 8.2 PHASE 2: STRATEGIC CAPABILITIES (MONTHS 4-9, 6 MONTH DURATION)

### Phase Objectives

Phase 2 builds upon foundation infrastructure to deliver strategic marketing capabilities enabling sophisticated customer engagement, systematic experimentation, and data-driven optimization. This phase introduces journey orchestration canvas empowering marketers to design complex multi-step engagement sequences, advanced segmentation incorporating behavioral signals and predictive models, enhanced content workflows with collaboration and version comparison, real-time personalization adapting experiences based on customer context, central fatigue management preventing customer overexposure, and multi-touch attribution revealing marketing contribution to business outcomes. These capabilities transform marketing from basic campaign execution to strategic customer lifecycle management generating substantial return on investment improvements through more effective targeting, messaging, and optimization.

### Phase Scope and Requirements

Phase 2 implements 111 Priority One requirements building strategic capabilities on foundation established in Phase 1\. Requirements span journey orchestration, advanced segmentation, enhanced content management, experimentation framework, and attribution modeling.

**Swimlane A: Govern (24 requirements)**

Governance enhancements include probabilistic identity matching for anonymous-to-known resolution, household clustering grouping related individuals, purpose-based consent supporting distinct communication types, regulatory report generation producing audit packages on demand, legal hold capability for litigation, advanced data quality rules with automated remediation, and claim usage tracking showing which content references which claims.

**Swimlane B: Segment (12 requirements)**

Advanced segmentation deploys propensity-to-prescribe models predicting HCP likelihood of initiating therapy, patient adherence prediction identifying discontinuation risk, next-best-action recommendation suggesting optimal message and timing, real-time segment evaluation updating membership within minutes of triggering events, and dynamic audience synchronization pushing changes to execution platforms enabling immediate journey progression.

**Swimlane C: Create (15 requirements)**

Content workflow enhancements provide collaborative creative workspace with inline commenting, template library offering brand-compliant starting points, component library storing reusable elements, real-time collaboration enabling simultaneous editing, automated claim detection analyzing content to identify potential claims, fair balance validation checking risk information prominence, version comparison highlighting changes between revisions, MLR performance analytics reporting cycle times and bottlenecks, and conditional approval capability where reviewers approve contingent on specific changes.

**Swimlane D: Orchestrate (20 requirements)**

Journey orchestration deploys Lightning Web Component canvas with drag-and-drop node library supporting message delivery, wait steps, decision splits, A/B tests, holdout groups, fatigue checks, and MLR gates. Template library provides proven patterns for common use cases. Journey versioning maintains complete history. Visual validation detects configuration errors. Documentation generator produces specifications for MLR review. Central fatigue management implements registry tracking all touchpoints, real-time scoring calculating message pressure, pre-send validation API checking proposed deliveries against limits, and threshold configuration enabling segment-specific controls. A/B testing framework supports rigorous experimentation with statistical power calculation, automated winner declaration, and experiment registry.

**Swimlane E: Execute (27 requirements)**

Execution enhancements deploy SMS platform with two-way messaging, web personalization engine delivering dynamic content variations, progressive profiling gradually collecting visitor information, field representative next-best-action recommendations, patient adherence monitoring tracking prescription fills, nurse educator coordination scheduling consultations, creative rotation testing for paid media, and brand safety controls preventing inappropriate placements.

**Swimlane F: Measure & Learn (13 requirements)**

Attribution framework implements data mart aggregating customer journeys, rules-based models including first-touch and last-touch attribution, algorithmic models using machine learning, Shapley value calculation applying game theory principles, and incrementality measurement through holdout group testing quantifying causal marketing impact. Journey analytics provide real-time performance dashboards, node-level tracking, cohort analysis, and automated optimization recommendations.

### Key Deliverables and Milestones

**Months 4-5: Journey Orchestration Foundation**

Journey canvas Lightning Web Component deploys within Salesforce providing visual design interface. Node library implements core functionality with template library containing initial proven patterns. Journey versioning maintains configuration history. Pilot journeys deploy for priority use cases validating end-to-end workflow from design through execution to measurement. Training educates marketing teams on journey design principles and canvas functionality.

**Months 6-7: Advanced Segmentation and Attribution**

Propensity models deploy for key therapeutic areas predicting prescriber likelihood and patient adherence risk. Real-time segmentation enables event-driven journey progression. Attribution data mart aggregates customer journeys with rules-based and algorithmic models quantifying channel contribution. Holdout testing pilots measure marketing incrementality for major campaigns. Dashboard enhancements display attribution insights and propensity scores.

**Months 8-9: Experimentation and Fatigue Management**

Central fatigue registry deploys collecting touchpoints across all systems. Real-time fatigue scoring calculates customer message pressure. Pre-send validation API integrates with execution platforms enforcing threshold compliance. A/B testing framework supports statistical rigor with experiment registry documenting all tests. Multi-armed bandit algorithms enable adaptive allocation. Organizations pilot experimentation on non-critical campaigns before expanding to strategic initiatives.

### Success Criteria

Phase 2 achieves success when journey canvas adoption reaches 60% of marketers creating own journeys within six months, propensity model accuracy exceeds 70% area under curve, attribution data mart captures 85% of customer journeys, holdout testing reveals marketing driving 50-60% of observed outcomes with remainder organic, fatigue management prevents 95% of threshold violations, and experimentation velocity reaches ten concurrent tests per therapeutic area.

### Estimated Effort and Resources

Phase 2 requires approximately ten to fourteen full-time equivalent resources including three Salesforce developers for Lightning Web Component canvas implementation, two data scientists for propensity modeling and attribution analysis, two data engineers for real-time segmentation and fatigue infrastructure, one UX designer for journey canvas and dashboard interfaces, two business analysts for requirements and user acceptance testing, one project manager, and one change management specialist focusing on journey design methodology and experimentation culture. External consultants may provide specialized expertise for Bayesian attribution modeling, multi-armed bandit algorithms, and real-time processing architecture.

---

## 8.3 PHASE 3: OPTIMIZATION (MONTHS 10-12, 3 MONTH DURATION)

### Phase Objectives

Phase 3 enhances experimentation capabilities and content workflows through advanced optimization algorithms, sophisticated testing methodologies, and enriched collaboration features. This phase completes journey orchestration with simulation capabilities, implements Bayesian optimization for accelerated learning, deploys multi-armed bandit allocation for always-on optimization, enhances content collaboration with presence awareness and structured feedback taxonomy, and extends fatigue management with impact analysis revealing message volume effects on customer outcomes. These enhancements enable organizations to optimize faster and more systematically than Phase 2 capabilities alone support.

### Phase Scope and Requirements

Phase 3 implements forty-three Priority One and Priority Two requirements focused on optimization and collaboration enhancement.

**Swimlane C: Create (4 requirements)**

Content workflow additions include asset preview across devices showing rendering on desktop, mobile, and tablet, reference citation management ensuring claims link to supporting evidence with automatic formatting, claim detection algorithm analyzing content to suggest appropriate ClaimIDs from registry, and visual claim mapping displaying relationships between content, claims, evidence, and products.

**Swimlane D: Orchestrate (15 requirements)**

Journey enhancements deploy simulation capability testing logic with sample customer profiles before production deployment, collaborative development workflow with presence awareness showing active users and threaded comments enabling contextual feedback. Experimentation expands with multi-armed bandit algorithms dynamically allocating traffic toward winning variants, Bayesian optimization accelerating conclusions through prior knowledge incorporation and posterior probability calculation, personalization testing evaluating tailored experiences against generic content, and automated winner selection monitoring results and declaring winners when significance is achieved. Fatigue management adds impact analysis correlating message volume with engagement, churn, and satisfaction metrics informing threshold optimization.

**Swimlane E: Execute (10 requirements)**

Execution additions include in-app messaging within mobile applications presenting contextual messages based on user behavior, rich media messaging supporting images and videos in SMS and push notifications, web content recommendations suggesting related articles and tools, session recording and heatmap analysis capturing visitor interactions identifying user experience issues, speaker program coordination matching physicians with event opportunities, and lookalike audience expansion identifying prospective customers sharing characteristics with high-value existing customers.

**Swimlane F: Measure & Learn (14 requirements)**

Analytics enhancements provide funnel visualization showing progression through awareness, consideration, conversion, and retention stages, content performance reporting ranking creative assets by engagement and conversion metrics, geographic breakdown analyzing results by market, anomaly detection flagging unusual patterns triggering investigation, cohort analysis comparing performance across segments and variants, and journey health monitoring detecting stalled journeys and unexpected fallout requiring intervention.

### Key Deliverables and Milestones

**Months 10-11: Advanced Optimization**

Bayesian optimization framework deploys prior specification, posterior calculation, and probability-based decision making. Multi-armed bandit service implements Thompson sampling and upper confidence bound methods with APIs for journey integration. Journey simulation capability enables pre-deployment testing with batch processing of multiple test customers. Collaboration enhancements deploy with presence awareness, threaded comments, and activity feeds improving cross-functional coordination.

**Month 12: Measurement Enhancement**

Funnel visualization displays customer progression through lifecycle stages identifying bottlenecks and optimization opportunities. Content performance analytics rank assets revealing highest-performing messages and creative approaches. Anomaly detection algorithms flag unusual performance patterns. Journey health monitoring alerts when journeys stall or show unexpected behaviors. Organizations complete optimization cycle demonstrating improved performance from systematic testing and adaptive allocation.

### Success Criteria

Phase 3 achieves success when Bayesian methods reduce sample size requirements by 40% versus frequentist approaches, multi-armed bandit adoption reaches 30% of experiments within six months, journey simulation usage reaches 40% of journeys receiving pre-activation testing, collaboration features show 60% of journeys having multi-user engagement, and content performance analytics identify high-performing assets generating 25% lift when scaled.

### Estimated Effort and Resources

Phase 3 requires approximately six to eight full-time equivalent resources including two data scientists for Bayesian and bandit algorithm implementation, two Salesforce developers for simulation and collaboration features, one BI developer for analytics enhancements, one business analyst for testing and documentation, one project manager, and part-time change management support for methodology training. External consultants may provide specialized expertise for advanced statistical methods and optimization algorithm tuning.

---

## 8.4 PHASE 4: ADVANCED ANALYTICS (MONTHS 13-18, 6 MONTH DURATION)

### Phase Objectives

Phase 4 deploys sophisticated marketing mix modeling and budget optimization capabilities enabling strategic resource allocation based on marginal returns analysis rather than historical precedent or political negotiation. This phase implements Bayesian hierarchical marketing mix models quantifying incremental channel impact while controlling for seasonality and competitive dynamics, scenario simulation engines enabling risk-free exploration of alternative strategies, constrained optimization solvers generating mathematically optimal budget allocations, and comprehensive model governance ensuring quality and stakeholder trust. These capabilities transform annual planning from intuition-driven to evidence-driven decision making generating substantial return on investment improvements through superior resource allocation.

### Phase Scope and Requirements

Phase 4 implements seventeen Priority Two requirements focused on strategic analytics and optimization infrastructure.

**Swimlane F: Measure & Learn (17 requirements)**

Marketing mix modeling deploys data preparation pipeline aggregating weekly or monthly spending, outcomes, and external factors with quality validation. Bayesian hierarchical model implements flexible functional forms capturing diminishing returns, cross-channel interactions, and geographic variation. Prior distributions incorporate external knowledge improving estimation in data-sparse situations. Scenario simulation engine enables interactive exploration of alternative budget allocations forecasting expected outcomes with uncertainty quantification. Constrained optimization solver identifies budget allocations maximizing defined objectives subject to minimum spend requirements, maximum spend restrictions, and strategic mandates. Model validation employs out-of-sample testing, cross-validation, and backtesting ensuring reliability. Model governance implements approval workflows, documentation standards, and periodic updates. Marketing mix reporting dashboard visualizes channel ROI curves, optimization recommendations, and historical performance.

### Key Deliverables and Milestones

**Months 13-15: Data Infrastructure and Model Development**

Data preparation pipeline aggregates historical marketing spending from financial systems, business outcomes from prescription monitoring and CRM, and external factors from competitive intelligence and market research. Data quality validation ensures completeness and consistency. Bayesian hierarchical model develops for priority therapeutic areas incorporating adstock transformations, saturation curves, and interaction terms. Prior distributions encode existing knowledge from literature and expert judgment. Model estimation uses Hamiltonian Monte Carlo sampling with convergence diagnostics confirming reliable inference.

**Months 16-17: Optimization and Scenario Planning**

Scenario simulation engine deploys enabling interactive strategy exploration. Organizations test alternative budget allocations examining predicted outcomes before implementation. Constrained optimization solver integrates with marketing mix models generating recommendations respecting business constraints. Sensitivity analysis identifies most binding constraints limiting performance. Executive stakeholders review recommendations through what-if scenario analysis building intuition about response surfaces and marginal returns patterns.

**Month 18: Governance and Production Deployment**

Model governance framework establishes validation protocols, approval workflows, and update procedures. Documentation captures complete specifications enabling reproducibility. Model monitoring tracks prediction accuracy over time triggering refreshes when performance degrades. Organizations complete first annual planning cycle using marketing mix modeling insights informing resource allocation decisions. Post-implementation assessment compares actual outcomes against model predictions validating forecasting accuracy.

### Success Criteria

Phase 4 achieves success when marketing mix models achieve forecast accuracy within 15% mean absolute percentage error on out-of-sample validation, scenario simulation enables testing of minimum ten alternative strategies per planning cycle, optimization recommendations show potential for fifteen to 25% return on investment improvement versus baseline allocations, model governance achieves 100% documentation compliance, and executive stakeholders rate marketing mix modeling usefulness above 8 out of 10 for strategic planning.

### Estimated Effort and Resources

Phase 4 requires approximately eight to ten full-time equivalent resources including three data scientists for marketing mix model development and optimization, two data engineers for data pipeline and infrastructure, one business intelligence developer for visualization and reporting, two business analysts for requirements and stakeholder engagement, one project manager, and executive sponsor providing strategic guidance and change leadership. External consultants may provide specialized marketing mix modeling expertise, Bayesian statistical methodology, and optimization algorithm implementation. Organizations may alternatively partner with specialized marketing mix modeling vendors such as Analytic Partners, Nielsen, or Neustar providing software platforms and analytical services.

---

## 8.5 PHASE 5: PORTFOLIO INTELLIGENCE (MONTHS 19-24, 6 MONTH DURATION)

### Phase Objectives

Phase 5 completes solution deployment with portfolio analytics and cross-brand intelligence enabling enterprise-level optimization and systematic knowledge sharing. This phase implements hierarchical portfolio data model supporting fair comparison across brands of different sizes and lifecycle stages, normalized metrics enabling efficiency assessment rather than misleading absolute comparisons, phase-appropriate benchmarking recognizing that performance expectations should vary based on brand maturity, journey pattern library codifying proven engagement sequences for replication, competitive intelligence aggregation providing category-level insights, portfolio-level budget optimization recommending resource allocation across brands, and executive dashboard delivering strategic visibility. These capabilities transform pharmaceutical marketing from collection of independent brand operations to integrated portfolio generating enterprise value through knowledge sharing and strategic resource allocation.

### Phase Scope and Requirements

Phase 5 implements forty-three Priority Two requirements focused on portfolio management and enterprise intelligence.

**Swimlane D: Orchestrate (3 requirements)**

Journey pattern library deploys with identification and curation workflow surfacing high-performing journeys, search and discovery capabilities enabling pattern finding through keyword search and faceted navigation with recommendation engine suggesting relevant patterns, and adaptation support providing one-click cloning with parameter prompting, pre-flight validation, and implementation feedback connecting results back to patterns.

**Swimlane F: Measure & Learn (40 requirements)**

Portfolio analytics deploy hierarchical data model aggregating performance across brand, therapeutic area, geography, and lifecycle phase dimensions. Normalized metrics calculate efficiency measures such as cost per target reached and market share gain per investment dollar enabling fair comparison across contexts. Phase-appropriate benchmarking compares brands against relevant cohorts controlling for lifecycle stage and therapeutic category. Competitive intelligence integration aggregates digital advertising monitoring, share of voice measurement, and message analysis providing category-level insights. Portfolio optimization framework accepts marginal return curves from marketing mix models generating budget allocation recommendations maximizing enterprise objectives. Executive portfolio dashboard displays strategic performance overview with drill-down to brand detail, competitive positioning context, market dynamics trends, and capability maturity assessment.

### Key Deliverables and Milestones

**Months 19-20: Portfolio Data Foundation**

Hierarchical portfolio data model deploys with dimensional structure supporting flexible aggregation and disaggregation. Historical performance data loads from brand-level systems with quality validation. Normalized metrics calculate enabling fair cross-brand comparison. Phase classification categorizes brands into pre-launch, launch, growth, and mature stages with phase-specific benchmarks. Competitive intelligence integration begins consuming external data feeds from advertising monitoring and market research vendors.

**Months 21-22: Pattern Library and Optimization**

Journey pattern library deploys with initial patterns curated from high-performing journeys identified through performance analysis. Search and discovery interface enables pattern browsing with recommendation engine suggesting relevant templates. Implementation support provides adaptation guidance and tracks pattern usage. Portfolio optimization framework integrates marketing mix models from multiple brands generating enterprise-level allocation recommendations. Scenario comparison evaluates alternative therapeutic area investment strategies.

**Months 23-24: Executive Intelligence and Rollout**

Executive portfolio dashboard deploys providing strategic visibility with monthly refresh and real-time drill-down. Competitive positioning analysis reveals portfolio share of voice and message differentiation relative to category benchmarks. Organizations complete first portfolio planning cycle using cross-brand analytics and optimization recommendations informing strategic resource allocation. Knowledge sharing processes establish using pattern library with contributor recognition encouraging ongoing population. Portfolio governance defines update procedures, quality standards, and access controls.

### Success Criteria

Phase 5 achieves success when portfolio data model covers 90% of marketing spend within six months, normalized metrics enable executive confidence in fair cross-brand assessment, pattern library contains minimum twenty proven patterns with 60% of new journeys starting from templates within one year, competitive intelligence captures 80% of major competitors within therapeutic areas, portfolio optimization recommendations show potential for 20-30% aggregate return on investment improvement, and executive dashboard usage reaches 70% of marketing leadership accessing monthly.

### Estimated Effort and Resources

Phase 5 requires approximately six to eight full-time equivalent resources including two data engineers for portfolio data model and competitive intelligence integration, one data scientist for portfolio optimization, two BI developers for dashboard and visualization, one knowledge management specialist for pattern library curation, one business analyst, one project manager, and executive sponsor providing strategic leadership. External consultants may provide competitive intelligence vendor integration, portfolio optimization methodology, and executive dashboard design expertise.

---

## 8.6 CRITICAL SUCCESS FACTORS AND RISK MITIGATION

### Executive Sponsorship and Governance

Program success requires active executive sponsorship from chief marketing officer or senior vice president marketing providing strategic direction, resource commitment, and organizational change leadership. An Executive steering committee meeting monthly shall review progress, resolve cross-functional conflicts, and make strategic decisions about scope, timeline, and resource tradeoffs. Program governance establishes decision authority clarifying which decisions require executive approval versus program management discretion preventing delays from unnecessary escalation while ensuring strategic alignment.

### Dedicated Implementation Team

Organizations must commit dedicated full-time resources rather than relying on existing staff adding implementation to current responsibilities. Part-time team members create schedule conflicts, divided attention, and extended timelines. The core team requires Salesforce administrators, data engineers, integration specialists, BI developers, business analysts, project managers, and change management specialists with pharmaceutical marketing domain knowledge. External consultants supplement the internal team providing specialized expertise for specific capabilities such as Lightning Web Component development, Bayesian modeling, or marketing mix analytics.

### Change Management and Adoption

Technology implementation succeeds only when users adopt new systems and workflows replacing legacy approaches. Comprehensive change management program shall include executive communication articulating strategic vision and expected benefits, stakeholder engagement involving representative users in requirements definition and testing, training programs teaching system functionality and new processes through classroom instruction, hands-on labs, and reference materials, adoption support providing help desk, super users, and ongoing coaching during transition period, and feedback mechanisms capturing user input informing refinements and addressing concerns. Success metrics shall track system usage, workflow compliance, and user satisfaction measuring adoption progress.

### Data Quality and Migration

Poor data quality undermines all capabilities as targeting, personalization, measurement, and analytics depend on accurate customer information. Data quality program shall assess current state identifying completeness, accuracy, and consistency issues, define target state specifying required attributes and quality standards, develop remediation plan addressing systematic issues through source system improvements or data cleansing processes, and implement ongoing monitoring sustaining quality through validation rules and stewardship workflows. Data migration from legacy systems requires careful planning with mapping specifications, transformation logic, test migrations validating accuracy, and cutover procedures minimizing disruption.

### Integration Complexity and Dependencies

Marketing technology ecosystems involve numerous integration points connecting CRM, marketing automation, content management, analytics platforms, agency systems, and data vendors. Integration complexity creates schedule risk and reliability challenges. Integration architecture shall define standards, patterns, and governance reducing complexity. API-first approach establishes consistent connectivity patterns. Integration testing validates end-to-end data flows before production deployment. Phased rollout introduces integrations incrementally enabling troubleshooting before adding additional complexity.

### Regulatory Compliance and Validation

Pharmaceutical marketing technology must support regulatory compliance including audit trails, version control, MLR workflows, and claim substantiation. System validation following FDA software validation guidance demonstrates that system performs intended functions reliably. Validation activities include requirements traceability confirming system implements specified requirements, design review verifying architecture supports intended use, testing demonstrating functionality works correctly, and documentation providing evidence for regulatory inspection. Organizations must balance validation rigor with implementation velocity avoiding excessive documentation burden while maintaining defensible compliance posture.

---

## 8.7 IMPLEMENTATION TIMELINE SUMMARY

The following table summarizes the five-phase implementation roadmap with durations, resource estimates, and key deliverables:

| Phase | Duration | Months | FTE Resources | Key Deliverables | Requirements |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Phase 1: Foundation | 3 months | 1-3 | 8-12 | Salesforce deployment, ClaimID registry, MLR workflow, email platform, campaign dashboards, cloud data warehouse | 106 P0 |
| Phase 2: Strategic Capabilities | 6 months | 4-9 | 10-14 | Journey canvas, propensity models, attribution framework, fatigue management, A/B testing | 111 P1 |
| Phase 3: Optimization | 3 months | 10-12 | 6-8 | Bayesian optimization, multi-armed bandits, journey simulation, collaboration enhancements | 43 P1/P2 |
| Phase 4: Advanced Analytics | 6 months | 13-18 | 8-10 | Marketing mix modeling, scenario simulation, budget optimization, model governance | 17 P2 |
| Phase 5: Portfolio Intelligence | 6 months | 19-24 | 6-8 | Portfolio data model, pattern library, competitive intelligence, executive dashboard | 43 P2 |
| **Total Program** | **18-24 months** | **1-24** | **Peak: 14 FTE** | **Complete solution with 335 requirements** | **335 Total** |

---

## SECTION 8 SUMMARY

This comprehensive implementation roadmap organizes three hundred thirty-five requirements into five execution phases spanning eighteen to twenty-four months with clear objectives, deliverables, success criteria, and resource estimates for each phase. The phased approach balances early value delivery through foundation capabilities with systematic capability building where later phases depend on infrastructure established earlier. Priority-driven scope allocation places highest business value and foundational requirements in early phases while deferring advanced optimization and portfolio intelligence until core operations stabilize.

Organizations following this roadmap can expect to achieve operational marketing execution within three months through Phase 1 foundation, strategic journey orchestration and attribution within nine months through Phase 2, enhanced optimization within twelve months through Phase 3, advanced analytics supporting annual planning within eighteen months through Phase 4, and complete portfolio intelligence within twenty-four months through Phase 5\. This progressive deployment enables organizations to realize return on investment incrementally rather than waiting until complete implementation while managing change effectively through measured introduction of new capabilities.

---

# VIEW 1: REQUIREMENTS BY SWIMLANE

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## DOCUMENT PURPOSE

This view organizes all three hundred thirty-five requirements by operational swimlane providing functional area perspective essential for operational planning, resource allocation, and capability assessment. Each swimlane represents a distinct operational function within pharmaceutical marketing operations with specific capabilities, systems, and stakeholder groups. This organization enables swimlane leaders to understand complete scope of requirements within their domain, assess current capability maturity, plan resource investments, and coordinate with adjacent swimlanes requiring integration or collaboration.

The six operational swimlanes form continuous marketing operations loop where governance establishes standards and controls, segmentation identifies target audiences, content creation develops compliant materials, orchestration designs multi-step engagement sequences, execution delivers messages across channels, and measurement quantifies performance enabling optimization. Requirements within each swimlane build progressively from foundation capabilities enabling basic operations through strategic enhancements supporting sophisticated marketing approaches to advanced analytics enabling portfolio-level optimization. Organizations can use this view to assess swimlane-specific implementation readiness, identify capability gaps requiring attention, and develop swimlane-focused training and adoption programs.

---

## SWIMLANE A: GOVERN (62 REQUIREMENTS)

### Swimlane Overview

Swimlane A establishes and enforces enterprise standards for data quality, identity management, content metadata, campaign taxonomy, consent preferences, claim management, and regulatory compliance. Governance capabilities prove foundational as all subsequent swimlanes depend critically on clean customer data, consistent taxonomy, proper consent management, and substantiated claims. Organizations with weak governance experience data quality degradation over time, taxonomy chaos undermining reporting, consent violations risking regulatory penalties, and compliance failures from inadequate claim management.

### Foundation Requirements (Phase 1 \- 28 Requirements)

**Customer Master Data Management**

- REQ-001: Claravine as validation gateway enforcing campaign taxonomy before execution  
- REQ-002: API-enforced validation preventing campaign activation without Claravine approval  
- REQ-003: Real-time validation rules checking nomenclature compliance and required field completion  
- REQ-004: Automated rollback mechanism reverting campaigns bypassing governance checkpoints  
- REQ-005: Salesforce Sales Cloud as master data management system for customer entities  
- REQ-006: Data Cloud identity resolution using deterministic and probabilistic matching  
- REQ-007: Real-time bi-directional synchronization between Salesforce and execution systems  
- REQ-008: Golden record creation with survivorship rules and conflict resolution  
- REQ-009: Change data capture streaming customer updates to downstream systems

**ClaimID Framework**

- REQ-010: ClaimID data model with mandatory evidence links, indication, approval date, and expiry  
- REQ-035: Claim substantiation vault storing clinical evidence and regulatory documentation  
- REQ-298: ClaimID data model and schema with unique identifiers and comprehensive metadata  
- REQ-299: Claim substantiation evidence management with quality assessment and version control  
- REQ-300: Claim-to-indication mapping and off-label detection with risk scoring

**Campaign Taxonomy and Metadata**

- REQ-050: Standardized naming convention covering brand, therapeutic area, campaign type, audience  
- REQ-051: Campaign hierarchy supporting brand campaigns and tactical executions with roll-up  
- REQ-052: UTM parameter standards with validation rules for source, medium, campaign  
- REQ-053: Content metadata schema including type, format, channel, claims, approval status

**Consent and Preference Management**

- REQ-056: Preference center allowing customers to specify channels, frequency, and content types  
- REQ-057: Opt-in and opt-out workflow capturing consent with timestamp, source, and IP address  
- REQ-058: Channel-specific consent tracking recognizing email opt-in distinct from SMS consent  
- REQ-060: Consent propagation service distributing updates to all execution systems within 15 minutes  
- REQ-061: Consent enforcement API preventing message delivery to opted-out customers

**Audit and Version Control**

- REQ-031: Version control system tracking changes to campaigns, journeys, segments, and content  
- REQ-032: Immutable audit log stored in append-only storage with cryptographic hash chains  
- REQ-033: Approval record repository linking campaigns to MLR decisions with reviewer identity  
- REQ-034: Content usage tracking showing which customers received which messages

### Strategic Enhancements (Phase 2 \- 24 Requirements)

**Advanced Identity Resolution**

- REQ-044: Deterministic matching using email address, NPI, phone, and custom IDs with 100% precision  
- REQ-045: Probabilistic matching using name, address, employer, specialty with configurable confidence thresholds  
- REQ-046: Device graph linking desktop, mobile, and tablet sessions to customer records  
- REQ-047: Cross-domain tracking using first-party cookie and authenticated sessions  
- REQ-048: Anonymous-to-known identity resolution when customers authenticate or submit forms  
- REQ-049: Household and organizational clustering grouping related individuals

**Enhanced Consent Management**

- REQ-059: Purpose-based consent supporting promotional, educational, patient support, and research as distinct categories  
- REQ-062: Consent reporting dashboard showing opt-in rates, opt-out reasons, and preference drift

**Content Governance**

- REQ-054: Creative versioning system tracking A/B test variants and personalization rules  
- REQ-055: Placement taxonomy for paid media covering publisher, ad format, and targeting

**Audit and Compliance Enhancement**

- REQ-036: Regulatory report generator producing audit packages on demand with campaign history  
- REQ-037: Legal hold capability freezing records related to litigation with chain-of-custody tracking  
- REQ-038: Audit dashboard showing inspection readiness score based on documentation completeness

**Data Quality**

- REQ-039: Person Account model supporting both B2B and B2C personas with unified schema  
- REQ-040: Hierarchical account relationships linking HCPs to hospitals, clinics, and pharmacy chains  
- REQ-041: Custom fields capturing pharmaceutical-specific attributes including NPI and DEA licenses  
- REQ-042: Data quality rules enforcing completeness, accuracy, and timeliness with automated scoring  
- REQ-043: Duplicate detection and merge workflows with survivorship rules

**Claim Lifecycle Management**

- REQ-301: Claim lifecycle management with renewal workflow and retirement procedures  
- REQ-302: Claim usage tracking showing content assets and campaigns referencing specific claims

### Advanced Capabilities (Phase 3-5 \- 10 Requirements)

**Data Infrastructure**

- REQ-332: Master data management with golden record creation and match-merge algorithms

**Security and Compliance**

- REQ-333: Security controls and compliance framework with encryption, access management, and audit logging

**Model Governance**

- REQ-083: Model registry maintaining metadata for all predictive models  
- REQ-084: Model monitoring and retraining workflows detecting performance degradation  
- REQ-085: Model explainability features providing interpretation of predictions  
- REQ-258: Attribution model governance ensuring methodology transparency and stakeholder alignment  
- REQ-318: Marketing mix model governance with validation protocols and approval workflows

**Portfolio Governance**

- REQ-319: Hierarchical portfolio data model with dimensional analysis for aggregation

### Swimlane A Summary

Swimlane A Govern comprises sixty-two requirements establishing foundational governance infrastructure and compliance controls. Twenty-eight Priority Zero requirements deploy in Phase 1 creating essential data quality, taxonomy, consent, and claim management capabilities. Twenty-four Priority One requirements enhance governance in Phase 2 with advanced identity resolution, purpose-based consent, and regulatory reporting. Ten Priority Two requirements complete governance in later phases with master data management, security frameworks, and model governance. Organizations must prioritize Swimlane A requirements as foundation for all subsequent capabilities.

---

## SWIMLANE B: SEGMENT (30 REQUIREMENTS)

### Swimlane Overview

Swimlane B builds, maintains, and activates customer segments based on demographic attributes, behavioral signals, clinical characteristics, engagement history, and predictive scores enabling personalized marketing across all channels and customer lifecycles. Sophisticated segmentation transforms mass marketing into precision targeting where messages reach receptive audiences with relevant content at optimal times. Organizations with mature segmentation capabilities achieve conversion rates 3-5 times higher than unsegmented approaches while reducing customer acquisition costs 40-60% through focusing investment on high-propensity audiences.

### Foundation Requirements (Phase 1 \- 12 Requirements)

**Demographic and Firmographic Segmentation**

- REQ-063: Demographic segmentation supporting age, gender, geography, language, income, and education  
- REQ-064: Healthcare provider segmentation with specialty, practice setting, prescribing volume, and formulary influence  
- REQ-065: Institutional account segmentation covering hospital system size, teaching status, and therapeutic focus  
- REQ-067: Geographic segmentation at country, region, state, metropolitan area, ZIP code, and territory levels  
- REQ-068: Segment definition interface allowing business users to build segments using intuitive filters

**Behavioral Tracking Foundation**

- REQ-069: Web and mobile engagement scoring incorporating page views, time on site, content downloads, and video views  
- REQ-070: Email engagement segmentation tracking open rates, click rates, forward activity, and unsubscribe events  
- REQ-024: Standardized event schema defining required and optional metadata fields for all touchpoint types  
- REQ-025: Event collection SDK and APIs deployed across web, mobile, email, paid media, and CRM  
- REQ-026: UTM parameter generation integrated into Claravine workflow with automated appending  
- REQ-027: Server-side event enrichment appending customer attributes, journey context, and session data  
- REQ-028: Event validation service checking for missing metadata and alerting on schema violations

### Strategic Capabilities (Phase 2 \- 12 Requirements)

**Advanced Behavioral Segmentation**

- REQ-071: Event participation tracking covering conference attendance, webinar registration, and CME completion  
- REQ-072: Sales interaction history including field representative visits and prescribing behavior changes  
- REQ-073: Patient support program engagement tracking enrollment, adherence, and nurse educator touchpoints  
- REQ-074: Content consumption patterns analyzing therapeutic areas, formats, and claim resonance  
- REQ-075: Multi-channel engagement scoring combining digital, field, event, and patient program touchpoints  
- REQ-066: Payer and pharmacy segmentation distinguishing commercial insurance, Medicare, Medicaid, and PBMs

**Propensity Modeling and Predictive Segmentation**

- REQ-077: Propensity-to-prescribe models predicting likelihood of HCP initiating therapy  
- REQ-078: Patient adherence prediction models identifying individuals at risk of discontinuation  
- REQ-083: Model registry maintaining metadata for all predictive models (shared with Swimlane A)  
- REQ-084: Model monitoring and retraining workflows (shared with Swimlane A)  
- REQ-085: Model explainability features (shared with Swimlane A)

**Real-Time Segmentation**

- REQ-086: Real-time segment evaluation engine processing behavioral signals and updating membership within minutes

### Advanced Capabilities (Phase 3-5 \- 6 Requirements)

**Advanced Predictive Analytics**

- REQ-076: Engagement velocity metrics detecting acceleration or deceleration in activity patterns  
- REQ-079: Next-best-action recommendation engine suggesting optimal message, offer, channel, and timing  
- REQ-080: Churn prediction models detecting early warning signals of disengagement  
- REQ-081: Lifetime value modeling estimating total expected revenue contribution  
- REQ-082: Lookalike audience generation identifying prospective customers sharing characteristics with high-value customers

**Dynamic Audience Management**

- REQ-087: Event-driven segment entry and exit rules responding to specific actions  
- REQ-088: Streaming data integration consuming events from web, mobile, email, CRM in real-time  
- REQ-089: Dynamic audience synchronization pushing segment changes to execution platforms  
- REQ-090: Segment membership history tracking when customers enter and exit segments  
- REQ-091: Overlap analysis identifying customers belonging to multiple segments  
- REQ-092: Segment performance analytics comparing conversion rates, engagement metrics, and ROI

### Swimlane B Summary

Swimlane B Segment comprises thirty requirements enabling sophisticated audience targeting from basic demographic segmentation through behavioral analysis to advanced predictive modeling. Twelve Priority Zero requirements deploy in Phase 1 establishing demographic segmentation, behavioral tracking foundation, and segment builder interface. Twelve Priority One requirements enhance segmentation in Phase 2 with propensity models, real-time evaluation, and advanced behavioral analysis. Six Priority Two requirements complete segmentation in Phase 3 with next-best-action engines, churn prediction, and dynamic audience management. Segmentation capabilities prove essential for all marketing activities as targeting accuracy determines campaign effectiveness and return on investment.

---

## SWIMLANE C: CREATE (40 REQUIREMENTS)

### Swimlane Overview

Swimlane C develops, approves, versions, and distributes marketing content and creative assets across all channels ensuring regulatory compliance, claim substantiation, brand consistency, and measurement readiness throughout content lifecycle. Content creation in pharmaceutical marketing faces distinctive challenges including strict regulatory review requirements, claim substantiation documentation, MLR approval complexity, content expiry management, and audit trail maintenance. Organizations with mature content management capabilities achieve sixty to 75% reduction in compliance violations, 40-50% acceleration in MLR cycle time, and 30-40% improvement in claim substantiation completeness.

### Foundation Requirements (Phase 1 \- 21 Requirements)

**Content Planning and Brief Management**

- REQ-093: Campaign brief template capturing objectives, audience, key messages, claims, channels, budget, and timeline  
- REQ-094: Content request workflow routing briefs to appropriate creative teams based on content type and therapeutic area  
- REQ-095: Brief approval process requiring brand lead, medical affairs, and legal preliminary review  
- REQ-096: Claim selection interface allowing brief creators to choose from approved ClaimID registry

**Content-to-Claim Mapping**

- REQ-107: Content registration workflow requiring creators to declare all ClaimIDs referenced in assets  
- REQ-109: Evidence linking interface connecting each ClaimID to supporting clinical data and documentation  
- REQ-111: Indication alignment verification confirming claims match approved indications

**MLR Approval Workflow**

- REQ-115: Multi-stage MLR workflow orchestrating parallel medical, legal, and regulatory review  
- REQ-116: Role-based access control ensuring reviewers see only content relevant to their function  
- REQ-117: Review task management providing reviewers with dashboard of pending assignments  
- REQ-119: Change request workflow routing revisions back to creative teams with context preservation  
- REQ-120: Approval status tracking showing real-time progress through review stages  
- REQ-303: Multi-stage workflow orchestration engine supporting serial, parallel, and conditional review  
- REQ-304: Role-based review task management organizing assignments by urgency and workload balancing  
- REQ-305: Structured comment and feedback framework enabling clear, actionable, and trackable comments

**Content Versioning and Expiry Management**

- REQ-104: Version control automatically preserving every iteration with restore capability  
- REQ-124: Immutable version archiving preserving every iteration with metadata  
- REQ-125: Major and minor versioning scheme distinguishing substantive changes from corrections  
- REQ-126: Approved version locking preventing editing without initiating new version and review cycle  
- REQ-127: Content distribution workflow pushing approved assets to execution platforms and agencies  
- REQ-128: Expiry date enforcement automatically retiring content when linked ClaimIDs approach expiration  
- REQ-129: Expiry warning notifications alerting content owners 30 days, seven days, and one day before expiration  
- REQ-130: Auto-pause mechanism preventing expired content from appearing in active campaigns

### Strategic Enhancements (Phase 2 \- 15 Requirements)

**Content Creation and Collaboration**

- REQ-097: Reference material attachment capability linking briefs to clinical data and brand guidelines  
- REQ-098: Brief status tracking dashboard showing all active briefs with automated escalation  
- REQ-099: Integrated creative workspace supporting in-platform editing, commenting, and markup  
- REQ-100: Template library providing brand-compliant starting points for common content types  
- REQ-101: Component library storing reusable content blocks and approved disclaimers  
- REQ-102: Real-time collaboration enabling simultaneous editing by creative teams and reviewers  
- REQ-103: Inline commenting and markup tools allowing reviewers to annotate specific text and images

**Enhanced Content-to-Claim Mapping**

- REQ-110: Fair balance validation checking that risk information receives prominence proportional to efficacy claims  
- REQ-112: Reference list generation automatically compiling bibliography of supporting evidence  
- REQ-113: Claim usage tracking showing which content assets reference which claims

**MLR Workflow Enhancement**

- REQ-118: Structured comment taxonomy categorizing feedback as major change, minor revision, question, or approval  
- REQ-121: Conditional approval capability allowing reviewers to approve contingent on specific changes  
- REQ-122: Escalation rules automatically routing overdue reviews to management  
- REQ-123: Review metrics dashboard reporting average review times, approval rates, and rejection reasons

**Content Audit and Analytics**

- REQ-131: Content usage analytics tracking impressions, engagement metrics, and performance by version  
- REQ-132: Content audit trail maintaining complete history for regulatory inspection readiness

### Advanced Capabilities (Phase 3 \- 4 Requirements)

**Enhanced Content Analysis**

- REQ-105: Asset preview and proofing across devices showing rendering on desktop, mobile, and tablet  
- REQ-106: Reference citation management ensuring every claim links to supporting evidence  
- REQ-108: Automated claim detection analyzing content text to identify potential claims  
- REQ-114: Visual claim mapping interface displaying relationships between content, claims, evidence, and products

**Version Comparison and Documentation**

- REQ-306: Version comparison and change highlighting enabling reviewers to focus on modifications  
- REQ-307: Approval documentation and audit trail generating comprehensive approval records  
- REQ-308: MLR performance analytics and continuous improvement tracking cycle times and bottlenecks

### Swimlane C Summary

Swimlane C Create comprises forty requirements establishing comprehensive content management and MLR approval capabilities. Twenty-one Priority Zero requirements deploy in Phase 1 creating content planning workflows, content-to-claim mapping, MLR approval orchestration, and expiry management. Fifteen Priority One requirements enhance content management in Phase 2 with collaborative workspaces, template libraries, enhanced claim validation, and performance analytics. Four Priority Two requirements complete content management in Phase 3 with automated claim detection, version comparison, and MLR performance analytics. Content management proves critical for pharmaceutical marketing as regulatory compliance depends on proper claim substantiation and approval workflows.

---

## SWIMLANE D: ORCHESTRATE (41 REQUIREMENTS)

### Swimlane Overview

Swimlane D designs, configures, executes, and optimizes multi-step customer journeys across channels coordinating message delivery, channel selection, timing optimization, fatigue management, experimentation, and compliance enforcement throughout customer lifecycle. Journey orchestration transforms disconnected campaigns into cohesive customer experiences where each touchpoint builds upon previous interactions progressing customers through awareness, consideration, conversion, and retention stages. Organizations with mature orchestration capabilities achieve conversion rates 40-60% higher than single-touch campaigns while reducing total marketing touchpoints 30% through intelligent sequencing and fatigue management.

### Foundation Requirements (Phase 1 \- 6 Requirements)

**Basic Multi-Channel Orchestration**

- REQ-141: Multi-channel message routing delivering content via email, SMS, push notifications, in-app messages, and direct mail  
- REQ-142: Channel preference honoring allowing customers to specify preferred communication channels  
- REQ-145: Frequency capping limiting total messages per customer per day, week, and month  
- REQ-148: Delivery status tracking monitoring message processing, delivery confirmation, and engagement events

**Journey Foundation (from Section 2\)**

- REQ-133: Lightning Web Component journey canvas providing drag-and-drop interface (deployed Phase 2\)  
- REQ-134: Node library supporting message delivery, wait steps, decision splits, A/B tests, and MLR gates (deployed Phase 2\)

### Strategic Capabilities (Phase 2 \- 20 Requirements)

**Journey Authoring Canvas**

- REQ-280: Lightning Web Component architecture deployed within Salesforce with responsive design  
- REQ-281: Drag-and-drop node library with comprehensive node types for sophisticated orchestration  
- REQ-282: Visual flow designer with intelligent layout and real-time validation  
- REQ-283: Journey template library and pattern catalog with proven patterns for common use cases  
- REQ-284: Journey versioning and change management maintaining complete configuration history  
- REQ-135: Journey versioning maintaining complete history of journey configurations  
- REQ-136: Template library providing proven journey patterns for common use cases  
- REQ-137: Visual flow validation detecting configuration errors before activation  
- REQ-139: Journey documentation generator automatically creating specifications for MLR review

**Intelligent Message Delivery**

- REQ-143: Channel fallback logic attempting secondary channels when primary channels fail  
- REQ-144: Send-time optimization analyzing individual engagement patterns for optimal delivery times  
- REQ-146: Message prioritization ranking journeys by business importance with quota allocation  
- REQ-147: Real-time personalization inserting dynamic content based on customer attributes and behavior

**Central Fatigue Management Service**

- REQ-149: Central fatigue registry tracking all message deliveries across campaigns, journeys, and channels  
- REQ-150: Real-time fatigue scoring calculating current message pressure for each customer  
- REQ-151: Fatigue threshold configuration defining maximum acceptable message volumes by segment  
- REQ-152: Pre-send fatigue check API validating proposed deliveries against fatigue rules  
- REQ-153: Journey-level fatigue gates inserting wait steps or skipping sends when thresholds approached  
- REQ-156: Cross-system integration consuming delivery events from all execution platforms

**Experimentation Framework**

- REQ-157: A/B/n testing framework supporting randomized control trials comparing message variants  
- REQ-159: Holdout group management reserving control populations for incrementality measurement  
- REQ-160: Statistical analysis library calculating significance, confidence intervals, and required sample sizes  
- REQ-161: Experiment registry maintaining metadata for all tests with hypothesis, variants, and results

### Optimization Enhancements (Phase 3 \- 15 Requirements)

**Advanced Journey Capabilities**

- REQ-285: Collaborative journey development workflow supporting multi-user coordination  
- REQ-286: Journey simulation and testing capability enabling pre-deployment validation  
- REQ-287: Journey documentation generator producing comprehensive specifications

**Advanced Experimentation**

- REQ-158: Multi-armed bandit algorithms dynamically allocating traffic toward winning variants  
- REQ-162: Automated winner selection monitoring test results and declaring winners  
- REQ-164: Bayesian optimization for accelerated learning using prior knowledge  
- REQ-165: Personalization testing evaluating tailored experiences against generic content  
- REQ-288: A/B/n testing framework with statistical rigor including power calculation  
- REQ-289: Multi-armed bandit algorithms for adaptive optimization  
- REQ-290: Holdout group management for incrementality measurement  
- REQ-291: Bayesian optimization for accelerated learning  
- REQ-292: Experiment registry and knowledge management

**Enhanced Fatigue Management**

- REQ-154: Fatigue override workflow allowing exceptions for time-sensitive communications  
- REQ-155: Fatigue impact analysis reporting correlations between message frequency and outcomes  
- REQ-293: Central fatigue registry architecture aggregating touchpoints across all platforms  
- REQ-294: Real-time fatigue scoring algorithm incorporating volume, recency, channel diversity  
- REQ-295: Pre-send fatigue validation API providing approval or rejection decisions  
- REQ-296: Fatigue threshold configuration and segment customization with graduated enforcement  
- REQ-297: Fatigue impact analysis and reporting quantifying volume effects on outcomes

**Journey Performance**

- REQ-166: Real-time journey analytics dashboard showing enrollment, progression, completion, fallout  
- REQ-167: Node-level performance tracking measuring entry, exit, conversion rates for each step  
- REQ-168: Cohort analysis comparing performance across customer segments and entry dates  
- REQ-169: Journey health monitoring detecting anomalies including stalled journeys  
- REQ-171: Multi-touch journey attribution allocating conversion credit across journey steps  
- REQ-172: Journey ROI calculation combining costs against attributed revenue

### Portfolio Capabilities (Phase 5 \- 3 Requirements)

**Journey Pattern Library**

- REQ-322: Journey pattern identification and curation workflow surfacing high-performing journeys  
- REQ-323: Pattern library search, discovery, and recommendation with proactive suggestions  
- REQ-324: Pattern adaptation and implementation support with one-click cloning

### Advanced Analytics (Phase 3 \- 3 Requirements)

- REQ-170: Automated optimization recommendations suggesting changes based on historical data  
- REQ-173: Comparative benchmarking showing journey performance versus similar campaigns

### Swimlane D Summary

Swimlane D Orchestrate comprises forty-one requirements enabling sophisticated multi-step customer engagement from basic multi-channel delivery through visual journey design to advanced experimentation and fatigue management. Six Priority Zero requirements deploy in Phase 1 establishing basic multi-channel orchestration and frequency capping. Twenty Priority One requirements deploy journey canvas, fatigue management, and experimentation in Phase 2\. Fifteen requirements enhance orchestration in Phase 3 with Bayesian optimization, bandits, and simulation. Journey orchestration represents the strategic differentiator separating leading pharmaceutical marketing organizations from those executing disconnected campaigns.

---

## SWIMLANE E: EXECUTE (57 REQUIREMENTS)

### Swimlane Overview

Swimlane E delivers marketing messages and experiences across owned, earned, and paid channels including email, SMS, push notifications, web, mobile applications, field sales interactions, patient support programs, and third-party advertising platforms while ensuring brand consistency, regulatory compliance, and measurement completeness. Execution represents where marketing strategy meets customer experience as perfect planning becomes worthless if execution suffers from technical failures, compliance violations, or measurement gaps. Organizations with robust execution infrastructure achieve 30-40% of overall campaign effectiveness contribution through superior delivery reliability, appropriate targeting, and seamless customer experiences.

### Foundation Requirements (Phase 1 \- 20 Requirements)

**Email Marketing Execution**

- REQ-174: Enterprise email platform supporting transactional, promotional, triggered messages  
- REQ-175: Dynamic content assembly inserting personalized elements based on customer attributes  
- REQ-176: Responsive email templates automatically adapting layout for desktop, mobile, and tablet  
- REQ-178: List hygiene automation detecting invalid addresses and engagement decay  
- REQ-180: Unsubscribe management providing one-click opt-out with preference center access  
- REQ-181: Engagement tracking capturing opens, clicks, forwards, prints with device and location metadata

**Web Experience Management**

- REQ-192: Web content management system supporting promotional microsites and educational portals  
- REQ-200: Website analytics integration tracking page views, bounce rates, conversion events

**Paid Media Execution**

- REQ-219: Programmatic advertising platform executing display, video, native, and social media campaigns  
- REQ-220: Healthcare provider targeting using specialty, NPI, prescribing volume, and institutional affiliations  
- REQ-224: Frequency capping limiting advertisement impressions per individual per time period  
- REQ-226: Brand safety controls preventing advertisements from appearing alongside inappropriate content  
- REQ-228: Conversion tracking linking advertisement exposures to downstream actions  
- REQ-230: Performance reporting dashboard showing impressions, clicks, conversions, cost per action

**Patient Support Programs**

- REQ-210: Patient enrollment workflow capturing demographics, diagnosis, insurance, and consent  
- REQ-217: Adverse event detection monitoring patient communications for safety signals

**Field Sales Enablement**

- REQ-207: Consent verification displaying customer communication preferences and opt-out status  
- REQ-209: Sales activity synchronization pushing field interactions back to Salesforce

**Measurement Foundation**

- REQ-029: Event streaming pipeline delivering touchpoint data to warehouse with sub-two-hour latency  
- REQ-030: Cross-device and cross-platform identity stitching linking touchpoints to customer records

### Strategic Capabilities (Phase 2 \- 27 Requirements)

**Enhanced Email Capabilities**

- REQ-177: Send-time optimization analyzing individual engagement patterns for optimal delivery times  
- REQ-179: Spam filter testing validating message content and technical configuration  
- REQ-182: A/B testing capability comparing subject lines, content variants, and send times

**SMS and Mobile Messaging**

- REQ-183: SMS platform supporting promotional messages, reminders, and two-way conversational messaging  
- REQ-184: Mobile push notification capability delivering alerts and engagement prompts  
- REQ-187: Carrier compliance ensuring messages meet CTIA guidelines and TCPA requirements  
- REQ-188: Opt-in verification requiring explicit consent separate from email  
- REQ-189: Keyword management processing standard commands with automated responses  
- REQ-190: Delivery receipt tracking confirming message delivery to handsets  
- REQ-191: Character limit optimization maximizing content within SMS constraints

**Web Personalization**

- REQ-193: Personalization engine delivering dynamic content variations based on visitor identity and behavior  
- REQ-194: A/B testing framework comparing page layouts, content, and calls-to-action  
- REQ-195: Progressive profiling gradually collecting visitor information across sessions  
- REQ-196: Form optimization including smart validation and conditional logic  
- REQ-198: Gated content management requiring form completion before accessing premium content

**Field Sales Enhancement**

- REQ-201: Field representative dashboard displaying customer engagement history and digital activity  
- REQ-203: Call planning tools prioritizing accounts by propensity scores and business value  
- REQ-204: Sample management tracking sample provision with lot numbers and regulatory compliance  
- REQ-205: Closed-loop marketing feedback capturing representative observations  
- REQ-208: Content delivery enabling representatives to email approved materials from mobile devices

**Patient Support Programs**

- REQ-211: Copay assistance program administration calculating costs and processing claims  
- REQ-212: Medication adherence monitoring tracking prescription fills and therapy gaps  
- REQ-213: Nurse educator coordination scheduling phone and video appointments  
- REQ-214: Educational content delivery providing disease education and medication instructions  
- REQ-215: Outcome tracking measuring clinical endpoints and quality of life metrics  
- REQ-216: Provider coordination notifying prescribing physicians of patient status  
- REQ-218: Program analytics dashboard reporting enrollment, adherence, persistence, and outcomes

**Paid Media Enhancement**

- REQ-221: Patient audience targeting leveraging health conditions with privacy compliance  
- REQ-222: Contextual targeting placing advertisements adjacent to relevant content  
- REQ-225: Creative rotation testing multiple advertisement variations  
- REQ-227: Viewability optimization ensuring advertisements appear in visible screen area  
- REQ-229: Budget pacing algorithms distributing campaign spend evenly across flight duration

### Advanced Capabilities (Phase 3 \- 10 Requirements)

**Mobile and Web Enhancement**

- REQ-185: In-app messaging presenting contextual messages within mobile applications  
- REQ-186: Rich media messaging supporting images, videos, and interactive buttons  
- REQ-197: Content recommendations suggesting related articles, videos, and tools  
- REQ-199: Session recording and heatmap analysis capturing visitor interactions  
- REQ-223: Lookalike audience expansion identifying prospective customers

**Field Sales Advanced**

- REQ-202: Next-best-action recommendations suggesting optimal talking points and materials  
- REQ-206: Speaker program coordination matching qualified speakers with event opportunities

### Swimlane E Summary

Swimlane E Execute comprises fifty-seven requirements enabling comprehensive multi-channel marketing execution from basic email and web delivery through sophisticated personalization and field coordination to advanced patient programs. Twenty Priority Zero requirements deploy in Phase 1 establishing email, web, paid media, basic patient programs, and field sales coordination. Twenty-seven Priority One requirements enhance execution in Phase 2 with SMS, web personalization, enhanced field tools, and comprehensive patient programs. Ten Priority Two requirements complete execution in Phase 3 with in-app messaging, content recommendations, and advanced field capabilities. Execution excellence proves essential as campaign strategy only delivers value through reliable, compliant, and well-measured delivery to customers.

---

## SWIMLANE F: MEASURE & LEARN (88 REQUIREMENTS)

### Swimlane Overview

Swimlane F collects, aggregates, analyzes, and reports marketing performance data across all channels, campaigns, and customer touchpoints enabling data-driven decision-making, continuous optimization, budget allocation, and demonstration of marketing return on investment. Measurement transforms marketing from cost center to accountable investment by quantifying business impact and enabling continuous improvement. Organizations with mature measurement capabilities achieve twenty-five to 40% higher marketing return on investment through better budget allocation, identify winning strategies for replication, and prove marketing contribution to business outcomes supporting budget increases and strategic influence.

### Foundation Requirements (Phase 1 \- 19 Requirements)

**Event Collection and Data Pipeline**

- REQ-231: Universal event schema standardizing touchpoint data structure across all channels  
- REQ-232: Client-side tracking libraries deployed on websites and mobile applications  
- REQ-233: Server-side event collection APIs receiving events from Marketing Cloud, CRM, and platforms  
- REQ-234: Real-time event streaming delivering touchpoints to warehouse with sub-two-hour latency  
- REQ-235: Event enrichment service appending customer attributes, campaign context, and derived fields  
- REQ-236: Data quality monitoring validating event completeness, schema compliance, and timestamp accuracy  
- REQ-237: Historical data retention maintaining minimum twenty-four months of detailed event data  
- REQ-238: Privacy-compliant data handling implementing safeguards for HCP and patient data

**Campaign Performance Dashboards**

- REQ-239: Campaign performance dashboard displaying impressions, reach, engagement, conversions, cost per action  
- REQ-240: Real-time metrics updating dashboard data hourly for active campaigns  
- REQ-241: Historical trend analysis comparing current performance against previous periods and targets  
- REQ-245: Channel effectiveness comparison evaluating relative performance across channels

**Technical Infrastructure (from Section 7\)**

- REQ-329: Cloud data infrastructure with data warehouse, real-time streaming, and data lake storage  
- REQ-330: Business intelligence and visualization platform for self-service analytics and dashboards  
- REQ-331: API-first integration framework establishing connectivity patterns  
- REQ-334: Performance, scalability, and reliability targets for system characteristics  
- REQ-335: DevOps practices enabling rapid feature delivery and reliable operations

### Strategic Capabilities (Phase 2 \- 13 Requirements)

**Attribution Framework**

- REQ-249: Attribution data mart aggregating touchpoints, outcomes, and conversions with journey reconstruction  
- REQ-250: Rules-based attribution models including first-touch, last-touch, linear, time-decay, position-based  
- REQ-253: Multi-touch attribution allocating credit across entire customer journeys  
- REQ-256: Incrementality measurement through holdout group testing quantifying causal impact  
- REQ-257: Attribution reporting dashboard visualizing credit distribution by channel and campaign  
- REQ-309: Attribution data mart and journey reconstruction with identity resolution  
- REQ-310: Rules-based attribution models with consistent output formats  
- REQ-313: Incrementality measurement through holdout testing with experimental designs

**Enhanced Analytics**

- REQ-242: Cohort analysis segmenting results by demographics, entry date, and variants  
- REQ-243: Funnel visualization showing progression through lifecycle stages  
- REQ-244: Content performance reporting ranking creative assets by metrics  
- REQ-246: Geographic breakdown analyzing results by market  
- REQ-247: Automated anomaly detection flagging unusual performance patterns  
- REQ-248: Scheduled report distribution delivering performance summaries automatically

### Advanced Attribution (Phase 3 \- 17 Requirements)

**Algorithmic and Advanced Attribution**

- REQ-251: Algorithmic attribution using machine learning to determine optimal credit distribution  
- REQ-252: Shapley value attribution calculating marginal contribution using game theory  
- REQ-254: Segment-specific attribution recognizing channel effectiveness varies by customer type  
- REQ-255: Attribution model comparison evaluating methodologies side-by-side  
- REQ-258: Attribution model governance ensuring methodology transparency  
- REQ-311: Algorithmic attribution using machine learning with logistic regression, random forests  
- REQ-312: Shapley value attribution for fair credit allocation with cooperative game theory

**Journey Performance Analytics**

- REQ-163: Multi-touch attribution for experiments tracking downstream conversions

### Marketing Mix Modeling (Phase 4 \- 17 Requirements)

**MMM Foundation**

- REQ-259: Marketing mix model development using Bayesian hierarchical modeling  
- REQ-260: Data preparation pipeline aggregating spending, outcomes, and external factors  
- REQ-261: Diminishing returns curves quantifying declining marginal returns  
- REQ-262: Channel interaction effects modeling synergies and conflicts  
- REQ-263: Time lag effects accounting for delayed impact of marketing activities  
- REQ-264: Geographic variation modeling recognizing differential effectiveness by market  
- REQ-314: Marketing mix data preparation pipeline aggregating data at weekly or monthly frequency  
- REQ-315: Bayesian hierarchical marketing mix model quantifying incremental channel impact

**Optimization and Scenario Planning**

- REQ-265: Scenario simulation engine testing what-if budget reallocation strategies  
- REQ-266: Constrained optimization solver maximizing objective function subject to constraints  
- REQ-267: Confidence intervals and sensitivity analysis quantifying uncertainty  
- REQ-268: Model validation using out-of-sample testing and comparison against actuals  
- REQ-269: Marketing mix reporting dashboard visualizing channel ROI curves  
- REQ-316: Scenario simulation and what-if analysis engine exploring alternative strategies  
- REQ-317: Constrained budget optimization solver identifying mathematically optimal allocations

**Model Governance**

- REQ-318: Marketing mix model governance and validation with quality standards

### Portfolio Analytics (Phase 5 \- 22 Requirements)

**Portfolio Data Foundation**

- REQ-270: Portfolio data model aggregating performance across brands, therapeutic areas, and geographies  
- REQ-271: Normalized metrics enabling fair comparison across brands of different sizes  
- REQ-272: Launch phase tracking categorizing brands by lifecycle stage  
- REQ-278: Therapeutic area benchmarking comparing performance against category norms  
- REQ-319: Hierarchical portfolio data model with dimensional analysis  
- REQ-320: Normalized metrics for fair cross-brand comparison  
- REQ-321: Phase-appropriate benchmarking and cohort analysis

**Best Practice and Competitive Intelligence**

- REQ-273: Best practice identification analyzing top-performing campaigns for replication  
- REQ-274: Competitive intelligence integration incorporating competitor digital presence  
- REQ-275: Journey pattern library cataloging proven engagement sequences  
- REQ-276: Cross-brand learning dashboard highlighting successful tactics  
- REQ-325: Competitive intelligence aggregation and analysis across therapeutic areas

**Portfolio Optimization**

- REQ-277: Portfolio optimization recommendations suggesting budget reallocation across brands  
- REQ-279: Executive portfolio dashboard providing C-suite visibility  
- REQ-326: Portfolio-level budget optimization framework maximizing enterprise objectives  
- REQ-327: Executive portfolio dashboard and strategic reporting with comprehensive visibility

### Swimlane F Summary

Swimlane F Measure and Learn comprises eighty-eight requirements establishing comprehensive measurement from event collection through campaign dashboards, attribution modeling, marketing mix optimization, to portfolio analytics. Nineteen Priority Zero requirements deploy in Phase 1 creating event infrastructure, data warehouse, and basic dashboards. Thirteen Priority One requirements enhance measurement in Phase 2 with attribution framework and advanced analytics. Seventeen Priority Two requirements deploy advanced attribution in Phase 3 with algorithmic models and Shapley values. Seventeen Priority Two requirements implement marketing mix modeling in Phase 4 for strategic budget optimization. Twenty-two Priority Two requirements complete portfolio analytics in Phase 5 enabling enterprise-level insights and cross-brand learning. Measurement capabilities prove essential for demonstrating marketing value, optimizing investments, and supporting strategic decision-making.

---

## CONSOLIDATED SWIMLANE SUMMARY

The following table provides consolidated view of requirements distribution across six operational swimlanes:

| Swimlane | Total Requirements | Phase 1 (P0) | Phase 2 (P1) | Phase 3 (P1/P2) | Phase 4 (P2) | Phase 5 (P2) |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| A: Govern | 62 | 28 | 24 | 0 | 0 | 10 |
| B: Segment | 30 | 12 | 12 | 6 | 0 | 0 |
| C: Create | 40 | 21 | 15 | 4 | 0 | 0 |
| D: Orchestrate | 41 | 6 | 20 | 15 | 0 | 0 |
| E: Execute | 57 | 20 | 27 | 10 | 0 | 0 |
| F: Measure & Learn | 88 | 19 | 13 | 17 | 17 | 22 |
| Technical (cross-cutting) | 8 | 7 | 1 | 0 | 0 | 0 |
| **Total Requirements** | **326** | **113** | **112** | **52** | **17** | **32** |

Note: The swimlane view accounts for 326 requirements as 12 technical requirements from Section 7 are distributed across supporting swimlanes rather than forming separate swimlane.

---

# VIEW 2: REQUIREMENTS BY PRIORITY AND PHASE

## Enhanced Requirements Document for Regeneron Pharmaceutical

---

## DOCUMENT PURPOSE

This view organizes all three hundred thirty-five requirements by priority level and implementation phase providing program management perspective essential for execution planning, resource allocation, risk management, and progress tracking. Priority levels indicate business criticality with Priority Zero representing foundational must-have capabilities, Priority One representing strategic enhancements, and Priority Two representing advanced optimization features. Phase assignments sequence requirements across five implementation waves spanning eighteen to twenty-four months balancing early value delivery with systematic capability building.

Program managers use this view to understand implementation scope for each phase, assess resource requirements, identify dependencies requiring coordination, manage risks through appropriate sequencing, and track progress against plan. The phased approach enables incremental value delivery where each phase produces working capabilities generating measurable business value while establishing foundation for subsequent phases. Organizations can adjust phase boundaries and timelines based on resource availability, organizational readiness, and strategic priorities while maintaining logical dependency sequencing.

---

## PHASE 1: FOUNDATION (MONTHS 1-3, 113 PRIORITY ZERO REQUIREMENTS)

### Phase Overview

Phase 1 establishes foundational infrastructure and core operational capabilities enabling basic marketing operations. This phase deploys customer master data management, campaign taxonomy governance, basic content workflows with MLR approval, multi-channel execution across email and paid media, measurement infrastructure, and technical platform including Salesforce, cloud data warehouse, and business intelligence tools. Foundation capabilities prove essential as all subsequent phases depend critically on clean customer data, proper governance, measurement instrumentation, and technical infrastructure.

### Governance Foundation (35 Requirements)

**Customer Data and Identity**

- REQ-001: Claravine as validation gateway  
- REQ-002: API-enforced validation  
- REQ-003: Real-time validation rules  
- REQ-004: Automated rollback mechanism  
- REQ-005: Salesforce as master data management system  
- REQ-006: Data Cloud identity resolution  
- REQ-007: Real-time bi-directional synchronization  
- REQ-008: Golden record creation with survivorship rules  
- REQ-009: Change data capture streaming updates

**Campaign Taxonomy**

- REQ-050: Standardized naming convention  
- REQ-051: Campaign hierarchy  
- REQ-052: UTM parameter standards  
- REQ-053: Content metadata schema

**ClaimID Framework**

- REQ-010: ClaimID data model  
- REQ-035: Claim substantiation vault  
- REQ-298: ClaimID data model and schema  
- REQ-299: Claim substantiation evidence management  
- REQ-300: Claim-to-indication mapping and off-label detection

**Consent Management**

- REQ-056: Preference center  
- REQ-057: Opt-in/out workflow  
- REQ-058: Channel-specific consent  
- REQ-060: Consent propagation service  
- REQ-061: Consent enforcement API

**Audit and Version Control**

- REQ-031: Version control system  
- REQ-032: Immutable audit log  
- REQ-033: Approval record repository  
- REQ-034: Content usage tracking

**Data Quality**

- REQ-039: Person Account model  
- REQ-040: Hierarchical account relationships  
- REQ-041: Pharmaceutical-specific attributes  
- REQ-042: Data quality rules  
- REQ-043: Duplicate detection and merge

**Claim Lifecycle**

- REQ-301: Claim lifecycle management

### Segmentation Foundation (12 Requirements)

- REQ-063: Demographic segmentation  
- REQ-064: Healthcare provider segmentation  
- REQ-065: Institutional account segmentation  
- REQ-067: Geographic segmentation  
- REQ-068: Segment definition interface  
- REQ-069: Web and mobile engagement scoring  
- REQ-070: Email engagement segmentation

**Event Collection Infrastructure**

- REQ-024: Standardized event schema  
- REQ-025: Event collection SDK and APIs  
- REQ-026: UTM parameter generation  
- REQ-027: Server-side event enrichment  
- REQ-028: Event validation service

### Content Management Foundation (21 Requirements)

**Content Planning**

- REQ-093: Campaign brief template  
- REQ-094: Content request workflow  
- REQ-095: Brief approval process  
- REQ-096: Claim selection interface

**Content-to-Claim Mapping**

- REQ-107: Content registration workflow  
- REQ-109: Evidence linking interface  
- REQ-111: Indication alignment verification

**MLR Workflow**

- REQ-115: Multi-stage MLR workflow  
- REQ-116: Role-based access control  
- REQ-117: Review task management  
- REQ-119: Change request workflow  
- REQ-120: Approval status tracking  
- REQ-303: Multi-stage workflow orchestration  
- REQ-304: Role-based review task management  
- REQ-305: Structured comment framework

**Versioning and Expiry**

- REQ-104: Version control  
- REQ-124: Immutable version archiving  
- REQ-125: Major and minor versioning scheme  
- REQ-126: Approved version locking  
- REQ-127: Content distribution workflow  
- REQ-128: Expiry date enforcement  
- REQ-129: Expiry warning notifications  
- REQ-130: Auto-pause mechanism

### Basic Orchestration (6 Requirements)

- REQ-141: Multi-channel message routing  
- REQ-142: Channel preference honoring  
- REQ-145: Frequency capping  
- REQ-148: Delivery status tracking

### Execution Channels (20 Requirements)

**Email Platform**

- REQ-174: Enterprise email platform  
- REQ-175: Dynamic content assembly  
- REQ-176: Responsive email templates  
- REQ-178: List hygiene automation  
- REQ-180: Unsubscribe management  
- REQ-181: Engagement tracking

**Web Platform**

- REQ-192: Web content management system  
- REQ-200: Website analytics integration

**Paid Media**

- REQ-219: Programmatic advertising platform  
- REQ-220: Healthcare provider targeting  
- REQ-224: Frequency capping (paid media)  
- REQ-226: Brand safety controls  
- REQ-228: Conversion tracking  
- REQ-230: Performance reporting dashboard

**Patient Programs**

- REQ-210: Patient enrollment workflow  
- REQ-217: Adverse event detection

**Field Sales**

- REQ-207: Consent verification  
- REQ-209: Sales activity synchronization

**Event Infrastructure**

- REQ-029: Event streaming pipeline  
- REQ-030: Cross-device identity stitching

### Measurement Foundation (19 Requirements)

**Event Collection**

- REQ-231: Universal event schema  
- REQ-232: Client-side tracking libraries  
- REQ-233: Server-side event collection APIs  
- REQ-234: Real-time event streaming  
- REQ-235: Event enrichment service  
- REQ-236: Data quality monitoring  
- REQ-237: Historical data retention  
- REQ-238: Privacy-compliant data handling

**Campaign Dashboards**

- REQ-239: Campaign performance dashboard  
- REQ-240: Real-time metrics  
- REQ-241: Historical trend analysis  
- REQ-245: Channel effectiveness comparison

### Technical Infrastructure (7 Requirements)

- REQ-328: Salesforce platform foundation  
- REQ-329: Cloud data infrastructure  
- REQ-330: Business intelligence platform  
- REQ-331: API-first integration framework  
- REQ-332: Master data management  
- REQ-333: Security controls and compliance framework  
- REQ-334: Performance, scalability, and reliability

### Phase 1 Deliverables

**Month 1:** Platform foundation deployed (Salesforce, data warehouse, security baseline) **Month 2:** Core capabilities operational (Claravine, ClaimID registry, MLR workflow, email platform) **Month 3:** Production launch with pilot campaigns validating end-to-end workflows

---

## PHASE 2: STRATEGIC CAPABILITIES (MONTHS 4-9, 112 PRIORITY ONE REQUIREMENTS)

### Phase Overview

Phase 2 builds strategic marketing capabilities including journey orchestration canvas, advanced segmentation with propensity models, enhanced content workflows, real-time personalization, central fatigue management, experimentation framework, and multi-touch attribution. These capabilities transform marketing from basic campaign execution to strategic customer lifecycle management.

### Governance Enhancements (24 Requirements)

**Advanced Identity**

- REQ-044: Deterministic matching  
- REQ-045: Probabilistic matching  
- REQ-046: Device graph  
- REQ-047: Cross-domain tracking  
- REQ-048: Anonymous-to-known resolution  
- REQ-049: Household clustering

**Enhanced Consent**

- REQ-059: Purpose-based consent  
- REQ-062: Consent reporting dashboard

**Content Governance**

- REQ-054: Creative versioning system  
- REQ-055: Placement taxonomy

**Audit Enhancement**

- REQ-036: Regulatory report generator  
- REQ-037: Legal hold capability  
- REQ-038: Audit dashboard

**Claim Management**

- REQ-302: Claim usage tracking

### Advanced Segmentation (12 Requirements)

**Behavioral Segmentation**

- REQ-071: Event participation tracking  
- REQ-072: Sales interaction history  
- REQ-073: Patient program engagement  
- REQ-074: Content consumption patterns  
- REQ-075: Multi-channel engagement scoring  
- REQ-066: Payer/pharmacy segmentation

**Propensity Modeling**

- REQ-077: Propensity-to-prescribe models  
- REQ-078: Patient adherence prediction  
- REQ-083: Model registry  
- REQ-084: Model monitoring and retraining  
- REQ-085: Model explainability

**Real-Time Segmentation**

- REQ-086: Real-time segment evaluation engine

### Enhanced Content Management (15 Requirements)

**Collaboration**

- REQ-097: Reference material attachment  
- REQ-098: Brief status dashboard  
- REQ-099: Integrated creative workspace  
- REQ-100: Template library  
- REQ-101: Component library  
- REQ-102: Real-time collaboration  
- REQ-103: Inline commenting

**Enhanced Claim Validation**

- REQ-110: Fair balance validation  
- REQ-112: Reference list generation  
- REQ-113: Claim usage tracking

**MLR Enhancement**

- REQ-118: Structured comment taxonomy  
- REQ-121: Conditional approval  
- REQ-122: Escalation rules  
- REQ-123: Review metrics dashboard

**Content Analytics**

- REQ-131: Content usage analytics  
- REQ-132: Content audit trail

### Journey Orchestration (20 Requirements)

**Journey Canvas**

- REQ-280: Lightning Web Component architecture  
- REQ-281: Drag-and-drop node library  
- REQ-282: Visual flow designer  
- REQ-283: Journey template library  
- REQ-284: Journey versioning  
- REQ-135: Journey versioning (duplicate reference)  
- REQ-136: Template library (duplicate reference)  
- REQ-137: Visual flow validation  
- REQ-139: Journey documentation generator

**Intelligent Delivery**

- REQ-143: Channel fallback logic  
- REQ-144: Send-time optimization  
- REQ-146: Message prioritization  
- REQ-147: Real-time personalization

**Central Fatigue Management**

- REQ-149: Central fatigue registry  
- REQ-150: Real-time fatigue scoring  
- REQ-151: Fatigue threshold configuration  
- REQ-152: Pre-send fatigue check API  
- REQ-153: Journey-level fatigue gates  
- REQ-156: Cross-system integration

**Experimentation**

- REQ-157: A/B/n testing framework  
- REQ-159: Holdout group management  
- REQ-160: Statistical analysis library  
- REQ-161: Experiment registry

### Enhanced Execution (27 Requirements)

**Email Enhancement**

- REQ-177: Send-time optimization  
- REQ-179: Spam filter testing  
- REQ-182: A/B testing capability

**SMS and Mobile**

- REQ-183: SMS platform  
- REQ-184: Mobile push notifications  
- REQ-187: Carrier compliance  
- REQ-188: Opt-in verification  
- REQ-189: Keyword management  
- REQ-190: Delivery receipt tracking  
- REQ-191: Character limit optimization

**Web Personalization**

- REQ-193: Personalization engine  
- REQ-194: A/B testing framework  
- REQ-195: Progressive profiling  
- REQ-196: Form optimization  
- REQ-198: Gated content management

**Field Sales**

- REQ-201: Field representative dashboard  
- REQ-203: Call planning tools  
- REQ-204: Sample management  
- REQ-205: Closed-loop feedback  
- REQ-208: Content delivery

**Patient Programs**

- REQ-211: Copay assistance administration  
- REQ-212: Medication adherence monitoring  
- REQ-213: Nurse educator coordination  
- REQ-214: Educational content delivery  
- REQ-215: Outcome tracking  
- REQ-216: Provider coordination  
- REQ-218: Program analytics dashboard

**Paid Media**

- REQ-221: Patient audience targeting  
- REQ-222: Contextual targeting  
- REQ-225: Creative rotation testing  
- REQ-227: Viewability optimization  
- REQ-229: Budget pacing algorithms

### Attribution and Analytics (13 Requirements)

**Attribution Framework**

- REQ-249: Attribution data mart  
- REQ-250: Rules-based attribution  
- REQ-253: Multi-touch attribution  
- REQ-256: Incrementality measurement  
- REQ-257: Attribution dashboard  
- REQ-309: Attribution data mart and journey reconstruction  
- REQ-310: Rules-based attribution models  
- REQ-313: Incrementality measurement through holdout testing

**Enhanced Analytics**

- REQ-242: Cohort analysis  
- REQ-243: Funnel visualization  
- REQ-244: Content performance reporting  
- REQ-246: Geographic breakdown  
- REQ-247: Automated anomaly detection  
- REQ-248: Scheduled report distribution

### DevOps Enhancement (1 Requirement)

- REQ-335: DevOps practices and operational excellence

### Phase 2 Deliverables

**Months 4-5:** Journey orchestration foundation with canvas and template library **Months 6-7:** Advanced segmentation and attribution with propensity models **Months 8-9:** Experimentation and fatigue management operational

---

## PHASE 3: OPTIMIZATION (MONTHS 10-12, 52 REQUIREMENTS)

### Phase Overview

Phase 3 enhances experimentation capabilities and content workflows through advanced optimization algorithms, sophisticated testing methodologies, and enriched collaboration features including Bayesian optimization, multi-armed bandits, journey simulation, and enhanced content collaboration.

### Content Enhancement (4 Requirements)

- REQ-105: Asset preview and proofing  
- REQ-106: Reference citation management  
- REQ-108: Automated claim detection  
- REQ-114: Visual claim mapping interface

### Journey Optimization (15 Requirements)

**Advanced Journey Features**

- REQ-285: Collaborative journey development  
- REQ-286: Journey simulation and testing  
- REQ-287: Journey documentation generator

**Advanced Experimentation**

- REQ-158: Multi-armed bandit algorithms  
- REQ-162: Automated winner selection  
- REQ-164: Bayesian optimization  
- REQ-165: Personalization testing  
- REQ-288: A/B/n testing with statistical rigor  
- REQ-289: Multi-armed bandit for adaptive optimization  
- REQ-290: Holdout group management  
- REQ-291: Bayesian optimization for accelerated learning  
- REQ-292: Experiment registry and knowledge management

**Enhanced Fatigue**

- REQ-154: Fatigue override workflow  
- REQ-155: Fatigue impact analysis  
- REQ-293: Central fatigue registry architecture  
- REQ-294: Real-time fatigue scoring algorithm  
- REQ-295: Pre-send fatigue validation API  
- REQ-296: Fatigue threshold configuration  
- REQ-297: Fatigue impact analysis and reporting

**Journey Performance**

- REQ-166: Real-time journey analytics  
- REQ-167: Node-level performance tracking  
- REQ-168: Cohort analysis  
- REQ-169: Journey health monitoring  
- REQ-171: Multi-touch journey attribution  
- REQ-172: Journey ROI calculation

### Enhanced Execution (10 Requirements)

**Mobile and Web**

- REQ-185: In-app messaging  
- REQ-186: Rich media messaging  
- REQ-197: Content recommendations  
- REQ-199: Session recording and heatmaps  
- REQ-223: Lookalike audience expansion

**Field Sales**

- REQ-202: Next-best-action recommendations  
- REQ-206: Speaker program coordination

### Advanced Attribution (17 Requirements)

**Algorithmic Attribution**

- REQ-251: Algorithmic attribution using machine learning  
- REQ-252: Shapley value attribution  
- REQ-254: Segment-specific attribution  
- REQ-255: Attribution model comparison  
- REQ-258: Attribution model governance  
- REQ-311: Algorithmic attribution with ML techniques  
- REQ-312: Shapley value for fair allocation

**Journey Analytics**

- REQ-163: Multi-touch attribution for experiments  
- REQ-170: Automated optimization recommendations  
- REQ-173: Comparative benchmarking

### Advanced Governance (6 Requirements)

- REQ-306: Version comparison and change highlighting  
- REQ-307: Approval documentation and audit trail  
- REQ-308: MLR performance analytics

### Phase 3 Deliverables

**Months 10-11:** Advanced optimization with Bayesian methods and multi-armed bandits **Month 12:** Enhanced measurement with algorithmic attribution and journey analytics

---

## PHASE 4: ADVANCED ANALYTICS (MONTHS 13-18, 17 REQUIREMENTS)

### Phase Overview

Phase 4 deploys sophisticated marketing mix modeling and budget optimization capabilities enabling strategic resource allocation based on marginal returns analysis using Bayesian hierarchical models, scenario simulation, and constrained optimization solvers.

### Marketing Mix Modeling (17 Requirements)

**MMM Foundation**

- REQ-259: Marketing mix model development using Bayesian hierarchical modeling  
- REQ-260: Data preparation pipeline  
- REQ-261: Diminishing returns curves  
- REQ-262: Channel interaction effects  
- REQ-263: Time lag effects  
- REQ-264: Geographic variation modeling  
- REQ-314: Marketing mix data preparation  
- REQ-315: Bayesian hierarchical MMM model

**Optimization and Scenario Planning**

- REQ-265: Scenario simulation engine  
- REQ-266: Constrained optimization solver  
- REQ-267: Confidence intervals and sensitivity analysis  
- REQ-268: Model validation  
- REQ-269: MMM reporting dashboard  
- REQ-316: Scenario simulation and what-if analysis  
- REQ-317: Constrained budget optimization

**Model Governance**

- REQ-318: MMM model governance and validation

### Phase 4 Deliverables

**Months 13-15:** Data infrastructure and model development with Bayesian hierarchical MMM **Months 16-17:** Optimization and scenario planning with constrained solvers **Month 18:** Governance framework and production deployment with first annual planning cycle

---

## PHASE 5: PORTFOLIO INTELLIGENCE (MONTHS 19-24, 44 REQUIREMENTS)

### Phase Overview

Phase 5 completes solution deployment with portfolio analytics and cross-brand intelligence including hierarchical portfolio data model, normalized metrics, phase-appropriate benchmarking, journey pattern library, competitive intelligence, portfolio optimization, and executive dashboards.

### Advanced Segmentation (6 Requirements)

- REQ-076: Engagement velocity metrics  
- REQ-079: Next-best-action recommendation engine  
- REQ-080: Churn prediction models  
- REQ-081: Lifetime value modeling  
- REQ-082: Lookalike audience generation

### Dynamic Audience Management (6 Requirements)

- REQ-087: Event-driven segment entry/exit rules  
- REQ-088: Streaming data integration  
- REQ-089: Dynamic audience synchronization  
- REQ-090: Segment membership history  
- REQ-091: Overlap analysis  
- REQ-092: Segment performance analytics

### Journey Pattern Library (3 Requirements)

- REQ-322: Journey pattern identification and curation  
- REQ-323: Pattern library search and discovery  
- REQ-324: Pattern adaptation and implementation support

### Portfolio Analytics (22 Requirements)

**Portfolio Data Foundation**

- REQ-270: Portfolio data model  
- REQ-271: Normalized metrics  
- REQ-272: Launch phase tracking  
- REQ-278: Therapeutic area benchmarking  
- REQ-319: Hierarchical portfolio data model  
- REQ-320: Normalized metrics for comparison  
- REQ-321: Phase-appropriate benchmarking

**Best Practice and Intelligence**

- REQ-273: Best practice identification  
- REQ-274: Competitive intelligence integration  
- REQ-275: Journey pattern library  
- REQ-276: Cross-brand learning dashboard  
- REQ-325: Competitive intelligence aggregation

**Portfolio Optimization**

- REQ-277: Portfolio optimization recommendations  
- REQ-279: Executive portfolio dashboard  
- REQ-326: Portfolio-level budget optimization  
- REQ-327: Executive portfolio dashboard and reporting

### Governance Enhancement (7 Requirements)

- REQ-332: Master data management (advanced features)  
- Additional advanced governance capabilities

### Phase 5 Deliverables

**Months 19-20:** Portfolio data foundation with hierarchical model and normalized metrics **Months 21-22:** Pattern library and optimization with cross-brand insights **Months 23-24:** Executive intelligence and rollout with first portfolio planning cycle

---

## CONSOLIDATED PRIORITY AND PHASE SUMMARY

| Phase | Duration | Months | Priority | Requirements | Key Focus |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Phase 1: Foundation | 3 months | 1-3 | P0 | 113 | Platform, governance, basic execution, measurement foundation |
| Phase 2: Strategic Capabilities | 6 months | 4-9 | P1 | 112 | Journey orchestration, attribution, fatigue management, propensity models |
| Phase 3: Optimization | 3 months | 10-12 | P1/P2 | 52 | Bayesian optimization, bandits, simulation, advanced attribution |
| Phase 4: Advanced Analytics | 6 months | 13-18 | P2 | 17 | Marketing mix modeling, scenario simulation, budget optimization |
| Phase 5: Portfolio Intelligence | 6 months | 19-24 | P2 | 44 | Portfolio analytics, pattern library, competitive intelligence |
| **Total Program** | **18-24 months** | **1-24** | **P0-P2** | **335** | **Complete pharmaceutical marketing technology solution** |
